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ABSTRACT 
Background - The clinical diagnosis and categorisation of Acute Coronary Syndrome (ACS) 
has changed repeatedly over the last decade as have routine treatment strategies.  
Hypothesis - that adverse clinical events following PCI, may be predicted from the 
identification of markers of risk at the time of PCI.   
Methods - Informed consent was obtained from 968 patients fulfilling detailed inclusion and 
exclusion criteria surrounding a diagnosis of ACS requiring PCI. Standard medical ACS care 
was provided. PCI operators, techniques, methods and any decision to treat followed usual 
practice.  Data collection took place at the time of intervention and during active follow-up. 
Blood sample were collected at baseline and 4 and 12 hours after PCI, being processed and 
refrigerated. Platelet function was assessed at baseline using the VerifyNow test method.  
Results – Data collection was over a median follow-up time of 3.56 years. Patients were aged 
27 to 90 years and a majority were male (75%).  Angiographic complications occurred in 13.2% 
and total complications in 17.1%.  A majority (844; 86%) had neither restenosis nor subsequent 
unplanned revascularization.  Recurrent ACS was 6.7% for year 1 and 1.8% additionally for 
each year thereafter. Stent thrombosis was observed in 18 (1.8%) cases. Bleeding occurred in 
9% across the entire follow-up period, being greatest in the first 12 months. Platelet reactivity 
was highly variable and optimal with regard to outcome in the range of 179 to 243 (Platelet 
Reactivity Units PRU). Cardiac biomarkers were commonly elevated after PCI but procedural 
MI was very rare. H-FABP at baseline was strongly predictive of outcome. 
Conclusion – Adverse clinical events following PCI, such as stent thrombosis, bleeding and in-
stent restenosis, may be predicted from the identification of markers of risk at the time of PCI, 
particularly by the use of risk scores, platelet function testing and measuring biomarker levels.   
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GLOSSARY OF TERMS, ACRONYMS AND ABBREVIATIONS 
ACS Acute Coronary Syndrome: a clinical syndrome characterised by chest 
pain and other symptoms due to myocardial ischaemia; includes unstable 
angina, non ST segment-elevation myocardial infarction and ST segment-
elevation myocardial infraction 
ADP Adenosine diphosphate: an organic compound involved in many metabolic 
pathways; has an important role in the platelet activation/propagation 
cascade required for arterial thrombosis, essential for normal haemostasis 
following tissue injury; stored in platelet „dense granules‟; binds to platelet 
membrane via receptors including P2Y12 and P2Y1 to induce activation 
Angiogram An invasive diagnostic procedure in which an X-ray image of an arterial 
lumen is obtained by injecting radio-opaque contrast medium, usually 
iodine-based, into an artery via a long catheter. Coronary angiography is 
used to diagnose coronary artery disease, with coronary catheterization 
achieved percutaneously via the femoral or radial arteries 
ARC Academic Research Consortium: a group of international experts and 
industry leaders who have published criteria to define cardiovascular 
adverse endpoints such as cardiac death, MI and stent thrombosis for the 
purpose of clarity and reproducibility among clinical trials 
Atherosclerosis A range of pathological degenerative changes which develop in arteries 
throughout the body with advancing age; characterised by the combination 
of fatty deposits and sclerosis (hardening) due to fibrosis and calcification; 
the cause of end-organ ischaemic damage due to arterial stenosis 
(narrowing) and/or thrombosis. Coronary atherosclerosis is the commonest 
cause of myocardial infarction 
BARC Bleeding Academic Research Consortium: a group of international experts 
and industry leaders who have published criteria to define the clinical 
severity of bleeding for the purpose of clarity and reproducibility among 
clinical trials; graded from BARC 1 (minor) to BARC 5 (fatal) 
BMS Bare Metal Stent 
CABG Coronary Artery Bypass Surgery: coronary revascularization in which a 
coronary stenosis is bypassed by the surgical formation of a conduit (graft) 
between the aorta and the coronary artery distal to the stenosis; usually 
achieved via a median sternotomy with the patient on cardiac bypass with 
cross-clamping of the aorta; grafts are fashioned from the patients‟ 
superficial leg veins (saphenous veins), internal mammary arteries or 
radial arteries 
CA III Carbonic Anhydrase III; an enzyme found only in skeletal muscle 
CK-MB Creatine Kinase BM isoenzyme; an enzyme found almost exclusively in 
cardiac muscle; a „cardio specific‟ cardiac biomarker 
Convalescent 
PCI 
Non-emergent PCI following presentation with STEMI following 
chemical revascularisation by antiplatelet and thrombolytic therapy 
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CoV Coefficient of Variation: the ratio of the standard deviation and the mean 
of a population; a measure of dispersion and the accepted method for 
measuring the precision of a test; good biochemical assays should have a 
CoV of < 10% at the 99
th
 percentile of a healthy population 
CTO Chronic Total Occlusion: a coronary artery which has been blocked for 
more than 3 months 
DES Drug-eluting stent 
EuroSCORE A risk scoring system to estimate the pre-treatment probability of 
surviving cardiac surgery generated from the historical results of 
thousands of patients at many European centres; calculated from the sum 
of points allocated for adverse baseline characteristics 
ECG Electrocardiograph: a recording of the electrical activity of the heart 
produced using electrodes to measure changes in the electrical potential of 
the skin caused by myocardial depolarization and repolarisation with each 
heart beat. Characteristic dynamic ECG changes occur during myocardial 
ischaemia and infarction, such as ST segment depression or elevation 
GPBB Glycogen phosphorylase isoenzyme BB; a cardiac biomarker 
H-FABP Human Fatty Acid Binding Protein: a cardiac biomarker 
MI Myocardial Infarction: death of cardiac myocytes, usually due to 
ischaemia resulting from coronary atherosclerotic disease; the commonest 
cause of death worldwide 
NSTEMI Non ST elevation myocardial infarction: cardiomyocyte necrosis due to 
ischaemia without ECG ST segment elevation; usually caused by a 
severely stenotic and/or thrombotic atherosclerotic coronary artery lesion; 
investigated by early inpatient coronary angiography  
MACE, MACCE Major Adverse Cardiac Event; Major Adverse Cardiac and 
Cerebrovascular Event: composite adverse endpoint commonly reported in 
clinical trials of revascularisation; endpoint usually includes the 
combination of MI, death (usually cardiac) stent thrombosis and 
unplanned further revascularisation, sometimes include „procedural MI‟ 
based on cardiac enzyme levels, with the addition of stroke in MACCE; 
composite endpoints are slightly different between studies and therefore 
should not be directly compared 
Myoglobin A non-cardio specific cardiac biomarker 
PCI Percutaneous Coronary Intervention: any procedure involving the 
instrumentation of the coronary arteries by means of a cardiac catheter 
which is introduced by cannulation of  a peripheral artery 
PES Paclitaxel-Eluting Stent; usually refers to Taxus „lst generation‟ DES 
PPCI Primary Percutaneous Coronary Intervention: emergency PCI for STEMI 
PRU P2Y12 Reactivity Units: a measure of  the degree of platelet reactivity in 
response to ADP produced by the VerifyNow device; a low PRU level 
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implies a high level of pharmacological P2Y12 receptor inhibition i.e. good 
response to clopidogrel, prasugrel or ticagrelor 
P2Y12 receptor A large molecule found on the surface of platelets with a binding site for 
ADP; ADP binding leads to platelet activation and arterial thrombus 
formation; the target of several common drugs used for prevention of 
coronary thrombosis including clopidogrel, prasugrel and ticagrelor 
Rescue PCI Emergent PCI for STEMI when pharmacological thrombolysis has been 
attempted but has been unsuccessful i.e. failure of resolution of ECG ST 
segment elevation 
Revascularisation Restoration of an adequate arterial blood supply to an ischaemic organ 
SES Sirolimus-Eluting Stent; usually refers to the Cypher „1
st
 generation‟ DES 
ST Stent Thrombosis: sudden thrombotic occlusion of a stent associated with 
a high rate of MI and death 
Staged PCI  PCI to multiple lesions undertaken at more than 1 sitting 
STEMI ST elevation myocardial infarction: cardiomyocyte necrosis due to 
ischaemia with ECG ST segment elevation; usually caused thrombotic 
occlusion of a large epicardial coronary artery at the site of a ruptured 
atherosclerotic plaque; requires emergency coronary revascularisation by 
thrombolysis and/or PPCI 
SYNTAX score Angiographic grading system published in 2005 to objectively measure the 
extent and severity of coronary artery disease; developed by investigators 
at the Thoraxcenter, Erasmus Medical Centre, the Netherlands, headed by 
senior investigator Prof. Patrick Serruys. Points are assigned for each 
stenosis of > 50% in arteries of ≥ 1.5 mm, weighted more heavily for 
proximal disease in major vessels, with additional points for adverse 
features such as chronic total occlusion and diffuse disease. The score has 
been validated in patients undergoing PCI to show that higher scores are 
associated with higher rates of adverse cardiovascular events. 
TnI Troponin I; an enzyme found exclusively in cardiac muscle; a „cardio-
specific‟ cardiac biomarker 
ULN Upper Limit of Normal: cut-off level for the normal range of a substance 
measured in blood plasma, such as a cardiac biomarker; usually defined as 
the 99
th
 percentile of a healthy population 
VerifyNow test Rapid bedside platelet function test based on light transmission 
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Chapter 1 Introduction and literature review 
This introductory chapter is an overview of the aetiology and contemporary 
diagnosis and management of coronary artery disease and the acute coronary 
syndromes. „Acute coronary syndrome‟ (ACS) is a clinical diagnosis given to patients 
who present with rapidly progressive or at-rest symptoms suggestive of myocardial 
ischaemia which is supported by positive results from a range of clinical tests. The most 
common symptom is a discomfort felt in the upper body, particularly the chest, known 
as „angina pectoris‟. The diagnosis of ACS constitutes a medical emergency as patients 
are at risk of myocardial infarction and sudden death. Prompt treatment both reduces the 
risk of death and limits the extent of myocardial necrosis and permanent impairment of 
cardiac function in survivors. The commonest underlying disorder found in people with 
ACS is atherosclerotic coronary artery disease, which remains the commonest cause of 
death worldwide, with 7.4 million deaths in 2012 (WHO online fact sheet number 310, 
2014). 
1.1. Coronary atherosclerosis 
Atherosclerosis is a systemic disorder of arteries characterised by the presence of 
fibro-fatty plaques and calcification of the arterial wall. This can lead to arterial 
thrombosis, compromise of blood flow and ischaemic dysfunction or infarction of the 
downstream organ or tissue. Lloyd-Jones et al (1999) found that the lifetime risk of 
developing clinical coronary heart disease (angina, acute myocardial infarction or 
cardiac death), measured from the age of 40 years in 7733 healthy participants in the 
landmark Framingham Heart Study, was 48.5% for men and 31.7% for women. This 
population was almost exclusively white and from the same town in North America. At 
this time a number of risk factors for the condition were identified, known as „major‟ or 
„classical‟ cardiovascular risk factors. Non-modifiable risk factors include positive 
family history and increasing age; modifiable factors include tobacco smoking, 
hypertension, hyperlipidaemia, diabetes mellitus and a sedentary lifestyle. 
1.1.1. Prevalence of coronary atherosclerosis 
Coronary atherosclerosis develops during an initial asymptomatic (subclinical) 
phase and may remain clinically silent during an individual‟s entire lifetime, so the true 
prevalence of anatomical disease cannot be quantified merely by observing the rate of 
clinical events. However, there are several studies involving very large numbers of 
asymptomatic patients who have self-referred for screening for coronary artery calcium, 
which is deposited in atherosclerotic plaque, using the sensitive technique of computed 
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tomography calcium scoring. These studies were performed in the USA in the early 
1990s, mainly on white individuals.  
The coronary calcium score was found to vary widely with age, between the 2 
sexes and between subjects with and without the conventional cardiovascular risk 
factors. In a study by Janowitz et al, 1993, the prevalence of calcium was seen to 
gradually increase with age. The prevalence in women was about half that found in men 
until the age of 60 years after which this difference diminished. In male and female 
subjects between the ages of 0 and 29 years the prevalence was 11% and 6%; in male 
and female subjects between the ages of 50 and 59 years the prevalence was 72% and 
35%; and in subjects between the ages of 80 and 89 years the prevalence was 100% in 
both sexes.  
In other words, if human beings live long enough they will all eventually develop 
at least some degree of coronary atherosclerosis. This only becomes clinically apparent, 
however, in about half of men and a third of women. 
1.1.2. Pathogenesis of atherosclerotic coronary disease 
While there are well-established risk factors for the development of coronary 
disease, no single common aetiological agent of atherogenesis has been identified. 
Extensive study over decades at the cellular and now molecular level has lead to the 
current hypothesis of the atherosclerotic plaque as largely the result of a chronic 
inflammatory response to repeated or sustained injury to the vascular endothelium, 
associated with lipid accumulation in the arterial wall. The pathophysiology of coronary 
atherosclerosis is explored in an extensive review by Libby et al, 2005. 
1.1.2.1. A disorder of lipid storage? 
Lipid accumulation in the arterial wall was recognised early on as a crucial 
component of atherogenesis and is known to start very early in life. Although the 
clinical manifestations of coronary atherosclerosis are rare before the age of around 30 
years, histological pre-atherosclerotic changes can be identified even in infants. The 
earliest manifestation of atheromatous disease is the presence in the arterial wall of 
lipid-filled „foam cells‟. As demonstrated by Gerrity et al in 1981, foam cells are 
macrophages, thought to be derived from blood monocytes, which have scavenged and 
stored lipid, particularly low density lipoprotein (LDL) particles. However, it is still not 
clear whether lipid accumulation in the early stages of life is a passive process of 
diffusion from the bloodstream, or whether there is a pathological mechanism of active 
lipid transportation. Both of these mechanisms of lipid deposition are known to occur. 
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By puberty, most children have increasing numbers of foam cells in their arteries 
accompanied by accumulations of extracellular lipid. These are visible macroscopically 
and known as fatty streaks. Some individuals at this age have already developed 
atheromata, characterised by a single confluent fatty core. Smooth muscle cells 
proliferate in these lesions and secrete an extracellular matrix to create a fibrotic cap, 
which can be identified in individuals from the age of 20 years onwards. [Notes: 
macrophages are white blood cells which colonise injured/inflamed tissue, induce 
connective tissue proliferation and have a central role in wound healing. Lipoproteins 
are particles of cholesterol and triglycerides enclosed by a thin layer of phospholipid 
and an apolipoprotein molecule. Phospholipids are amphipathic molecules, consisting 
of a hydrophobic tail binding with the lipid, and a hydrophilic head which faces 
outwards, making lipoproteins water-soluble for transportation in the bloodstream]. 
For some years, therefore, atherosclerosis was considered primarily a disease of 
aberrant lipid storage. However, additional pathological processes were noted and it was 
realised that the disorder had a more complex pathophysiology. These discoveries were 
outlined by Ross in a review article of 1986, with a further update in 2010, in which 
evidence is presented for vascular injury as an early step in atherogenesis, resulting in 
an inflammatory response in the vessel wall, endothelial dysfunction and endothelial 
cell death. 
1.1.2.2.  Endothelial injury and dysfunction 
Vascular endothelial cells line arteries in a delicate monolayer and perform a 
pivotal role in vascular homeostasis. The endothelium is involved in the regulation of 
vascular tone, inflammation, coagulation, platelet activation and the activities of 
vascular smooth muscle cells, co-ordinated by multiple signalling pathways. With all 
these paracrine and autocrine functions, a cell count of 6×10
13
, a surface area of >1000 
m
2
 and a weight of 1.5 kg, the endothelium may be regarded as an autonomous organ. 
During normal life, the vascular endothelium is subject to damage inflicted by the 
combination of chronic mechanical stress in the pressurised arterial system over time 
and exposure to substances carried in the blood which are toxic to endothelial cells. The 
interaction of injured endothelial cells with the inflammatory, immune and 
anticoagulation systems interacting with accumulated lipid within the arterial wall can, 
over a period of decades, develop into a variety of different types of atherosclerotic 
plaque. (Anderson et al, 1995; Kinlay and Ganz, 1997). 
Endothelial dysfunction has been demonstrated in numerous studies to be 
associated with the presence of atherosclerotic plaque. Dysfunction can be detected 
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clinically by observing an abnormal vasomotor response to different stimuli. The 
smooth muscle in coronary arteries enables dilatation and constriction, allowing for 
autoregulation of myocardial blood flow in response to changes in metabolic demand. 
Hasdai et al (1997) showed that patients with angiographically minor coronary disease 
develop myocardial perfusion defects on nuclear perfusion scanning following the 
infusion of acetylcholine (ACh) into the left anterior descending artery (LAD) due to 
coronary vasospasm; this procedure usually induces vasodilatation in healthy arteries. 
Schachinger et al (2000), using various tests of vasoreactivity, found that impaired 
coronary endothelial vasodilatation was an independent predictor of cardiovascular 
events during long-term follow up in 147 patients, albeit with a small number of events 
(16 over 7.7 years). 
Endothelial injury leads to the „activation‟ of endothelial cells: the expression of 
vascular cell adhesion molecules (VCAMs) capable of interacting with circulating 
leucocytes and platelets. VCAMs are up-regulated in the presence of inflammatory 
cytokines including IL-1, TNF-α and IFN-γ, both in vitro and in vivo. Activated 
endothelial cells also bind to, ingest and modify circulating plasma lipoproteins to 
enable ingestion by subendothelial monocytes. Oxidisation of subendothelial LDL by 
oxygen free radicals initiates a complex cascade of pro-inflammatory effects including 
further accumulation of cells (monocytes, CD-4 and CD-8 lymphocytes and smooth 
muscle cells) in the intima, apoptosis of endothelial cells and platelet activation. 
VCAM-1 in particular has been shown to be strongly linked to atherosclerosis, 
demonstrated by Cybulsky et al in 2001 in their work on gene knock-out mice. 
1.1.3. Causes of vascular injury  
Although advancing age is the most powerful risk factor for coronary 
atherosclerosis, people with atherosclerotic syndromes are more likely to have a family 
history of the disorder, and recent advances in gene sequencing have allowed the 
identification of genotypes associated with the disease. Environmental factors interact 
with genetic factors to determine each individual‟s risk of developing atherosclerosis. 
Environmental factors found to cause vascular endothelial injury in animals 
include classical vascular risk factors such as raised serum LDL, tobacco toxins and 
hyperglycaemia, which were identified in studies during the 1950s and 60s such as the 
Framingham Heart Study (Dawber et al, 1957). However, it is recognised that a 
proportion of patients in fact have no identifiable classical risk factors. Further markers 
of atherosclerosis and coronary events were identified subsequently, including 
hyperhomocystinaemia, Lp(a) lipoprotein, the serum inflammatory markers CRP and 
serum amyloid protein A, the prothrombotic factors PAI-I, D-dimer, fibrinogen, and 
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von Willebrand factor, and microalbumineamia (Folsom, 2006). Infectious agents have 
also been shown to cause endothelial dysfunction, as discussed by Danesh et al in 1997, 
although their exact role in the clinical manifestations of coronary disease is unclear. 
Chronic platelet activation, platelet adherence and thrombosis appear to have a 
role in endothelial injury and subsequent atheromatous plaque formation. Platelets do 
not normally adhere to healthy endothelial cells, which secrete platelet inhibiting agents. 
However, platelets will adhere to activated endothelium, undergoing activation and 
degranulation. Degranulating platelets release many inflammatory substances required 
for wound healing including platelet derived growth factor (PDGF), a chemotactic 
agent, and TGF beta, which stimulates the creation of extracellular matrix. Platelets are 
discussed further in subsequent sections. The evidence for an aetiological role of 
platelets in atherosclerotic disease is discussed by Rondina et al, 2013. 
Work to identify a common pathophysiological mechanism by which these diverse 
factors provoke endothelial injury has highlighted the importance of nitric oxide in 
normal endothelial function. Nitric Oxide (NO) is a humoral signalling agent produced 
by endothelial cells from the action of nitric oxide synthase (NOS) on L-arginine. NO 
production is highly regulated in response to haemodynamic and humoral factors and 
has several vasoprotective effects. It causes arterial vasodilatation (nitrovasodilating 
drugs such as GTN work by releasing NO within the vasculature), inhibits platelet 
activation and aggregation and promotes platelet disaggregation, inhibits smooth muscle 
proliferation and inhibits leukocyte adhesion. It is thought that impaired NO production 
may be responsible for many of the processes leading to plaque formation and 
disruption. A review of the evidence for this was written by Napoli et al, 2006. 
1.1.4. Neovascular vasa vasorum in atheromatous plaque 
„Vasa vasorum‟ is the term given to a network of small blood vessel providing the 
vascular supply to a larger blood vessel. The human aorta has a vasa vasorum extending 
distally as far as the level of the renal arteries; distal to this, the metabolic requirements 
of the aorta are met by diffusion of oxygen and nutrients (interestingly the incidence of 
aortic aneurysm formation is greater below this level). The coronary arteries also have a 
vasa vasorum. Pathological neovascularisation – the growth of abnormal micro vessels 
within the adventitia - has been well documented in atherosclerotic coronary arteries 
and is thought to have an important role in both plaque growth and rupture, first 
proposed by Barger et al in 1984. 
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1.1.5. Mechanical factors 
Mechanical factors have a crucial role in atherogenesis. Arterial hypertension is a 
well established classical vascular risk factor, strongly associated with atherosclerosis, 
as demonstrated in the Framingham studies. Blood pressure is regulated by the renin-
angiotensin-aldosterone system. Elevated aldosterone levels have been shown to 
correlate with adverse clinical outcomes in ACS patients, independent of other risk 
factors, as shown in studies such as the one by Tomaschitz et al, 2010. Treatment to 
lower blood pressure by the use of antihypertensive drugs which act on the rennin-
angiotensin-aldosterone system results in decreased frequency of vascular events. This 
was shown by Hall et al in 1993 with the AIREX trial, which studied the effects of 
ramipril on mortality after ACS compared to placebo over 3 years. 
In addition, variations in endothelial shear stress within the vessel appear to have a 
role in the location of plaque formation; for example, stenoses occur more commonly at 
branch points where there are changes in blood velocity and direction. Furthermore, the 
coronary vasculature is subject to external mechanical forces unique to the heart – the 
heart beat itself produces in the coronary arteries marked and sustained torsion and 
stretching forces, again particularly at branch points. This was explored in detail in a 
review by Chatzizisis et al, 2007. Furthermore, haemodynamic instability from a range 
of factors is often observed in the days leading up to an ACS. It is thought that changes 
in coronary endothelial shear stress during these trigger events can mechanically disrupt 
a pre-existing inflammatory plaque and give rise to ACS. For example, Tanaka et al 
(2008) demonstrated that this depends on atherosclerotic plaque morphology and is 
particularly likely if the plaque has a thin fibrous cap. This leads us on to a more 
detailed discussion of the pathophysiological causes of ACS. 
1.2. The Acute Coronary Syndromes 
Coronary atherosclerosis may be asymptomatic throughout an individual‟s 
lifetime, or may give rise to several different clinical syndromes including chronic 
stable angina (CSA), acute coronary syndrome (ACS), acute or chronic cardiac failure, 
the development of arrhythmias and sudden cardiac death. Chest pain is a common but 
not universal feature of these coronary syndromes. The type of syndrome experienced 
by a patient depends to a large extent on differences in morphology of atherosclerotic 
plaque. The clinical syndromes of ACS may be caused by one or more of a wide range 
of pathological mechanisms, with atherosclerosis being central or at least contributory 
to most cases.  
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1.2.1. Coronary thrombosis and plaque rupture. 
The pathological mechanism responsible for most cases of ACS is thought to be 
the formation of thrombosis within the arterial lumen adjacent to an atheromatous 
plaque (which may have been silently present for many years), often in response to a 
haemodynamic or inflammatory trigger. Coronary atherosclerotic plaques tend to grow 
outwards into the peri-arterial tissue, an effect termed „arterial positive remodelling‟; 
and often cause no obstruction to the flow of blood along the artery. Sometimes, 
particularly at certain points of haemodynamic stress along the artery, a plaque will 
gradually grow inwards to encroach on the arterial lumen causing a narrowing (stenosis) 
sufficient to provoke myocardial ischaemia on physical exertion: the clinical syndrome 
of chronic stable angina. However, certain types of plaque, often non-stenotic, may 
undergo rapid alterations in structure („unstable‟ plaques) which can induce intra-
arterial thrombus formation. Coronary thrombosis can lead to unstable, rapidly 
progressing or rest symptoms referred to as ACS; or sudden cardiac death. This process 
is discussed in detail by Libby in his 2001 review article. 
Coronary thrombosis causing sudden occlusion of a coronary artery can cause 
death of cardiac myocytes, myocardial infarction (MI). Total thrombotic occlusion of a 
large epicardial artery by thrombus produces the syndrome of ST segment elevation MI 
(STEMI), characterised by sudden ischaemia of a large portion of the myocardium. The 
volume of myocardium under threat depends on the extent of the territory supplied by 
the artery, the relative size and patency of the other major coronary vessels (both of 
which factors are highly variable) and the presence of collateral arterial supply. All 
other types of myocardial infarction are known as non ST elevation MIs (NSTEMI). 
The occurrence of unstable symptoms of myocardial ischaemia in the absence of 
myocardial necrosis is known as unstable angina (UA). 
Coronary thrombosis is a common cause of sudden cardiac death. Burke et al in 
1997 performed post mortem studies of the coronary arteries of 113 men who had a 
sudden unexplained death, all with known stable coronary disease, mean age 50±10 
years. Fresh coronary thrombus was seen in 59 cases. 41 had „plaque ruptures‟: luminal 
thrombus continuous with underlying lipid core; and 18 had „plaque erosions‟: 
thrombus in direct contact with a plaque but without rupture of a lipid pool on serial 
sections. The remaining 54 cases had a coronary artery stenosis of greater than 75% but 
without identifiable thrombus. Unstable plaques are characterised by particular 
microscopic features: there is often a large pool of necrotic, lipid-rich material; there is 
often a thin fibrous cap; and there is often „neovascularisation‟ within the plaque 
associated with plaque haemorrhage. 
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1.2.2. Triggers of onset of ACS 
Coronary atherosclerosis is very widespread in the population, but myocardial 
infarction occurs only in certain individuals and usually infrequently. This has led to a 
search for triggers of rupture of a previously stable coronary artery plaque. In a review 
article on triggers of ACS, Servoss et al wrote in 2002: 
“The association between external triggers and MI onset (relative risk of 2-fold to 
over 20-fold) is well beyond what is to be expected by chance alone, and its magnitude 
is comparable with that of the known long-term risk factors of cardiac disease. In 
aggregate, the known triggers of onset appear to be responsible for at least 20% of acute 
coronary syndromes.” 
In 2011 Nawrot et al performed an analysis of the published data on documented 
triggers of non fatal MI to create a „population-attributable risk‟ for each factor. This 
value was calculated from both the magnitude of the effect of exposure to the factor on 
an individual and its prevalence within the population, and indicates the proportion of 
cases which would be avoided if the risk was no longer present.  In order of decreasing 
magnitude of effect, these factors (population-attributable risk) included traffic 
exposure/air pollution (7.4%), physical exertion (6.2%), alcohol (5%), coffee (5%), 
anger (3.1%), heavy meal (2.7%), cocaine use (0.9%) and respiratory infections (0.6%). 
Cocaine was the factor most likely to trigger an ACS within an individual (probably by 
triggering coronary artery spasm), but traffic exposure has a much greater effect at a 
population level. The included studies were mostly of case-crossover design, which has 
the ability to control for confounding, increasing the strength of the analysis. 
Limitations of the study include the fact that the data for several triggers, for example 
alcohol consumption, were from a single study; and the trigger with the greatest effect, 
traffic exposure, could be considered a composite effect of air pollution and emotional 
stress. 
External triggers of MI are not the same as the risk factors for atherosclerosis, and 
the same factor can have opposite effects on the two processes. For example, sudden 
physical exercise can trigger an MI, yet it has been well established that regular 
moderately strenuous exercise can impede the progression of cardiovascular disease. 
1.2.3. Arterial versus venous thrombosis 
Arterial thrombosis is an essential survival mechanism to prevent exsanguination 
and enable repair of tissue following injury. Coronary thrombosis is an undesirable 
consequence of this mechanism. It has been recognized for over 150 years that the risk 
of thrombosis within any blood vessel is dependent on the three-way interaction 
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between the coagulability of blood, the blood vessel wall and changes in blood flow. An 
ACS may be precipitated by any combination of factors causing any or all of these 
processes. This concept is commonly known as Virchow‟s triad (although not exactly 
described in this way in Rudolph Virchow‟s 1850s work on venous thrombosis and 
pulmonary embolism). His contribution to the understanding of thrombosis is described 
by Kumar et al, 2010. In contrast to venous thrombosis, stasis of blood is not the most 
important factor in arterial thrombosis; nevertheless the concept can still provide a 
framework to outline this complex area. 
1.2.3.1. Coagulability and inflammation 
The coagulability (propensity to clot) of blood is determined by the balance of 
multiple pro- and anticoagulant factors. Platelets are crucial to the formation of arterial 
thrombus, in contrast to venous thrombosis, and bind to each other and to fibrin to 
initiate the formation of an arterial clot. Systemic inflammation has a central role in 
coronary thrombosis: it is associated with platelet activation and with increased blood 
concentration of numerous pro-coagulant factors. Elevation of blood C-reactive protein 
(CRP), a general inflammatory marker, has been well documented to be a marker of 
increased risk in ACS, as discussed by Armstrong et al in 2006. The platelet is central to 
both haemostasis and inflammation.  
Davi and Patrono provide a good summary of the role of platelets in inflammation 
in their 2007 review. The inflammation and coagulation systems are extremely 
interconnected and co-dependent. In experimental models, tissue factor (produced in 
abundance by macrophages in atherosclerotic plaque) is the pivotal initiator of thrombin 
generation in inflammation. On exposure to blood, tissue factor binds to factor VIIa 
creating a structure with an expanded 3-D conformation (Banner et al, 1996) with the 
properties of an enzyme which generates thrombin. Thrombin causes conversion of 
fibrinogen to fibrin but is also the most powerful known trigger of platelet activation. 
Platelet activation causes a positive feedback loop of further tissue factor-mediated 
activation of coagulation, via the expression of P-selectin on platelet membranes. Blood 
P-selectin levels are increased both during acute coronary syndromes and in systemic 
inflammation (Polgar et al, 2005). Platelets are discussed further in Section 1.6. 
Coagulation induces inflammation in other ways. Coagulation proteases 
(thrombin, tissue factor-VIIa complex, factor Xa) bind to protease activated receptors 
(PARs). PARs are G-protein coupled receptors on endothelial cells, mononuclear cells, 
platelets, fibroblasts and smooth muscle cells, which have a variety of pro-inflammatory 
affects. For example, in 2003 de Jonge et al demonstrated that administration of 
recombinant factor VIIa to healthy humans induces a 4-fold rise in plasma IL-6 and IL-
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8, important mediators of inflammation.  There are many causes of systemic 
inflammation in addition to acute infection including surgery, trauma, malignancy and 
autoimmune illnesses, all of which have been shown to be associated with ACS. It is 
possible that some of the triggers of ACS discussed above induce MI by increases in 
inflammation and coagulability, such as tobacco and air pollution. However, the most 
common cause of a systemic inflammatory response is acute infection. 
Acute influenza infection can induce inflammatory changes in atherosclerotic 
plaques in coronary arteries in apolipoprotein E knockout mice which are similar to 
those seen in coronary plaques following fatal MI (Naghavi et al, 2003). Multiple 
prothrombotic changes during infection in humans have been observed, even in 
previously healthy individuals with clinically mild infections. Acute respiratory 
symptoms precede almost one third of ACS cases; there is a 5-7% incidence of ACS in 
patients with pneumococcal pneumonia; and MI is 30% more likely during influenza 
season. As Corrales-Medina et al postulated in their 2010 review, the strength of the 
evidence supports a causal relationship between acute respiratory infection and ACS. 
1.2.3.2. The blood vessel wall in ACS 
Early changes which occur in the vascular endothelium, already described, and the 
interaction of endothelial cells, platelets, smooth muscle cells and macrophages give 
rise to atheromatous plaque formation. Thin-capped atheromata are prone to rupture, 
exposing a highly thrombogenic lipid core which causes platelet adhesion and activation 
(even in fast-flowing arterial blood) and the formation of thrombus and ACS. However, 
there are several types of systemic vasculitis for which there are reports of coronary 
artery involvement and which can cause ACS, including Churg-Strauss syndrome 
(Heleman‟s et al, 1997) and Wegener‟s granulomatosis (Goodfield et al, 1995). 
Systemic vasculitis rarely affects the coronary arteries, with the exception of Kawasaki 
disease (mucocutaneous lymph node syndrome), a disease of young children of 
unknown aetiology with frequent coronary artery involvement leading to myocardial 
infarction and coronary aneurysm formation (Kawasaki et al, 1974; Tsuda 2011). 
An often very aggressive coronary vasculitis is seen after cardiac transplantation, 
termed cardiac allograft vasculopathy, and is the main reason for loss of the graft 
beyond the acute rejection stage. The immune system response has been thought to be 
the principle mechanism behind this – a form of chronic rejection – although transplant 
patients are exposed to many additional sources of potential vascular injury including 
immunosuppressive drugs, hypertension, hypercholesterolaemia and infections. This is 
discussed in a review article by Schmauss and Weis, 2008. 
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An additional plaque-mediated cause of ACS is haemorrhage within the plaque 
due to rupture of micro vessels, a consequence of pathological neovascularisation, 
causing rapid reduction in luminal area of the coronary artery and unstable angina. 
Destabilisation of a plaque due to internal haemorrhage from these abnormal vessels 
may be the trigger for some cases of plaque rupture, particularly when 
neovascularisation occurs close to the arterial lumen as observed by Kato et al, 2012, in 
a study using optical coherence tomography (OCT). It is thought that recurrent micro 
ruptures of fatty plaques cause progressive thickening (sclerosis) of the arterial wall 
resulting in the formation of a stenosis (narrowing), resulting in angina or ACS. 
Another cause of ACS is coronary artery dissection. This can occur spontaneously 
or after trauma but also includes iatrogenic dissection from cardiac catheterisation. 
Haemodynamic shear forces weaken the connection between the different layers of the 
arterial wall, allowing the formation of a false lumen between two of the layers (intima 
and media, or media and adventitia). Arterial blood entering the false lumen causes 
rapid expansion, with consequent rapid contraction of the true coronary lumen, 
provoking an ACS. Spontaneous coronary artery dissection was diagnosed by OCT in 
4% of patients with ACS by Nishiguchi et al, 2013, and was seen more in women, often 
in the absence of traditional coronary risk factors. In addition, ACS can arise if aortic 
dissection extends proximally to involve the coronary arteries. 
1.2.3.3. Changes in blood flow and coronary vasospasm 
Many cases of ACS are triggered by sudden changes in blood pressure and pulse 
rate, such as emotional stress and unusually intense physical exertion.  Arteries are 
highly specialised biological conduits for blood transportation, but the very factors 
which make arteries efficient enough to allow animals to function at a high metabolic 
level (high pressure and rapid blood flow) are a relentless source of injury to the 
delicate, single-layer vascular endothelial cells. The coronary arteries in particular 
experience uniquely powerful haemodynamic forces. For example, the left coronary 
artery is completely compressed during systole and only transmits blood during 
diastole. The heart undergoes rapid changes in morphology during the cardiac cycle, 
including torsion, all of which forces are transmitted to the coronaries as shear and 
stress in a pulsatile fashion. Davies et al (2006) have described in detail coronary blood 
flow (in normal coronary arteries) by pressure wave analysis, describing at least 6 
different pressure waves during the cardiac cycle. Furthermore, the heart has a high but 
very variable oxygen demand and the coronaries have capacity to autoregulate blood 
flow by dilating and contracting.  In 1964 Mosher et al showed that there is a large 
range of perfusion pressures in canine hearts over which coronary flow is relatively 
independent of pressure, although this ability becomes impaired in the presence of some 
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of the risk factors associated with coronary disease such as hypertension (Panza et al, 
1990). 
There is a circadian rhythm in the incidence of MI: a morning peak at 9am and a 
second smaller peak at 8pm. A significant proportion of cardiac events occur during 
sleep: in a literature review of nocturnal acute cardiac events, Lavery et al (1997) found 
the peak incidence of MI occurred from midnight to 1 am, and the peak incidence of 
sudden cardiac death between 1 and 2 am. Furthermore, there is also a weekly (peak 
incidence Monday) and a seasonal (peak in the winter months) variation. These rhythms 
are thought to be due to changes in autonomic nervous system activity during sleep or 
physical or emotional stress which affect blood pressure and coronary tone. 
As described above, endothelial dysfunction with non-physiological 
vasoconstriction is often seen in atherosclerotic coronary arteries. There are also 
endothelium-independent mechanisms for vasoconstriction. Yasue et al in 1986 
demonstrated severe coronary spasm angiographically after administration of 
subcutaneous adrenaline in patients with variant (atypical, Printzmetal‟s or non-
exertional) angina. These attacks could be aborted by phenoxybenzamine (an alpha 
blocker) but not propranolol (a beta blocker); leading to the conclusion that severe 
spasm of coronary arteries mediated by alpha adrenoreceptors was the cause of these 
patients‟ symptoms. Vasospasm can provoke an ACS even in the absence of plaque 
rupture or an obstructive coronary lesion, leading to MI or even sudden death. 
Printzmetal‟s angina, cocaine and several chemotherapeutic agents used in cancer 
treatment (5-fluorouracil and derivatives) can induce severe coronary spasm leading to 
an ACS. Yasue et al also provide a general overview of the condition (1997) 
1.3. Clinical diagnosis and categorisation of ACS  
The term ACS incorporates patients with unstable angina (UA), non ST segment 
elevation (subendocardial) myocardial infarction (NSTEMI) and ST segment elevation 
myocardial infarction (STEMI). The diagnosis is first suspected from the clinical 
history in the presence of typical symptoms supported by the presence of traditional 
cardiovascular risk factors. Ischaemic changes on the electrocardiograph (ECG) support 
the diagnosis, but a normal initial ECG does not exclude it. Over subsequent hours, 
blood is drawn for measurement of cardiac biomarkers. Biomarker negative ACS is 
known as UA; a rise in biomarkers is required to diagnose acute myocardial infarction 
(AMI). 
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1.3.1. The definition of acute myocardial infarction 
The universal definition of MI document (Thygesen et al, 2012) defines AMI 
based largely on the detection of elevation in cardiac biomarkers in conjunction with 
one or more clinical features:  
“Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at 
least one value above the 99
th
 percentile of the upper reference limit (URL) together 
with evidence of myocardial ischaemia with at least one of the following: 
 Symptoms of ischaemia; 
 ECG changes indicative of new ischaemia (new ST-T changes or new left 
bundle branch block [LBBB]); 
 Development of pathological Q waves in the ECG; 
 Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality.” 
The document also provides definitions for 5 different categories of AMI: 
 Type 1: spontaneous MI due to a primary coronary event e.g. plaque 
rupture; 
 Type 2: MI due to increased demand or decreased supply of oxygen; this 
includes “coronary artery spasm, coronary embolism, anaemia, arrhythmias, 
hypertension, or hypotension”; 
 Type 3: sudden cardiac death; 
 Type 4: MI due to PCI. 4a: procedural MI; 4b: stent thrombosis; 
 Type 5: MI associated with CABG. 
1.3.2. Differential diagnosis of ACS; diagnostic uncertainty 
Chest pain is a common complaint with several potential causes. The likelihood of 
the diagnosis being ACS is estimated from the clinical history, ECG and coronary 
angiogram; although even after these diagnostic procedures, the diagnosis can remain 
unclear. Elevation in cardiac biomarkers, with or without cardiac symptoms, is very 
common with the haemodynamic stress induced by acute illness. However, the 
universal definition of MI document makes it clear that these episodes should often not 
be classified as MI. Conversely, we may misclassify chest pain as ACS, particularly if 
incidental coronary disease has been demonstrated by angiography. 
1.3.3. Clinical history 
Cardiac ischaemia may be asymptomatic (silent) or induce a range of symptoms 
which often includes discomfort in the upper body, known as angina pectoris. This pain 
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may originate from the local release of adenosine in response to myocardial hypoxia 
(Crea et al, 1990). Chest pain which is located retrosternally, is crushing in nature and 
has a distinct pattern of radiation (arms, jaw) is known as classical cardiac chest pain; 
pain of a possible cardiac origin which does not share these features is known as 
atypical. In a study of 903 patients admitted with suspected AMI, Everts et al (1996) 
showed that pain can be distributed anywhere over the chest, back, neck and arms; the 
distribution of cardiac pain tends to be wide rather than localised; and the most sensitive 
discriminator for MI was pain in the right arm. Silent ischaemia is common in diabetes, 
possibly due to diabetic neuropathy of afferent nerve fibres, but is also common in non-
diabetic patients with coronary disease (Deedwania et al, 1991). 
Patients may also present with other symptoms such as dyspnoea, nausea and 
syncope, with or without anginal pain. 
1.3.4. The Electrocardiogram 
Electrocardiography was invented by Willem Einthoven who published a report of 
his discovery in 1902. The story of the development of electrocardiography is told in 
detail (and very well) by Fye, 1994; today the electrocardiogram (ECG) is central to the 
initial assessment of any patient with chest pain. All emergency medical personnel are 
trained to obtain and interpret an ECG trace. ST segment elevation on the ECG occurs 
due to acute proximal occlusion of a major epicardial coronary artery and is an 
indication for emergency revascularisation therapy. Dynamic ST segment depression 
implies ischaemia or subendocardial infarction; these ECG changes often resolve 
rapidly following initial medical therapy, in which case immediate revascularisation 
may be deferred (ESC Guidelines for the management of acute coronary syndromes in 
patients presenting without persistent ST-segment elevation, 2011, Hamm et al; ESC 
guidelines for the management of acute myocardial infarction in patients presenting 
with ST-segment elevation, 2012, Steg et al). 
1.3.5. Cardiac biomarkers 
Cardiac biomarkers are molecules whose presence (above a prespecified normal 
reference range) in the bloodstream indicates myocardial injury. Numerous different 
blood tests to detect a range of cardiac biomarkers have been developed, from aspartate 
aminotransferase reported by Karmen et al in 1954, to cardio-specific creatine kinase 
(CK-MB), to modern highly sensitive troponin assays. Troponins  (Adams, 1993) are 
large protein fragments released after cell membrane breakdown of necrotic 
cardiomyocytes, a process taking several hours; a delay of 12 hours from onset of chest 
pain to drawing of the blood sample is required to definitely „rule out‟ MI, as per the 
ESC guidelines. Blood levels can take weeks to return to baseline following an MI. 
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A novel cardiac biomarker, human fatty acid binding protein (H-FABP), is a small 
molecule which is rapidly detectable in blood after myocardial ischaemia, even in the 
absence of cell necrosis (Glatz et al, 1998). It is released into the bloodstream more 
rapidly and in greater quantity than other cardiac biomarkers, being detectable within 
minutes rather than hours. 
The effective use of a biomarker requires a reliable assay. Assay precision may be 
measured using a value known as the coefficient of variation (the ratio of the standard 
deviation to the mean value) for a molecular concentration of biomarker at the level of 
99
th
 centile of the normal range of a healthy population. The Universal Definition of MI 
document recommends the use of assays with a coefficient of variation of less than 10% 
at the 99
th
 centile. Highly sensitive troponin assays, the current „gold standard‟ in the 
diagnosis of MI, should have at least this level of precision. 
1.3.6. Coronary angiography  
Coronary angiography is an invasive radiological procedure for examination of the 
coronary arteries, first credited to Proudfit et al in 1966. The Seldinger technique 
(Seldinger, 1953) is used to introduce a catheter into the arterial system, common entry 
points being the femoral or radial arteries. Selective intubation of the right and left 
coronaries allows injection of radio-opaque contrast agent during which multiple frames 
are acquired in rapid succession (15 to 30 frames per second). After computer generated 
post-processing a black and white movie is produced of the opacification of coronary 
artery lumen; it is therefore more accurate to call this procedure „lumenography‟. 
Although this term is seldom used routinely it emphasises the fact that the image 
produced is only an outline of the lumen of the vessel. A lumenogram is two 
dimensional, but multiple angiograms in different planes are obtained by changing the 
projection of the image intensifier so that stenoses which are eccentric or hidden behind 
branches are not missed. The cardiologist records the approximate severity (usually 
expressing it as a percentage luminal compromise) and location of the stenoses. 
Broadly, the number and severity of stenoses and how proximally they are located are 
the main determinates in the decision to recommend medical management or 
revascularisation by either CABG or PCI, as discussed in the following section. A 
„normal‟ coronary angiogram does not exclude the presence of extraluminal coronary 
disease. 
1.4. Treatment of ACS 
National cardiology societies have collaborated to produce detailed and 
comprehensive international guidelines which are frequently updated in accordance 
with emerging research results. Management of ACS is detailed separately in European 
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and American guidelines. The latest European guidelines on myocardial 
revascularisation were produced jointly by representatives from European Society of 
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery 
(Windecker et al, 2014). 
In brief, contemporary management of ACS begins with the rapid initiation of 
strategies intended to relieve symptoms, to abort imminent death, to treat arrhythmias 
and to avoid or at least limit the extent of myocardial infarction. All patients are 
administered a range of pharmaceutical agents. Ventricular fibrillation and tachycardia 
are treated by D.C. cardioversion; bradycardia may require may require pacing. Selected 
patients will undergo myocardial revascularisation by either PCI or CABG.  
Longer term management consists of managing residual ischaemic symptoms, 
psychological support and „secondary prevention‟, involving strategies to prevent future 
cardiovascular events. In addition to pharmacological therapy, patients undergo „cardiac 
rehabilitation‟ intended to restore/improve exercise capacity and encourage appropriate 
lifestyle modifications. 
1.4.1. Pharmacology 
Patients receive an evidence-based combination of medication including 
analgesics, antiplatelet agents, anticoagulants, vasodilators, ACE-inhibitors, beta-
blockers and HMG-CoA reductase inhibitors („statins‟). Pharmacology at the time of 
PCI is discussed further in Section 1.5.5. Adequate antiplatelet therapy in particular is 
crucial to a successful outcome following PCI and antiplatelet agents are discussed 
further in Sections 1.6 to 1.8. 
1.4.2. Invasive investigation and revascularization  
It is recommended that the majority of patients with ACS undergo invasive 
investigation (a coronary angiogram) soon after presentation, leading to coronary 
revascularisation where indicated. There are two complementary methods of coronary 
revascularisation: CABG and PCI. 
The first method of revascularization to be developed was coronary artery bypass 
surgery (CABG), and the first operation on a human being was carried out in the USA 
in 1960 (Goetz et al, 1961). CABG is a major undertaking requiring sternotomy and 
cardiopulmonary bypass, with considerable risk of morbidity and a recovery period of 
weeks to months. The risk is highest in the presence of co-morbidities; each patient‟s 
risk profile is often formalised by applying a risk score such as the EuroSCORE 
(Section 1-5-4-1). In ACS patients who are haemodynamically stable and pain–free, 
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with complex anatomy thought to be more suitable for CABG than PCI, 
revascularisation may be delayed to allow adequate planning, multidisciplinary team 
discussion and further investigations if required. Certain patterns of disease including 
multiple long and/or complex lesions, left main disease and chronic total occlusions 
(CTO) are preferentially revascularised surgically. 
PCI (Section 1-5) requires less planning than CABG, can usually be undertaken 
rapidly and has overtaken CABG to become by far the more frequent method of 
revascularisation for ACS patients. PCI is a minimally invasive method of 
revascularization which has been developed using coronary angiography catheters to 
introduce balloons into the coronary arteries to widen the lumen (angioplasty). Any 
technique to treat coronary artery disease with catheter technology via peripheral 
arteries is currently known as percutaneous coronary intervention (PCI) (formally 
percutaneous transluminal coronary angioplasty, PTCA). When the coronary anatomy at 
angiography reveals one or more culprit lesions thought suitable for PCI, the operator 
may proceed directly to intervention at the same sitting. This is known as „ad hoc‟ PCI 
and is recommended for patients with ACS.  
STEMI is an indication for immediate revascularisation. Previously this was 
achieved by administration of an intravenous thrombolytic agent, but a high failure rate 
of this therapy led to development of 24 hour cardiac catheterisation services capable of 
providing primary PCI (PPCI). 
 
1.5. Percutaneous Coronary Intervention (PCI) 
1.5.1. Brief history of PCI 
PCI was first performed on a human being in 1977 (reported in a letter to The 
Lancet in 1978) in Switzerland by a team led by Andreas Gruntzig. Initially the 
technique involved balloon angioplasty alone (plain old balloon angioplasty, or POBA). 
Subsequently, balloon-expanded stents were invented to provide a scaffold to prop the 
artery open following angioplasty, reducing the incidence of the two problems of abrupt 
vessel closure and restenosis. Bare metal stents (BMS) were first used in humans in 
1986 in France. Puel reported the first cases in 1987, published in French; Sigwart then 
published a series of (presumably the same) cases later in 1987 in the English language. 
The first drug eluting stent (DES), the Cypher sirolimus-eluting stent, was approved in 
Europe in 2002. A history of the development of percutaneous coronary stent insertion 
is provided by Iqbal et al, 2013. 
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Stent technology is continually evolving. The most commonly used DES at the 
time of writing is the Xience everolimus-eluting stent (Abbott Vascular, U.S.A.), but 
even this single brand has now been produced in several different versions. The Xience 
V stent was comprised of a metallic scaffold, a polymer compound which coats the 
struts and a drug-containing compound which „elutes‟ a cell division inhibiting agent. 
The stent struts are only 0.0032 inches (0.081 mm) thick and made of a complex alloy 
mainly composed of cobalt, chromium, nickel and tungsten. The stent is coated with 
poly n-butyl methacrylate (PBMA), a polymer that adheres to the stent and drug 
coating; and the drug coating is known as PVDF-HFP, which is comprised of 
vinylidene fluoride and hexafluoropropylene monomers. This latter compound is mixed 
with everolimus, a semi-synthetic cell division inhibiting drug derived from sirolimus. 
This stent was investigated in the SPIRIT series of trials, in which clinical superiority 
over an earlier drug-eluting stent was seen (SPIRIT IV, Stone et al, 2010). 
1.5.2. Current indications and guidelines for PCI 
Detailed and comprehensive international guidelines, already discussed in Section 
1-4, are available which advise on all aspects of coronary revascularisation. Advances in 
technology and pharmacology and the rapid dissemination of new data require 
increasingly frequent guideline updates to remain in line with emerging evidence. Stable 
angina is managed differently to ACS. In the former, the emphasis tends to be on 
symptom control and there is less urgency to embark on invasive investigation and 
revascularisation. In the latter, early invasive investigation and revascularisation is 
encouraged. This has been reinforced by data (notably from the COURAGE trial, 
Boden, 2007) which indicated that PCI may not be a superior treatment to medical 
therapy in patients with stable coronary disease, contrary to the case for CABG which, 
in the original trials of the 1970s and 80s, was shown to have a mortality benefit in 
certain patient groups such as those with multivessel disease in combination with LV 
dysfunction (Yusuf, 1994). 
That PCI in contemporary studies often fails to produce a clear mortality benefit is 
of concern and has led to much questioning of current interventional practice; but the 
interpretation of trial data is not straightforward. Overall mortality in IHD has decreased 
dramatically in recent years (Smolina et al, 2012) probably due to a combination of 
many improvements to treatment: revascularisation, novel pharmaceutical agents, 
improved infrastructure to provide emergency healthcare and the invention of 
implantable defibrillators. This low death rate makes achieving statistical significance in 
randomised studies difficult. Furthermore, high risk patients such as those with critical 
angiographic lesions, unstable symptoms or a large volume of ischaemic myocardium 
on a functional test are unlikely to be placed into trials in which they may be 
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randomised to medical therapy without revascularisation – such a trial would be 
unlikely to gain ethical approval – leading to selection bias. Therefore, the number of 
PCI cases continues to rise in spite of these apparent gaps in the published evidence; but 
two thirds of cases are now performed to treat ACS rather than stable angina (National 
Audit of PCI, British Cardiac Intervention Society, 2014). 
1.5.3. Determining the culprit lesion in acute coronary syndromes 
It does not always follow that an angiographically severe lesion is responsible for 
an ACS. Sometimes an isolated lesion in a coronary artery will be identified which 
corresponds with the distribution of the ECG changes and has signs of acute rupture, for 
example visible thrombus. The diagnosis and management become straightforward in 
these circumstances. However, angiography often cannot distinguish between 
atherosclerosis which is stable (histologically, predominantly fibromuscular or 
fibrocalcific) and which is acute (ruptured thin fibrous plaque overlying a lipid pool) or 
„vulnerable‟ – with a high risk of future rupture. There are many confounding factors: 
the presence of multiple lesions, any or all of which may be unstable; a lack of 
localising ECG changes; or the unstable lesion may not be angiographically severely 
stenotic. This is discussed in detail in a review by Waxman et al, 2006. The merits of 
PCI to culprit lesions only vs. treating all lesions are currently being investigated 
(PRAMI and CULPRIT trials; Wald et al, 2013 and Gershlick et al, 2015). 
Work is currently being undertaken to develop methods of highlighting areas of 
vulnerable plaque, for example by intravascular ultrasound (IVUS) and „virtual 
histology‟, in the hope of more targeted therapy. Virtual histology has been used to 
demonstrate both the progression and regression of coronary lesions (Kubo et al, 2010). 
Angioscopy, a research technique in which a small camera is percutaneously inserted 
into the coronary artery lumen, can distinguish vulnerable high-lipid content coronary 
plaques, which appear yellow, from stable plaques which appear white. Angioscopically 
yellow plaque, shown to have a thin fibrous cap and large underlying lipid pool, is 
known to be associated with a higher rate of clinical events. Asakura et al in 2001 used 
this technique to examine 32 patients 1 month post PCI for STEMI. All patients had 
widespread disease and yellow plaque was seen in all three major coronary arteries. 
Most culprit plaques had associated thrombus. 
IVUS virtual histology has yet to be validated, and angioscopy is technically 
challenging and increases the procedural risk. In the absence of technology to routinely 
identify acutely inflamed plaque, the current guidelines recommend revascularisation of 
obstructive proximal lesions with at least 70% stenosis, or at least 50% if the lesion is 
located in the left main stem (LMS). It is known that stable patients are less likely to 
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benefit from revascularisation in the absence of objective evidence of inducible 
myocardial ischaemia. If required, the functional significance of a stenosis can be 
determined by pressure wire assessment before proceeding to PCI; the FAME I study 
showing the benefits of fractional flow reserve included a proportion of ACS patients 
(Tonino et al, 2009). 
1.5.4. Risk scoring systems to guide revascularisation 
Many risk scoring systems are available in cardiology. For example, the TIMI and 
GRACE risk scores (both available as online calculators) were devised to allow risk 
stratification of ACS patients to help decide the management strategy. These scoring 
systems are used widely for research purposes and have been validated for prognosis 
following ACS (Antman, 2010; Elbarouni, 2009). They have not been generally 
adopted in contemporary day-to-day practice, where the main objective factors used to 
determine treatment are the ECG, Troponin level and clinical status of the patient. Other 
scoring systems have been created to estimate the risk posed by a revascularisation 
procedure, and in contrast to the above, are frequently used in routine clinical practice. 
Two of these, the EuroSCORE and the SYNTAX score, are discussed below. 
1.5.4.1. Clinical risk scoring: the EuroSCORE. 
The EuroSCORE (Nashef et al, 1999) was developed from registry outcome data 
to predict the risk of in-hospital mortality following CABG. The score is calculated 
from the results of 17 readily available variables including age, significant past medical 
history and clinical presentation. Additive and logistic versions are available. Bhatti et 
al (2006) found that the logistic score was a reasonable predictor of death after CABG, 
although overestimated the risk; area under ROC 0.79; predicted mortality 5.7% and 
observed mortality 3.3% in 9995 patients. EuroSCORE has also been validated as a 
predictor of long term outcomes following PCI. 
The EuroSCORE in the UK and Ireland is recorded for all patients undergoing 
surgical revascularisation and the statistics are available to the public (Society of 
Thoracic Surgery of Great Britain and Ireland). Between 2004 and 2008, information on 
112251 operations for isolated coronary disease was analysed. 94764 (84.4%) of these 
were performed on patients in EuroSCORE group 0 to 5.9%; 9339 (8.3%) had a 
EuroSCORE over 10%. This indicates that estimated surgical risk (formalised as a 
EuroSCORE) of patients with severe coronary disease is crucial to the decision as to 
whether they are accepted for surgery. Many surgical turn-downs probably go on to 
have PCI, but we do not have data to support this, as there is no formal method for 
tracking these patients: surgical turndown patients are not recorded in surgical 
databases; EuroSCORE is not routinely recorded in PCI databases; „surgical turndown‟ 
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is never formally listed as a PCI indication in databases; and no PCI verses CABG 
outcome studies focusing on EuroSCORE have been undertaken. 
Logistic EuroSCORE is comprehensive, but there are many other factors which 
can lead to the surgeon turning a patient down. Efforts to incorporate some of these in 
the score have led to the release of EuroSCORE II in 2012 (Nashef et al), which 
features several additional fields: DM, poor mobility (a general marker of frailty and 
poor prognosis), and renal function as a continuous rather than a dichotomous variable. 
The scale has also been adjusted to be more representative of current surgical mortality 
rates. 
1.5.4.2. Angiographic risk scoring: the SYNTAX score 
The EuroSCORE does not include information on angiographic complexity, which 
is important in predicting outcomes after PCI. Lesion characteristics influence both 
procedural success and future prognosis (Yadav, 2013). Outcomes are worse with 
increasing number and length of stenoses requiring treatment, smaller vessel diameter, 
and the presence of diffuse disease, tortuosity, bifurcations, calcium and thrombus. The 
SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) trial was a 
randomised comparison of outcomes after revascularisation of patients with severe 
coronary disease treated by either CABG or PCI (Taxus stents). The SYNTAX score 
was developed from this trial.  
The SYNTAX score is derived purely from assessment of the coronary 
angiogram. Angiographic reporting is subjective and there is substantial inter-interpreter 
variability. Nevertheless, terciles of SYNTAX score have been shown to predict 
outcome after PCI (Serruys a and b, 2009). In contrast, lesion complexity proved 
relatively unimportant with regard to CABG outcomes, providing there is a reasonable 
calibre distal target vessel to which a graft can be anastamosed. These patients were 
representative of the normal CABG population, with mean (SD) EuroSCORE of 3.9 (± 
2.9). One third of patients had severe LMS disease, and the other two thirds had severe 
3 vessel coronary disease (3VD). 
There is now data to 4 years for this trial, which was separated into LMS and 3VD 
cohorts for presentation at the Transcatheter Cardiovascular Therapeutics conference in 
2011. In the LMS disease group overall, the PCI patients fared slightly worse than the 
CABG patients in every outcome other than stroke; however, there was no difference in 
MACCE between the two revascularisation methods for LMS disease patients in the 
bottom two SYNTAX terciles (SYNTAX 0 to 22 and 23 to 32), with a big difference in 
MACCE in the top tercile (over 33) of 42.6% versus 26.3% for PCI and CABG 
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respectively. In the 3VD group, all SYNTAX terciles did worse with PCI than with 
CABG, although this difference was not statistically significant in the lower tercile. 
Interpretation of these results should be done with caution, as analysis of subgroups of 
subgroups is hypothesis generating only; however, this is the most comprehensive and 
contemporary data available in this area. 
1.5.5. Adjunctive pharmacotherapy 
The safety of PCI has been greatly increased by a number of pharmacological 
agents, both during and after the procedure. 
Anticoagulation 
Anticoagulation is used in every PCI case for the prevention of thrombus 
formation on angioplasty equipment. This is usually achieved by the administration of a 
weight-adjusted bolus of heparin at the start of the case, which may be topped up 
according to the ACT result. Low molecular weight heparins have been shown to be 
non-inferior to unfractionated heparin. The direct thrombin inhibitor, bivalirudin, has 
been approved for use as an anticoagulant during PCI in patients with ACS. This drug 
was developed to overcome some of the limitations of heparin such as unpredictability 
of response, heparin-mediated platelet activation and heparin-related thrombocytopenia. 
Trials in ACS patients have shown reduced rates of cardiovascular events and bleeding 
compared to heparin, although a more recent trial in STEMI patients showed high acute 
stent thrombosis rates (Shahzad, 2013). Anticoagulation in PCI is reviewed by Rao and 
Ohman, 2010. 
Antiplatelet agents 
All patients are pre-loaded with drugs which inhibit platelet activation and 
consequently the formation of platelet thrombus. These drugs are vital to prevent stent 
thrombosis during and after PCI, particularly in ACS patients in whom thrombus is 
already present. The agents with the most powerful antiplatelet effect are the 
intravenous IIb IIIa inhibitors. This subject is explored further in Chapter 3. 
Other medication  
Local anaesthetic, sedatives and opiate analgesic agents are used to limit 
discomfort during PCI, which is undertaken without general anaesthetic. Vasodilators 
such as nitrates, adenosine and verapamil may be used at various stages of the 
procedure. Antimuscarinic agents can be employed to correct bradycardia induced by 
autonomic disturbance, particularly a problem during right coronary artery PCI. 
Inotropic agents are used in cardiogenic shock. 
- 26 - 
1.5.6. Complications of PCI: early 
PCI, in common with all invasive procedures, has a range of potential 
complications. These may be loosely categorised into peri-procedural (complications 
occurring during or shortly after PCI but before discharge) and post-procedural, usually 
occurring after discharge home. Most PCI clinical trials now use standardised 
definitions for reporting adverse events during the clinical follow up period. The 
Academic Research Consortium (ARC) (Cutlip et al, 2007) definitions for clinical 
endpoints are now used in clinical research when possible. 
1.5.6.1. Peri-procedural complications 
The common or serious peri-procedural complications are listed on the patient 
consent form. They occur during the procedure or early after it. 
1.5.6.2. Procedural myocardial infarction, „no-reflow‟ and acute stent 
thrombosis 
Myocardial necrosis following PCI is frequent and may be of sufficient magnitude 
to induce permanent loss of myocardium detectable by cardiac magnetic resonance 
imaging (MRI); these studies are cited by Lansky and Stone in their 2010 review article 
on periprocedural MI. In 2005 Herrmann analysed 60 studies detailing procedural 
myocardial necrosis, excluding ACS patients. Post-procedural elevation above the upper 
limit of normal of CK-MB mass, troponin T, and Troponin I was found in 0 to 47%, 7% 
to 69%, and 5% to 53% (mean 23% ± 12, 23% ± 11, and 27% ± 12) of patients, 
respectively. Nearly all the studies showed an association between procedural 
biomarker elevation and future risk of adverse cardiovascular events. However, many 
baseline characteristics associated with procedural MI, such as lesion complexity, were 
also associated with long-term outcome. This clearly leads to confounding in such 
observational studies. 
The Universal Definition of MI document defines a separate category for 
procedural MI: type 4a. By “arbitrary convention”, the biomarker cut off is an increase 
in cardiac biomarker of more than three times the 99
th
 percentile of the upper reference 
limit in a healthy population. The definition does discriminate between biomarkers of 
differing sensitivity – for example, more MIs would be diagnosed using troponin than 
CK-MB. The U.S.A. 2011 revascularization guidelines (Levine et al) recommend 
testing for procedural MI in patients with signs or symptoms of MI, or after a significant 
persistent angiographic complication (class I level C recommendation); and routine 
monitoring of all patients “may be reasonable” (class IIb, level C). Troponin I, Troponin 
T or CK-MB may be used. The latest European revascularisation guidelines (2014) do 
not appear to discuss procedural biomarker elevation. 
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Although many studies have shown an association between procedural myocardial 
necrosis and adverse outcome, there has been little to suggest a causal relationship. The 
value of screening for procedural MI in ACS patients (who often have elevated 
biomarkers pre-procedure, and who now make up the majority of PCI cases) is 
particularly uncertain, as it is difficult to distinguish the proportion of biomarker from 
iatrogenic myocardial injury from that produced by the spontaneous MI. Miller et al in 
2006 found that pre-procedural, not post-procedural, troponin elevations influenced 
prognosis. Another contentious issue is how to manage the patient when procedural MI 
is diagnosed. For these reasons, procedural MI is not routinely monitored in many 
institutions, except in clinical trials where it often forms an important component of 
combined clinical end points. 
There is some evidence to show that procedural MI may have independent 
prognostic importance. The frequency of peri-procedural MI in the TRITON-TIMI 38 
trial (Wiviott et al, 2007), which tested prasugrel against clopidogrel in ACS patients, 
was 600/13608 = 4.4%. After adjustment for clinical characteristics, peri-procedural MI 
was associated with a 3.2% increase in the risk of cardiovascular death at 180 days, 
P=0.001. Rigorous criteria to define peri-procedural MI were used in this study, whose 
design preceded the publication of the universal MI document. Events were mostly 
identified using CK-MB, requiring a value 3 times the upper reference limit on 2 
samples after PCI, or 5 times on a single sample within 48 hours of PCI. In addition, 
because this was a study of ACS (82% of TRITON patients had elevated biomarkers 
pre-PCI), for patients who were biomarker positive the biomarker had to be shown to be 
falling pre-procedure AND had to rise to >50% of the pre-procedural nadir to make the 
diagnosis. Therefore, procedural MI rate may have been underestimated according to 
universal definition of MI criteria. 
The cause of most cases of low level myocardial necrosis in PCI is thought to be 
coronary micro-embolisation of particles of thrombus and atheromatous debris (Heusch 
et al, 2009), although other potential causes include procedural complications such as 
trapped side branches and no-reflow. Herrmann et al summarised known predictors of 
procedural MI into patient-, lesion- and procedure-related factors. Patient factors 
include advancing age, DM, LV dysfunction, renal failure and multi vessel disease. 
Lesion related factors associated with procedural MI include the presence of thrombus, 
saphenous vein graft (SVG) PCI and American Heart Association (AHA) Type C 
lesions. Procedural factors include the level complexity and the occurrence of 
procedural complications such as side branch occlusion, embolisation of atheromatous 
or thrombotic material to distal branches, and loss of a coronary vessel due to 
dissection. 
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There is evidence to show that procedural MI is more likely in patients with high 
platelet reactivity. Patti et al in 2008 found higher procedural MI with increasing PRU 
measured with the Verify Now device in 160 patients receiving clopidogrel prior to 
PCI: mean PRU levels were 258 ± 53 in patients with peri-procedural MI verses 219 ± 
69 in patients without; P = 0.03. These procedural MIs were based on CK-MB > 3x the 
ULN; there was in fact no statistically significant variation in post-procedural troponin 
based on PRU level in this study. 
It has been postulated that there are more subtle causes for periprocedural 
myocardial necrosis than mechanical obstruction of the vessel during PCI. A potential 
cause of procedure-related procedural MI is „no-reflow‟, a poorly understood 
phenomenon in which there is poor circulation of blood through the microvasculature 
but in the absence of macroscopic obstruction. Chan et al (2012) found this 
complication in 4.8% of 5286 of patients, mostly transient. No-reflow was a predictor of 
30 day major adverse clinical events, odds ratio 2.79 (95% confidence interval 1.84 to 
4.25), P<0.001. No-reflow is unlikely to be due only to micro-vascular obstruction as 
described by Niccoli et al, 2009. It may also be related to „reperfusion injury‟, explained 
in a review article by Yellon and Hausenloy, 2007. This is another poorly understood 
process in which restoration of arterial flow in an MI causes further myocardial 
infarction, ischaemic endothelial cell damage and microcirculatory dysfunction. 
A specific type of peri-procedural MI due to definite macroscopic mechanic 
obstruction of the artery is acute thrombosis of the newly implanted stent, classified as 
MI type 4b in the universal MI document. Thrombosis can occur at any point during or 
after the procedure; however, ST before the end of the procedure is not a complication 
according to ARC definitions. Complete thrombotic occlusion of the stent causes chest 
pain accompanied by ST segment elevation on the ECG. It may result in further 
myocardial necrosis, but prompt reperfusion can usually be achieved by a repeat PCI 
procedure. Due to the combination of peri-procedural anticoagulant and antiplatelet 
medication, acute ST is rare; for example, Kuchulakanti et al (2006) reported only 5 
cases of acute ST in 2574 (0.19%) patients within 24 hours of 1
st
 generation DES 
implantation. In patients who have not been preloaded with antiplatelet medication with 
a high coronary thrombus burden, such as primary PCI for STEMI, acute ST may be 
more frequent. In a recent study by Shahzad et al (2014) acute ST was seen in 2.9% of 
905 PPCI patients treated with bivalirudin (the rate was only 0.9% in the heparin arm). 
Subacute ST (> 24 hours, < 29 days) is discussed further in Section 1.5.7.3. 
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1.5.6.3. Stroke 
In the setting of PCI, stroke can occur due to embolisation to the brain of 
atheromatous material or thrombus which becomes dislodged by the procedure, and is a 
particular hazard in cases with a large volume of proximal coronary artery thrombus. 
There is also the potential for formation of thrombus on intravascular angioplasty 
equipment, although minimised by the use of anticoagulants. Less commonly, stroke 
can occur due to cerebral haemorrhage precipitated by anticoagulant and antiplatelet 
medication, and particularly by thrombolytic therapy. 
In stable patients undergoing PCI, the rate of peri-procedural stroke is low but 
associated with high mortality. From a 2009 analysis of 706,782 patients from the multi 
centre National Cardiovascular Data Registry (U.S.A.) by Aggarwal et al, the incidence 
of in-hospital stroke after PCI was 0.22%. After multivariate analysis, factors strongly 
associated with stroke included a previous history of cerebrovascular disease, older age, 
admission with an ACS, and use of an intra-aortic balloon pump. Peri-procedural stroke 
patient in-hospital mortality was 30 times higher than in non-stroke patients. This study 
did not detail whether strokes were due to haemorrhage or infarction. However, 
Hoffman et al (2012) analysed stroke following PCI in another North American registry 
of over 20 000 patients from a single centre over 19 years was. The in-hospital 
cerebrovascular event rate was 0.37%; major predictors were age and previous stroke, 
but patients had also undergone more complex procedures and rotational atherectomy. 
Of these cases of stroke 7% were haemorrhagic. 
1.5.6.4. Coronary perforation and rupture 
Loss of integrity of the coronary arterial wall may occur during PCI, detected by 
observing the extravasation of contrast during angiography. A perforation may be 
localised to the peri-arterial tissue, or may result in a leak of blood from the coronary 
artery into the pericardial space, which can cause rapid loss of cardiac output (cardiac 
tamponade). Proximal perforations may leak into the thoracic cavity and can cause 
hypovolaemic shock. 
While small, self-limiting perforations with or without localised contrast staining 
(perforation types I and II) may be reasonably common (up to 3%), frank coronary 
rupture (type III) is extremely rare. Analysis of prospectively collected data from two 
institutions on 24465 interventions over a 16 year period (Al-Lamee et al, 2011) 
detected only 56 cases. 28.6% had tamponade requiring pericardiocentesis with a 14.8% 
in-hospital death rate. Ruptures in this series were sealed by a variety of methods 
including prolonged balloon inflation, deployment of a stent (standard or covered), 
emergency CABG and in one case coil embolisation. 
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1.5.6.5. Damage to the peripheral vascular system and haemorrhage 
Complications relating to the vascular access site are not infrequent in PCI, 
particularly when access is via the femoral artery. Ohlow et al (2009) found an 
incidence of arteriovenous fistula formation and pseudoaneurysm formation of 0.6% 
and 1.2% respectively in 18165 consecutive femoral access cases. Most of these cases 
could be treated conservatively and neither complication appeared to be associated with 
increased mortality. 
Arterial bleeding following PCI is a more important complication - major bleeding 
after PCI has been associated with increased mortality, although whether this is cause-
and effect or whether bleeding is just a general marker of high risk in a patient is 
unclear (Doyle et al, 2009). Note that bleeding complications are reported in multiple 
different ways by different trials; Bleeding Academic Research Consortium (BARC) 
definitions (Mehran et al, 2011) have been devised in an effort to standardise reporting. 
Bleeding may occur via the puncture site, from the GI or GU tracts, intracerebrally and 
intraocularly. 
External puncture site bleeding is obvious and can be quickly identified and 
usually stopped by compression. However, femoral procedures can be complicated by 
the more insidious retroperitoneal haemorrhage, sometimes with huge loss of blood into 
the retroperitoneal space requiring blood transfusion and surgical repair. Efforts to 
devise strategies to minimise bleeding have resulted in a recent change from femoral to 
radial access: radial artery haemorrhage tends to be small volume and easy to stop. In a 
2008 report from Rao et al on data from 593 094 PCI cases from the U.S.A. National 
Cardiovascular Data Registry, total bleeding (including access site bleeding, 
retroperitoneal bleeding, gastrointestinal bleeding, genitourinary bleeding, or other 
bleeding) complicated 1.83% of femoral procedures, but only 0.79% of the radial access 
procedures (only 1.32% procedures were radial). 
1.5.6.6. Allergy 
Although unusual with modern contrast agents, allergic reactions including 
anaphylaxis may occur. Patients who are prone to allergy or who have had a previous 
contrast allergy may still undergo angiography if they are pre-treated with antihistamine 
and corticosteroid. Patients may also of course be allergic to any of the antiplatelet or 
other medications they are administered for PCI.  
1.5.6.7. Acute renal failure 
Most cases of post-procedural renal failure occur at 3 to 5 days and are the result 
of contrast nephropathy (Persson et al, 2005). The 2 main risk factors for this are pre-
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existing renal impairment and the volume of contrast administered. The risk can be 
limited by pre-and/or post-hydration with intravenous fluid, and by limiting the volume 
of contrast administered. Modern intra-arterial contrast agents are solutions of iodine 
which may be bound as an ionic or non-ionic (organic) compound; the latter have lower 
osmolality than the former. The incidence of nephropathy has been reduced by the use 
of non-ionic contrast agents (Rudnick et al, 1995); available molecules include 
iopromide (Ultravist 370 TM); and iodixanol (Visipaque 320 TM). Iodixanol has an 
osmolality of 290 mOsm/kg H2O, which is the same as blood (iso-osmolar). 
More rarely, the kidneys can be damaged by embolisation of lipid particles, often 
accompanied by a necrotic rash on the lower limbs. 
1.5.7. Complications of PCI: Late 
These are complications due to problems with the stent or concomitant medical 
therapy occurring after the immediate recovery period. 
1.5.7.1. Bleeding 
The increased risk of bleeding continues after PCI for the duration of antiplatelet 
therapy, as does the apparent association between bleeding and increased risk of other 
adverse clinical events. In a report from the E-SELECT post marketing surveillance 
registry of outcomes after SES stent implantation, in 15400 subjects the rate of major 
bleeding (STEEPLE criteria) was 1% at one year and had a 10% mortality rate, 
compared to 1.7% mortality for patients without bleeding (Urban et al, 2011). Note that 
patients at high risk of bleeding may not have had a DES implanted and so may be 
under-represented in this registry. Advancing age, use of warfarin and use of IIbIIIa 
inhibitors correlated with the occurrence of major bleeding. 
1.5.7.2. Radiation damage 
PCI requires the use of ionizing radiation which can cause predictable, dose-
related skin damage, from mild erythema to full thickness necrosis. There are also long 
term stochastic (unpredictable) effects, such as a probable increased risk of cancer 
(Pierce and Preston, 2000). A true picture of the negative effects of medical radiation is 
difficult to realise, as most of our information comes from nuclear bomb blast survivors. 
In the U.K. Ionizing Radiation (Medical Exposure) Regulations (IRMER) require that 
radiation dose („effective radiation dose‟ calculated using body surface area; 
McCollough Schueler, 2000) is monitored and procedures are usually stopped before a 
prespecified threshold which varies between departments. 
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1.5.7.3. Sub acute, late and very late stent thrombosis 
Thrombotic occlusion of a stent more than 24 hours after insertion is a serious 
post-procedural complication associated with a high rate of death. Sudden thrombotic 
occlusion of a coronary stent is an uncommon but frequently devastating complication 
of PCI. In contrast to the other major post-discharge complication of PCI, restenosis, ST 
has an important negative impact on survival (Urban et al, 2011). ST can occur at any 
time after the procedure, from hours to years. I will describe the risk factors for, 
incidence and sequelae of ST which have been reported in the literature. 
The main problem encountered with the first stents was early re-occlusion. This 
was observed from the outset of PCI (Serruys et al, 1991) with early series reporting a 
rate of early abrupt vessel closure of 25%. It was rapidly recognised that changes in 
pharmacology and procedural technique could reduce this considerably, and subsequent 
series in the 1980s reported rates of 3 to 4% as discussed in the 2009 editorial by Cook 
and Windecker. It was also recognised that most cases were sub acute (occurring 
between 2 and 30 days), with few cases of acute ST (<24hrs) or late ST (>30 days). 
Clinical presentation was often insidious and, because ST usually occurred after the 
patient was discharged from hospital, rapid revascularisation often could not be 
achieved, resulting in high rates of MI and death. Subsequent PCI trials have observed 
ST at lower rates, but attempts to completely eradicate this complication have so far 
failed. 
Late (30 days to 1 year) and very late (> 1 year) ST was initially an unrecognised 
problem and so not reported in earlier PCI trials. Large scale prospective registry data 
on stent thrombosis is now available. In a report by Armstrong et al, 2012, the definite 
angiographic late and very late stent thrombosis rates in 401 662 patients undergoing 
PCI in 2009 and 2010 (CathPCI Registry) were 0.3% and 1.1%. Wenaweser et al (2008) 
studied ARC defined ST in 8146 European patients receiving DES (Cypher and Taxus) 
between 2002 and 2005. There was an estimated cumulative incidence of 5.7% of 
definite/probable ST at 4 years (95% CI: 5.15% to 6.39%). Two thirds of cases occurred 
before 30 days, after which there was a steady rate of late/very late ST which did not 
appear to be levelling off at the end of the 4 year study period. Another study looked at 
5 year rate of ARC defined ST in 12824 patients from the Japanese J-cypher registry, 
who had Cypher stents implanted from 2004 to 2006. Kimura et al (2012) reported a 
cumulative 5 year incidence of definite ST as 1.6%, with 27% of events occurring 
before 30 days followed by a low steady rate of ST during the subsequent 5 years, a 
pattern similar to that seen by Wenaweser et al (2008). 
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There are concerns that assessment of the true rate of ST, and comparison of rate 
of ST between studies, is likely to be confounded by difficulties with diagnosis. The 
only ways in which ST can be diagnosed unequivocally are by coronary angiography or 
post mortem examination. However, patients may present insidiously and the case may 
go unrecognised, especially in the elderly; or they may present in cardiogenic shock or 
pulmonary oedema, and may be too unwell for angiography. In addition, patients with 
stents who subsequently have an ACS may not be investigated invasively due to 
physician preference in the presence of frailty or co-morbidities, or patient preference. 
For those presenting with out of hospital cardiac arrest, many do not have cause of 
death confirmed by post mortem. 
The ARC guidelines for reporting stent thrombosis were devised in an effort to 
overcome these diagnostic problems. Contemporary interventional trials now report ST 
based on these definitions. However, there is concern that the ARC definitions may 
result in under-reporting of ST. Cutlip et al (2011) applied the criteria to a post mortem 
(PM) registry of 139 patients with a history of coronary stenting with DES. 51 were 
found to have ST by PM. Although ARC definition specificity was high for definite 
(99%) and definite plus probable (83%) criteria, sensitivity was poor: 18% and 51% 
respectively. There is therefore the potential to under-report definite/probable ST by as 
much as half even when ARC criteria are used. The ARC definitions were particularly 
insensitive for late stent ST: sensitivity for definite/probable late ST was only 20% (CI: 
7 to 39). This is of concern because many cases of ST result in death, as discussed 
below; but overall mortality rates after PCI are low, potentially obscuring the clinical 
importance of the problem. 
In light of reservations about in the sensitivity of ARC criteria for later ST, and 
problems with completeness of data (some large centres reported no ST at all; the 
Japanese study did not include probable ST), the true ST rate in both these studies may 
be higher than reported. In the Wenaweser study, mortality after definite ST was 15.6% 
after 2 years. Definite/probable ST mortality was not given. In the Kimura study, all 
except one of the 611 patients with definite stent thrombosis were diagnosed by 
angiography after the patient presented with an ACS; the remaining one was diagnosed 
by PM. Two thirds presented with STEMI, one third with NSTEMI. 11% of early ST 
patients had had a cardiac arrest. Although >96% were treated by PCI, the cumulative 
risk of death after ST at 2 years was high at around 25%. Note that this mortality figure 
only applies to patients who actually reach hospital to have angiography – many more 
cases from this population may have gone unrecognised, as no effort was made to 
identify probable ST in the deceased patients. In the Wenaweser study, DM 
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independently predicted early ST; ACS, young age and Taxus stent independently 
predicted late ST. 
1.5.7.4. Restenosis and target lesion revascularisation 
The term „restenosis‟ refers to the re-narrowing of a coronary artery at the site of 
previous angioplasty; in-stent restenosis (ISR) when this occurs within a stent. 
Haemodynamically significant ISR is usually treated by target lesion revascularisation 
(TLR); ISR is the cause of most cases of TLR which occur after the first few weeks; 
before this procedural complications or ST are the cause of TLR. ISR is discussed in the 
following section. PCI injures the arterial wall. The healing process following 
angioplasty, with or without stent implantation, leads to the growth of a layer of tissue 
(neointima) on the luminal surface of the treated artery known as neointimal 
hyperplasia. Techniques such as intravascular ultrasound (IVUS) and optical coherence 
tomography (OCT) can accurately measure the thickness of this layer in vivo. The 
volume of neointima varies within stents, between stent type, between lesions within the 
same patient and between different patients. Restenosis may also be due to the 
formation of lipid-rich atherosclerotic tissue with foam cells, with the potential to 
rupture and cause ACS as in de novo lesions. The possible causes of restenosis, referred 
to as „late lumen loss‟, are discussed in detail in a review article by Farooq et al, 2011. 
Neointimal hyperplasia develops within all coronary arteries as they heal 
following angioplasty in response to direct mechanical injury to the vessel wall. 
Komatsu et al (1998) outlined this process after studying post mortem samples of 
stented human coronary arteries and observed the formation of thrombus at the site of 
injury, which rapidly become populated with macrophages. This was followed by the 
appearance of spindle-shaped cells which matured into smooth muscle cells, within a 
large volume of extracellular matrix. There was in addition a varying degree of 
inflammatory cell infiltration, the extent of which correlated with the volume of 
neointima formation. A layer of neoendothelium formed on the luminal surface of the 
neointimal layer, although complete re-endothelialisation did not occur for months. 
Some lesions underwent massive neointimal growth accompanied by extensive 
neovascularisation and extensive macrocyte infiltration – seen as severe ISR on 
angiography – the cause of which remains largely unexplained. 
Both BMS and DES undergo neointimal hyperplasia. Chieffo et al (2009) 
performed histological analysis of coronary restenotic tissue obtained from directional 
atherectomy in both BMS and DES in 44 patients. DES was smaller volume and more 
frequently focal, but all types of stent produced basically the same histological type of 
neointima, with proteoglycan-rich smooth muscle cells and fibrolipidic regions. 
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However, although cell density was the same between samples, different stents had 
different smooth muscle types, possibly suggesting more than one mechanism of 
restenosis. 3 DES patients had an abundant inflammatory cell infiltrate. 
Kornovski et al noted that, in animal models, the volume of neointima created was 
proportional to both the extent of injury (which potentially could be limited by correctly 
sizing stents) and the subsequent inflammatory reaction to the stent struts (which 
possibly could be controlled using ant proliferative agents). A range of factors have 
been postulated to explain why excessive neointimal hyperplasia causing ISR occurs in 
some stents and not others, summarised in reviews by Farooq et al (2011). Factors 
which are potentially modifiable are: resistance to the effect of the cytotoxic drug, 
thought to have a genetic basis; hypersensitivity reactions to the polymer (latest 
generation stents have biocompatible polymers which do not produce such excessive 
inflammatory responses); strut shape and thickness; and procedural factors such as 
incomplete stent expansion, geographical miss and barotrauma to un-stented segments.  
Kastrati et al (2006) studied 1845 patients undergoing Cypher or Taxus stent 
implantation, all consenting to have follow-up angiography, for predictors of restenosis. 
1495 underwent a follow-up coronary angiogram 193 ± 63 days after the index 
procedure; 350 patients either died before the angiogram was scheduled or declined the 
investigation. In this study the independent predictors of DES restenosis following 
multivariate analysis were female sex, history of CABG, chronic occlusions, vessel size, 
maximal balloon pressure, drug-eluting stent type, and final diameter stenosis. The most 
important factors were vessel size and stent type, with Taxus stents associated with 
higher ISR rates. Other studies have found length of stented segment and diabetes to be 
additional risk factors for ISR. 
Comparing restenosis rate between different studies would be impossible without 
standardized definitions. By coronary angiography (quantitative coronary angiography 
(QCA) is often used in research studies), restenosis is traditionally said to have occurred 
if more than 50% of the lumen of the vessel is compromised. This is known as the 
„binary restenosis rate‟ – binary refers to the two states of no restenosis and restenosis. 
There are several problems with this method. A 50% stenosis may not cause functional 
ischaemia:  meta-analysis from Cutlip et al (2002) found a disparity between binary 
restenosis rate and clinical outcome as only about half required repeat revascularisation. 
Furthermore, neointimal tissue volume is a continuous rather than a binary variable. 
Late lumen loss may be a more useful way of assessing hyperplasia following 
stent implantation: this is the minimal luminal diameter immediately post-procedure, 
minus the minimal luminal diameter at follow up, measured using QCA in the same 
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projection. Yet a third way of characterising neointimal hyperplasia is using IVUS. 
IVUS can clearly delineate both the stent and the position of the endothelium and from 
this calculate the volume of neointimal hyperplasia. IVUS can also determine the cross 
sectional area of the lumen: less than 4 mm
2
 in a proximal epicardial vessel is correlated 
with ischaemia and worse outcomes. 
In the very earliest studies of PCI, following balloon angioplasty alone (POBA), 
the incidence of restenosis was reported to be 30-40%. Restenosis has become less 
common since the introduction of stents, and has decreased further with improved stent 
design. The exact rate of ISR is difficult to compare between trials because of differing 
rates of angiographic follow up: contemporary large scale revascularisation trials do not 
perform routine follow-up coronary angiography in the absence of symptoms. Instead, 
studies report a range of different surrogate endpoints, often composite, such as 
ischaemia-driven revascularization or target vessel failure. In Kastrati‟s study, 211 
(14.1%) patients developed ISR defined as diameter stenosis >50% by QCA. The 
method chosen to identify ISR in this study was binary restenosis, which may be a poor 
judge of haemodynamic and therefore clinical significance. 
Target lesion revascularisation (TLR) is another way of effectively comparing ISR 
rates between trials. In an influential meta analysis of double blinded, randomised trials 
of DES vs. BMS (2009), Kirtane et al reported TLR rates of 23.6% and 7.8% 
respectively for pooled studies of BMS vs. SES, median follow-up 4.0 years, 1748 
patients; and 20.0% and 10.1% for pooled studies of BMS vs. PES, median follow-up 
3.2 years, 3513 patients. In all 9 trials in the analysis a high proportion of subjects 
(42.5% to 97% depending on the study) underwent routine follow up angiography at 
between 6 and 9 months post PCI, reducing the possibility of missing clinically silent 
ISR. Note that the TLR rate is not interchangeable with ISR rate: TLR rate also includes 
patients with stent thrombosis in the absence of ISR; and some patients with ISR may 
not have undergone further revascularisation. 
Registry data provides another way of quantifying the frequency of ISR. Fröbert et 
al (2009) reported an angiographic restenosis rate of 3.5% after 1 year and 4.9% after 2 
years in 19 004 patients from the Swedish coronary angiography and angioplasty 
registry (SCAAR). These patients had any of 4 types of DES inserted (Cypher, Taxus 
Express, Taxus Liberté and Endeavor) and were not consented for routine follow-up 
angiography. This study has the advantage of including every patient who had PCI in an 
entire country (Sweden) so is definitely „real-world‟; however, the true restenosis rate 
will be underestimated, as a proportion of patients will have had asymptomatic 
restenosis not leading to angiography and therefore remaining undiagnosed. 
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In contemporary practice, SES and PES are being superseded by newer generation 
stents. Claessen et al (2009) reported the 2 year angiographic and IVUS results of 152 
patients from the SPIRIT II trial, which randomised patients to receive a Xience V 
everolimus eluting stent (EES) or a Taxus paclitaxel eluting stent (PES) in a 3 to 1 ratio. 
95 patients had 2 year angiography and IVUS. For EES and PES respectively, in-
segment binary angiographic restenosis at 2 years was 5.2% and 8.6%, P=0.44; in–
segment mean late loss was 0.21±0.37 and 0.34±0.34, P=0.63; mean percentage volume 
obstruction by IVUS was 5.18±6.22 and 5.80±6.31, P=0.65; and TLR was 3.7% and 
6.5%. It is likely that the true rate of haemodynamically significant ISR lies somewhere 
around the 5% mark with Xience V stents at 2 years. However, this may be reduced 
even further with the latest stent designs such as Xience Prime (Abbott Vascular) and 
Resolute Integrity (Medtronic), both „third generation‟ devices with very thin struts, 
good radial strength and biocompatible polymers. 
ISR can manifest clinically with exertional angina or with ACS. Adlam et al 
(2012) reported the indication for repeat revascularisation in 10509 patients who had 
undergone a first stenting procedure for any indication, over a median follow up of 3.8 
years (60% BMS only, 35% DES only, 4% both BMS and DES). In this registry, 11.2% 
required repeat PCI and 2.0% required CABG. Of patients having a second PCI, in 250 
(20.9%) the procedural indication was „stent related disease‟, mainly ISR; there were 
also some cases of stent thrombosis, but exact figures are not given (of the remaining 
patients, nearly half had new disease unrelated to the stent and a quarter had planned 
(staged) PCI). Excluding staged PCI, the presenting syndrome leading to repeat stenting 
was stable angina in just over half the patients; troponin negative UA in about a quarter; 
and MI (STEMI and NSTEMI) in the remaining patients (again, exact numbers are not 
reported).  
Severe ISR or even complete vessel occlusion may also be asymptomatic. 
Ruygrock et al (2001) found that of 2690 patients following PCI with POBA or BMS, 
607 had binary angiographic restenosis which was clinically silent in 55% of cases. 
However, only in 20% of those with restenosis was the stenosis >70%, so it is likely 
that many of these cases were not haemodynamically significant. 
Work to reduce ISR led to the invention of the DES, in which the metal scaffold of 
the stent has a polymer coating impregnated with an antimitotic drug, often one of the 
„limus‟ family, to inhibit neointimal growth. The drug is released (eluted) slowly and 
has a high concentration at the stent site but very low concentration elsewhere in the 
body, minimising systemic effects of the drug. DES use reduces the requirement for 
TLR, and possibly also mortality, compared to BMS. However, not all patients are 
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considered suitable for DES, such as those thought to be at high risk of bleeding who 
cannot take long term dual antiplatelet therapy (DAPT). Furthermore, restenosis due to 
intimal hyperplasia still occurs with DES, albeit at a lower rate than with BMS. 
Angiographic ISR may be treated conservatively if thought not to be 
haemodynamically significant (non-ischaemic ISR). Repeat revascularisation of 
obstructive lesions may take place by either PCI or CABG. Before the DES era, efforts 
to treat BMS ISR by POBA, cutting balloon or further BMS implantation resulted in a 
high re-restenosis rate. A technique of irradiating the restenotic segment with locally 
delivered ionizing radiation called brachytherapy was developed. Brachytherapy was an 
effective short-term ant proliferative strategy but was limited by logistical difficulties 
and high rates of long-term target lesion revascularisation (Ruef, 2007). 
1.5.8. Adverse Event Reporting: ARC and BARC Definitions 
In recognition of the importance of standardised reporting of clinical events, a 
collaboration between European and North American research institutions with 
representation from the U.S. Food and Drug Administration (FDA) and commercial 
device companies known as the Academic Research Consortium (ARC) has produced 
specific criteria for the most important safety and efficacy endpoints after PCI: 
 Death; ARC recommend reporting all-cause mortality and also death 
classified by cause into (i) cardiac, (ii) vascular and (iii) non-cardiovascular. 
„Cardiac death‟ is any death of unknown cause, including “unexpected death 
even in patients with coexisting potentially fatal noncardiac disease”; and 
any procedure-related death 
 MI (see below for categories) 
 Repeat revascularisation; the ARC recommend reporting this as „target 
lesion revascularisation‟ (TLR) (clinically and non-clinically indicated) and 
„target vessel revascularisation‟ (TVR) 
 Stent thrombosis (ST). Acute (less than 24 hours), subacute (24 hours to 
30 days), early (<30 days; acute plus subacute), late (30 days to 1 year) and 
very late (more than one year). Definite ST must be diagnosed 
angiographically (must also be accompanied by clinical evidence of 
myocardial ischaemia) or by post mortem examination. Probable ST is any 
unexplained death within 30 days of PCI, or any MI (at any time point) 
documented to be in the territory of the stented segment in the absence of 
angiographic evidence. Possible ST is any unexplained death occurring 
more than 30 days after PCI. 
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Bleeding is another major complication following PCI; the risk of bleeding is 
increased due to antiplatelet and anticoagulant medication. Each major trial group – for 
example the TIMI and GUSTO groups - has used different definitions consisting of a 
combination of laboratory parameters (decreases in haemoglobin and haematocrit 
scores) and clinical bleeding events combined to create some form of ranking of 
severity. This impedes direct comparison of true bleeding rates between trials. However, 
another group of researchers has recently devised a new system, weighted towards 
clinical severity and prognosis, which is simple to use and may help standardise 
reporting of bleeding. The proposed Bleeding Academic Research Consortium (BARC) 
definitions are as follows: 
 Type 0: No bleeding 
 Type 1: Minor bleeding that is not actionable; for example, bruising or a 
small self-limiting nosebleed 
 Type 2: minor bleeding which requires action (a test, a treatment or 
withdrawal of a drug) from a health care professional, but not sufficient to 
cause significant blood loss or compromise to any organ system; for 
example, a nosebleed requiring temporary cessation of antiplatelet 
medication. 
 Type 3: severe bleeding.  
 Type 3a is any overt bleed requiring a transfusion with a Hb drop of 3 to 
5g/dL 
 Type 3b is life-threatening bleeding: it includes overt bleeding requiring a 
transfusion with a Hb drop of more than 5g/dL; cardiac tamponade; 
bleeding requiring surgical intervention to stop it; or bleeding with shock 
requiring inotropes 
 Type 3c is intracranial or intraocular haemorrhage 
 Type 4: CABG related bleeding 
 Type 5: fatal bleeding 
1.6. Platelets, antiplatelet agents and platelet function testing 
Antiplatelet drugs are the cornerstone in the prevention of coronary thrombosis 
during and after PCI. This section contains a brief overview of platelet function and 
mode of action; and describes the available antiplatelet medications and their 
limitations. 
1.6.1. Platelets and thrombosis 
Platelets are anucleate cells which are produced in the bone marrow and circulate 
for approximately 10 days. They have a vital role in rapid haemostasis following injury, 
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their primary function being the initiation of thrombosis at the site of arterial damage by 
the processes of adhesion, activation and aggregation. 
1.6.1.1. Platelet adhesion 
Platelets do not adhere to healthy endothelial cells, which have several antiplatelet 
properties: they carry a negative charge, and they secrete the antiplatelet agents nitric 
oxide, prostacyclin and ADP-ase. However, where the endothelial layer is interrupted in 
spontaneous plaque rupture or angioplasty, platelets rapidly bind to exposed 
subendothelial collagen. As described by Ruggeri and Ware in 1993, in the presence of 
the high sheer forces found in fast flowing blood in small vessels and around arterial 
stenoses, this attachment is largely mediated by von Willebrand factor (vWF). This 
glycoprotein, the largest known soluble globular protein, is generated in endothelial 
cells and released into both the blood and the subendothelium. It is also produced by 
megakaryocytes, the cells which give rise to platelets, and is stored in platelet α-
granules. vWF changes shape from a globular structure to an extended chain 
conformation both on binding to collagen and under conditions of shear stress above a 
critical value (Siedlecki et al, 1996). This conformational change allows the binding of 
platelets via platelet membrane glycoprotein receptors such as GP 1bα. Platelet 
adhesion triggers activation of the platelet. 
1.6.1.2. Platelet activation 
Activation is a complex collection of different molecular processes and 
conformational changes which must occur before the aggregation of platelets into a 
stable platelet plug. Several platelet activating agents are known including collagen and 
vWF/thrombin complex in subendothelial tissue, and the soluble agonists ADP, 
thrombin and thromboxane A2 (TXA2), each with its specific platelet membrane 
receptor (see below). Binding of an agonist rapidly causes a marked rise in platelet 
intracellular calcium, triggering a number of events. The platelet loses its cytoskeletal 
structure to change shape from a disc to a globule with multiple arm-like extensions and 
blebs. The blebs are shed as microvesicles and the arms increase the surface area 
available for platelet-platelet binding. Highly pro-coagulant factors are released from α- 
and dense granules into the immediate vicinity; and the surface of the platelet become 
highly pro-coagulant due to the redistribution of phospholipid molecules. Platelet 
activation also leads to a conformational change in the IIbIIIa (Integrin αIIbβ3) complex 
in the platelet membrane (Seiss, 1989), the final event required for agonist-mediated 
aggregation. 
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Activation is propagated by several mechanisms, including the binding of the 
adenine nucleotide ADP (released from platelet granules) to the purinergic P2Y1 and 
P2Y12 G protein-coupled platelet receptors. 
1.6.1.3. Platelet aggregation 
Activated platelets form stable clumps by the cross linking of cell membrane 
IIbIIIa molecules. IIbIIIa is part of the integrin family, large proteins which span the cell 
membrane. Integrins have 2 main functions: to mediate cell attachment to surrounding 
tissue, and as cell signalling intermediaries (they have also been studied for their 
potential roles in invasion of tissue by metastatic cancer cells, the functioning of viruses 
and allergic disorders such as asthma). IIbIIIa is the most abundant platelet 
glycoprotein, with approximately 80 000 molecules per platelet (Scarborough et al, 
1999). 
Recent work has shown that platelets are also capable of forming clumps without 
activation, independent of soluble agonists and IIbIIIa, in response to high shear stress. 
Nesbitt, Jackson et al (2009) showed that discoid platelets could form stable clumps, via 
membrane tethers, in injured non-stenosed mouse vessels. These initially formed 
downstream from the site of vascular injury and had sufficient strength to occlude 
vessels. Secondary, agonist-dependent consolidation of the platelet clump then occurred 
at the site of tissue injury in the areas of lower shear created around the developing 
thrombus. 
1.6.2. Platelet agonist receptors and inhibitors used in PCI 
Identification of the various cell receptors involved in platelet function has led to 
the development of drugs designed to block these receptors in order to reduce arterial 
thrombosis in patients with cardiovascular disease. A detailed review of contemporary 
antiplatelet therapy has been provided by White, 2011. 
1.6.2.1. IIbIIIa inhibition 
Platelet activation leads to a conformational change in the IIbIIIa molecule in the 
platelet cell membrane and allows permanent cross-linking of platelets and the 
formation of a platelet plug. Activated platelet IIbIIIa can bind to multiple soluble 
ligands, such as fibrinogen, fibronectin and vWF. Intravenously administered IIbIIIa 
inhibiting drugs have been in routine clinical use for many years to treat coronary 
thrombosis (Nurden et al, 2009). Intravenous IIbIIIa inhibitors are still used during PCI, 
particularly when coronary thrombus is present or when flow appears poor, although 
less than before. An unexpected event in the evolution of antiplatelet therapy was that in 
all 5 trials of oral IIbIIIa agents, increased mortality and increased bleeding rates and, 
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paradoxically, increased thrombotic events. Chew et al presented these results in a 2001 
meta-analysis. These findings were never fully explained but use of oral IIbIIIa 
inhibitors ceased and attention was turned to different antiplatelet agents affecting 
alternative platelet receptors. 
1.6.2.2. Thromboxane A2 and aspirin 
TXA2 is produced by platelets from arachidonic acid by the cyclooxygenase 
(COX-1) pathway, involved in prostaglandin synthesis (Vane, 1971). Platelets have 2 
variants of TXA2 receptor, TPα and TPβ. Both are G-protein linked receptors which 
trigger an increase in intracellular calcium levels and further platelet activation. TXA2 is 
also widely produced by other mechanisms, such as the COX-2 pathway, by several 
other cell types. Roth and Majerus in 1975 suggested that aspirin exerted its antiplatelet 
effect by the rapid and permanent acetylation and inactivation of platelet 
cyclooxygenase. Aspirin has been shown to improve cardiovascular outcomes in 
secondary prevention in several studies e.g. in ISIS-2, 1988, the death rate 34 days post 
MI was 9.4% on aspirin and 12.0% on placebo, risk ratio 0.78. Aspirin‟s role in primary 
prevention is less clear, when bleeding may outweigh the benefit. 
1.6.2.3. Adenosine diphosphate (ADP) and P2Y12 receptor inhibitors 
ADP is released by damaged endothelial cells and erythrocytes, but is also 
excreted (in much larger amounts) by activated platelets, causing a self-propagating 
cascade of platelet activation leading to the formation of a platelet plug at the site of an 
endothelial breach. It is thought that the binding of ADP to P2Y1 is responsible for the 
change in shape of activating platelets via changes in intracellular calcium level. The 
binding of ADP to P2Y12 inhibits adenylate cyclase, a transmembranous G protein-
coupled enzyme catalysing the conversion of ATP to cAMP. The inhibition of cAMP 
production reduces the activity of protein kinases, which can no longer phosphorylate 
vasodilator stimulated phosphoprotein (VASP). VASP phosphorylation is required for 
GP IIb/IIIa receptor inhibition; reduced cAMP therefore results in activation of IIb/IIIa 
receptors and promotion of platelet aggregation (Jin and Kunapuli, 1998). P2Y1 is 
widely expressed throughout the body and so has not been a focus of antiplatelet 
research in humans. P2Y12 is expressed only in platelets and the brain; several P2Y12 
inhibitors have been developed which are in clinical use, including the thienopyridines 
clopidogrel and prasugrel; and ticagrelor, a nucleoside analogue (White, 2011). 
1.6.2.4. Thrombin and thrombin inhibitors 
Thrombin is an essential component in thrombus formation. It is the final protease 
in the coagulation cascade, cleaving fibrinogen to form a fibrin clot. Antithrombin is the 
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primary natural inhibitor of blood coagulation proteases, which only exerts its effect 
when in contact with heparin-like glyocosaminoglycans with which it forms a ternary 
complex (Li, 2004) – the basis of heparin as an anticoagulant. However, thrombin also 
has a direct effect on platelets unrelated to its interaction with fibrinogen (Davey and 
Luscher, 1967), and is a potent platelet agonist. 
Two human platelet thrombin receptors have now been demonstrated: the protease 
activated receptors (PAR) 1 and 4 (Kahn 1998). PARs are G protein-coupled receptors, 
very widespread in all organs, which have complex interactions with multiple agonists 
and antagonists. Vorapaxar and atopaxar are novel oral drugs in development, both 
targeting PAR1, for potential use in the treatment of ACS. A major clinical trial in 
which vorapaxar was added to standard therapy after NSTE-ACS was halted early due 
to excess bleeding without a reduction in the composite primary endpoint. Intracranial 
haemorrhage rates were 1.1% in the vorapaxar group vs. 0.2% in the placebo group 
(Tricoci et al, 2012). Atopaxar has been tested in Phase II clinical trials with promising 
results (Wiviott, 2011). 
 
1.7. Platelet function testing 
The ability to test platelet reactivity has been used in clinical research to assess the 
effect of antiplatelet therapy and has been particularly useful in the study of „clopidogrel 
resistance‟. Several of the available point-of-care devices have been studied for their 
clinical utility in routine care but at the time of writing none are recommended for 
routine clinical use, although studies are ongoing. There is no „gold standard‟ platelet 
function test, but several different techniques have been used to measure the different 
aspects of platelet function (for example platelet reactivity, quantification of activated 
platelets, platelet-platelet and monocyte-platelet aggregates and platelet micro particles). 
Generally the test involves the response of platelets to the addition of an agonist such as 
ADP or thrombin. Platelet function testing for clinical purposes has recently been 
extensively reviewed by Gorog and Fuster, 2013. Briefly, the available methods of 
platelet function assessment are: 
 Bleeding time 
 Platelet aggregometry (turbidometry or electrical impedance)  
 Flow cytometry VASP MoAbs 
 Testing for urinary or blood markers of platelet activation 
Bleeding time is the time taken for a small standardized iatrogenic wound to stop 
bleeding. It is prolonged in any disorder of platelet function, but not in haemophilia or 
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warfarin therapy. Rodgers and Levin (1990) reviewed 1083 studies in humans and 
found the test generally unsatisfactory, being neither specific nor reproducible – and it 
leaves a scar. Plasma assays of platelet factor 4, soluble P-selectin, b-thromboglobulin 
and plasma and urinary assays of thromboxane A2 metabolites have all been used as 
indirect markers of platelet activation. However, aggregometry and flow cytometry 
appear to be more reliable methods of platelet function. 
1.7.1. Aggregometry 
Platelet aggregometry is the measurement of platelet aggregation (a marker of the 
extent of activation), used as an indicator of platelet reactivity. Aggregation may be 
measured in the laboratory by detecting changes in light transmission in a sample of 
platelet-rich plasma, which may have been exposed to an agonist of activation, a 
method sometimes called „turbidometry‟, as explained by Michelson (2004). Activated 
platelets form clumps and fall out of suspension, so increasing light transmission. This 
is usually compared to the light transmission through a sample of platelet-poor plasma; 
hence, each patient acts as his own control. Platelet aggregation can also be 
demonstrated in whole blood by measuring changes in electrical impedance caused by 
platelet aggregation on the electrodes. 
Light transmission aggregometry (LTA) is impractical for routine large scale 
clinical use due to the complexity of the technical aspects of the procedure. However, a 
number of point of care assays have now been developed, including the VerifyNow 
system (formerly known as the Ultegra rapid platelet function analyzer), Accumetrics, 
California, discussed below. Several electrical impedance devices have also been 
developed. Of available bedside devices, VerifyNow has the largest body of supporting 
evidence and has been used most frequently in clinical trials of platelet function (Breet 
et al. 2010). 
1.7.2. Flow cytometry 
Platelet aggregation may also been studied using flow cytometric techniques. A 
flow cytometer is a device for studying the various properties of large numbers of small 
particles. Fluid containing the particles is streamed through the device; the particles are 
fluorescently labelled; a laser is directed at the stream; and the characteristic fluoresced 
light patterns can be analysed. Flow cytometry allows the accurate study of even very 
small numbers of individual particles. Platelets can be studied both for their degree of 
activation, degree of reactivity and response to individual agonists in their physiological 
environment of whole (anticoagulated) blood. They are labelled using monoclonal 
antibodies to the various platelet receptors. (Michelson 2004). Drawbacks of the 
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technique are that it requires a flow cytometer, is labour and expertise intensive and is 
not conducive to routine clinical use. 
1.7.3. VerifyNow P2Y12 receptor point-of-care assay 
The VerifyNow device is a rapid whole blood assay of platelet function based on 
optical aggregometry, used for point of care platelet function testing. It was first 
marketed as the Integra Rapid Platelet Function Analyzer by Accumetrics incorporated, 
San Diego, California. Separate assays are available to test the response to P2Y12 
inhibitors, aspirin and IIbIIIa inhibitors. Van Werkum et al (2006) described the 
principles behind its operation and its accuracy compared to LTA, and described the 
evidence for its clinical application (2008). Briefly, citrated blood is mixed with 
fibrinogen coated beads to which activated platelets will bind. In the presence of a 
platelet agonist, platelet-coated beads fall out of suspension so that light transmission 
through the sample will gradually increase over time. The rate of change in transmission 
is altered in the presence of antiplatelet drugs which will tend to keep the beads in 
suspension for longer and so increase sample turbidity. 
The P2Y12 assay has individual chambers in which different agonists can be mixed 
with the blood sample. One chamber mixes blood with PAR-1 and PAR-4 (platelet 
thrombin receptors) agonists, which act independently of the P2Y12 and thromboxane 
receptors to cause very complete platelet aggregation (thrombin is the most potent 
platelet agonist known). A proprietary algorithm is applied to produce a value known as 
the „baseline PRU‟ value (PRU stands for P2Y12 Reaction Units). There is a wide 
normal range given by the manufacturer for the baseline value of 212 to 398. If the 
value is less than this range, the device will not report the result and reads „error‟ – a 
low baseline value implies abnormal platelet function due to factors other than P2Y12 
inhibition, such as IIbIIIa treatment or a platelet disorder. The higher the value, the 
more reactive the platelets are. 
A second chamber mixes blood with 20 µmol of ADP and 22 nmol of 
prostaglandin E1 (the addition of the latter compound reduces the contribution of ADP 
binding to P2Y1 receptors to aggregation). This generates a „PRU‟ value which 
corresponds with the extent of ADP/ P2Y12-mediated aggregation. 
A percent inhibition value is then generated using the following equation: 
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All 3 values are displayed by the device. This method allows the effect of the 
P2Y12 inhibiting drug to be quantified using a single blood sample, rather than before- 
and after-dose samples. 
The VerifyNow test appears to be precise: Paniccia et al in 2011 reported the 
coefficient of variation (CV) for the P2Y12 test to be 3.2% when tested in patients with 
coronary artery disease. Furthermore, the results appear to correlate well with platelet 
reactivity measured by conventional LTA. Using 10 µmol/L ADP for LTA, 
concordance with VerifyNow was 79.1%, (κ = 0.43, P < 0.0001; ρ = 0.64, P < 0.0001) 
(same study). Several studies have correlated antiplatelet resistance as defined by the 
VerifyNow device with subsequent adverse cardiovascular outcomes. Moreover, the 
VerifyNow P2Y12 test appears to compare favourably with other available point-of-care 
tests with regard to subsequent clinical events (Breet et al, 2010). 
1.8. Platelet reactivity, drug resistance and clinical outcome 
Trip et al (1990) were among the first investigators to show that platelet reactivity 
following MI correlates with recurrent ischaemic events. Spontaneous platelet 
aggregation was tested in 149 survivors of MI at intervals of 6 months using light 
transmission aggregometry. This study recruited patients prior to 1990, when aspirin 
was the only antiplatelet in routine use. Patients were asked to stop aspirin for 1 week 
before each blood test. The relative risk of cardiac death in the group with a high level 
of aggregation compared to the group with low aggregation was 5.4 (95% confidence 
interval 2.2 to 13.4). 
Despite the widespread contemporary use of DAPT (and other beneficial medical 
therapies) in ACS and PCI, there remains a significant rate of recurrent cardiovascular 
events. As an example, in the large HORIZONS trial (Mehran et al, 2009), the major 
adverse cardiovascular event rate between 30 days and 1 year in 3602 patients 
presenting with STEMI who underwent primary PCI was around 7% (7.3% in the 
control group, 6.8% in the bivalirudin group). This was a randomised controlled trial; 
„real world‟ patients may have even higher rates. It is currently thought that an 
important number of these cases of recurrent ischaemia were due to antiplatelet 
resistance, particularly to the thienopyridines. 
1.8.1. Aspirin resistance 
Aspirin was discovered in the 1970s to be an inhibitor of platelet arachidonic acid 
(AA) metabolism, leading to inhibition of thromboxane A2 production and a decrease in 
platelet reactivity (see Section 1-6-2-2). Aspirin is recommended in all patients 
undergoing PCI, unless contraindicated, as part of the standard dual antiplatelet therapy 
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(DAPT) regime. Variability in response to aspirin resulting in adverse clinical outcomes 
has been noted by many authors. Chen et al (2007) found procedural myonecrosis (CK-
MB) was increased in 151 patients undergoing elective PCI on DAPT as measured by 
the Ultegra Rapid Platelet Function Assay.  
However, as pointed out in a 2011 review by Fitzgerald and Pirmohamed, 
although aspirin resistance may be a clinically important entity, there is currently no 
accepted definition of aspirin resistance, no recognised gold standard test, and no clear 
indication of how to treat it when detected. At present, the International Society on 
Thrombosis and Haemostasis working group on aspirin resistance and the international 
PCI guidelines do not recommend testing for aspirin resistance. Furthermore, it is 
thought to be much less common than resistance to P2Y12 inhibitors. 
1.8.2. P2Y12 inhibitor resistance 
P2Y12 inhibitors suppress ADP-induced platelet activation and aggregation, 
thereby inhibiting arterial thrombosis. Clopidogrel is currently the most widely used 
agent with a strong evidence base to demonstrate reduced MACE after ACS and PCI 
when compared to aspirin alone. It is known on the basis of laboratory platelet function 
testing that there is a wide range of response to clopidogrel: a large proportion of the 
population, thought to be about 30%, are completely or partially resistant to its action as 
a P2Y12 inhibitor. The other thienopyridine currently in routine use, prasugrel, also has 
evidence of resistance although much less commonly than clopidogrel. 
In contrast to the case with aspirin resistance, PCI guidelines approve the concept 
of testing for clopidogrel resistance, because studies have shown a correlation with 
bedside platelet function testing and clinical events. Brar et al in 2011 produced a 
collaborative, patient level meta-analysis of 6 of these studies looking at clinical 
outcome following PCI in a total of 3059 patients treated with clopidogrel who had a 
VerifyNow test. There was a 4% increase in frequency of the primary composite 
outcome of death, MI and stent thrombosis for every 10-unit increase in PRU (HR: 
1.04; 95% CI: 1.03 to 1.06; P < 0.0001. The event rate at 2 years was 5.5% in the lowest 
PRU quartile and 15.8% in the highest (P < 0.001). Using a receiver-operator curve 
statistical method, the authors suggest that a PRU cut off of >230 offers the greatest 
discriminatory value for predicting adverse events. 
Other authors have observed worse outcomes in patients with both high and low 
on-treatment platelet reactivity. Mangiacapra et al, 2012, observed optimal clinical 
outcomes in patients with VerifyNow PRU within the range 179 to 238. Patients with 
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higher PRU had more ischaemic events and those with lower PRU more bleeding 
events. 
1.9. Hypothesis, Aims and Objectives   
1.9.1. Main hypothesis 
The main hypothesis of this work is that adverse clinical events following PCI, 
such as stent thrombosis, bleeding and in-stent restenosis, may be predicted from the 
identification of markers of risk at the time of PCI, particularly by the use of risk scores, 
platelet function testing and measuring biomarker levels. 
1.9.2. The secondary hypotheses 
 P2Y12 inhibition with clopidogrel is variable and „clopidogrel resistance‟ 
may be measured. 
 Thrombotic adverse cardiovascular events in patients undergoing PCI can 
be related to clopidogrel resistance. 
 Bleeding can be related to high levels of P2Y12 inhibition. 
 Further revascularisation/ISR can be related to angiographic and procedural 
complexity (SYNTAX score, procedural complications). 
 Procedural MI can be diagnosed with novel biomarker HFABP. 
 Procedural MI is important for long-term prognosis. 
1.9.3. The aims of this work 
 To record the clinical outcome (MACCE) of patients with ACS undergoing 
PCI. 
 To correlate adverse events with already known or postulated risk factors 
including baseline clinical features, procedural factors, clopidogrel 
resistance and genetic profile. 
 To define procedural MI using the novel biomarker HFABP. 
 To identify novel risk factors for adverse outcomes following PCI. 
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Chapter 2 Methods: the OPERA study   
The Outcomes from PCI by Evaluation of Risk Attributes (OPERA) study was 
established in 2005 as a registry of patients with ACS undergoing PCI. The purpose was 
to record a comprehensive array of clinical and procedural characteristics, including 
procedural complications, biomarkers, clopidogrel resistance and genotyping, and 
prospectively follow patients for adverse clinical events. 
2.1. Study structure, protocol and patients 
2.1.1. Ethical approval 
Version 4 of the study protocol (see appendix) was approved by Leeds (West) 
Research Ethics Committee on 25 Oct 2005 (ref 05/Q1205/54). 
2.1.2. Consent, inclusion and exclusion criteria 
Patients were recruited to the study if they had presented to hospital with an ACS 
– UA, NSTEMI or STEMI – and went on to have PCI. Patients who were unwilling or 
unable to provide written consent were not included, hence this study does not contain 
patients with an impaired conscious level such as in cardiogenic shock; and patients 
with a terminal illness were not recruited. There were no other exclusion criteria. 
For patients where PCI was planned, informed consent was obtained before the 
procedure where possible after reading the information sheet. For ad hoc PCI, verbal 
assent to take part and remove a blood sample was sought after the angiogram but 
before PCI. The patient then underwent the informed consent process when they were 
feeling well enough, usually on the ward within a few hours of the procedure. 
2.1.3. ACS diagnosis 
The final diagnosis in suspected ACS patients was made by the local medical team 
responsible for the patient‟s clinical care. Unstable angina (UA) was diagnosed if the 
symptoms were attributable to myocardial ischaemia in the absence of elevated cardiac 
biomarkers. Myocardial infarction was diagnosed when ischaemic symptoms were 
accompanied by elevated cardiac biomarker levels and categorised as NSTEMI or 
STEMI on the basis of the ECG changes. The STEMI patients recruited into this study 
may have had primary, rescue (failed thrombolysis) or convalescent PCI. 
The standard cardiac biomarker was Troponin I. Because patients were admitted 
to several different hospitals over a period of several years, TnI assays by a range of 
different manufacturers were used. Note that most of the assays used over this period of 
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time had not been tested for precision at the level of rigor required to meet the definition 
of a „high-sensitivity‟ troponin assay according to the most recent recommendations. 
2.1.4. Participating hospitals 
All PCI was undertaken at a single tertiary cardiology centre (Leeds General 
Infirmary). However, the patient may have initially presented to any one of ten or more 
surrounding district general hospitals within the West Yorkshire cardiac network; see 
Table 3.1. 
2.1.5. Standard medical ACS care 
Unless contra-indicated, all ACS patients received contemporary standard 
evidence-based medical therapy including dual antiplatelet therapy (DAPT), statins, 
beta blockers, ACE inhibitors and anticoagulant agents. The antiplatelet regime was 
300mg aspirin administered soon after first presentation, often by paramedic staff pre-
hospital, followed by 75 mg per day. The standard second antiplatelet agent was 
clopidogrel, given as a loading dose of 300 mg on arrival to hospital followed by 75 mg 
per day. If the total clopidogrel dose ingested was less than 600 mg at the time of PCI, 
additional clopidogrel was administered pre-procedure to bring the total to 600 mg. In 
2009 prasugrel was introduced for use in PPCI or for patients with clopidogrel 
sensitivity, given as a 60 mg loading dose followed by 10 mg per day, or 5 mg per day 
if aged over 75 years. 
Anticoagulants were prescribed shortly after arrival to hospital to patients in 
whom ACS was strongly suspected, administered subcutaneously, and continued for a 
minimum of 48 hours in patients found to be troponin positive. The standard 
anticoagulants were weight-adjusted low molecular weight heparin or fondaparinux. 
IIbIIIa inhibitors, usually tirofiban, were administered by continuous intravenous 
infusion to patients with ongoing pain with ECG ischaemia after the initial medical 
therapy, or for recurrent symptoms. Abciximab tended to be reserved for administration 
in the cath lab. 
Patients with STEMI underwent urgent reperfusion therapy by thrombolysis 
and/or PPCI. 
2.1.6. PCI operators, techniques, methods and decision to treat 
PCI was undertaken by several different operators. Equipment, pharmacology, 
devices and implantation techniques were selected by each operator according to his 
individual preferences but within local procedural guidelines and availabilities. 
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Diagnostic coronary angiography was usually performed by the district general 
hospital (DGH) for patients presenting to hospitals other than Leeds General Infirmary, 
so in many cases the PCI strategy could be planned in advance and discussed with 
colleagues at an MDT meeting if required. In unstable cases and in patients presenting 
directly to the Leeds General Infirmary, „ad hoc‟ emergent PCI was performed (decision 
to treat made on-table after diagnostic images obtained; PCI carried out directly during 
the same procedure). 
2.2. Study Funding 
The materials used in the study were partially funded by unrestricted educational 
awards from Eli Lilly and the Medicines Company. Assistance with nursing support 
was provided by the NIHR. Randox funded biomarker analysis. 
2.3. Data collection 
Data was collected by the study nurses and cardiology registrar using a paper case 
report form (CRF). The data was then transferred to a computer database by the study 
nurse, medical staff and data entry staff. 
2.4. Data storage and security 
Paper CRFs were stored in numerical order in a locked filing cabinet. The 
electronic database was located in the University of Leeds and was password protected. 
2.5. Data fields 
See for the CRF in the Supplementary Material for data points collected. 
2.5.1. Identification and demographic data 
 Name, date of birth, gender, general practitioner details, address and 
telephone numbers 
 Mode (UA, NSTEMI, STEMI, PPCI), date and hospital of presentation, and 
occurrence of cardiac arrest or malignant arrhythmia. 
2.5.2. Previous medical background 
 History of coronary disease and prior revascularisation details 
 Co-morbid medical conditions (respiratory problems, cerebrovascular 
disease) 
 Cardiovascular risk factors (diabetes mellitus, hypertension, smoking 
history, family history, hypercholesterolaemia) 
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2.5.3. Pre-PCI clinical details 
 Medication etc 
2.5.4. Angiographic data, PCI procedural details and complications 
Coronary angiograms were reported by UMS and IRP. The location of each lesion 
was recorded by allocating the lesion to a numbered coronary segment: 1 segment for 
the LMS, 5 segments for the LAD territory, 4 for the Cx territory and 4 for the RCA 
territory. The following angiographic and procedural details were recorded for each 
lesion: 
 Visual estimate of vessel diameter and percent stenosis 
 Presence of thrombus, calcification 
 ACC/AHA classification of lesion complexity – see table 2-1 
 TIMI grade flow before and after procedure. Note: TIMI 0 flow is absence 
of antegrade flow; TIMI 1 flow is faint antegrade coronary flow with 
incomplete filling of the distal coronary bed; TIMI 2 flow is reduced flow 
but with complete filling of the distal territory; TIMI 3 flow is normal brisk 
flow (ref) 
 Use of pre- or post-dilatation and balloon sizes 
 Types and sizes of each stent 
 Procedural success/complications 
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Table 2-1   ACC/AHA lesion complexity characteristics; Ellis modification, Circulation 
1990; 82:1193-1202 
Type A lesion 
High success rate, low risk 
Type B lesion 
Moderate success, moderate risk 
(Type B1 lesions: one B characteristic 
only; Type B2 lesions: more than one 
B characteristic) 
Type C lesion 
High risk, low success rate 
Discrete (<10mm in length) Tubular (10 to 20mm in length) Diffuse lesion (>20mm in length) 
Concentric Eccentric Excessive tortuosity 
Readily accessible Moderate tortuosity Extremely angulated (>90°) 
Non-angulated Moderately angulated (45 to 90°) Inability to protect major side 
branch 
Smooth contour Moderate calcification Degenerated vein graft 
Little or no calcium Irregular contour Total occlusion > 3 months old 
No thrombus Some thrombus  
Not located at ostium or 
bifurcation 
Requires double guidewires  
 Ostial lesion  
 Bifurcation lesion  
 Total occlusion < 3 months old  
2.5.5. Procedural success and complications 
Angiograms and clinical records were reviewed independently by UMS and IRP 
for complications and procedural success.  
2.5.5.1. Technical success 
Technical success was said to have occurred if at the end of the procedure:  
 There was no angiographically significant obstructive disease (<50% 
residual angiographic stenosis) within 10 mm either side of the treated 
lesion 
 There was brisk flow (TIMI III) in all major branches (>1.5 mm in 
diameter) involved in the treated lesion. 
NB if a side branch was angiographically „pinched‟ or „trapped‟ but with brisk 
flow, as per convention this was reported as technical success for the lesion. 
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For lesions without technical success an explanation was recorded, classified into 
the following categories: 
 Unable to penetrate the lesion – chronic total occlusion 
 Lesion crossed but unable to dilate – heavy calcium 
 Lesion crossed and dilated but residual stenosis >50%, but with good flow 
 Lesion crossed and dilated but residual stenosis >50%, but with poor flow 
(<TIMI III) 
 No mechanical obstruction/stenosis but poor flow at the end of the case due 
to microvascular obstruction: „no-reflow‟ phenomenon 
 Loss of any significant calibre vessel (>1.5 mm) 
2.5.5.2. Periprocedural complications 
Periprocedural complications were given a detailed description and further 
categorized into an intra-procedural thrombotic event*, MACCE event† or BARC 
bleeding event 
 Distal embolization of thrombus 
 Slow flow/no reflow main vessel 
 Thrombus formation 
 Transient vessel closure 
 Localised edge dissection requiring no treatment or one further stent without 
loss of flow to vessel (does not include intended 2 stent strategy) 
 Extensive dissection requiring multiple extra stents 
 Loss of a side branch – less than TIMI III flow in the side branch at the end 
of the procedure; vessels greater than 1.5 mm in diameter 
 Angiographic pinching/trapping or dissection of side branch but normal 
flow 
 Coronary perforation 
 Ventricular fibrillation 
 Complete heart block or other bradycardia requiring temporary pacing 
 Acute neurological symptoms/signs compatible with ischaemia i.e. stroke 
 Acute neurological symptoms/signs compatible with contrast reaction 
 Allergic reaction 
 Cardiac tamponade requiring drainage 
 False aneurysm 
 GI bleed 
 Retroperitoneal bleed 
 Intracranial bleed 
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 Access site haemorrhage 
 Peripheral arterial occlusion requiring any intervention 
 Acute stent thrombosis (within 24 hours) 
 Infection 
 Acute renal failure 
 Pulmonary oedema 
 Death on table 
 Non VF cardiac arrest 
 Catheter tip dissection (not related to treatment of a lesion) 
* „Intra-procedural thrombotic event‟ is a composite of distal embolisation, 
slow/no flow, new thrombus formation and transient vessel closure 
† „MACCE event‟ is major adverse cardiac or cerebrovascular event 
2.5.6. Reporting the SYNTAX score 
A single operator (U. M. Sivananthan) calculated SYNTAX scores using the 
online calculator. 
2.5.7. Pre- and post-procedural ECG 
The ECG with the most marked ischaemic changes was used as the „pre ECG‟; the 
„post ECG‟ was taken within an hour after PCI in the recovery ward. If the patient‟s 
admission ECG changes had resolved by the time of PCI, the post ECG recorded new 
changes relative to the immediately pre-procedure ECG rather than the admission ECG, 
in order to capture changes which would indicate a procedural MI. ECGs were reported 
by a cardiologist or experienced study nurse. The following parameters were recorded: 
 ST deviation or T wave changes 
 Distribution of changes (anterior, inferior, posterior, lateral) 
 Bundle branch block 
 Paced rhythm 
2.6. Follow up 
Cardiac symptoms, further hospital admissions, MACCE events (ACS, stroke, 
unplanned revascularisation or death), and bleeding events were recorded. Attempts 
were made to contact every patient by telephone; the GP was contacted for information 
about medication or clinical details. DGHs were contacted to supply copies of medical 
notes when there had been an admission or outpatient clinic review when this pertained 
to the study. 
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The NHS Information Centre provided the certified date and cause of death. When 
the death had been cardiovascular, the hospital notes were inspected where possible. 
When a post mortem examination had taken place the pathologist‟s report was obtained 
by application to the coroner‟s office. 
2.7. Arbitration of clinical events 
All MACE events were defined using ARC criteria (see introduction for 
discussion) after case review by an events committee. 
 Death: total, cardiac, vascular and non-cardiovascular as per ARC criteria 
 Spontaneous MI: the ARC has agreed to define MI according to Universal 
Criteria of MI definitions. A troponin positive event which was provoked by 
a non-cardiac acute illness such as chest infection, without symptoms or 
ECG changes, was not counted as an MI. 
 Stent thrombosis: as per ARC criteria for definite, probable and possible 
 Target lesion revascularisation as per ARC  
 Target vessel revascularisation as per ARC 
 Stroke. No ARC criteria. Stroke was defined as a sudden neurological event 
attributable to acute cerebral ischaemia or intracranial haemorrhage. CT or 
MRI scan reports were obtained where possible. 
 Bleeding was defined according to BARC criteria 
Procedural MI was diagnosed according to the Universal Definition of MI 2012 
as follows: 
If troponin below 99th percentile of upper reference limit (URL) of the normal 
range in a healthy population at baseline, then must rise to greater than 5 times this 
level.   
If elevated above 99
th
 percentile URL at baseline and the level is stable or falling, 
the level must rise to greater than 20% of the initial value. 
If biomarkers are rising (as in primary PCI patients) procedural injury cannot be 
reliably calculated 
The 2012 Universal Definition requires additional clinical features in addition to 
biomarker elevation for the diagnosis of procedural MI. These are:  (i) symptoms 
suggestive of myocardial ischaemia or (ii) new ischaemic ECG changes or (iii) 
angiographic findings consistent with a procedural complication or (iv) the loss of 
viable myocardium or a new regional wall motion abnormality demonstrated by cardiac 
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imaging. Biomarker elevation following PCI without these clinical features is referred 
to as „procedural myocardial injury‟ rather than „procedural MI‟. 
2.8. Blood tests 
Study blood samples were collected at 3 time points: baseline (from the arterial 
sheath just prior to PCI), 4 hours post PCI and 12 hours post PCI (by standard 
venesection). 
2.8.1. VerifyNow test methods 
Blood was drawn from the arterial sheath pre-PCI into a 2ml citrated (3.2%) 
Greiner tube and processed according to the manufacturer‟s instructions. In brief, 
samples were allowed to stand for at least 20 minutes and were analysed within 4 hours. 
The collection tube was inserted into an individual assay platform and then into the 
analyser, after which point the test was fully automated. The analyser was frequently 
calibrated using its own calibration system as per manufacturer‟s instructions, usually 
before each new sample but at least once per day. The test result, available in less than 3 
minutes, was immediately recorded on the paper CRF front sheet and later transcribed 
into the e-CRF. 
2.8.2. Biomarker measurement methods 
Blood samples for biomarker measurement were drawn into 4ml clot activating 
gel separator serum Greiner tubes and spun at 1500 RPM for 10 minutes. The serum 
was transferred to a freezer tube and placed in a -21°C freezer situated at the research 
work station for temporary storage. Samples were transferred in batches every few days 
to permanent storage at -80°C. In addition, 2 × 4ml citrate Greiner tubes were filled 
from the arterial sheath pre PCI and were spun and stored as above. 
All samples were labelled in the following ways: 
 Each freezer tube had an individual patient code written in permanent 
marker pen, derived from the first 3 letters of the surname, first 3 letters of 
the first name and the date of birth. For example, the code for John Smith 
with date of birth 10
th
 May 1950 would be SMIjoh100550. 
 The time the sample was taken was indicated by the colour of the tube‟s 
cap: red for time 0, orange for 4 hour and green for 12 hour. A blue cap was 
used to indicate the (time 0) citrated sample. 
 An adhesive label with a unique barcode was applied to each tube, with a 
copy of the barcode placed on the front sheet of the paper CRF with the type 
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of sample and time taken clearly indicated. At a later date these barcodes 
were scanned into the electronic CRF. 
The stored serum was couriered in liquid nitrogen to the Randox laboratory, N. 
Ireland, for biomarker measurement. Results were delivered by e-mail to the Leeds 
cardiology data manager (R.G.), matched using the unique barcode number allocated 
when the sample was first taken and imported into the Leeds study database for analysis 
by A.S.H. and I.R.P. 
Biomarker measurement at Randox was undertaken using the patented RANDOX 
cardiac biomarker array. The array measures 6 cardiac biomarkers: heart-type fatty acid 
binding protein (HFABP), myoglobin, glycogen phosphorylase BB, TnI, CK-MB mass 
and carbonic anhydrase III. See Supplementary Appendix (CD) for further product 
information. Note that carbonic anhydrase III is not a cardiac biomarker, being found 
exclusively in skeletal muscle, but is used with myoglobin (not a cardiac-specific 
biomarker) to indicate the proportion of the latter which may be from a cardiac origin. 
In addition, a high sensitivity cardiac troponin I level (Advia Centaur TnI Ultra, 
Siemens) was measured at Randox Laboratories. For this assay the published 99
th
 
centile of a healthy pop of 648 individuals (aged 17 to 91 years) testing 1845 fresh 
samples was 0.04 µg/L; CoV is <10% at this level. The minimum detectable 
concentration was 0.006 µg/L. 
These biomarkers have differing release kinetics following myocardial injury: CK-
MB peaks at approximately 18 to 36 hours and is cleared over several days; myoglobin 
peaks after a few hours and is rapidly cleared; and cTnI peaks at 12 to 24 hours but may 
not be cleared for 2 to 3 weeks. HFABP rises and falls very rapidly compared to the 
other biomarkers, within minutes to hours. Hence we have studied myocardial injury 
using the baseline and 12 hour samples for CK-MB and cTnI; and baseline and 4 hour 
samples for myoglobin and HFABP. 
2.8.3. Sample storage for genetic analysis 
Blood for genetic analysis was taken from the arterial sheath pre PCI (3 9ml 
EDTA Greiner tubes). The tubes were labelled with the patient code as above and 
frozen at -21°C. Twice weekly, batches were processed to remove the red cells and lyse 
the white cells, producing a stable solution containing DNA. This solution can be stored 
for several years at room temperature. Each sample was labelled with a unique lab 
number which was recorded in a lab book with the patient code. The lab number was 
also entered into the electronic CRF. 
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2.8.4. Other blood parameters 
Pre procedure full blood count and renal function were recorded from the patient 
notes. Lipid levels were documented when these had been checked. 
2.9. Statistical analysis 
The population was described using crude numerical data (with percentages) for 
categorical variables; and by medians with interquartile range (IQR), or mean with 
standard deviation (SD) when normally distributed, for continuous variables. Groups 
were compared using two-sided Student‟s t-tests and one-way ANOVA for continuous 
parametric data and the Mann-Whitney U (if two categories) and Kruskal-Wallis (if 
more than two categories) tests for non-parametric variables. Categorical data were 
compared using
 
a two-sided Pearson Chi-squared test. A linear by linear association 
Chi-squared test was used to identify differences between the expected and observed 
frequencies if more than 2 categories. 
Survival time was calculated from the date of PCI to the date of censorship (the 
first on-treatment adverse event or last clinical contact). Unadjusted survival estimates, 
stratified by the presence of risk factors, were depicted using Kaplan–Meier curves, and 
the Mantle log rank test used to compare distributions.  Survival was studied using Cox 
proportional hazards models, proportional assumptions were tested and not violated. 
Initially, models were fitted using clinically and statistically (p<0.01) significant patient 
and treatment characteristics as univariables, from which a parsimonious models were 
built for time to the combined endpoint. Regression model parameter estimates were 
represented by adjusted hazard ratios (aHR) and 95% confidence intervals (CI). All 
analyses were conducted using IBM SPSS Statistics Version 20. 
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Chapter 3     Description of overall patient population 
3.1. Selection of patients for this analysis 
 1018 patients provided informed consent to be included in the study 
 9 patients subsequently withdrew consent and their data was removed from 
the electronic database (PAT IDs: 1038, 1039, 925, 928, 930, 513, 994, 995, 
1042) 
 6 patients provided prior written consent but did not undergo PCI or 
attempted PCI (5 had normal coronaries, 1 underwent IVUS examination 
only); their data was retained but the patients were excluded from all 
analyses (PAT IDs: 174, 427, 481, 706, 998, 1032) 
 35 patients either had no record of ACS prior to PCI  and were re-
categorised as elective stable patients, or the ACS was very remote (the 
initial management strategy was medical and the patient discharged home 
without a plan for PCI: patients were effectively elective/stable at the 
eventual time of PCI); data for these 35 were retained in the database but 
not included in this analysis (PAT IDs: 67, 83, 246, 397, 446, 550, 583, 683, 
684, 685, 686, 693, 699, 702, 703, 710, 717, 733, 734, 735, 736, 737, 741, 
746, 749, 750, 760, 765, 767, 769, 771, 772, 773, 778). Patients for whom 
the initial management strategy was revascularisation but for whom this was 
unusually delayed for any reason (for example co-morbid conditions 
requiring medical work-up, patient indecision, outstanding investigations or 
surgical assessments) were not excluded, hence prolonged time from ACS 
to PCI for some patients. 
 Therefore, data for 968 patients with valid written informed consent, 
presenting with ACS and undergoing PCI, are included in these analyses. 
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3.2. Recruitment timescale 
The first patient had PCI on 1
st
 June 2006 and the final patient 6
th
 July 2011. 
Figure 3-1 illustrates recruitment rates over the 5 year period. There were 2 distinct 
recruitment time phases; no patient recruitment took place between 29
th
 Oct 2008 and 
1
st
 June 2010. 
  
Figure 3-1   Histogram showing the changes in patient recruitment rate over time 
 
 
3.1. Time from ACS to PCI 
The median (IQR) time from ACS to PCI was 6 (6) days for 873 patients 
presenting with ACS, excluding PPCI patients. 941 (97%) patients had PCI within 30 
days of first hospital admission. 5 patients had severely delayed PCI (PAT IDs 755, 
181, 889, 697, 715 and 761 had PCI 119, 129, 138, 140, 150 and 176 days following 
ACS). Patients presenting directly to the PCI centre (Leeds) received intervention 
sooner than those presenting to a district general hospital (DGH), shown in Table 3-1. 
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Table 3-1   Time from admission to PCI for patients presenting to different hospitals 
Admitting Hospital Number of days from ACS to PCI 
(Excluding 96 patients presenting with PPCI and 4 
patients with missing data) 
Median days Number of patients 
Leeds (LGI or St James') 4 248 
Airedale 7 51 
Bradford 8 12* 
Dewsbury 5 57 
Harrogate 6 23 
Huddersfield 7 90 
Pinderfields (Wakefield) 10 107 
Pontefract 11 64 
Calderdale (Halifax) 6 80 
York 7 136 
All 6 868 
*Bradford Royal Infirmary had PCI capability during the study recruitment period, hence the small 
numbers of referrals relative to the other hospitals. 
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3.2. Data completeness and patient follow-up 
3.2.1. Missing clinical and procedural characteristics  
For the 968 patients in these analyses, data was >98% complete for all fields 
except: 
 A VerifyNow P2Y12 receptor Platelet Function Test result was missing in 
103 (10.6%) cases. Of these, 63 patients had received pre-treatment with a 
IIbIIIa inhibitor making testing impossible; in the most of the remainder the 
test was deliberately not performed because of inadequate P2Y12 inhibitor 
loading time in PPCI patients. According to the study protocol, testing was 
to be carried out using blood drawn at the time of PCI; we therefore did not 
attempt to bring patients with missing results back for a test at a later date 
 In 491 (50.7%) patients we could find no record of an assessment of Left 
Ventricular Systolic Function in the Leeds or the DGH medical case files 
or electronic records, either pre-procedurally or during follow-up. Although 
this is an important prognostic variable, the requesting of tests to assess LV 
function was not part of the study protocol and an LV function measurement 
was often omitted from routine medical care 
 Pre-procedural Renal Function was not documented for 21 (2.2%) patients; 
and post-procedural renal function was unrecorded for the majority of 
patients (777, 80%) 
 A pre-procedural Full Blood Count was unrecorded for 78 (8.1%) patients 
 Data on pre-procedural ACE-inhibitor use and B-blocker use were 
unrecorded for 55 (5.7%) and 52 (5.4%) patients respectively 
 A SYNTAX score was missing for 20 (2.1%) patients (angiograms 
irretrievable) 
 A post-procedural ECG was not stored for 70 (7.2%) patients 
3.2.2. Length and completeness of patient follow-up 
The median (IQR) time from PCI to final clinical follow-up or death was 3.56 
(1.31) years, giving a total of 3,226 patient-years of clinical follow-up. 
The median (IQR) time from PCI to death (censored 13
th
 June 2013) was 5.35 
(3.42) years, giving a total of 4590 patient-years of mortality tracking. 
All surviving patients had at least 1 episode of clinical follow-up by telephone or 
outpatient clinic. Of the 940 patients alive at 1 year, 14 (1.5%) patients had less than 12 
months clinical follow-up. These patients are listed in Table 3-2. 
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Table 3-2   Patients with less than 12 months clinical follow-up 
Patient ID Time from PCI to last clinical 
follow-up 
Reason 
75 31 days Patient emigrated, lost to F/U 
907 36 days No record of 1 year F/U on database 
840 99 days Unable to trace patient 
432 184 days No record of 1 year F/U on database 
987 223 days No record of 1 year F/U on database 
1045 248 days No record of 1 year F/U on database 
1020 249 days No record of 1 year F/U on database 
831 253 days Had CABG at 6 months, censored 
494 277 days Unable to trace patient 
1000 300 days No record of 1 year F/U on database 
990 315 days No record of 1 year F/U on database 
909 341 days No record of 1 year F/U on database 
984 343 days No record of 1 year F/U on database 
988 343 days No record of 1 year F/U on database 
3.3. Baseline characteristics 
In this section are presented the baseline clinical characteristics on admission of 
the OPERA study patients. I have included some of the important procedural 
characteristics, including pharmacotherapy and stent type. This study recruited patients 
over a long time period (2006 to 2011) and in 2 distinct phases. While the incidence of 
many characteristics remains stable over time, several important characteristics became 
more or less frequent; these are discussed in the following sections. In this section I 
have also highlighted the inter-relationship between many of the important baseline 
characteristics. 
3.3.1. Age 
The mean (SD) age on the date of PCI of the total cohort was 62.2 (12.0) years. 
The age distribution is shown in Figure 3-2. Only 25 (2.6%) patients were under 40 
years. The youngest patient was 27, a previously well South Asian male smoker who 
presented with a NSTEMI. He was treated with 3 „Cypher‟ sirolimus-eluting stent to his 
LAD. 
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There were 70 (7.2%) patients aged 80 years or more; the oldest patient was 90. 
He presented with a NSTEMI on a background of previous CABG, previous PCI and 
diabetes. He had PCI to his native circumflex artery with a „Xience‟ everolimus-eluting 
stent. 
The age of the overall cohort did not change significantly by year of presentation, 
see Figure 3-3. However, when patients with UA or NSTEMI were considered (STEMI 
excluded), the mean age increased slightly between the 2 recruitment phases: 62.7 
(12.0) years vs. 65.0 (12.9) years in the first and second phases, p = 0.04 (Figure 3-4). 
STEMI patients tended to be younger and formed a greater proportion of the patients 
recruited in the second phase, discussed further in Section 3.5.6. 
 
Figure 3-2   Histogram showing age distribution in the OPERA cohort 
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Figure 3-3   Comparison of patient age by year of procedure 
 
 
Figure 3-4   Comparison of age of patients in first and second recruitment phases, 
stratified according to clinical syndrome 
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3.3.2. Gender and other baseline characteristics 
Women comprised 25% of all patients recruited into this study, a proportion which 
remained stable over the time course of the recruitment period. There were 2 main 
differences in baseline characteristics between men and women. Firstly, there was a 
difference in clinical syndrome at presentation between men and women, with women 
being more likely to present with UA and men with STEMI, see Table 3-3. Secondly, 
women were older than men by nearly 6 years on average in this study: 66.3 (12.1) 
years vs. 60.8 (11.7) years, p < 0.01. 
There were no significant differences in the rates of other baseline characteristics 
or co-morbidities between the 2 sexes. 
3.3.3. Body Mass Index; incidence of overweight and underweight 
patients 
The median (IQR) BMI was 28 (6) for the entire cohort. The lowest BMI was 15 
and the highest was 76 (this patient was only 105 cm tall but weighed 86 kg). According 
to the classification proposed on the NHS Patient Choices website, 80.4% of patients in 
this study were either „overweight, obese or very obese‟ with a BMI ≥ 25. Of the total 
cohort, 37.1% of patients had a BMI ≥ 30, and in 3.8% the BMI was ≥ 40.  Only 7 
(0.7%) patients had a BMI < 20 (underweight). 
Patients with diabetes had higher BMIs than those without, 30 (7) vs. 28 (6), p < 
0.01. Also, BMI increased slightly between the first and second recruitment phases: 
27.9 (6) vs. 28.9 (5), p = 0.01. There was no significant difference in BMI between men 
and women, or between patients presenting with different clinical syndromes. 
3.3.4. Diabetes and other baseline characteristics 
The proportion of patients known to have had diabetes mellitus (DM) of any type 
was 16.5% for the overall cohort. The incidence of Type I DM was 2.6% and of Type II 
DM was 13.8%, with missing data in 2 patients. Patients with diabetes tended to be 
older: the mean age in those with and without DM was 65.5 (12.1) vs. 61.6 (11.9) years, 
p < 0.01. 
The proportion with DM (any type) was slightly higher (17.9%) when PPCI 
patients were excluded from the analysis. Some of the PPCI patients may have had 
undiagnosed diabetes, whereas undiagnosed DM would be very unlikely in UA and 
NSTEMI patients who have spent several days in hospital. We did not record the 
incidence of new diagnoses of DM following emergent PCI for ACS in this study. 
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Patients with DM had an increased incidence of co-morbidities compared to those 
without.  These included a previous history of angina (67.9% in those with DM vs. 
40.0% in those without DM, p < 0.01); previous MI (37.7% vs. 20.7%, p < 0.01); 
previous PCI (18.9% vs. 10.2%, p < 0.01); a history of CABG (14.5% vs. 6.1%, p < 
0.01); a previous diagnosis of heart failure (5.0% vs. 0.9%; p < 0.01); a history of 
hypertension (67.9% vs. 47.2%, p < 0.01); a history of hyperlipidaemia (65.4% vs. 
54.7%, p = 0.01); a history of obstructive airways disease (18.9% vs. 9.0%, p < 0.01); 
renal failure (Cr >200 µmol/L) (6.3% vs. 1.6%, p < 0.01); and a past history of stroke 
(8.2% vs. 4.5%, p = 0.05). Patients with DM were also more likely to be anaemic 
(Haemoglobin < 10g/dL) (6.2% vs. 1.1%, p < 0.01). 
The proportion of patients with DM increased over the time course of the study 
from 14.7% during the first recruitment phase to 21.6% in the second, p = 0.01. See 
Figure 3-5 for numbers of patients with and without DM per year of recruitment. 
 
Figure 3-5   Bar chart showing the numbers of patients with and without diabetes by year 
of procedure 
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3.3.5. Previous ischaemic heart disease and other baseline characteristics 
Of the total cohort 44.6% of patients reported a previous history of angina and 
23.5% a previous history of MI. 17.1% had undergone revascularisation previously, 
11.6% by PCI and 7.4% by CABG. Overall, nearly half of the total cohort (462 patients, 
47.7%) had a previous history of some type of clinical/symptomatic IHD. 
The clinical syndrome at presentation was different in patients with and without 
previous symptomatic IHD. Most of the patients presenting with UA had a prior history 
of IHD (81.5%), compared to 47.8% of the NSTEMI patients but only 28.1% of the 
STEMI patients, p < 0.01. 
Previous IHD (any type) was associated with a higher incidence of DM (24.3% vs. 
9.3%, p < 0.01); obstructive airways disease (13.0% vs. 8.5%, p = 0.02); a history of 
stroke (7.1% vs. 3.2%, p < 0.01); and a history of renal failure (serum creatinine > 200 
µmol/L) (4.3% vs. 0.6%, p < 0.01). Patients with prior IHD were older than those 
without: 65.0 (12.3) years vs. 59.7 (11.3) years, p < 0.01. There was no difference in the 
incidence of previous IHD between men and women. 
The proportion of patients presenting with a past history of clinical IHD decreased 
over time: 50.2% in the first phase of recruitment compared to 40.4% in the second 
phase, p < 0.01. Likewise the proportion of patients with a previous history of angina 
decreased over the course of the study from 48.7% during the first phase to 32.7% in the 
second phase, p < 0.01. Conversely, there was a small increase from the first to the 
second recruitment phase in the number of patients having had a previous MI (21.9% 
vs. 28.2%, p = 0.04). The proportion of patients with previous revascularisation was not 
significantly different over time. 
Most patients in this study (93.4%) underwent PCI to „de novo‟ lesions – i.e. 
lesions in native coronary arteries which have undergone no previous revascularisation 
attempts. However, several patients had PCI following an ACS which resulted from 
failure of a previous revascularisation. There were 31 cases of saphenous vein graft 
(SVG) PCI in patients with degenerated bypass grafts, 33 cases of PCI to treat in-stent 
restenosis after an earlier PCI, and 3 cases of SVG PCI which were re-interventions due 
to restenosis of a bypass graft following a previous PCI. 
3.3.6. Clinical syndrome and other baseline characteristics 
Of the total cohort, 124 (12.8%) patients presented with unstable angina (UA), 627 
(64.8%) with NSTEMI, and 217 (22.4%) with STEMI. Of the STEMI patients, 121 
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(12.5% of the total cohort) received pharmacological thrombolysis followed by 
convalescent PCI; and 96 (9.9% of the total cohort) received PPCI. 
Patients unable to provide informed consent such as those in cardiogenic shock 
were not recruited into the OPERA study as retrospective consent was not part of the 
protocol. However, a few patients did receive some form of cardiopulmonary 
resuscitation prior to PCI: 8 (1.4%) patients with NSTEMI; and 11 (5.2%) patients with 
STEMI. 
Patients presenting with UA, NSTEMI and STEMI had different baseline 
characteristics, see Table 3-4. Patients with STEMI were younger than patients with 
NSTEMI or UA, were more likely to be current smokers and were much less likely to 
have a previous history of IHD. STEMI patients were also less likely to have a prior 
diagnosis of several co-morbidities including hypertension and diabetes; and they were 
less likely to have poor renal function. Patients presenting with MI were more likely to 
have a history of smoking and were more likely to be male compared to UA patients. 
Despite these differences in baseline characteristics there was no significant 
difference in either EuroSCORE or in SYNTAX score between patients presenting with 
different clinical syndromes. Median (IQR) EuroSCORE and median SYNTAX score 
were both relatively low in the OPERA study: for the overall cohort these were 3.1 (4.5) 
and 9.0 (10.0) respectively. 
Note: ethnicity is omitted from Table 3-4. Of the whole cohort, 920 (95.0%) of the 
patients were White, 43 (4.4%) South Asian (India, Pakistan or Bangladesh), 3 Afro-
Caribbean, 2 South East Asian (China), and 1 patient described himself as Mixed Race. 
3.3.7. Changes in clinical syndrome over time 
Over the course of the recruitment period of this study a regional primary PCI 
service was established resulting in changes in the proportions of patients admitted with 
the different clinical syndromes. PCI for STEMI became more frequent and PCI for UA 
less so. In the first and second recruitment phases the proportions with UA, NSTEMI 
and STEMI were 15.5%, 67.8% and 16.7% and 4.9%, 55.9% and 39.2%, p < 0.01. PPCI 
gradually replaced thrombolysis as the treatment for STEMI across the region during 
the study recruitment period: only 1 of the 44 STEMI patients recruited in 2006 
received PPCI, compared to 32 of the 35 STEMI patients recruited in 2011; see Figure 
3-6  
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Table 3-3   Comparison of baseline characteristics in patients presenting with unstable 
angina, NSTEMI and STEMI 
Characteristic 
Dichotomous characteristics expressed as Number 
(% within clinical syndrome)  
UA 
N = 124 
NSTEMI 
N = 627 
STEMI 
N = 217 
P value 
Demographics     
Mean (SD) age, years 61.8 (10.9) 63.4 (12.4) 59.0 
(10.9) 
<0.01 
Female 38 (30.6) 160 (25.5) 44 (20.3) 0.09 
Median (IQR) Body Mass Index 28.1 (7) 27.9 (6) 28.1 (5) 0.81 
Recruited in first phase (2006 to 2009) 112 (90.3) 490 (78.1) 121 (55.8) 
< 0.01 
Recruited in second phase (2010 to 2012) 12 (9.7) 137 (21.9) 96 (44.2) 
Any history of chronic smoking 74 (59.7) 431 (69.2) 161 (74.5) 0.02 
            Ex-smoker 52 (42.4) 243 (39.0) 63 (29.2) <0.01 
            Current smoker (within 4 weeks of ACS) 22 (17.6) 188 (30.2) 98 (45.4) <0.01 
Family history of IHD, 1
st
 degree relatives 69 (57.5) 313 (52.3) 107 (51.4) 0.53 
Medical history     
Angina 98 (78.4) 288 (45.9) 46 (21.2) <0.01 
Previous MI 35 (28.0) 157 (25.0) 35 (16.1) 0.01 
Previous PCI 29 (23.3) 67 (10.7) 16 (7.4) <0.01 
Previous CABG 17 (13.6) 49 (7.8) 6 (2.3) <0.01 
Diabetes, any type 22 (17.6) 112 (17.9) 25 (11.5) 0.09 
Hypertension 73 (58.4) 334 (53.3) 82 (37.8) <0.01 
Lung disease, any type 14 (11.2) 72 (11.5) 17 (7.8) 0.32 
Previous stroke, any type 4 (3.2) 37 (5.9) 8 (3.7) 0.26 
Peripheral vascular disease 2 (1.6) 35 (5.6) 6 (2.8) 0.06 
Clinical heart failure, any class 0 14 (2.2) 1 (0.5) 0.06 
Untreated moderate or severe aortic stenosis 2 (1.6) 10 (1.6) 0 0.17 
Pre PCI blood results     
Median (IQR) serum creatinine, µmol/L 92 (30) 95 (24) 94 (19) 0.51 
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            Serum Cr ≥ 200 µmol/L 1 (0.8) 19 (3.0) 3 (1.4) 0.18 
            eGFR <60ml/min/1.73m
2
 38 (30.6) 211 (34.6) 44 (20.8) <0.01 
Median Haemoglobin, g/dL 14.1 (2.0) 14.0 (2.1) 14.1 (2.2) 0.58 
            Haemoglobin <10 g/dL 1 (0.9) 13 (2.3) 3 (1.5) 0.55 
Median platelet count x10
9
/L 244 (71) 248 (87) 253 (106) 0.07 
Median (IQR) VerifyNow Base value* 318 (94) 309 (80) 296 (103) 0.06 
Median (IQR) VerifyNow PRU value* 259 (156) 241 (116) 239 (148) 0.69 
Median (IQR) VerifyNow %inhibition value* 21 (41) 20 (39) 18 (42) 0.93 
*PPCI patients excluded from VerifyNow analysis     
Medication at PCI     
Aspirin 120 (96.0) 609 (97.3) 209 (97.2) 0.73 
Clopidogrel 124 (100.0) 626 (99.8) 165 (76.0) <0.01 
Prasugrel 0 3 (0.5) 52 (24.0) <0.01 
Dual antiplatelet therapy 119 (96%) 609 (97.3) 209 (97.2) 0.73 
Loaded with P2Y12 inhibitor <24hrs before PCI 9 (7.2) 16 (2.6) 99 (45.6) <0.01 
Loaded with P2Y12 inhibitor >3 days before PCI 105 (84.8) 512 (81.7) 98 (45.2) <0.01 
Heparin during PCI 121 (98.4) 576 (91.9) 137 (63.4) <0.01 
Bivalirudin during PCI 3 (2.4) 54 (8.6) 89 (41.6) <0.01 
IIbIIIa inhibitor use before/during PCI 27 (21.6) 207 (33.0) 78 (35.9) 0.02 
ACE inhibitor 56 (47.9) 447 (75.1) 114 (56.4) <0.01 
B blocker 93 (78.2) 483 (81.2) 116 (57.1) <0.01 
HMG-CoA reductase inhibitor 110 (88.8) 559 (89.2) 134 (61.8) <0.01 
Proton pump inhibitor 44 (35.2) 210 (33.5) 40 (18.4) <0.01 
Warfarin pre-ACS (stopped before PCI) 2 (1.6) 13 (2.1) 4 (1.8) 0.93 
Risk scores     
Median (IQR) EuroSCORE 1 3.1 (3.5) 3.1 (4.9) 3.0 (3.2) 0.77 
Median (IQR) SYNTAX score 9.0 (11.0) 9.0 (11.0) 8.0 (11.0) 0.40 
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Figure 3-6   Bar chart showing the change in proportions of patients with different clinical 
syndromes over time 
 
3.3.8. Pharmacology and other baseline characteristics 
Dual oral antiplatelet therapy (DAPT) was administered prior to PCI to 97.3% of 
patients. 28 (2.3%) patients received single antiplatelet therapy (29 patients clopidogrel 
only, 1 prasugrel only) due to aspirin intolerance. More than 80% of the UA, NSTEMI 
and convalescent STEMI patients received loading with a P2Y12 inhibitor 3 or more 
days prior to PCI, and only 28 (3.2%) received a P2Y12 inhibitor less than 24 hours 
prior to PCI. By far the most commonly used P2Y12 inhibitor was clopidogrel. Prasugrel 
was introduced in July 2010 and this drug was mainly used in PPCI (48 of the 55 
patients receiving prasugrel underwent PPCI). 
The most commonly used IIbIIIa inhibitor was abciximab in 261 (26.9% of the 
total cohort) followed by tirofiban (40, 4.1%), with eptifibitide used only in 2 patients. 
IIbIIIa inhibitors were administered more frequently in the presence of „high-risk‟ 
angiographic characteristics such as SVG PCI (48.6% vs. 31.6%, p = 0.03), bifurcation 
lesions (36.3% vs. 29.7%, p = 0.03), Type C lesions (43.9% vs. 24.7%, p < 0.01) and 
thrombotic lesions (48.8% vs. 26.7%, p < 0.01). Patients receiving a IIbIIIa inhibitor 
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were more likely to have an angiographic procedural complication reported (48.4% vs. 
29.9%, p < 0.01) and more commonly had presented with an MI than with UA (33.8% 
vs. 21.8%, p < 0.01). The use of IIbIIIa inhibitors declined steadily over the course of 
the recruitment period, from 47.0% in 2006 to 23.2% in 2011. 
The majority of patients were anticoagulated during their procedure with 
unfractionated heparin (86.3%), but bivalirudin was also used throughout the course of 
the study and was received by 146 (15.1%) patients, half of whom had PPCI (78 of the 
94 PPCI cases featured Bivalirudin use). 
At the time of PCI, Beta-blockers were received by 75.5%, ACE-inhibitors by 
67.6% and „Statins‟ by 83.1% of patients overall. The utilization of these medications at 
PCI appears to have decreased over time:  the proportions receiving the same drugs in 
2006 and 2011 were 80% vs. 62.8 %, 70.5% vs. 54.3% and 94.4% vs. 68.7%. However, 
when PPCI patients (who are taken immediately to the catheter laboratory on arrival at 
hospital) are excluded from the analysis this decrease is no longer seen (80.4% vs. 
87.3%, 70.8% vs. 73.0% and 94.4% vs. 89.6% in 2006 and 2011 for Beta-blockers, 
ACE-inhibitors and Statins). 
3.3.9. Arterial access route 
The most frequent arterial access route in the study, femoral, was used in 762 
(78.8%) patients, while 205 (21.2%) had radial access procedures (data missing for 1 
person). Over the course of the study recruitment period radial access gradually became 
more frequent than femoral, performed in only 3.5% of procedures in 2006 but in 71.7% 
in 2011. 
Radial access was used more frequently in patients undergoing PPCI (66.3%) 
compared to the other clinical syndromes. 
3.3.10. Stent selection and other baseline characteristics 
Both „first generation‟ and „second generation‟ stents were used in this study. The 
„first generation‟ DES used in this study were the „Taxus‟ paclitaxel-eluting and 
„Cypher‟ sirolimus-eluting devices. The „second generation‟ stents were the „Endeavor‟ 
zotarolimus-eluting and „Xience‟ everolimus-eluting devices. Small numbers of other 
DES types were used e.g. 8 patients received a „Biomatrix‟ absorbable-polymer DES, 
and 2 patients received a „Resolute Integrity‟ DES. 
At least 1 DES was deployed in 571 (59.0%) patients and at least 1 BMS in 423 
(43.7%), with 44 (4.5%) patients receiving both types. POBA („Plain Old Balloon 
Angioplasty‟) only was used in 12 (1.2%). 
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There was a tendency for more females than males to be treated with DES (62.0% 
vs. 55.4%, p = 0.08); and patients receiving DES were younger than those receiving 
BMS (mean age 61.2 years vs. 63.4 years, p < 0.01). Patients receiving BMS had 
shorter total stent length than those receiving DES (median 18mm vs. 27mm, p < 0.01), 
although the diameter of the smallest stent used was the same for DES and BMS 
(median 3.0mm). 
The types of stent implanted changed over the course of the study, shown in 
Figure 3-7. BMS were used in half of the patients during the first phase of recruitment, 
but only in 11.4% recruited in the second phase. Even during the first recruitment phase, 
second generation DES use had superseded first generation DES use (24.7% vs. 18.1%). 
In the second recruitment phase, only 7% received a first generation DES. BMS was the 
most frequently implanted stent type in the first recruitment phase (49.5%), followed by 
„Cypher‟ DES (16.2%). „Xience‟ DES was the most frequently implanted stent type in 
the second phase (76.7%) followed by BMS (11.4%). 
 
3.3.11. Angiography screening (fluoroscopy) time 
The total fluoroscopy (length of X-ray screening) time was recorded for every 
procedure in this study. After arranging all fluoroscopy times in ascending order as a 
graph (Figure 3-8), there appears to be a relatively normal range for this parameter, up 
to about 10 minutes. After this time there is an inflection point in the graph, which may 
prove useful as a cut-off to define more complex cases. 
3.3.12. Intravascular imaging 
Intravascular ultrasound (IVUS) was not a recorded data field; its use during this 
study was very limited. Optical coherence tomography (OCT) was not yet available. 
3.3.13. Rotational atherectomy 
 Rotational atherectomy was used in only 4 patients, 2.2% of the patients with 
heavily calcified lesions. 
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Figure 3-7  Bar chart showing changes in stent selection over time 
 
 
Figure 3-8   Fluoroscopy times for all cases arranged in ascending order; straight line 
indicates approximate normal range 
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3.3.14. SYNTAX score and other baseline characteristics 
The median (IQR) SYNTAX score for the whole cohort was 9.0 (10.0); Figure 3-8 
shows the distribution of scores. The SYNTAX score was different in patients with 
different baseline characteristics, shown in Table 3-4. Elderly patients had higher 
scores, as did those with a previous history of IHD (but not PCI), DM, hypertension, 
stroke and heart failure. Patients with renal dysfunction and anaemia had higher 
SYNTAX scores. Patients in the lowest EuroSCORE quartile had lower SYNTAX 
scores, and those in the highest quartile had higher SYNTAX scores, but the overall 
correlation between SYNTAX and EuroSCORE was only modest; correlation 
coefficient 0.359 (Spearman‟s rho); p < 0.01. 
SYNTAX score also increased between the first and second recruitment phases. 
A history of current or past smoking was, conversely, associated with lower 
SYNTAX scores. There was no apparent difference in SYNTAX score between men 
and women, or between patients presenting with different clinical syndromes. 
 
Figure 3-9   Histogram showing distribution of SYNTAX score for whole cohort 
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Table 3-4   Comparison of median SYNTAX scores in patients with and without selected 
baseline characteristics 
 
Baseline characteristic Number of 
patients with 
characteristic 
(proportion of 
total cohort) 
Median (IQR) 
SYNTAX 
score when 
characteristic 
present 
Median (IQR) 
SYNTAX 
score when 
characteristic 
absent 
P 
value 
Female 236 (24.9) 8.5 (10.0) 9.0 (11.0) 0.73 
Age ≥ 80 years 69 (7.3%) 19.0 (18.0) 8.0 (10.5) < 0.01 
First recruitment phase 718 (75.7) 8.0 (10.0) 11.0 (13.6) < 0.01 
History of smoking 651 (69.0%) 8.0 (10.0) 10.0 (11.0) < 0.01 
Presented with UA 124 (13.1%) 9.0 (11.0) 8.0 (11.0) 0.17 
Presented with NSTEMI 624 (65.8%) 9.0 (11.0) 9.0 (11.0) 0.66 
Presented with STEMI 200 (21.1%) 8.0 (11.0) 9.0 (10.0) 0.54 
Previous history of MI 222 (23.4%) 12.0 (16.6) 8.0 (9.1) < 0.01 
Previous history of PCI 110 (11.6%) 10.0 (12.0) 8.0 (11.0) 0.26 
Previous history any clinical IHD 456 (48.1%) 11.0 (12.0) 7.0 (8.0) < 0.01 
DM 157 (16.6%) 12.0 (14.3) 8.0 (10.0) < 0.01 
Hypertension 477 (50.3%) 10.0 (11.0) 8.0 (10.0) < 0.01 
Obstructive airways disease 101 (10.7%) 9.0 (12.0) 8.0 (11.0) 0.40 
Previous history of stroke 45 (4.7%) 12.0 (21.6) 8.0 (11.0) 0.08 
Previous history of heart failure 15 (1.6%) 23.5 (12.0) 8.0 (11.0) < 0.01 
Renal dysfunction (eGFR < 60 
ml/min/1.73m
2
) 
287 (31.0%) 12.0 (14.0) 8.0 (9.0) < 0.01 
Anaemia (Hb < 10 g/dL) 16 (1.8%) 20.5 (14.4) 8.0 (11.0) < 0.01 
Lowest EuroSCORE quartile (1.5 to 1.9) 247 (26.1%) 7.0 (7.5) 10.0 (12.0) < 0.01 
Highest EuroSCORE quartile (> 6.4) 230 (24.3%) 14.3 (17.1) 7.0 (9.0) < 0.01 
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3.3.15. Changes in patient risk profile over time 
The risk profile of the patients, as measured by EuroSCORE, increased between 
the first and second phases of recruitment. For the whole cohort, median EuroSCORE 
(IQR) was 2.8 (4.1) in the first phase and 4.4 (7.7) in the second. This change appeared 
to be due to an increase in EuroSCORE in patients undergoing non-emergent 
procedures: excluding patients undergoing PPCI (i.e. emergent cases), median 
EuroSCORE was 2.7 (4.0) in the first phase and 3.4 (8.4) in the second, p < 0.01. For 
PPCI patients only, EuroSCORE was not significantly different between the 2 phases of 
recruitment: 4.8 (8.1) in the first and 4.9 (7.1) in the second, p = 0.73. 
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3.4. Summary points and discussion for Chapter 3 
 The OPERA cohort contained nearly one thousand patients presenting with all types 
of acute coronary syndrome, all undergoing PCI or attempted PCI. 
 There were no formal exclusion criteria, but no patients with cardiogenic shock 
could be recruited owing to lack of informed consent. 
 Data completeness was generally very good, except for left ventricular function 
where only 50% of patients had a formal assessment. 
 Follow-up of at least 1 year was achieved in 98.5% of patients surviving to 1 year; 
median length of detailed follow-up was 3.5 years and mortality was tracked for a 
median of 5.4 years. 
 There were several important differences in baseline characteristics of patients 
presenting with STEMI compared to the other clinical syndromes, including 
younger age and much higher rate of current smoking (45%). 
 A high proportion, nearly 50%, had a previous clinical history of IHD. 
 Patients were recruited over a broad time frame of 5 years, in 2 distinct cohorts 
separated by a gap of about 18 months. There were several important changes in 
baseline characteristics over this time 
 
3.4.1. Comparison of baseline characteristics of OPERA patients with 
patients from contemporary data sources 
It is useful to examine the clinical outcomes of patients from the OPERA study in 
the context of published data. However, we first need to establish that the OPERA 
patient cohort is broadly comparable in baseline characteristics and treatment to patients 
in contemporary studies. There are 2 very large, international, multicentre studies of 
PCI oral antiplatelet therapy in ACS patients contemporary with the OPERA study 
which should have a comparable patient population: the TRITON-TIMI 38 trial 
(Wiviott et al, 2007) and the PLATO invasive study (Cannon et al, 2009). Regarding 
registry data, the British Cardiovascular Intervention Society (BCIS) publishes its audit 
returns annually. Table 3-5 compares some of the key baseline characteristics of 
patients from OPERA with those 3 data sources. Note that the BCIS figures refer to PCI 
patients presenting with all clinical syndromes including stable elective patients unless 
indicated; also that PLSATO Invasive contained 5.8% of patients having CABG rather 
than PCI, all other studies were PCI only. 
The age and gender balance of the patient cohorts in these studies are similar, but 
other characteristics are considerably different. For example, STEMI patients are clearly 
over-represented in the PLATO Invasive trial, a fact which has not been commented 
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upon by the authors. In both randomised trials, patients with DM appear to be over-
represented and patients with previous MI under-represented compared with UK data. 
Note that both these trials had exclusion criteria, mainly to do with perceived risk of 
bleeding. Therefore although the patients are broadly comparable, caution should be 
used when interpreting the OPERA results in the context of these published data. 
3-5   Crude comparison of important baseline characteristics of patients in the OPERA, 
TRYTON-TIMI 38 and PLATO Invasive studies and BCIS ACS patients in 2007 and in 
2010 
 OPERA TRYTON 
2007 
PLATO 
2010 
BCIS 
2007 
BCIS 
2010 
Mean age, years 62 61 61 64 65 
Female 25% 26% 25% 26% 26% 
Cardiogenic shock 0% 0% 0% 3% Not given 
Presented with STEMI 22% 26% 49% 25%* 39%* 
DM 17% 23% 23% 18% 17%* 
Previous MI 24% 18% 17% 30% 29% 
Mean BMI 28 28 Not given Not given Not given 
IIbIIIa use 31% 55% 35% 40%
‡
 24%
‡
 
DES use 59% 47% Not given 57%
†
 67%
†
 
* ACS patients only          †UA/NSTEMI patients only         ‡NSTEMI only 
 
3.4.2. Possible impact of baseline characteristics and missing data on 
study outcomes 
The OPERA study has a relatively large patient cohort for a single centre platelet 
function study which should help to limit any potential bias when comparing groups. 
We have a very long clinical follow up period so both early and late complications of 
PCI can be detected. Follow-up was thorough and it is unlikely that any major MACCE 
events have been missed. Furthermore the OPERA study cohort does appear broadly 
representative of contemporary ACS PCI patients (see above), with the exception of 
patients with cardiogenic shock. These patients were also excluded from TRYTON-
TIMI 38 and PLATO. However, this is a small (3% of total UK PCI) and uniquely high-
risk category of patient requiring special study for which OPERA was not designed; 
their omission from this study is unlikely to detract from the overall results. 
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 LV systolic function is possibly a more important missing prognostic variable – 
with only 50% of available data we excluded this parameter from most analyses. This 
data is also missing from both PLATO Invasive and TRYTON-TIMI 38. In an ACS 
population an estimation of LV systolic function at around the time of PCI is of 
questionable value. Myocardium may be temporarily dysfunctional („stunned‟) due to 
ischaemia and may well improve with time, particularly following successful 
revascularisation. The time length required for complete recovery is unknown but 
probably several months should be allowed. Therefore, LV function at the time of 
recruitment somewhat loses its relevance as a reliable prognostic variable in this type of 
population and its absence becomes less important to the overall results. 
Some STEMI patients have been recruited into the OPERA study. However, 
STEMI patients had different baseline characteristics to the UA/NSTEMI group – they 
were younger, more likely to smoke and had less co-morbidities. Separate in-depth 
analysis of this sub-group is difficult owing to its small relative size, particularly as 2 
different treatment modalities were used: half the STEMI patients had convalescent PCI 
following thrombolysis and half PPCI. During the platelet function analyses (one of the 
most important aspects of this study) emergent PCI patients have been excluded due to 
uncertain validity of the VerifyNow test in patients without adequate clopidogrel 
preloading. Therefore, the findings from this study are probably more applicable to the 
UA/NSTEMI group of ACS patients rather than STEMI patients. 
 
3.4.3. Possible impact of prolonged recruitment time scale on study 
outcomes 
There were many changes in treatment which occurred over the recruitment period 
of the OPERA study, including: 
1. There was an increase in numbers of patients undergoing primary PCI and a 
decrease in those presenting with UA. 
2. The baseline risk of the patients increased: there was more diabetes, higher BMI, 
older age, higher SYNTAX score and higher EuroSCORE in the 2
nd
 recruitment 
phase than in the 1
st 
phase. 
3. Stent type changed from BMS and older first generation DES to modern low-
profile DES. 
4. Arterial access site changed from mostly femoral to mostly radial over the course 
of recruitment. 
5. There was a decrease in the amount of IIbIIIa inhibitor used and an increase in 
bivalirudin used. 
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These factors are important but, providing they are born in mind when interpreting 
results, are not necessarily detrimental to the study. The 2 distinct recruitment phases 
allow separate analysis of the associations between baseline characteristics and clinical 
outcomes and could in fact improve the ability of this study to achieve its primary 
purpose in detecting possible causes of recurrent ACS. In particular, the impact of 
changing stent type can be studied by this method. Furthermore, arguably the most 
important factor influencing clinical outcome in these patients from the above list is the 
oral antiplatelet regime, strongly linked to both thrombotic and bleeding events over 12 
months. This remained largely unchanged throughout the OPERA study with aspirin 
and clopidogrel given to most patients and so, despite the relatively long recruitment 
span, this cohort studied as a whole should be expected to provide important and valid 
associations. 
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Chapter 4 Procedural outcomes, restenosis and further 
revascularisation 
4.1. Procedural success 
Procedural „technical success‟, as defined by <50% residual stenosis and good 
flow in all major branches in all attempted lesions, was achieved in 942 (97.2%) cases. 
Table 4-1 shows the reasons for lack of procedural success, the most common reason 
being the inability to penetrate a total occlusion. Procedural success rates were not 
significantly different between the first and second recruitment phases (2.9% vs. 2.4%, 
p = 0.71). 
Table 4-1   Details of cases lacking procedural success 
 
4.2. Incidence of procedural complications and associations with 
baseline characteristics 
Procedural angiographic and clinical complications are listed in table 4-2 
(haemorrhagic complications are discussed in detail in Chapter 6). Angiographic 
complications as reported by UMS occurred in 128 cases (13.2%), the majority of these 
complications being either a localised dissection or a trapped side branch. Angiographic 
complications rates were not significantly different between the first and second 
recruitment phases (12.2% vs. 13.9%, p = 0.49). Other (non-angiographic, non-
haemorrhagic) procedural complications were less frequent in the first recruitment 
phase compared to the second (0.6% vs. 3.3%, p < 0.01). This was due mainly to the 
increase in the proportion of patients undergoing PPCI in the second recruitment phase, 
as PPCI patients had the highest non-angiographic, non-haemorrhagic complication 
rate. In patients with UA, NSTEMI, convalescent STEMI and PPCI the rates were 0%, 
1.3%, 0% and 4.2%, p = 0.02. 
Reason for lack of procedural success Number of cases 
Unable to cross a total occlusion 11 
Persistent poor flow in, or occlusion of, a major side branch 10 
Lesion crossed but unable to dilate 2 
Lesion dilated but unable to deliver stent 2 
Guide catheter dissection of non-culprit artery, procedure abandoned 1 
Side branch was mistaken for main vessel, hence main vessel left untreated 1 
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Table 4-2   Frequency of sub-types of procedural complications as reported by UMS 
Type of procedural complication 
(Patients could have more than 1 type of complication) 
Number of events 
(% of all patients) 
Angiographic complication  128 (13.2%) 
     Localised dissection 44 (4.5%) 
     Trapped side branch 43 (4.4%) 
     No-reflow (transient or persistent) 23 (2.4%) 
     Unable to dilate lesion fully or under-deployed stent 12 (1.2%) 
     Extensive coronary dissection 4 (0.4%) 
     Thrombus formation during procedure 1 (0.1%) 
     Perforation 1 (0.1%) 
Procedural Bleeding  25 (2.6%) 
     Groin haematoma (≥BARC 2) 16 (1.7%) 
     Pseudo-aneurysm 3 (0.3%) 
     Required blood transfusion post procedure 4 (0.4%) 
     Upper GI bleed with melaena 1 (0.1%) 
     Retroperitoneal bleed 1 (0.1%) 
Other procedural clinical complication                         12 (1.2%) 
     VF arrest during procedure 6 (0.6%) 
     Complete heart block – temporary pacing wire 1 (0.1%) 
     Pulmonary oedema 1 (0.1%) 
     Allergic reaction 1 (0.1%) 
     Ischaemic leg (fatal) 1 (0.1%) 
     Contrast nephropathy 1 (0.1%) 
     TIA (transient expressive dysphasia) 1 (0.1%) 
Total procedural clinical complications of any type 165 (17.1%) 
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Baseline clinical characteristics were not different between those with and without 
complications. Regarding procedural characteristics, angiographic complications were 
more frequent in patients with bifurcation lesions (18.5% vs. 11.0% in non-bifurcation 
lesions, P < 0.01) and in lesions with reduced TIMI flow at the start (26.2% vs. 12.0% 
in lesions with TIMI 3 flow at the start, P < 0.01). Heavy calcification did not 
predispose to angiographic complications (12.6% vs. 12.6% without heavy 
calcification). Median SYNTAX score (IQR) was higher in those with angiographic 
complications: 11.0 (10.0) vs. 8.0 (11.0), p < 0.01. 
4.2.1. Procedural death 
There was 1 death which resulted directly from a procedural complication (this 
was the only peri-procedural death). This patient had presented with a NSTEMI and had 
a history of peripheral vascular disease, severe airways disease and a number of other 
co-morbidities. He was unsuitable for CABG due to a calculated EuroSCORE of 41 and 
maximal medical therapy had failed to alleviate his symptoms of intractable angina, 
which had led to frequent hospital admissions over the previous 18 months. His only 
vascular access route was via a femoro-popliteal bypass graft conduit. PCI was 
complicated by no-reflow and he was administered a IIbIIIa inhibitor during the 
procedure. Several hours after the procedure he developed bleeding from the puncture 
site leading to leg ischaemia and hypovolaemic shock. He died despite emergent 
vascular surgery. 
The 1 year mortality rates in patients with and without a non-haemorrhagic 
complication were numerically, but not significantly, different: all-cause mortality, 
5.1% vs. 2.5%, p = 0.10; and cardiac mortality, 3.6% vs. 1.7%, p = 0.13. A lack of 
„procedural success‟ had no obvious association with cardiac or all-cause mortality – 
however, this is a very small group. 
4.3. Follow-up coronary angiography and staged PCI 
In all, 197 patients (20.4% of the total cohort) underwent at least 1 further 
coronary angiogram during follow-up. Further angiography in most (170, 17.6%) cases 
was to investigate recurrent angina or following a further ACS, but an additional 27 
patients (2.8%) underwent planned angiography for „staged‟ PCI. There were no 
unstable symptoms or adverse clinical events between the 2 procedures in patients 
undergoing staged PCI. Staged PCI took place in all of the 27 (2.8%) patients in whom 
it was planned. 
More follow-up angiography took place in those with a history of coronary 
revascularisation prior to the index procedure (34.3% vs. 17.5%, p < 0.01), those having 
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PCI to more than 1 vessel (32.8% vs. 17.0%, p < 0.01), patients having PCI to restenotic 
lesions (38.9% vs. 19.6%, p = 0.02) and in patients receiving small diameter (≤ 2.5mm) 
stents (24.5% vs. 19.2%, p = 0.04).There was a tendency for higher rates of follow-up 
angiography in men compared to women (21.6% vs. 16.5%, p = 0.06). 
4.4. Further revascularisation and binary restenosis rates 
4.4.1. Incidence and types of unplanned revascularisation 
Unplanned further revascularisation for any reason was undertaken in 118 patients 
(12.2% of the whole cohort) over long-term follow-up. Further unplanned 
revascularisation rates at 30 days and 1 year, and the Kaplan-Meier estimated rate at 3.3 
years (median follow-up), were 0.7%, 6.9% and 12.3%. Further revascularisation was 
attempted by PCI in 101 cases and by CABG in 17 cases. In 49 patients, further 
revascularisation took place urgently following a recurrent episode of ACS; and in 69 
patients, further revascularisation took place electively following recurrent angina. 
Note: these figures do not include further revascularisation which was planned at 
the time of the index PCI („staged‟ procedures).  
4.4.2. Incidence of angiographic binary restenosis 
Binary restenosis (>50% stenosis by angiography) was diagnosed in 60 patients, 
making the long-term „clinically-driven‟ detected restenosis rate 6.2% over long-term 
follow-up (the subclinical restenosis rate is of course unknown as only 1 in 5 had 
follow-up angiography). The median (IQR) time from PCI to further revascularisation 
in patients with restenosis was 307 (489) days. 
4.4.3. Incidence of target lesion versus non-target lesion 
revascularisation 
Of 118 cases of further unplanned revascularisation, 63 (53.4%) were classified as 
target lesion revascularisation (TLR). The Kaplan-Meier estimated TLR rates at 1 year 
and 3.3 years were 3.7% and 6.4%. However, there was almost as much non-target 
lesion revascularisation (non-TLR), occurring in 55 patients over long-term follow-up. 
The 1 year and 3.3 year rates of non-TLR were 3.2% and 5.8%. Of the cases of non-
TLR, there were 20 cases of target vessel/non target lesion revascularisation (16.9% of 
all further revascularisation) and 35 cases of non-target vessel revascularisation (29.7% 
of all further revascularisation). Note: I have not included „staged PCI‟ (planned at the 
time of the index procedure but deferred) in the further revascularisation figures. 
Figures 4-1 and 4-2 show KM curves of the cumulative incidence of TLR and 
non-TLR, showing a frequency and distribution of events which is strikingly similar for 
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each. There are higher rates early after the index PCI which gradually decline during 
median follow-up; and there are similar numbers of events in each category. 
 
Figure 4-1   KM estimated incidence of target lesion revascularisation 
4.4.1. Clinical characteristics of further revascularisation 
Further revascularisation was mostly attempted by repeat PCI, occurring in 90% 
of TLR and 80% of non-TLR, with the remaining patients undergoing CABG. All of the 
17 patients who had CABG were referred directly for surgery after angiography without 
further attempts at PCI. The clinical syndrome leading to further revascularisation was 
recurrent ACS in many cases, especially TLR: of the 63 patients undergoing TLR, 
49.2% required emergent/urgent treatment compared with 32.7% in those undergoing 
non-TVR. 
Restenosis was a major cause of further revascularisation, known to have occurred 
in half of the 49 patients undergoing urgent further revascularisation and 28 of the 65 
patients undergoing elective further revascularisation over long-term follow-up for the 
entire cohort (restenosis is discussed further in Section 4.5). In patients undergoing 
TLR, severe in-stent restenosis was the causal factor in 51 (81%) cases and stent 
thrombosis in 9 (14%) cases. Of the other 3 cases of TLR, 2 cases took place for a 
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further attempt at a previously unsuccessful PCI; and there was 1 case of balloon 
angioplasty of a large trapped side branch without actual stent restenosis. 
 
 
Figure 4-2   KM estimated incidence of non-target lesion revascularisation 
4.4.2. Revascularisation rates at 1 year and recruitment phase 
Neither the overall 1 year TLR nor the 1 year total unplanned revascularisation 
rates changed significantly per year of PCI, although it should be noted that 
comparisons are hampered by low event numbers. In the first and second recruitment 
phases there were 29 and 6 cases of TLR up to 1 year, giving 1 year TLR rates of 4.0% 
vs. 2.4% (p = 0.26). The 1 year total unplanned revascularisation rates in the first and 
second recruitment phases were 6.6% vs. 6.9% (p = 0.87). 
In patients receiving only DES, the 1 year TLR in the first and second recruitment 
phases were 3.5% vs. 2.4% (p = 0.46); and 1 year total unplanned revascularisation 
rates in the first and second recruitment phases were 4.8% vs. 5.7% (p = 0.65). In 
patients receiving at least 1 BMS, the rates of these same events over the 2 recruitment 
periods were 4.3% vs. 3.3% (p = 0.80) and 7.9% vs. 16.7% (p = 0.10). 
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4.5. Baseline characteristics in patients undergoing further 
revascularisation and in patients with restenosis 
Baseline and procedural characteristics for patients without restenosis or any 
further revascularisation, patients with binary restenosis and patients undergoing any 
further revascularisation are shown in Table 4-3. 
4.5.1. Associations of baseline characteristics with further 
revascularisation 
Unplanned further revascularisation was less frequent in females than males and in 
patients undergoing convalescent PCI following thrombolysis for STEMI than in PPCI, 
NSTEMI or UA; but was more frequent in those with a previous history of angina, any 
known IHD or any previous revascularisation (but not in previous MI). In patients 
requiring repeat revascularisation, total stent length was greater; and they were more 
likely to have received a IIbIIIa inhibitor than those not requiring further 
revascularisation. There was no difference in EuroSCORE between patients who did 
and did not undergo further revascularisation. 
Patients receiving only DES were less likely to require repeat revascularisation, as 
were patients receiving only „second generation‟ DES and only „Xience‟ stents. There 
was a trend towards more unplanned revascularization among patients receiving only 
BMS.  A similar trend was also seen for patients with heavily calcified lesions. There 
was a strong trend for lower TLR rate in patients receiving only „Xience‟ DES 
compared to other stent types, 1.8% vs. 4.3% at 1 year (p = 0.07) and 3.8% vs.7.0% at 3 
years (Kaplan-Meier estimates; Log Rank p = 0.05). 
There was no association between angiographic or other procedural complications 
and unplanned revascularisation rates. 
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Characteristic 
Binary characteristics shown as Number (% within 
restenosis/revascularisation  groups) 
No restenosis or 
revascularisation 
N = 844 
Binary 
restenosis 
N = 60 
P value Any unplanned 
revascularisation 
N = 118 
P value 
Demographics and clinical syndrome      
Mean (SD) Age, years 62.3 (12.1) 61.2 (12.1) 0.50 62.1 (11.6) 0.98 
Female 222 (26.4) 11 (18.0) 0.19 20 (16.9) 0.03 
Recruited during first phase 626 (74.2) 52 (86.7) 
0.03 
92 (78.0) 
0.38 
Recruited during second phase 218 (25.8) 8 (13.3) 26 (22.0) 
Median (IQR) Body Mass Index 28 (6) 28 (6) 0.68 28 (6) 0.75 
Any history of smoking 578 (68.7) 46 (75.4) 0.28 83 (70.9) 0.66 
Family history of IHD 419 (51.9) 38 (63.3) 0.09 67 (58.3) 0.21 
Unstable angina 99 (11.8) 17 (28.3) <0.01 24 (20.3) 0.02 
Non-STEMI, 546 (64.6) 37 (61.7) 0.61 77 (65.3) 0.89 
ST elevation MI: Convalescent PCI 112 (13.3) 3 (5.0) 0.07 8 (6.8) 0.05 
ST elevation MI: Primary PCI 87 (10.3) 3 (5.0) 0.19 9 (7.6) 0.38 
ST elevation MI: any 199 (23.6) 6 (10.0) 0.02 17 (14.4) 0.03 
      
Previous medical history      
Table 4-3   Comparison of baseline characteristics in patients with and without binary restenosis, and with and without any further 
unplanned revascularisation, at any time during long-term follow-up 
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Angina 358 (42.4) 43 (71.7) <0.01 69 (58.5) <0.01 
MI 197 (23.3) 18 (30.0) 0.21 28 (23.7) 0.93 
PCI 84 (9.9) 19 (31.7) <0.01 25 (21.2) <0.01 
CABG 55 (6.5) 11 (18.3) <0.01 15 (12.7) 0.02 
Any previous revascularisation 127 (15.0) 25 (41.7) <0.01 36 (30.5) <0.01 
Any previous known IHD 386 (45.7) 44 (73.3) <0.01 70 (59.3) <0.01 
Diabetes mellitus 138 (16.4) 12 (20.0) 0.45 21 (17.8) 0.68 
Hypertension 421 (49.8) 35 (58.3) 0.21 65 (55.1) 0.28 
Hyperlipidaemia 473 (56.2) 37 (62.7) 0.31 67 (57.3) 0.85 
Peripheral vascular disease 40 (4.7) 1 (1.7) 0.28 3 (2.5) 0.29 
Respiratory disease 87 (10.3) 8 (13.3) 0.48 15 (12.7) 0.43 
Stroke 43 (5.1) 3 (5.0) 0.98 6 (5.1) 0.99 
Untreated aortic valve disease 9 (1.1) 2 (3.3) 0.13 3 (2.5) 0.17 
Heart failure 12 (1.4) 2 (3.3) 0.25 3 (2.5) 0.35 
      
Blood results (pre-procedural)      
Mean (SD) eGFR, ml/min/1.73m
2
 76 (30) 83 (41) 0.30 74 (31) 0.79 
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eGFR < 60 ml/min/1.73m
2
 264 (32) 18 (30.5) 0.94 28 (24.6) 0.11 
Mean (SD) Hb concentration, g/dL 14.0 (1.7) 14.1 (2.4) 0.88 13.9 (1.8) 0.69 
Mean (SD) platelet count, x10
9
/L 256 (68) 244 (93) 0.66 244 (112) 0.68 
Mean white cell count, x10
9
/L 8.9 (3.4) 8.8 (3.8) 0.99 8.8 (3.1) 0.86 
Median (IQR) PRU (VerifyNow) 247 (127) 247 (147) 0.73 247 (148) 0.67 
      
Risk scores      
Median (IQR) EuroSCORE I 3.1 (4.5) 3.2 (6.0) 0.57 3.3 (5.1) 0.60 
Median (IQR) SYNTAX score 8.0 (11.0) 11.5 (12.6) 0.06 11.5 (12.0) <0.01 
Lowest SYNTAX score quartile (≤4.0) 217 (26.2) 11 (18.3) 0.23 19 (16.4) 0.02 
Highest SYNTAX score  quartile (≥15.5) 191 (23.1) 19 (31.7) 0.19 40 (34.5) <0.01 
      
Medication      
Aspirin 815 (96.7) 59 (100) 0.17 118 (100) 0.05 
Clopidogrel 793 (94) 59 (98.3) 0.18 116 (98.3) 0.05 
Prasugrel 53 (6.3) 1 (1.7) 0.17 2 (1.7) 0.05 
Dual antiplatelet therapy 814 (96.7) 59 (100) 0.17 118 (100) 0.05 
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P2Y12 inhibitor loading <24 hours before PCI 110 (13) 5 (8.3) 0.29 14 (11.9) 0.75 
Heparin 725 (86.1) 54 (90.0) 0.34 103 (87.3) 0.75 
IIbIIIa 259 (30.7) 26 (43.3) 0.06 50 (42.2) 0.01 
Bivalirudin 129 (15.4) 7 (11.7) 0.44 17 (14.4) 0.81 
Thrombolysis on admission 70 (8.3) 2 (3.3) 0.17 8 (6.8) 0.59 
      
Procedural characteristics      
Arterial access: radial route 180 (21.3) 7 (11.7) 0.06 24 (20.3) 0.81 
Worst lesion treated: Type A 124 (14.7) 8 (13.6) 0.84 15 (13.2) 0.68 
Worst lesion treated: Type B1 208 (24.8) 10 (16.9) 0.17 24 (21.1) 0.39 
Worst lesion treated: Type B2 199 (23.6) 9 (15.3) 0.14 21 (18.4) 0.21 
Worst lesion treated: Type C 310 (36.8) 32 (54.2) <0.01 54 (47.4) 0.03 
Number vessels treated: 1 671 (79.4) 46 (76.7) 0.66 88 (74.6) 0.21 
Number vessels treated: 2 or 3 174 (20.6) 14 (23.3) 0.66 30 (25.4) 0.21 
Number vessels treated: 3 13 (1.5) 0 0.35 0 0.18 
LMS treated 19 (2.2) 4 (6.7) 0.04 6 (5.1) 0.07 
LAD treated 415 (49.1) 27 (45.0) 0.60 51 (43.2) 0.24 
- 95 - 
Circumflex treated 258 (30.5) 22 (36.7) 0.31 37 (31.4) 0.88 
Right coronary artery 340 (40.2) 20 (33.5) 0.23 53 (44.9) 0.32 
Restenotic lesion 26 (3.1) 8 (13.3) <0.01 7 (5.9) 0.17 
Bypass graft lesion 28 (3.3) 4 (6.7) 0.19 6 (5.1) 0.36 
Ostial lesion 52 (6.2) 5 (8.3) 0.50 8 (6.8) 0.78 
Chronic total occlusion 27 (3.2) 1 (1.7) 0.53 1 (0.8) 0.14 
Heavily calcified lesion 152 (18.0) 14 (23.3) 0.35 29 (24.6) 0.09 
Bifurcation lesion 318 (37.7) 22 (36.7) 0.85 44 (37.3) 0.90 
Lesion with angiographic thrombus 212 (25.1) 11 (18.3) 0.21 32 (27.1) 0.61 
Rotational atherectomy 3 (0.4) 1 (1.7) 0.12 1 (0.8) 0.43 
TIMI flow <III pre-PCI in any treated lesion 37 (4.4) 2 (3.3) 0.69 5 (4.2) 0.96 
Median (IQR) width of smallest stent, mm  3.0 (0.8) 3.0 (0.5) 0.35 3.0 (0.8) 0.46 
At least 1 small stent implanted (≤2.5mm) 192 (23.1) 16 (27.1) 0.45 24 (20.9) 0.54 
Median (IQR) total length all stents, mm 24 (21) 27 (27) 0.03 28.0 (24.0) 0.03 
2 or more stents implanted 229 (27.4) 23 (39.0) 0.07 44 (38.3) 0.02 
DES only 468 (55.5) 33 (55.0) 0.94 54 (45.8) 0.04 
BMS only 325 (38.5) 23 (38.3) 0.89 55 (46.6) 0.08 
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Combination of DES and BMS  37 (4.4) 3 (5.0) 0.86 6 (5.1) 0.76 
No stent, POBA only 11 (1.3) N/A N/A 1 (0.8) 0.68 
1
st
 generation DES only 125 (15.0) 13 (22.0) 0.13 17 (14.8) 0.89 
2
nd
 generation DES only 328 (39.6) 17 (28.8) 0.14 30(26.1) <0.01 
„Cypher‟ DES only 101 (12.0) 10 (16.7) 0.26 14 (11.9) 0.94 
„Taxus‟ DES only 24 (2.8) 3 (5.0) 0.31 3 (2.5) 0.81 
„Xience‟ DES only 247 (29.3) 10 (16.7) 0.04 21 (17.8) <0.01 
„Endeavor‟ DES only 81 (9.6) 7 (11.7) 0.51 9 (7.6) 0.51 
Staged PCI 22 (2.6) 2 (3.3) 0.79 5 (4.2) 0.31 
      
Procedural complications      
Unsuccessful procedure 23 (2.7) N/A N/A 4 (3.4) 0.67 
Angiographic complication, any (see table) 104 (12.3) 10 (16.7) 0.33 16 (13.6) 0.74 
Angiographic localised dissection (UMS) 34 (4.0) 3 (5.0) 0.86 9 (7.6) 0.09 
Angiographic trapped side branch (UMS) 42 (5.0) 1 (1.7) 0.28 1 (0.8) 0.04 
Other procedural clinical complication (non-
haemorrhagic) 
9 (1.1) 1 (1.7) 0.76 3 (2.5) 0.17 
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4.5.2. SYNTAX score and further revascularisation 
SYNTAX scores were higher in those requiring further unplanned 
revascularisation. When patients were stratified into SYNTAX score quartiles, further 
revascularization rates over long-term follow-up were: Q1 = 8.1% (SYNTAX score < 
5.0), Q2 = 9.8% (5.0 to 8.0), Q3 = 13.9% (9.0 to 15.0) and Q4 = 17.1% (≥ 15.5), p = 
0.01. The Kaplan-Meier cumulative incidence of further unplanned revascularisation of 
any sort, for patients stratified into SYNTAX score quartiles, are shown in Fig 4-3. Note 
that SYNTAX scores were different in patients with a variety of clinical characteristics, 
shown in Table 3-4, Section 5.5.13. 
 
Figure 4-3   KM estimated cumulative incidence of any type of unplanned 
revascularisation over median follow-up, stratified by SYNTAX score quartiles 
4.5.3. Associations of baseline characteristics with restenosis 
There were significant differences in baseline characteristics in patients who 
developed restenosis compared to those who did not. Those with restenosis were more 
likely to have presented during the first recruitment phase than the second. They were 
more likely to have presented with unstable angina, but less likely to have presented 
with STEMI. They had a greater incidence of a previous history of IHD and to have 
undergone prior revascularisation (PCI, CABG or both). More often they had undergone 
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PCI to Type C lesions, the index lesion treated was more likely to have been itself 
restenotic, and the total length of implanted stents was slightly greater. The restenosis 
rate in bypass grafts was not significantly higher than that in native vessels, although 
only 10 of the 35 patients having graft PCI underwent an angiogram during follow-up 
and subclinical graft occlusion rate is, therefore, unknown. 
Patients who experienced restenosis had a trend towards higher SYNTAX scores; 
however the difference in restenosis rates between patients stratified into SYNTAX 
score quartiles was not statistically significant. EuroSCOREs were not different in 
patients with and without restenosis. The occurrence of procedural complications was 
not associated with restenosis. 
The incidence of restenosis in patients receiving DES and BMS did not appear to 
be different: the rate in those receiving only DES was 6.4% and in those receiving at 
least 1 BMS was 6.1%; p = 0.84 (but note that there were important differences in 
baseline and procedural characteristics between patients receiving DES and those 
receiving BMS, see Section 3.5.4). By individual stent type, „Xience‟ stents appeared to 
have the lowest incidence of restenosis over long term follow-up: only 3.7% of patients 
treated exclusively with „Xience‟ stents experienced restenosis compared to 7.2% in 
patients not receiving Xience stents; p = 0.05. The KM estimated rate of target lesion 
revascularisation at 1 year was 2.0% in patients with only Xience stents vs. 4.8% in 
other patients, log rank P = 0.053; see Figure 4-4. 
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Figure 4-4   KM estimates of rate of target lesion revascularisation, stratified by Xience 
stent use only vs. other stent types/combinations 
4.5.4. Clinical outcomes in patients with restenosis 
Of the 60 patients with restenosis, 54 (90.0%) underwent further revascularisation 
(compared to 63 (6.9%) of those without restenosis over long term follow-up) and 51 
(85.0%) underwent target lesion revascularisation (TLR). More specifically, restenosis 
was managed as follows: 
 No further revascularisation, 6 patients 
 Revascularisation of non-target vessel, 3 patients 
 Target lesion PCI with DES, 36 patients 
 Target lesion PCI with BMS, 5 patients 
 Target lesion PCI with balloon angioplasty, 5 patients 
 CABG, 5 patients 
Further revascularisation for restenosis was undertaken electively after the patient 
presented with recurrent angina in 30 patients, 14 patients required urgent 
revascularisation after being admitted with troponin positive ACS, and 9 presented with 
troponin negative ACS (1 had missing data).  
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The median (IQR) time from index PCI to TLR for restenosis was 326 (588) days.  
The patients who were found to have restenosis but did not undergo TLR are listed 
in Table 4-4 with details explaining the management decision. 
Table 4-4   Details of patients who did not undergo revascularisation of a restenosis  
PAT ID Reason for no further revascularisation of restenotic target lesion 
453,757 No viability/reversible ischaemia in myocardium subtended by restenotic vessel, 
managed medically 
68, 72 Completely occluded native vessel stent, unattractive for PCI, PCI to another vessel 
754 Completely occluded native vessel stent, unattractive for PCI, managed medically 
993 Completely occluded SVG, managed medically 
677 Completely occluded SVG, PCI to another vessel 
399 Moderate restenosis managed medically 
543 Small vessel, thought high risk of further restenosis, managed medically 
Note on Table 4-4: 1 further patient with restenosis included in the list above as having TLR (PAT 
ID 60, not included in the table) had additional ISR in a second stent in a previously treated vessel; this 
was managed medically as cardiac MRI scanning showed no viability in the territory supplied by this 
vessel. 
Of the 46 patients with restenosis who underwent further successful PCI to the 
target lesion, 4 are known to have developed recurrent target lesion ISR. Of these, 1 
patient died of IHD without undergoing any further revascularisation attempts, 1 went 
on to have a successful CABG (alive), 1 had a third PCI to the target lesion (successful, 
alive) and 1 had further (successful) PCI to the target lesion but went on to die of 
ischaemic cardiomyopathy. 
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4.5.5. Further revascularisation, restenosis and death rates 
The need for further unplanned revascularisation for restenosis did not appear to 
have a substantial impact on mortality in the short to medium term, in contrast to further 
revascularisation for other indications, illustrated in Figure 4-5. Of the 6 deaths which 
occurred in the non restenosis group within 1 year of the further revascularisation 
procedure, 4 occurred in patients with definite stent thrombosis. 
 
Figure 4-5   Kaplan-Meier estimates of all-cause mortality rates following further 
unplanned revascularisation in 118 patients, stratified by presence or absence of binary in-
stent restenosis 
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4.6. Chapter 4 summary points and discussion 
 Procedural success rate was high at 97.5% and only 1 procedural death 
occurred. 
 Repeat angiography was mostly symptom-driven and occurred in 20%. 
 Unplanned further revascularisation took place in 12.2% altogether (rate of 
6.9% at 1 year) mainly by repeat PCI and often for recurrent ACS. 
 Rates of target lesion revascularisation (TLR) and non-target lesion 
revascularisation (non-TLR) were very similar, both at 12 months and at 3.3 
years, with higher rates over the 1
st
 year for both. 
 Certain baseline characteristics were more common in patients requiring 
further revascularisation including presentation with UA, previous IHD, 
Type C lesions and longer stent length. 
 Further revascularisation occurred less often in STEMI patients receiving 
convalescent PCI; and in those with Xience stents. 
 The 1 year ISR rate was only 2% in those with only with Xience stents 
compared to 4.8% with all other stent types. 
 Baseline SYNTAX score was directly proportional to the rate of unplanned 
further revascularisation. Roughly, patients with a SYNTAX score of 4 had 
a further revascularisation rate of 10%; SYNTAX 16 had a 15% rate and 
SYNTAX 27 had a 20% rate over long-term follow-up. 
 Angiographic complications such as localised dissection or trapped side 
branches occurred in 13.2%, but there was little to suggest that this type of 
complication had a significant impact on subsequent clinical outcome. 
 60 patients were found to have definite binary in-stent restenosis (ISR). 
 ISR rates were not different in patients with DES and BMS. 
 Most patients with ISR were treated by repeat target lesion revascularisation 
with insertion of drug-eluting stents. 
 ISR did not appear to have any impact on mortality rates. 
 
4.6.1. Comparison of OPERA study further revascularisation rates with 
contemporary data 
The 2 large contemporary antiplatelet trials discussed in Chapter 3, PLATO 
Invasive and TRYTON-TIMI 38, do not report unplanned revascularisation as a 
separate endpoint. Neither is this data available from BCIS. However, Stolker et al have 
published unplanned revascularisation rates at 12 months from a large prospective 
unselected PCI registry based in the US, the EVENT registry. From July 2004 to June 
2007 10144 patients were recruited from 55 PCI centres and were followed up by 
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telephone at 6 and 12 months. Of patients whose indication for PCI was non-STE ACS, 
8.4% underwent unplanned further revascularisation at 12 months compared to 6.9% in 
OPERA. Of all cases of unplanned revascularisation, TLR took place in 47% in EVENT 
and 54% in OPERA. These rates are broadly similar and suggest that the problem of 
recurrent coronary ischaemia requiring unplanned revascularisation is common and 
widespread, with about half the cases due to problems with the original intervention and 
half due to untreated or new lesions. 
4.6.2. Restenosis 
Most cases of TLR in OPERA were due to severe ISR. Several changes in stent 
technology took place during the OPERA recruitment period which were aimed at 
reducing restenosis rates, namely the increase of DES and decrease of BMS use; and the 
development of „2nd generation‟ DES. These changes do appear to have had a beneficial 
effect, with lower restenosis rates seen in the 2
nd
 recruitment phase compared to the 1st. 
In OPERA, 2
nd
 generation DES such as Xience stents do appear to be considerably less 
prone to restenosis than earlier stents. However, the patients in OPERA who received 
BMS were no more likely to experience restenosis than those receiving DES, indicating 
that the use of BMS may still be a reasonable choice in selected ACS patients. BMS 
have the advantage of requiring a much shorter duration of DAPT and remain a valuable 
option in patients at high risk of bleeding. 
4.6.3. The SYNTAX score 
This angiographic score was a powerful predictor of further unplanned 
revascularisation in ACS patients in OPERA; an approximately linear relationship was 
observed. The SYNTAX score was developed to assess coronary disease severity for 
patients in the SYNTAX trial (Serruys et al), a study of clinical outcomes in patients 
with complex disease randomised to treatment with either PCI or CABG. In the 
SYNTAX trial, the score was found to be highly predictive of adverse outcome in those 
patients undergoing PCI. The patients in OPERA had considerably lower SYNTAX 
scores than these patients, but even in the lower range the score still seems remarkably 
consistent. The SYNTAX score has been criticised for having high inter-observer 
variability i.e. of being too subjective; and also for not containing any information 
pertaining to functional assessment of myocardial ischaemia. However, in OPERA the 
SYNTAX score at baseline was one of the best predictors of the need for both short and 
long term unplanned revascularisation (Figure 4-3) and would seem to be a highly 
valuable risk stratification tool despite any perceived shortcomings in the literature. 
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Chapter 5 Recurrent ACS, stent thrombosis and cardiac 
death 
5.1. Incidence of recurrent ACS during long-term follow-up 
The Kaplan-Meier estimated cumulative rates of first episode of recurrent ACS 
(any type; excluding suspected non-cardiac symptoms) at 30 days, 1 year and 3.4 years 
were 1.4%, 6.7% and 11.2%. The rate of recurrent ACS was higher immediately 
following PCI and declined in the months that followed. After the first year, the rate 
remained stable at approximately 1.8% per year over the subsequent 3 years of follow-
up, see Figure 5-1. 
 
Figure 5-1   KM curve showing cumulative incidence of recurrent ACS over median 
follow-up; perforated straight reference line added to highlight relatively steady rate after 
the 1 year point 
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5.2. Sub-types of recurrent ACS 
The following sub-types of recurrent/secondary ACS could be identified based on 
presentation, clinical impression and subsequent investigations: 
 Unstable angina (troponin-negative but 
symptoms initially thought to be cardiac by 
admitting medical team) 
  
 NSTEMI 
 Includes cases of possible, 
probable or definite stent 
thrombosis 
 STEMI 
 Out-of-hospital witnessed cardiac arrest 
 Suspected ACS, unable to verify due to 
inadequate data 
  
 Hospital admission with suspected ACS but 
thought non-cardiac by admitting medical 
team 
  
NSTEMI was the commonest clinical syndrome by which patients presented with 
recurrent ACS, although admissions with NSTEMI were matched in frequency by 
admissions with chest pain thought (by the admitting medical team) to be of non-cardiac 
origin. The frequency of sub-types of recurrent ACS over the total follow-up period, 
including hospital attendances with atypical/suspected non-cardiac symptoms, is 
illustrated in Figure 5-2.  
The event rates for the different sub-types of ACS and ARC-defined stent 
thrombosis at 30 days, 1 year, and 3.4 year (median follow-up) are shown in Table 5-1. 
Note that biomarker data is missing for 5 recurrent ACS patients. 
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Figure 5-2   Pie chart showing relative frequency of different sub-types of recurrent ACS over total follow-up; also included are hospital attendances with 
suspected non-cardiac symptoms 
Notes: (i) Hospital admissions with symptoms suggestive of possible ACS but which were troponin-negative, without dynamic ECG changes, and concluded to be of likely non-cardiac origin by 
the admitting medical team were not recorded as ACS in the database, nor were they included in any analyses of ACS presented here, although I have included them in this chart for completeness; (ii) 
hospital admissions in which the predominant clinical features were in keeping with a diagnosis of cardiac failure but without evidence of new acute coronary ischaemia, even if the troponin was mildly 
elevated,  are not recorded as ACS in the database and are not included here; and (iii) although we had a low threshold for categorising troponin elevations as ACS when the clinical team had diagnosed 
it as such, troponin elevations in acutely ill patients thought secondary to haemodynamic instability from an acute non-coronary medical condition e.g. due to tachy/brady arrhythmias, sepsis, surgery, 
severe  anaemia etc have not usually been recorded as ACS in the database; for example: PAT ID 339 (small troponin rise after presenting with severe bradycardia); PAT ID 135 (small troponin rise 
after an episode of fast AF following surgery for an ischaemic leg); and PAT ID 280 (small troponin rise after an episode of fast AF following elective hip surgery). 
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Table 5-1   The KM estimated cumulative frequency of different sub-types of recurrent 
ACS at 30 days, 1 year and 3.4 years 
Type of ACS event 
(events may be included in >1 category) 
30 days 1 year 3.4 years 
Unstable angina 2 (0.2%) 24 (2.5%) 34 (3.9%) 
Witnessed out-of-hospital cardiac arrest 3 (0.3%) 8 (0.8%) 8 (0.9%) 
STEMI 5 (0.5%) 8 (0.8%) 11 (1.3%) 
NSTEMI 4 (0.4%) 22 (2.3%) 45 (5.3%) 
Possible stent thrombosis  0 3 (0.3%) 3 (0.3%) 
Probable stent thrombosis 2 (0.2%) 3 (0.3%) 3 (0.3%) 
Definite stent thrombosis 6 (0.6%) 8 (0.8%) 12 (1.3%) 
Definite or probable stent thrombosis 8 (0.8%) 11 (1.1%) 15 (1.6%) 
Definite, probable or possible stent 
thrombosis 
8 (0.8%) 14 (1.5%) 18 (2.0%) 
Total (spontaneous) MI including stent 
thrombosis 
12 (1.2%) 37 (3.8%) 63 (7.3%) 
All ACS (number = 111, 11.5% of total 
cohort) 
14 (1.4%) 64 (6.7%) 101 (11.2%) 
5.3. Aetiology of recurrent ACS 
In most cases of recurrent ACS, analysis of the clinical features, the results of 
repeat coronary angiography, the expert opinion of the arbitration committee and 
occasionally post-mortem exam results allowed us to arrive at a probable specific cause 
for the adverse cardiac event. Over long term follow-up, 82 (73.9%) of the patients who 
experienced a recurrent ACS of any type, and 53 (75.7%) of the patients who had a 
recurrent MI, underwent at least 1 further coronary angiogram. Patients with recurrent 
ACS were often found to have further obstructive coronary disease at angiography, 
either in the index „target‟ lesion or a „de novo‟ lesion. 
5.3.1. Recurrent ACS: Unstable angina 
There were 37 cases of UA during follow-up (3.8% of the total cohort); 27 were 
investigated by coronary angiography. Of these, 24 were found to have obstructive 
coronary disease of which 11 patients had restenosis (PAT ID: 133, 273, 286, 353, 543, 
551, 567, 584, 766, 906 and 1001) and 13 were found to have patent stents but severe 
non-target lesion disease (PAT ID: 69, 232, 235, 338, 585, 589, 645, 674, 748, 798, 
850, 909 and 920). No significant focal disease was found in a further 3 patients (PAT 
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ID: 634, 883 and 907). Of the 10 patients who were admitted with suspected UA but did 
not undergo further angiography, 5 were subsequently re-classified as probable non-
cardiac pain by a cardiologist, 3 after negative non-invasive functional testing (PAT ID: 
622, 111 and 1036)  and 2 without a functional test (PAT ID: 728, 1019). 2 patients 
were thought unsuitable for further invasive investigation, due in 1 case to multiple co-
morbidities (PAT ID: 780) and in the other to chronic alcohol dependence (PAT ID 
889); and in 3 the reason for no further angiogram is unclear or information is missing 
(PAT ID: 152, 428 and 562). 
5.3.2. Recurrent ACS: NSTEMI 
There were 52 patients (5.4% of the total cohort) who had a NSTEMI during 
follow-up of whom the majority, 42 patients, were investigated by invasive 
angiography. Of these, 22 (42.3% of patients with recurrent NSTEMI) were found to 
have severe restenosis of at least 1 stent which had been implanted at the index 
procedure (PAT ID: 60, 70, 102, 154, 162, 172, 184, 253, 311, 383, 399, 403, 436, 590, 
613, 628, 677, 757, 831, 942, 993 and 1049). A further 10 patients (19.2%) were found 
to have patent stents but severe disease elsewhere: 9 of these had „de novo‟ (new) 
disease (PAT ID: 14, 95, 264, 314, 336, 392, 662, 740 and 903) and 1 had restenosis of 
a previous non- study stent (PAT ID: 997). There was 1 patient who had angiographic 
evidence of a fractured stent without restenosis (PAT ID 254). In the remaining 9 
patients with recurrent NSTEMI undergoing invasive investigation (17.3%), their stents 
were found to be patent and no other severe disease or other angiographic abnormality 
was identified (PAT ID: 42, 58, 161, 197, 282, 366, 483, 811 and 1029). 
A further 10 patients (19.2% of patients with recurrent NSTEMI) were managed 
medically without undergoing angiography.  Of these, 2 were thought  unsuitable for 
invasive investigation due to severe co-morbidities (PAT ID: 171 (lung cancer) and 186 
(bilateral subdural haematoma); 1 patient declined angiography (PAT ID: 595); 1 
patient had a negative functional test (PAT ID: 665); 1 patient was critically ill on 
admission with metabolic acidosis and died shortly after (PAT ID: 864); and in 4 
patients the reason for medical rather than invasive management was unclear from the 
medical records (PAT ID: 198, 275, 803 and 856). There was missing data for 1 patient 
due to inability to obtain medical records from the district general hospital (PAT ID: 
115). 
Of interest 1 patient (PAT ID: 154) had both a STEMI due to stent thrombosis and 
a NSTEMI due to restenosis at different times during follow-up. Another patient (PAT 
ID: 997) who had a NSTEMI during follow-up was found to have restenosis of a non-
study stent and had a large thrombus aspirated from this stent during his repeat PCI 
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procedure, so has been classified as having both restenosis and definite stent thrombosis 
(none of the other patients with stent thrombosis were thought to have significant 
restenosis). 
5.3.3. Recurrent ACS: STEMI 
12 patients (1.2% of the total cohort) had a recurrent ACS presenting with ST 
segment elevation and all underwent emergent angiography with a view to PCI if 
required. Of these, 10 patients had a definite angiographic stent thrombosis treated by 
PPCI (PAT ID: 19, 154, 229, 278, 405, 447, 466, 563, 764 and 972). The other 2 
patients had ST elevation due to thrombosis of a non-target vessel (PAT ID: 34 and 72). 
As mentioned in the previous section, 1 patient (PAT ID 154) also had a NSTEMI (at 
another time) due to restenosis. 
5.3.4. Recurrent ACS: Out-of-hospital cardiac arrest 
A witnessed unexpected out-of-hospital cardiac arrest occurred in 8 patients 
(0.8%), 6 of whom died within 24 hours. There was 1 case of definite stent thrombosis 
confirmed by post mortem (P.M.) examination, and 4 other fatal cases were classified as 
probable or possible stent thrombosis but P.M. examination had not been performed. 2 
patients were found to have acute thrombosis of a non-target vessel (1 by P.M. 
examination and 1 by angiography), and the remaining patient had a new diagnosis of a 
(probably) non-ischaemic cardiomyopathy. All cases of cardiac arrest took place within 
the first year of PCI. The details are summarised in the Table 5-2. 
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Table 5-2   Details of all episodes of out-of-hospital cardiac arrest  
PAT ID  Details of cardiac arrest 
182 Arrested and died unexpectedly at home 3 days post PCI. Coroner‟s P.M. conclusion: definite stent 
thrombosis. 
299 VF arrest 81 days post PCI, survived; angiogram showed fully patent stent in circumflex, but a newly 
occluded diagonal branch of the LAD, managed medically. 
334 Collapsed suddenly at home 10 months post PCI, died later the same day. No P.M. performed. Death 
certified as (I) IHD; (II) Chronic pulmonary embolic disease. OPERA arbitration committee 
conclusion: „possible stent thrombosis‟. 
412 Collapsed suddenly in asystole 55 days post PCI, died later same day. Coroner P.M. concluded death 
due to acute MI: acute thrombotic occlusion of a non-study coronary vessel; the stent was patent. 
755 Collapsed suddenly at home 10 months post PCI; died later the same day in hospital. Non-specific 
ECG changes. No P.M. performed. Death certified as IHD. OPERA arbitration committee 
conclusion: „possible stent thrombosis‟. 
839 VF arrest 11 months post PCI, resuscitated and survived; angiogram showed stent widely patent; 
small troponin rise; found to have severe LV systolic dysfunction, thought to be some form of non-
ischaemic cardiomyopathy. 
843 Sudden collapse 1 month post PCI, CPR given but died before reaching hospital, no P.M. performed. 
OPERA arbitration committee conclusion: „probable stent thrombosis‟. 
890 Collapsed with VF 12 days post PCI, died later the same day; no P.M. Death certified as „acute left 
ventricular failure‟. OPERA arbitration committee conclusion: „probable stent thrombosis‟. 
5.4. Baseline factors associated with recurrent ACS 
Table 5-3 compares the frequencies of baseline characteristics in patients who 
experienced no further ACS with those who experienced any recurrent ACS (includes 
recurrent UA, NSTEMI, STEMI, out-of-hospital cardiac arrest and stent thrombosis, but 
excludes non-cardiac chest pain admissions); and with those who experienced a 
spontaneous MI (troponin-positive ACS and/or definite, probable or possible stent 
thrombosis and fatal MI) over long-term follow-up. 
There was a trend for patients with recurrent ACS to be older than those without, 
and patients with a history of tobacco smoking were more likely to experience recurrent 
ACS than patients who never smoked. Recurrent ACS was more common in those with 
a prior history of IHD, a history of stroke, those with diabetes and in those with a 
history of hypertension. Haemoglobin concentration pre-PCI was lower in patients with 
recurrent ACS, and patients with recurrent MI were more likely to have poor renal 
function. SYNTAX scores and EuroSCOREs were both higher. (Note: SYNTAX score 
is also discussed in Section 3.5.14 and baseline clinical characeristics associated with 
SYNTAX score are listed in Table 3.4). Neither age nor sex were significantly 
associated with recurrent ACS. 
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The rates of recurrent ACS and recurrent MI were particularly low in patients 
presenting originally with STEMI treated by pharmacological thrombolysis followed by 
convalescent PCI relative to the other clinical syndromes at presentation. Patients 
originally presenting with NSTEMI had the highest rates. Recurrent ACS and MI rates 
at 1 year in patients originally presenting with STEMI treated by 
thrombolysis/convalescent PCI were 1.8% and 0.9%; in patients with unstable angina, 
6.0% and 1.7%; in patients receiving PPCI for STEMI, 8.4% and 3.6%; and in patients 
presenting originally with NSTEMI, 8.2% and 5.2%. Of all recurrent MIs recorded in 
the study over total follow-up, 80% occurred in patients who originally presented with a 
NSTEMI. 
PCI of more than 1 vessel, implantation of more than 1 stent, PCI of restenotic 
lesions and heavily calcified lesions and longer stent length were all associated with a 
greater incidence of recurrent ACS. Recurrent ACS was seen more often in those 
receiving PCI to the LMS and to the circumflex artery than to the LAD and the RCA. 
AHA lesion type was not significantly associated with the incidence of recurrent ACS, 
although there was a trend for more MIs in patients with type C lesions. 
Regarding stent type, patients receiving „Taxus‟ stents had higher rates of 
recurrent ACS (although note should be made that this was a small subgroup of only 34 
patients) and those with „Xience‟ stents had lower rates. There was no significant 
difference in the recurrent ACS rates between patients receiving exclusively BMS 
compared to those receiving exclusively DES. 
Neither procedural angiographic nor procedural clinical complications were 
significantly associated with recurrent ACS. However, the rate of angiographic 
complications was numerically higher in patients with recurrent MI. 
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Table 5-3   Comparison of baseline characteristics in patients experiencing and not 
experiencing recurrent ACS of any sub-type; and between patients experiencing recurrent 
MI vs. no recurrent ACS; all events over total follow-up period are included 
Characteristic 
Binary characteristics shown as Number 
(%) 
No 
recurrent 
ACS 
N = 857 
ACS 
N = 111 
P value MI 
N = 71 
P value 
Demographics and clinical syndrome      
Recruitment in first study phase 640 (74.7) 83 (74.8) 0.98 55 (77.5) 0.58 
Mean (SD) age, years 62.0 (11.9) 64.1 (12.8) 0.08 65.0 (13.5) 0.04 
Age ≥80 years 59 (6.9) 11 (9.9) 0.25 9 (12.7) 0.07 
Female 217 (25.3) 25 (22.5) 0.52 19 (27.1) 0.66 
Median (IQR) Body Mass Index 28 (6) 28 (6) 0.56 27 (6) 0.19 
Any history of smoking 576 (67.5) 91 (82.0) < 0.01 57 (80.3) 0.04 
Family history of IHD, 427 (51.9) 63 (60.0) 0.12 37 (56.9) 0.48 
Unstable angina 107 (12.4) 19 (17.1) 0.16 8 (11.3) 0.67 
Non-STEMI 548 (63.9) 79 (71.2) 0.13 57 (80.3) <0.01 
ST elevation MI: Convalescent PCI 115 (13.4) 6 (5.4) 0.02 2 (2.8) 0.01 
ST elevation MI: Primary PCI 89 (10.4) 7 (6.3) 0.18 4 (5.6) 0.21 
      
Previous medical history      
Angina 357 (41.7) 75 (67.6) < 0.01 46 (64.8) < 0.01 
MI 183 (21.3) 44 (39.6) < 0.01 29 (40.8) < 0.01 
PCI 88 (10.3) 24 (21.6) < 0.01 12 (16.9) 0.15 
CABG 57 (6.6) 15 (13.5) < 0.01 9 (12.7) 0.07 
Previous IHD, any 384 (44.8) 78 (70.3) < 0.01 49 (69.0) < 0.01 
Diabetes mellitus 130 (15.2) 29 (26.1) < 0.01 19 (26.8) 0.02 
Hypertension 418 (48.7) 71 (64) < 0.01 43 (60.6) 0.07 
Hyperlipidaemia 478 (55.9) 67 (60.9) 0.32 43 (61.4) 0.40 
Respiratory disease 83 (9.7) 20 (18.0) < 0.01 13 (18.3) 0.03 
Stroke 38 (4.4) 11 (9.9) 0.01 6 (8.5) 0.16 
Peripheral vascular disease 38 (4.4) 5 (4.5) 0.97 3 (4.2) 0.92 
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Untreated aortic valve disease 9 (1.0) 3 (2.7) 0.14 3 (4.2) 0.02 
Heart failure 11 (1.3) 4 (3.6) 0.06 3 (4.2) 0.06 
      
Blood results (pre-procedural)      
Mean (SD) eGFR, ml/min/1.73m
2
 75 (36) 71 (37) 0.21 70 (43) 0.10 
eGFR  < 60 ml/min/1.73m
2
 253 (30.2) 40 (37.0) 0.15 30 (44.0) 0.02 
Mean (SD) Hb concentration, g/dL 14.0  (1.6) 13.5 (1.9) 0.05 13.3 (2.0) 0.03 
Hb <10g/dL 12 (1.5) 5 (5.1) 0.02 4 (6.1) 0.01 
Mean (SD) platelet count, x10
9
/L 248 (86) 249 (79) 0.89 249 (114) 0.84 
Mean white cell count, x10
9
/L 8.8 (2.9) 9.2 (3.2) 0.12 9.1 (2.7) 0.17 
      
Risk scores      
Median (IQR) EuroSCORE I 3.0 (4.4) 4.8 (8.0) < 0.01 5.1 (9.2) < 0.01 
Lowest EuroSCORE quartile (≤1.9) 228 (26.6) 19 (17.1) 0.03 11 (15.5) 0.04 
Highest EuroSCORE quartile (≥6.4) 204 (23.8) 39 (35.1) < 0.01 30 (42.3) < 0.01 
Median (IQR) SYNTAX score 8.0 (11.0) 12.0 (12.1) < 0.01 12.5 (12.5) < 0.01 
Lowest SYNTAX score quartile (≤4.0) 223 (26.6) 13 (11.8) < 0.01 8 (11.3) < 0.01 
Highest SYNTAX score  quartile (≥15.5) 194 (23.1) 40 (36.4) < 0.01 27 (38.0) < 0.01 
      
Medication      
Aspirin 828 (96.8) 110 (99.1) 0.18 70 (98.6) 0.44 
Clopidogrel 807 (94.2) 108 (97.3) 0.17 69 (97.2) 0.31 
Prasugrel 52 (6.1) 3 (2.7) 0.15 2 (2.8) 0.28 
Dual antiplatelet therapy 827 (96.8) 110 (99.1) 0.18 70 (98.6) 0.44 
P2Y12 inhibitor <24 hours before PCI 111 (12.9) 13 (11.7) 0.72 8 (11.3) 0.68 
Heparin 736 (86.1) 98 (88.3) 0.53 62 (87.3) 0.80 
IIbIIIa inhibitor 267 (31.1) 45 (40.5) 0.05 31 (43.7) 0.03 
Bivalirudin 132 (15.5) 14 (12.7) 0.45 9 (12.9) 0.57 
Thrombolysis on admission 72 (8.4) 6 (5.4) 0.28 2 (2.8) 0.09 
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Procedural characteristics      
Arterial access: radial route 181 (21.1) 24 (21.6) 0.90 13 (18.3) 0.53 
Worst lesion treated: Type A 125 (14.7) 14 (12.8) 0.61 10 (14.5) 1.0 
Worst lesion treated: Type B1 211 (24.9) 22 (20.2) 0.29 11 (15.9) 0.09 
Worst lesion treated: Type B2 198 (23.2) 24 (22.0) 0.78 15 (21.7) 0.78 
Worst lesion treated: Type C 318 (37.3) 49 (45.0) 0.12 33 (47.8) 0.08 
Number vessels treated: 1 686 (80.1) 78 (70.3) 0.02 51 (71.8) 0.12 
Number vessels treated: 2 or 3 171 (19.9) 33 (29.7) 0.02 20 (28.2) 0.12 
Number vessels treated: 3 12 (1.4) 1 (0.9) 0.67 1 (1.4) 0.96 
LMS treated 17 (2.0) 8 (7.2) < 0.01 6 (8.5) < 0.01 
LAD treated 415 (48.5) 52 (46.8) 0.75 31 (43.7) 0.41 
Circumflex treated 253 (29.5) 45 (40.5) 0.02 29 (40.8) 0.06 
Right coronary artery 356 (41.5) 38 (34.2) 0.14 24 (33.8) 0.23 
Restenotic lesion 27 (3.1) 9 (8.1) < 0.01 5 (7.0) 0.13 
Bypass graft lesion 28 (3.3) 7 (6.3) 0.12 3 (4.2) 0.74 
Ostial lesion 52 (6.1) 8 (7.2) 0.64 4 (5.6) 0.84 
Bifurcation lesion 322 (37.6) 44 (39.6) 0.67 30 (42.3) 0.43 
Chronic total occlusion 28 (3.3) 1 (0.9) 0.17 1 (1.4) 0.41 
Heavily calcified lesion 148 (17.2) 34 (30.6) < 0.01 22 (31.0) < 0.01 
Lesion with angiographic thrombus 217 (25.3) 27 (24.3) 0.83 15 (21.1) 0.42 
Rotational atherectomy 3 (0.3) 1 (0.9) 0.39 1 (1.4) 0.18 
TIMI flow <III pre-PCI, any treated lesion 39 (4.5) 3 (2.7) 0.37 1 (1.4) 0.21 
Median (IQR) width of smallest stent, mm  3.0 (0.8) 3.0 (0.3) 0.88 3.0 (0.3) 0.47 
At least 1 small stent implanted (≤2.5mm) 195 (23.2) 25 (22.5) 0.88 16 (22.5) 0.90 
Median (IQR) total length all stents, mm 24 (23) 32 (22) 0.04 32 (26) 0.15 
2 or more stents implanted 231 (27.5) 42 (37.8) 0.02 26 (36.6) 0.12 
DES only 469 (54.8) 58 (52.3) 0.62 38 (53.5) 0.88 
BMS only 334 (38.9) 46 (41.4) 0.61 30 (42.3) 0.60 
- 115 - 
Combination of DES and BMS  37 (4.3) 7 (6.3) 0.34 3 (4.2) 0.89 
No stent, POBA only 12 (1.4) 0 0.21 0 0.33 
1
st
 generation DES only 125 (14.9) 20 (18.0) 0.39 15 (21.1) 0.15 
2
nd
 generation DES only 330 (39.4) 30 (27.0) 0.01 20 (28.2) 0.08 
„Cypher‟ DES only 104 (12.1) 13 (11.7) 0.90 9 (12.7) 0.88 
„Taxus‟ DES only 21 (2.4) 7 (6.3) 0.02 6 (8.5) < 0.01 
„Xience‟ DES only 250 (29.3) 20 (18.0) 0.01 12 (16.9) 0.03 
„Endeavor‟ DES only 80 (9.3) 10 (9.0) 0.91 8 (11.3) 0.53 
Staged PCI 22 (2.6) 5 (4.5) 0.24 3 (4.2) 0.45 
      
Procedural complications      
Unsuccessful procedure 25 (2.9) 2 (1.8) 0.50 2 (2.8) 0.99 
Angiographic complication, any 107 (12.5) 15 (13.5) 0.76 12 (16.9) 0.26 
Angiographic localised dissection (UMS) 38 (4.4) 6 (5.4) 0.64 4 (5.6) 0.65 
Angiographic trapped side branch (UMS) 39 (4.5) 4 (3.6) 0.65 3 (4.2) 0.93 
Other procedural clinical complication 
(non-haemorrhagic) 
10 (1.2) 2 (1.8) 0.57 1 (1.4) 0.90 
  
- 116 - 
5.5. Baseline characteristics independently associated with 
recurrent ACS 
Baseline characteristics associated with recurrent ACS (as univariable 
characteristics)  are shown in Table  5-4. In a model incorporating individual factors 
without risk scores, only a background of smoking and a previous history of IHD were 
associated with an increased rate of recurrent ACS; while use of second generation DES 
and index presentation with STEMI treated by convalescent PCI were associated with a 
lower rate of recurrent ACS (Table 5-5). In a second model incorporating SYNTAX 
score, the same results were found with the addition of an independent association of 
SYNTAX score with recurrent ACS (Table 5-6). In a third model incorporating the 
SYNTAX and EuroSCOREs, the same results were found again, with EuroSCORE 
providing only a trend towards an independent association with recurrent ACS (Table 5-
7). 
Table 5-4   Characteristics individually associated with recurrent ACS; significance level 
of P ≤ 0.1 
Characteristic Hazard 
ratio (as 
univariate) 
95% C.I. P value 
Lower Upper 
Age, per year 1.02 1.00 1.03 0.04 
History of tobacco smoking 2.08 1.28 3.37 < 0.01 
Presentation with STEMI: convalescent PCI 0.36 0.16 0.82 0.02 
PMH of IHD 2.77 1.84 4.16 < 0.01 
PMH of Diabetes 2.00 1.31 3.06 < 0.01 
PMH of Hypertension 1.82 1.23 2.68 < 0.01 
PMH of respiratory disease 1.94 1.19 3.14 < 0.01 
PMH of stroke 2.44 1.31 4.55 < 0.01 
PMH of heart failure 3.23 1.19 8.77 0.02 
Haemoglobin concentration pre-procedure, 
per g/dL 
0.85 0.76 0.95 < 0.01 
PCI to more than 1 vessel 1.68 1.12 2.53 < 0.01 
PCI to left main stem 4.03 1.96 8.28 < 0.01 
PCI to circumflex artery 1.56 1.09 2.32 0.02 
PCI to restenotic lesion 2.58 1.30 5.10 < 0.01 
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PCI to heavily calcified lesion 2.04 1.37 3.06 < 0.01 
2 or more stents implanted 1.58 1.07 2.31 0.02 
Only 2
nd
 generation DES used 0.66 0.44 1.01 0.06 
Only Taxus DES used 1.98 0.92 4.27 0.08 
Risk scores     
EuroSCORE, per point 1.05 1.03 1.06 < 0.01 
SYNTAX score, per point 1.04 1.02 1.06 < 0.01 
 
Table 5-5   Results of Cox regression analysis for characteristics independently associated 
with recurrent ACS; Model 1, without risk scores 
Characteristic Adjusted 
HR 
95% Confidence Interval P value 
Lower Upper 
Only „second generation‟ DES inserted 0.51 0.31 0.83 < 0.01 
History of smoking 2.31 1.38 3.87 < 0.01 
PMH of IHD 2.09 1.31 3.32 < 0.01 
STEMI with convalescent PCI 0.35 0.13 0.97 0.04 
PCI to LMS 2.33 0.91 5.98 0.08 
Age per year 1.00 0.98 1.02 0.85 
PMH of diabetes 1.21 0.26 2.04 0.48 
PMH of hypertension 1.16 0.75 1.79 0.52 
PMH of chronic airways disease 1.17 0.65 2.08 0.61 
PMH of stroke 1.63 0.81 3.30 0.17 
PMH of heart failure 1.82 0.57 5.82 0.32 
Pre-procedural haemoglobin, per g/dL 0.95 0.83 1.08 0.44 
PCI to more than 1 vessel 0.92 0.44 1.96 0.84 
PCI to circumflex artery 1.33 0.85 2.07 0.21 
PCI to restenotic lesion 1.89 0.85 4.19 0.12 
PCI to heavily calcified lesion 1.50 0.89 2.54 0.13 
More than 1 stent inserted 1.17 0.62 2.21 0.64 
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Table 5-6   Results of Cox regression analysis for characteristics independently associated 
with recurrent ACS; Model 2, incorporating SYNTAX score 
Characteristic Adjusted HR 95% Confidence 
Interval 
P value 
Lower Upper 
SYNTAX score, per point 1.032 1.011 1.052 < 0.01 
PMH of IHD 2.026 1.275 3.218 < 0.01 
History of smoking 2.479 1.476 4.162 < 0.01 
Only second generation DES inserted 0.537 0.332 0.868 0.01 
STEMI with convalescent PCI 0.340 0.123 0.936 0.04 
PMH of diabetes 1.298 0.781 2.159 0.34 
PMH of hypertension 1.239 0.803 1.911 0.33 
PMH of chronic airways disease 1.327 0.761 2.316 0.32 
PMH of stroke 1.724 0.845 3.515 0.13 
PMH of heart failure 1.590 0.511 4.946 0.42 
Pre-procedural haemoglobin, per g/dL 0.956 0.841 1.086 0.49 
Age per year 0.993 0.974 1.013 0.50 
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Table 5-7   Results of Cox regression analysis for characteristics independently associated 
with recurrent ACS; Model 3, incorporating SYNTAX score and EuroSCORE 
Characteristic Adjusted HR 95% Confidence Interval P value 
 Lower Upper 
History of smoking 2.513 1.5 4.21 < 0.01 
Only second generation DES inserted 0.527 0.326 0.852 < 0.01 
PMH of IHD 1.979 1.243 3.149 < 0.01 
SYNTAX score, per point 1.026 1.005 1.047 0.02 
STEMI with convalescent PCI 0.35 0.127 0.962 0.04 
EuroSCORE, per point 1.022 0.998 1.048 0.08 
PMH of diabetes 1.347 0.823 2.206 0.24 
PMH of hypertension 1.173 0.762 1.805 0.47 
Pre-procedural haemoglobin, per g/dL 0.967 0.859 1.087 0.57 
 
5.6. SYNTAX score and adverse events 
There was a strong association between angiographic SYNTAX score and the 
frequency of recurrent ACS. Figure 5-3 shows Kaplan-Meier (unadjusted) estimates of 
the cumulative incidence of ACS in patients stratified by SYNTAX score quartile. 
Much of the difference in outcome between quartiles occurs within the first year, 
although the first and second quartiles continue to diverge from the third and fourth 
quartiles over the longer term. SYNTAX score was also strongly associated with rate of 
cardiac death long-term, shown in Figure 5-4. Figure 5-5 is a graph of the incidence of 
total combined adverse events over long-term follow-up by SYNTAX score, showing 
an approximately linear relationship. 
Note that SYNTAX score was different in patients with a number of baseline 
clinical characteristics also associated with recurrent ACS. Details of these differences 
are found in Section 3-5-13 and Table 3-4. 
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Figure 5-3   Unadjusted cumulative incidence of recurrent ACS over median follow-up, 
stratified by SYNTAX score quartile 
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Figure 5-4   KM estimates of cardiac death rate for the entire cohort over long-term 
follow-up, stratified by SYNTAX score quartile; event rates at 5.4 years (median follow-
up) shown 
 
5.7. Recurrent ACS: stent thrombosis  
Over long term follow-up there were 18 cases of stent thrombosis (12 definite, 3 
probable and 3 possible). The median (IQR) time from PCI to ST was 40 (390) days, 
with a range of 1018 days, a minimum time of 3 days and a maximum time of 1021 
days. Using the „early (< 30 days), late (30 days to 1 year) and very late (> 1 year)‟ 
classification, there were 8 cases of early, 6 late and 4 very late ST. There was not a 
single case of acute (< 24 hours) stent thrombosis. 
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Figure 5-5   Graph of incidence of combined adverse events (MI, further unplanned 
revascularisation or death) according to SYNTAX score (groups composed of deciles of 
SYNTAX score); automatic straight and quadrantic lines of best fit added 
 
5.7.1. Clinical presentation and subsequent outcome of stent thrombosis 
Stent thrombosis (any type) presented as several different clinical syndromes: 
STEMI (9 cases), out-of-hospital cardiac arrest (5 cases) and NSTEMI (3 cases). In the 
remaining case of probable ST there was insufficient data to classify the clinical 
syndrome. 11 patients with ST (any type) underwent coronary angiography and further 
PCI; 7 did not undergo further angiography either because they collapsed and died out-
of-hospital, or they survived to reach hospital but were too unwell for angiography. 
Only 1 of these 7 patients underwent a P.M. examination to confirm the ST; hence the 
others have been classified as „probable‟ or „possible‟. Table 5-8 summarises the 
clinical details of the patients with definite or suspected ST. 
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5.7.2. Associations of stent thrombosis with baseline characteristics 
There was a trend for a higher rate of stent thrombosis (ST) in patients with a 
background of smoking (2.4% vs. 0.7%, p = 0.07) and with DM (3.8% vs. 1.5%, p = 
0.05). There were no significant differences in age (64.1 years vs. 62.2 years, p = 0.51) 
or gender (22.2% vs. 25.1% female) between patients with and without ST. Regarding 
clinical syndrome at index presentation, 15 of the ST cases occurred in patients 
originally presenting with NSTEMI, 2 with STEMI and 1 with UA, a non-significant 
difference. There was no change over time in the rate of ST: there were 12 (1.7%) cases 
in the first recruitment phase and 6 (2.4%) in the second, p = 0.43. 
Regarding angiographic characteristics, ST occurred in patients whose worst AHA 
classification lesion type was A, B1, B2 and C in 2 (1.4%), 4 (1.7%), 4 (1.8%) and 8 
(2.2%) cases respectively, a non-significant difference. Median (IQR) SYNTAX scores 
were higher in those with ST (12.0 (10.6) vs. 8.5 (11.0), p = 0.04). ST was more 
common in patients with heavily calcified lesions (8 cases, 4.4% vs. 1.3%, p < 0.01) and 
there was a trend for more ST in patients having PCI of thrombotic lesions (8 cases, 
3.3% vs. 1.4%, p = 0.06). There was no difference in the rate of ST in patients with and 
without bifurcation lesions however (7 cases, 1.9% vs. 1.8%, p = 0.92). 
Regarding procedural characteristics, ST was more common following a 
procedural angiographic complication (6 cases, 4.9% vs. 1.4%, p < 0.01), 3 in 
procedures complicated by localised dissection (6.8% vs. 1.6%, p = 0.01) and 3 with 
angiographic no-reflow (13.0% vs. 1.6%, p < 0.01). Trapped side branches and non-
angiographic procedural complications were not associated with ST. Note that in most 
cases of ST there was no obvious angiographic complication: in 12 of the 18 cases of 
ST there were apparently good angiographic results. Median total stent length was non-
significantly greater in those with ST, 33mm vs. 24mm, p = 0.3. There was no 
difference in the rate of ST between patients with BMS vs. DES, or between patients 
with first vs. second generation DES. 
- 124 - 
Table 5-8   Table showing clinical details of each case of stent thrombosis 
PAT 
ID 
Age 
at 
index 
PCI 
ARC 
class 
Stent type Vessel Procedural details Time from 
PCI to ST, 
days 
Clinical 
presentatio
n of ST 
Further 
PCI 
Treatment and outcome Time 
from 
ST to 
death, 
days 
19 46 Definite 3 Cypher stents 
(3mm x 23mm; 
3mm x 13mm; 3mm 
x 13mm) 
LAD Long calcified 
bifurcation lesion; 
proximal dissection 
covered with extra 
stent 
4 (early ST) STEMI Yes Anterior STEMI, given thrombolysis with 
TNK followed by „rescue‟ angioplasty; 
cardiogenic shock; transferred to a heart 
transplant centre for assessment but died after 
a cardiac arrest. 
4 
154 66 Definite Cypher  (3.5mm x 
23mm) 
RCA Heavily calcified 
lesion; no procedural 
complications. Had 
LAD PCI at same 
sitting. 
982 (very 
late ST) 
STEMI Yes ST was the second ACS experienced by this 
patient since OPERA study enrolment. ST 
presented with inferior STEMI 2 weeks after 
a fem-pop bypass; RCA occluded by 
thrombus, aspirated and further stent inserted 
Alive 
182 80 Definite BMS (3mm x 
30mm; 2.75mm x 
8mm; 3mm x 9mm) 
LAD Complicated by local 
dissection, required 3 
layers of stent to seal; 
had PCI to Cx and 
RCA at same sitting. 
3 (early ST) OOH 
cardiac 
arrest 
No Cardiac arrest and death at home, coroner‟s 
P.M. confirmed acute thrombosis of LAD 
stent. 
0 
229 57 Definite Cypher (2.25mm x 
23mm) 
Diagon
al 
Uncomplicated; had 
PCI to RCA at same 
sitting. 
529 (very 
late ST) 
STEMI Yes PPCI, treated by POBA, no further problems. Alive 
278 38 Definite Endeavor  (3mm x 
15mm) 
LAD Uncomplicated 68 (late ST) STEMI Yes PPCI; treated by BMS deployed within 
thrombosed stent. Died suddenly after a 
cardiac arrest 3 months later; cause of death: 
recurrent ST in the same stent diagnosed at 
P.M. 
95 
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405 68 Definite BMS (3.5mm x 
20mm; 3.5mm x 
24mm) 
SVG to 
OM 
Initially slow flow in 
SVG but had 
improved by the end 
of the procedure 
6 (early ST) STEMI Yes PPCI; had thrombus aspiration followed by 
additional BMS; no further problems. 
Alive 
447 72 Definite BMS (4.0mm x 
12mm to ostium; 
3mm x 24mm and 
3mm x 12mm to 
mid vessel) 
RCA Uncomplicated; 
ostium and mid RCA 
bifurcation treated. 
12 (early 
ST) 
STEMI Yes PPCI complicated by catheter dissection to 
LMS during the diagnostic angiogram which 
required PCI; and then had thrombus 
aspiration to thrombosed RCA stent. Referred 
for CABG but fell and broke leg while 
awaiting surgery; died of E. coli sepsis. 
260 
466 63 Definite BMS (2.75mm x 
14mm) 
Cx Vessel completely 
occluded at start, TIMI 
3 at finish; 
uncomplicated. 
357 (late 
ST) 
STEMI Yes PPCI, new Xience stents to occluded Cx, 
good result and no further problems. 
Alive 
563 49 Definite Cypher (2.5mm x 
23mm) 
Cx Index lesion was a 
possible ST, possible 
restenosis. Thrombus 
visible, TIMI 2 at 
start, good flow at 
finish. Uncomplicated. 
1021 (very 
late ST) 
STEMI Yes Had PCI to Cx with thrombus aspiration and 
new Cypher stent, good result. 
Alive 
764 63 Definite BMS (2.25mm x 
18mm) 
RCA Uncomplicated, Type 
A lesion 
4 (early ST) STEMI Yes PPCI, further stent to RCA. Went on to have 
CABG for 3 vessel disease. Subsequently has 
had further PCI to a degenerated SVG. 
Alive 
972 61 Definite Xience (2.25mm x 
12mm; 2.25mm x 
23mm) 
Cx Complex bifurcation 
lesion, heavy 
calcification, TIMI 2 
flow at start, good 
flow at finish, 
uncomplicated 
11 (early 
ST) 
STEMI Yes Delayed presentation after 48 hours of chest 
pain. Presented in pulmonary oedema, had 
delayed PCI to re-open blocked stent but 
never recovered. 
2 
997 61 Definite Xience (3mm x 
8mm; 3mm x 8mm) 
LAD Bifurcation lesion, 
uncomplicated 
670 (very 
late ST) 
NSTEMI Yes Presented with a NSTEMI, had severe in-
segment (but not in-stent) restenosis of LAD 
proximal to the stent, with a large clot within 
the LAD stent which was removed by 
Alive 
- 126 - 
aspiration. Further stent to proximal LAD, no 
further problems. 
826 86 Probable BMS (4.0mm x 
15mm; 3mm x 
18mm) 
LAD Proximal and mid-
vessel lesions treated, 
both uncomplicated 
46 (late ST) New LBBB No Presented to hospital critically ill with new 
LBBB, no cardiac biomarkers were checked 
and she died shortly after with no P.M. 
25 
843 45 Probable Xience (4mm x 
12mm LAD; 3mm x 
18mm Cx) 
 
LAD 
and/or 
Cx 
Type A lesion in 
LAD, uncomplicated. 
C x occluded at start 
of procedure, good 
flow at finish, 
uncomplicated. 
13 (early 
ST) 
OOH 
cardiac 
arrest 
No Sudden collapse and death OOH; no P.M. 
performed. 
0 
890 66 Probable Xience LAD Heavily calcified 
lesion; uncomplicated. 
12 (early 
ST) 
OOH 
cardiac 
arrest 
No Sudden collapse at home, CPR, VF, shocked 
to asystole. No P.M. performed. 
0 
334 83 Possible BMS (3mm x 15mm 
RCA; 3mm x 18mm 
LAD) 
RCA 
and 
LAD 
RCA lesion heavily 
calcified, 
uncomplicated 
procedure. Had staged 
PCI to type A LAD 
lesion 1 week later, 
uncomplicated. 
311 (late 
ST) 
OOH 
cardiac 
arrest 
No Collapsed at home, found by son, CPR, and 
died before reaching hospital. No P.M. 
performed. Patient also had pulmonary 
hypertension secondary to chronic pulmonary 
embolic disease. 
0 
755 75 Possible BMS (3.5mm x 
18mm) 
Cx Heavy calcification; 
uncomplicated 
procedure. 
324 (late 
ST) 
OOH 
cardiac 
arrest 
No Collapsed and died suddenly at home, no 
P.M. performed. 
1 
864 74 Possible Xience (3mm x 
15mm; 3mm x 
18mm) 
Cx Occluded vessel, 
complicated by no-
reflow, TIMI 3 at 
finish 
34 (late ST) NSTEMI No Admitted with acute LVF and metabolic 
acidosis, died shortly after, no angiogram or 
P.M. 
0 
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5.8. Recurrent ACS and death 
The 1 year all-cause mortality and ARC-defined cardiac death rates for the whole 
cohort were 2.9% and 2.0%. The Kaplan-Meier estimated all-cause and cardiac death 
rates at median follow-up (5.4 years) were 13.2% and 4.8%. Mortality rate declined 
over the first 6 months and became fairly constant after 6 months, illustrated in Figure 
5-4. Mortality rates stratified by clinical syndrome at presentation are shown in Figure 
5-6. Over the first 6 months MI patients have a higher mortality rate than UA patients. 
Over the longer term, STEMI patients have a lower mortality rate than either NSTEMI 
or UA patients. 
Although patients overall were more likely to die of a non-cardiac than cardiac 
cause, recurrent ACS was an important cause of death in patients in the OPERA study 
particularly in the months immediately following PCI. Cardiac death as a proportion of 
total all-cause mortality before and after 1 year was 68% and 26%. Of note there were 
10 deaths directly attributable to possible, probable or definite stent thrombosis, all of 
which occurred in the first year following PCI. Furthermore, there were 9 deaths 
certified - usually in the community by a general practitioner - as being caused by 
„IHD‟, but only 1 of these underwent a post-mortem examination (the post mortem 
showed coronary atherosclerosis but no stent thrombosis). Only 2 of the deaths caused 
by recurrent MI were confirmed to be due to a non-index lesion. In marked contrast 
with stent thrombosis, in-stent restenosis, while frequently presenting with recurrent 
ACS, did not appear to be the direct cause of death in any patient. 
The cause of death by ARC category (Cutlip et al, 2007) and specific cause is 
shown in Table 5-9. Classification was complicated by the frequent co-existence 
multiple chronic illnesses and the post-mortem rate was low. Furthermore, death was 
often certified as „cardiac‟ when in fact there had been gradual deterioration due to 
advanced age or a non-cardiac severe illness such as chronic respiratory disease, motor 
neurone disease or renal failure. Nevertheless I have used the certified cause of death to 
guide the following categorisation, except in 1 patient who was certified as dying of 
cardiac failure when in fact the cause of death was more likely end stage pulmonary 
disease (he had a firm diagnosis of end-stage pulmonary fibrosis and good LV systolic 
function by echocardiography). 
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Table 5-9   Frequency of ARC-defined and specific cause of death  
Cause of death (ARC definitions) 
        Details/specific cause or mode of death 
Number of 
cases 
Proportion of total 
deaths 
Proportion of total 
cohort 
Cardiac 41 35.0% 4.2% 
 Heart failure, any cause 17 14.5%  
  „Pump failure‟, non-valvular cause 13 11.1%  
  „Pump failure‟ due to valvular disease 
+/- IHD 
4 3.4%  
 Acute MI, total 21 17.9%  
  MI, stent thrombosis (any type) 10 8.5%  
   Possible stent thrombosis 3 2.6%  
   Probable stent thrombosis  3 2.6%  
   Definite stent thrombosis 4 3.4%  
  MI, confirmed non-target vessel 2 1.7%  
  IHD - unspecified 9 7.7%  
 Upper GI bleeding while on dual antiplatelet 
therapy 
1 0.9%  
 Contrast nephropathy 1 0.9%  
 Vascular access site bleeding 1 0.9%  
     
Vascular 16 13.7% 1.7% 
 Cerebral infarction 9 7.7%  
 Aortic dissection/aneurysm rupture 2 1.7%  
 Pulmonary embolism 2 1.7%  
 Peripheral vascular disease/limb ischaemia 2 1.7%  
 Intracranial haemorrhage (off dual 
antiplatelet therapy) 
1 0.9%  
     
Non-cardiovascular 57 48.7% 5.9% 
 Metastatic/terminal cancer 31 26.5%  
 Sepsis 15 12.8%  
 Advanced lung disease 2 1.7%  
 End stage renal failure 2 1.7%  
 End stage liver disease 2 1.7%  
 Suicide/trauma 3 2.6%  
 Bowel obstruction 1 0.9%  
 Dementia 1 0.9%  
     
Data unavailable 2 1.7% 0.2% 
    
Total deaths, all cause 117 100% 10.3% 
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Figure 5-6   Cumulative all-cause mortality estimate for OPERA patients; a straight 
(dashed) line added to illustrate constant rate 
 
Figure 5-7   Cumulative all-cause mortality estimates for OPERA patients, stratified by 
clinical syndrome at presentation 
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5.9. Summary points and discussion for Chapter 5 
 The rate of recurrent ACS was 6.7% at 1 year and then 1.8% per year 
thereafter. 
 The rates of recurrent MI and of definite or probable stent thrombosis at 1 
year were 3.8% and 1.1%. 
 The rate of recurrent ACS did not appear to decrease over time 
 The most common clinical syndrome of recurrent ACS overall was 
NSTEMI. 
 Re-admission to hospital with non-cardiac chest pain was as common as 
NSTEMI. 
 Patients with recurrent ACS presenting either as UA or NSTEMI were 
usually found to have obstructive disease at repeat angiography, in more 
than half the cases due to restenosis. 
 Patients with recurrent ACS presenting as STEMI or cardiac arrest was 
usually due to stent thrombosis. 
 Stent thrombosis was rare but carried a high risk of death; of the total 18 
cases of definite, probable or possible stent thrombosis, only 7 were still 
alive at the last mortality check. 
 Multiple baseline characteristics were associated with recurrent ACS; a 
history of smoking, prior IHD and having a stent other than 2
nd
 generation 
DES were independent predictors. 
 SYNTAX score was also an independent predictor of recurrent MI; patients 
with SYNTAX > 8 were at particularly high risk. 
 Within 1 year of PCI, deaths were usually of cardiac cause; but after the first 
year, non-cardiac death was more common. 
5.9.1. Comparison of recurrent ACS rates with published data 
The rate of recurrent ACS is not given in either the PLATO Invasive or TRYTON 
TIMI 38 studies. The rate of non-fatal MI at 12 months in PLATO Invasive was 6.6% 
with clopidogrel (5.3% with ticagrelor); and the rate of MI in TRYTON TIMI 38 at 15 
months was 9.7% with clopidogrel (7.4% with prasugrel). In both studies the MI rates 
seem rather high in comparison to OPERA, in which the Kaplan Meier estimated total 
MI rate at 12 months was only 3.8%, including fatal and non-fatal MI and stent 
thrombosis. It is possible that this discrepancy is due to differences in the definition of 
MI. Both former studies were permitted to include MI events based on cardiac enzyme 
elevation following PCI and neither reported „clinical MI‟ alone as a study endpoint. In 
contrast, all OPERA ACS events required clinical judgement of symptoms, ECG 
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changes, biomarker levels, coronary angiography, functional imaging or post mortem 
examination; biomarker elevation alone was not considered an MI. 
Stent thrombosis rates in OPERA were also low compared to some contemporary 
data. Definite or probable stent thrombosis rate at 12 months was 1.1% in OPERA 
compared with 3.0% in the clopidogrel-treated arm of PLATO Invasive (2.2% with 
ticagrelor). The 15 months rate in TRYTON-TIMI 38 was 2.4% in the clopidogrel arm 
(1.1% with prasugrel). While this may not seem to be a large difference, stent 
thrombosis has a very high mortality rate: in OPERA 61% of all deaths at 12 months 
were in patients who had definite, probable or possible stent thrombosis. Published stent 
thrombosis rates 2 to 3 times higher than in our study therefore become much more 
important. The rate in OPERA is much more similar to that from another contemporary 
study of PCI in ACS patients, the ACUITY trial (Stone et al, 2007), of 1.4%. The 
relatively high rates in PLATO Invasive and TRYTON TIMI 38 were not commented 
upon by the authors and are difficult to explain. 
5.9.2. Change in rate of recurrent ACS over time 
As discussed in Chapter 4, improvements in stent technology over the course of 
OPERA recruitment appeared to lead to a reduction in the need for target lesion 
revascularisation. However, recurrent ACS rates did not follow the same trend. The rate 
of ACS within 12 months was 5.5% in the 1
st
 recruitment phase and 9.8% in the 2
nd
, p = 
0.02. This was seen in patients presenting with all clinical syndromes and may be 
explained by the increased baseline risk of the cohort over the years, demonstrated by 
the increase in both median SYNTAX score (8.0 vs. 11.0, p < 0.01) and median 
EuroSCORE (2.8 vs. 4.4, p < 0.01) between the 1
st
 and 2
nd
 phases. In patients in the 
lowest EuroSCORE quartile (EuroSCORE <2.0) there was no significant difference in 
recurrent ACS rates between the 1
st
 and 2
nd
 phases. 
The most likely explanation for the increasing risk profile of the patients in 
OPERA is that, previously, those deemed to be high risk would often have been 
managed with medical therapy and not been listed for invasive investigation, 
particularly the elderly. For example, the proportion of patients aged over 80 years in 
OPERA was 5.8% in the 1
st
 recruitment phase vs. 11.4% in the 2
nd
; p < 0.01. Clearly 
age and co-morbidities were perceived as less of a barrier to invasive investigation as 
time went on. The lowering of the threshold for invasive investigation and PCI is 
illustrated by the BCIS national audit data which shows an uninterrupted year-on-year 
rise in the number of PCI cases taking place in the UK: approximately 10,000 PCI cases 
took place in 1991 compared to almost 100,000 in 2014. The number of cases of CABG 
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by contrast has remained completely static over this time; there is currently a ratio of 5 
PCI cases to 1 CABG cases in the UK.  
5.9.3. Causes of recurrent ACS in OPERA 
In the OPERA study patients with recurrent UA and STEMI were usually found to 
have obstructive coronary disease on repeat angiography, often due to restenosis of a 
stent. Patients with the less common clinical syndromes of STEMI, out-of-hospital 
arrest and sudden death were often found to have had a stent thrombosis. As discussed 
in the previous chapter, patients who required TLR for restenosis had a low subsequent 
mortality rate; ISR appears to be a very benign entity in comparison with stent 
thrombosis, at least over the first few years after PCI. The rates of both cardiac death 
and stent thrombosis decline steeply after the first few months of PCI. 
The small number of cases of stent thrombosis hampers the search for associations 
with baseline characteristics and possible causative factors. Baring this in mind, 
however, stent thrombosis did appear to occur with greater frequency in patients with 
more complex disease such as Type C or calcified lesions; and also in patients with the 
angiographic complications of no-reflow and localised dissection (although most 
patients with ST did not have an angiographic complication). These „mechanical‟ 
factors are among many characteristics found by previous investigators to be associated 
with stent thrombosis, summarised in a 2008 review article by Lemesle et al. Stent 
thrombosis is also known to be strongly associated with low levels of platelet inhibition 
as measured by platelet function tests, explored further in Chapter 7. 
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Chapter 6   Bleeding and antiplatelet drugs 
6.1. Bleeding rates and severity 
Bleeding from any site, of any severity, was recorded in 85 patients over long-
term follow-up, 8.8% of the whole OPERA ACS cohort of 968 patients. The estimated 
rate of „clinically significant‟ bleeding (BARC 2 to 5) at 3.5 years was 5.7%. In 59 
patients there was a distinct bleeding event in which bleeding occurred at a well-defined 
time-point. However, 26 patients reported chronic bleeding, particularly epistaxis. For 
distinct bleeding events with a recorded date only, cumulative bleeding rates at 48 
hours, 30 days, 1 year and 3.5 years (K.M. estimates) are shown in Table 6-1. Figure 6-
1 shows the incidence of bleeding by clinical severity (BARC classification) for patients 
who reported bleeding from any site at any time over long-term follow-up. If patients 
had more than 1 episode of bleeding the worst episode is shown. 
The bleeding classification definitions are summarized here: 
BARC 1 bleeding: not actionable; does not cause the patient to seek any medical 
input 
BARC 2: bleeding which requires medical intervention, hospitalization or 
increased level of care 
BARC 3a: bleeding with a Hb drop of 3 to 5 g/dL; or any drop requiring 
transfusion 
BARC 3b: bleeding with Hb drop of > 5 g/dL, cardiac tamponade, requires 
surgical intervention or requires use of inotropes 
BARC 3c: intracranial haemorrhage 
BARC 4: CABG-related bleeding 
BARC 5: fatal bleeding (Type 5a probable; type 5b definite) 
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Table 6-1   Cumulative incidence of bleeding events stratified by BARC classification of 
clinical severity 
Severity of bleed 0 to 48 hours 0 to 30 days 0 to 1 year 0 to 3.5 years 
BARC 1 only 1 (0.1%) 1 (0.1%) 2 (0.2%) 6 (0.9%) 
BARC 2 only 14 (1.5%) 14 (1.5%) 24 (2.6%) 31 (3.6%) 
BARC 3 only 3 (0.3%) 3 (0.3%) 9 (1.0%) 15 (1.9%) 
BARC 4 only 0 0 0 0 
BARC 5 only 1 (0.1%) 2 (0.2%) 3 (0.3%) 4 (0.5%) 
     
BARC 2 to 5 18 (1.9%) 19 (2.0%) 35 (3.8%) 49 (5.7%) 
BARC 3 to 5 4 (0.4%) 5 (0.5%) 12 (1.3%) 19 (2.3%) 
     
All bleeding 19 (2.0%) 20 (2.1%) 37 (4.0%) 55 (6.5%) 
NB Most BARC 1 bleeds (21 of 30 BARC 1 cases) and some BARC 2 bleeds (5 
of 36 BARC 2 cases) were chronic or recurrent without a date of event and are not 
included in this table 
The rate of bleeding decreased over time from PCI in 3 distinct stages. There was 
a high peri-procedural (< 48 hours after PCI) rate; a lower rate up to approximately 400 
days; and a still lower rate from 400 days onwards. This is illustrated in Figure 6-2. The 
rate change at around 400 days occurs shortly after the majority of patients cease dual 
antiplatelet therapy (median (IQR) time on DAPT 366 (74) days). Peri-procedural 
bleeding was high mainly due to arterial access site bleeding: of the 19 patients who had 
a bleeding event within 48 hours of the procedure there were 15 cases of femoral 
puncture site bleeding, 1 case of radial puncture site bleeding, 1 of GI bleeding and 2 
cases of epistaxis. After this point there were no obvious time-dependent differences 
either in site or severity of bleeding. 
The 1 year bleeding rate was higher in the second phase of recruitment than in the 
first: 15 cases (6.1%) in the second phase vs. 22 cases (3.0%), p = 0.03. This was not 
obviously due to bleeding from any one particular site. 
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Figure 6-1   Pie chart showing relative proportions of total bleeding episodes classified by 
clinical severity using BARC categorisation NB: There were no recorded BARC Type 4 (related to 
CABG) bleeds; however, the details of CABG operations during follow-up were not carefully examined for this 
complication  
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Figure 6-2   Cumulative incidence of all distinct bleeding events for which a date was 
recorded; straight reference lines added to highlight rate changes (long dash); vertical 
dashed line at point of change in rate at approximately 400 days 
6.1.1. Fatal bleeding 
Although most cases of bleeding were trivial or had only minor clinical 
consequences (57 cases - 73.1% of bleeds, or 5.9% of the total cohort - were either 
BARC 1 or 2), bleeding was the direct cause of death in 5 patients (6.4% of bleeds; 
0.5% of the total cohort), see Table 6-2. Only 1 of these haemorrhagic deaths (PAT ID 
951, femoral access site haemorrhage) could be said to be directly related the procedure. 
Table 6-2   Table listing details of the 5 patients who died due to bleeding 
PAT ID Time from PCI to death Cause of death 
38 4 days Upper GI bleed, exact source unconfirmed 
186 221 days Spontaneous subdural haematomas 
317 1635 days Bleeding oesophageal varices – alcoholic liver disease 
353 722 days Bleeding from colo-vaginal fistula – unconfirmed cause 
951 1 day Bleeding from femoral puncture site 
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6.2. Bleeding from specific sites 
Figure 6-3 shows the frequency of bleeding by site of bleeding for 85 patients who 
reported bleeding of any severity. 1 patient reported „minor bleeding‟ but no site was 
recorded. Epistaxis and gastrointestinal tract bleeding were the 2 most common types of 
haemorrhagic adverse event overall, occurring with equal frequency and accounting for 
58% of all bleeding events. 
 
6-3   Pie chart showing site of bleeding for whole cohort over total follow-up 
6.2.1. Epistaxis 
The nasal mucosa was the commonest bleeding site. Most of the 25 documented 
cases of epistaxis had no, or only minor, immediate clinical consequences: 18 (72% of 
cases of epistaxis) were classified as BARC 1 and 23 (92%) were either BARC 1 or 2. 
The other 2 patients with epistaxis had rather more severe bleeding: PAT ID 856 
required multiple episodes of cauterisation and a 3 unit blood transfusion; and PAT ID 
36 required admission to hospital, cauterisation and had a 3g/dL drop in haemoglobin 
but no transfusion. 
More often than not, patients reported chronic recurrent epistaxis rather than 1 or 
more distinct episodes (14 (56%) cases were chronic). The vast majority of cases of 
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epistaxis occurred during longer term follow up (median (IQR) time to epistaxis: 382 
(1102) days), with only 2 cases recorded during the index inpatient stay. 
Epistaxis was more common in older patients: mean age 67.1 (12.9) vs. 62.1 
(12.0), p = 0.04; and there was a trend for more epistaxis in patients with a history of 
hypertension (3.5% vs. 1.7%, p = 0.08) and in those with a history of renal failure (8.7% 
vs. 2.4%, p = 0.06). 
6.2.2. Gastro-intestinal tract haemorrhage 
There were 25 cases of reported gastro-intestinal blood loss of any type or severity 
during long-term follow-up. These adverse events are shown in greater detail in Table 
6-3. 
Table 6-3   Table detailing the frequency of different types of gastro-intestinal bleeding 
Type/cause of GI bleed Number of patients 
(% of GI bleeds) 
PAT ID 
Fresh PR bleed; haemorrhoids 10 (40.0) 59, 170, 187, 192, 
240, 576, 740, 753, 
859, 904 
Upper GI bleed (haematemesis and/or melaena); peptic 
ulcer disease or oesophagitis on OGD 
10 (40.0) 38, 232, 431, 455, 
466, 507, 567, 657, 
841, 901 
Gastric varices/chronic liver disease 2 (8.0) 29, 317 
Positive faecal occult blood, anaemia: diverticulosis on 
colonoscopy 
1 (4.0) 629 
Iron deficiency anaemia, blood transfusion: bowel 
cancer on colonoscopy 
1 (4.0) 1001 
Unstable angina, anaemia, blood transfusion: erosive 
gastritis on OGD 
1 (4.0) 16 
The median (IQR) time from PCI to GI bleed was 512 (1053) days, with only 1 
case occurring during the index hospital stay (following PCI). There were 5 patients 
with chronic recurrent bleeding. GI bleeding was classified as BARC 1 in 4 (16%) 
cases, BARC 2 in 11 (44%), BARC 3a in 6 (24%) and 3b in 2 (8%). In the remaining 2 
patients, GI bleeding was the direct cause of death (BARC 5b): PAT ID 38 died of a 
massive upper GI bleed presenting with hypovolaemic shock 2 days after being 
discharged from hospital from her index admission; and PAT ID 317 had alcohol 
dependence and died of bleeding oesophageal varices more than 5 years after his index 
event. 
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The baseline characteristics associated with GI bleeding were: older age (mean 
67.7 (10.6) years vs. 62.1 (12.1) years, p = 0.03); a history of COPD (5.8% vs. 2.1%, p 
= 0.02); a history of renal failure (8.7% vs. 2.3%, p = 0.05); and a pre-procedural 
haemoglobin level of < 10g/dL (17.6% vs. 2.3%, p < 0.01). There was no significant 
difference in the rate of GI bleeding between men and women (2.3% vs. 2.9%, p = 
0.63), or between the 2 phases of recruitment. 
The use of pre-procedural ACE-inhibitors and the use of beta-blockers were 
associated with less GI bleeding (1.8% vs. 4.4%, p = 0.02 and 2.0% vs. 4.5%, p = 0.05 
respectively). There was no difference in the rate of GI bleeding in patients taking or not 
taking proton pump inhibitors at PCI (2.7% vs. 2.4%, p = 0.75); nor was there a 
difference in GI bleeding rates in patients receiving or not receiving IIbIIIa inhibitors at 
PCI (2.6% vs. 2.4%, p = 0.91). 
6.2.3. Arterial access site bleeding 
Arterial access site bleeding was the third most common form of bleeding. There 
were 16 arterial access site bleeds, 1 radial and 15 femoral, all recorded within 24 hours 
of PCI. 13 patients had simple haematomas (12 femoral, 1 radial) which required 
prolonged compression and/or increased length of hospital stay (BARC 2); and 1 of 
these patients required a blood transfusion (BARC 3a). There were 2 episodes of more 
serious access site bleeding: 1 patient (PAT ID 545) had a retroperitoneal bleed 
following PCI which required surgical repair, classified as BARC 3b (she survived this 
to die of stroke disease several years later); and 1 patient (PAT ID 951) died following a 
massive bleed from his femoral puncture site despite efforts to repair it surgically, 
BARC 5b (the femoral puncture in this case had been into a femoral graft rather than the 
native femoral artery due to lack of alternative vascular access sites). 
Analysis of arterial access site bleeding in relation to baseline characteristics was 
limited by the small event numbers; however, it was more common in patients over the 
age of 80 (7.1% vs. 1.2%, p < 0.01), in females (4.1% vs. 0.8%, p < 0.01) and in 
patients with a previous history of IHD (2.8% vs. 0.6%, p < 0.01). There was a trend for 
less access site bleeding in patients taking ACE-inhibitors (1.1% vs. 2.7%, p = 0.08) and 
in patients with a history of smoking (1.2% vs. 2.7%, p = 0.09). There was numerically 
more access site bleeding in patients with a history of hypertension (2.2% vs. 1.0%, p = 
0.14). There was no significant difference in arterial access site bleeding rates between 
patients receiving and not receiving IIbIIIa inhibitors (1.0% vs. 0.9%, p = 0.94). 
- 140 - 
6.2.4. Intracranial bleeding 
There were only 2 cases of intracranial bleeding during long-term follow-up: 1 
patient had haemorrhagic transformation of a cerebral infarction (PAT ID 1049); and 1 
patient developed bilateral subdural haematomas leading to her death (PAT ID 186). 
6.3. Bleeding and baseline clinical characteristics 
Table 6-4 shows the baseline clinical characteristics in patients who experienced 
any bleeding and BARC 2 or more bleeding at any point during follow-up.  
Many baseline characteristics were associated with a higher incidence of bleeding. 
These included age, female sex, low body weight and low BMI, a previous history of 
IHD, heart failure, chronic lung disease and hypertension. Bleeding rate increased with 
increasing EuroSCORE. Patients with anaemia or renal dysfunction pre-procedure were 
also more likely to have bleeding problems, as were patients who underwent PCI to 
Type C lesions and heavily calcified lesions. There was a non-significant trend for 
higher bleeding rates with increasing SYNTAX score. 
Characteristics associated with a lower rate of bleeding included presentation with 
STEMI, a history of tobacco smoking and treatment with an ACE-inhibitor. Patients 
with bleeding of any sort, but not BARC 2 to 5 bleeding, were less likely to have 
received aspirin at the time of PCI.  
The univariable characteristics associated with BARC 2 to 5 bleeding are shown 
in 6-5. After adjustment (Cox regression), the main factors independently associated 
with BARC 2 to 5 bleeding were age and pre-procedural haemoglobin level, whereas 
treatment with ACE inhibitors conferred a lower risk of bleeding. In a model with just 
these 3 variables, the adjusted hazard ratios (95% C.I.) were: for haemoglobin (Hb), 
0.73 (0.62 to 0.87) per gram/dL, p < 0.01; for age, 1.04 (1.01 to 1.07) per year, p < 0.01; 
and ACE-inhibitor use, 0.46 (0.26 to 0.81), p = 0.01. 
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Table 6-4   Table comparing baseline characteristics in patients with and without bleeding 
of any severity; and in patients with BARC 2 to 5 bleeding compared with no bleeding 
Baseline characteristic No bleeding 
N = 883 
Any bleed 
N = 85 
P 
value 
Type 2 to 5 
bleed  
N = 57 
P 
value 
Demographics and clinical syndrome      
Mean (SD) Age, years 61.6 (11.9) 68.5 (11.8) <0.01 69.7 (11.8) <0.01 
 Age over 80 years 52 (5.9%) 18 (21.2%) <0.01 13 (22.8%) <0.01 
Female 206 (23.3%) 36 (42.4%) <0.01 25 (43.9%) <0.01 
Median weight (IQR), kg 81.2 (19.8) 77.3 (18.7) 0.01 79.1 (20.0) 0.09 
Median (IQR) BMI 28.1 (6.0) 26.6 (5.0) 0.01 26.4 (4.0) 0.02 
Any history of smoking 618 (70.3%) 48 (57.1%) 0.01 31 (54.4%) 0.01 
Presented with unstable angina 109 (12.3%) 15 (17.6%) 0.16 10 (17.5%) 0.27 
Presented with NSTEMI 566 (64.1%) 61 (71.8%) 0.16 43 (75.4%) 0.08 
Presented with STEMI 208 (23.6%) 9 (10.6%) <0.01 4 (7.0%) <0.01 
 STEMI, convalescent PCI 117 (13.3%) 4 (4.7%) 0.02 1 (1.8%) 0.01 
 STEMI, Primary PCI 91 (10.3%) 5 (5.9%) 0.19 3 (5.3%) 0.23 
      
Risk scores      
Median (IQR) EuroSCORE 5.3 (4.2) 8.6 (10.1) <0.01 9.6 (11.5) <0.01 
 EuroSCORE 1
st
 quartile (0 to 1.9) 236 (26.7%) 11 (12.9%) 
<0.01 
6 (10.5%) 
<0.01 
 EuroSCORE
 
2
nd
 quartile (2.0 to 
3.0) 
212 (24.0%) 15 (17.6%) 11 (19.3%) 
 EuroSCORE 3
rd
 quartile (3.1 to 
6.3) 
229 (25.9%) 22 (25.9%) 13 (22.8%) 
 EuroSCORE 4
th
 quartile (6.4 to 
62.0) 
206 (23.3%) 37 (43.5%) 27 (47.4%) 
SYNTAX score 8.0 (11.0) 11.0 (14.3) 0.05 11.0 (16.3) 0.05 
 SYNTAX score 1
st
 quartile (1.0 to 
4.0) 
222 (25.7%) 14 (16.5%) 
0.15 
10 (17.5%) 
0.25 
 SYNTAX score 2
nd
 quartile (5.0 
to 8.0) 
212 (24.6%) 22 (25.9%) 13 (22.8%) 
 SYNTAX score 3
rd
 quartile (9.0 
to 15.0) 
223 (25.8%) 21 (24.7%) 14 (24.6%) 
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 SYNTAX score 4
th
 quartile (15.5 
to 48.0) 
206 (23.9%) 28 (32.9%) 20 (35.1%) 
      
Past medical history      
Prior coronary revascularisation, any 
type 
152 (17.2%) 14 (16.5%) 0.86 10 (17.5%) 0.94 
Previously known IHD, any 
syndrome 
410 (46.4%) 52 (61.2%) <0.01 37 (64.9%) <0.01 
Heart failure 10 (1.1%) 5 (5.9%) <0.01 4 (7.0%) <0.01 
Diabetes mellitus 146 (16.6%) 13 (15.3%) 0.76 10 (17.5%) 0.82 
Hypertension 438 (49.6%) 51 (60.0%) 0.07 36 (63.2%) 0.05 
Hyperlipidaemia 493 (56.1%) 52 (61.2%) 0.37 34 (59.6%) 0.63 
Peripheral vascular disease 39 (4.4%) 4 (4.7%) 0.90 3 (5.3%) 0.76 
Chronic lung disease 87 (9.9%) 16 (18.8%) 0.01 10 (17.5%) 0.08 
Stroke 44 (5.0%) 5 (5.9%) 0.72 2 (3.5%) 0.58 
      
Blood results      
Median (IQR) pre-procedural Cr, 
µmol/L 
94 (23) 96 (29) 0.31 100 (29) 0.12 
 Renal impairment, Cr >200 
µmol/L 
16 (1.8%) 7 (8.2%) <0.01 5 (8.8%) <0.01 
 Renal impairment, eGFR < 60 
ml/min/1.73m
2
 
252 (29.2%) 41 (49.4%) <0.01 30 (54.5%) <0.01 
Median (IQR) pre-procedural Hb, 
g/dL 
14.1 (2.1) 12.9 (3.0) <0.01 12.9 (3.1) <0.01 
 Hb < 10.0 g/dL 11 (1.4%) 6 (7.5%) <0.01 5 (9.1%) <0.01 
Median (IQR) platelet count x 10
9
 247 (87) 258 (89) 0.30 248 (103) 0.75 
      
Medications at PCI      
Aspirin 858 (97.5%) 79 (92.9%) 0.02 55 (96.5%) 0.79 
Clopidogrel 832 (94.2%) 83 (97.6%) 0.19 56 (98.2%) 0.20 
Prasugrel 52 (5.9%) 3 (3.5%) 0.37 2 (3.5%) 0.47 
Heparin 757 (85.9%) 77 (90.6%) 0.23 50 (87.7%) 0.75 
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Bivalirudin 138 (15.7%) 8 (9.6%) 0.14 7 (12.7%) 0.60 
IIbIIIa inhibitor 283 (32.0%) 29 (34.1%) 0.70 20 (35.1%) 0.63 
ACE inhibitor 574 (68.9%) 43 (53.8%) <0.01 28 (50.9%) <0.01 
Beta-blocker 634 (75.9%) 58 (71.6%) 0.39 39 (70.9%) 0.41 
HMG-CoA reductase inhibitor 734 (83.1%) 70 (82.4%) 0.86 50 (87.7%) 0.33 
Proton pump inhibitor 263 (29.8%) 31 (36.5%) 0.20 21 (36.8%) 0.27 
Warfarin (before admission with 
index event) 
17 (1.9%) 2 (2.4%) 0.79 2 (3.5%) 0.39 
      
Procedural characteristics      
Arterial access route: femoral 693 (78.6%) 69 (81.2%) 
0.58 
45 (78.9%) 
0.98 
Arterial access route: radial 189 (21.4%) 16 (18.8%) 12 (21.1%) 
More than 1 stent implanted 250 (28.9%) 23 (27.1%) 0.73 15 (26.3%) 0.68 
Drug eluting stent, any vessel 522 (59.1%) 49 (57.6%) 0.79 32 (56.1%) 0.65 
Staged PCI 27 (3.1%) 0 0.10 0 0.19 
Worst lesion type:      
 Type A 131 (15.0%) 8 (9.4%) 
<0.01 
7 (12.3%) 
0.05 
 Type B1 216 (24.7%) 17 (20.0%) 14 (24.6%) 
 Type B2 209 (23.9%) 13 (15.3%) 6 (10.5%) 
 Type C 320 (36.5%) 47 (55.3%) 30 (52.6%) 
Calcified lesion 156 (17.7%) 26 (30.6%) <0.01 17 (29.8%) 0.03 
Thrombotic lesion 224 (25.4%) 20 (23.5%) 0.71 13 (22.8%) 0.67 
Non-haemorrhagic procedural 
complication 
112 (12.7%) 10 (11.8%) 0.81 6 (10.5%) 0.63 
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Table 6-5   Table showing characteristics associated with BARC 2 to 5 bleeding for entire 
OPERA cohort (off or on treatment with P2Y12 inhibitors) 
 
6.3.1. Bleeding and pre-procedural haemoglobin concentration 
Bleeding rates were higher in patients who had low pre-procedural Hb 
concentration. This is illustrated in Figure 6-5 and explored further in Chapter 7. 
6.3.2. Bleeding and age 
Figure 6-4 shows the proportion of BARC 2 to 5 bleeding over long-term follow-
up for patients by decade of age at time of PCI, showing a steady increase in bleeding 
rate with age up to a threshold of approximately 80 years. Beyond 80 years the rate 
increases more sharply, with much of the excess bleeding occurring in the immediate 
post-PCI period; 30% of 30 day bleeding and 30% of access site bleeding occurred in 
the relatively small group of over-80s (70 patients) in the OPERA study. 
Characteristic Hazard Ration 
(as univariate) 
95% C.I. P value 
Lower Upper 
Haemoglobin (per g/dL) 0.65 0.56 0.75 < 0.01 
ACE inhibitor 0.45 0.26 0.78 < 0.01 
History of heart failure 8.29 2.97 23.16 < 0.01 
Type C lesion 2.15 1.25 3.72 < 0.01 
Age (per year) 1.07 1.04 1.10 < 0.01 
Female sex 2.52 1.46 4.35 < 0.01 
Body Mass Index 0.93 0.88 1.00 0.03 
Presentation with STEMI 0.30 0.11 0.83 0.02 
Previous IHD 2.53 1.40 4.55 < 0.01 
Chronic lung disease 1.88 0.92 3.85 0.07 
Hypertension 1.76 1.00 3.09 0.05 
Renal dysfunction, eGFR low 2.99 1.71 5.22 < 0.01 
Smoking 0.48 0.28 0.82 < 0.01 
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Figure 6-4   KM estimates of BARC 2 to 5 bleeding during long-term follow-up stratified 
by age (decades); number of events at median follow-up (3.4 years)/number in starting 
group shown 
 
6.3.3. Risk of bleeding from combination of age and anaemia 
Figure 6-5 shows the rates of BARC 2 to 5 bleeding stratified by the 2 main 
baseline risk factors, advanced age and anaemia. Age > 70 has been chosen to increase 
the group size; anaemia is defined as Hb < 12 g/dl. 
 
6.3.4. Bleeding and ACE-inhibitor use pre-PCI 
Figure 6-6 shows the unadjusted KM estimates of BARC 2 to 5 bleeding up to the 
median follow-up of 1273 days for patients stratified into groups in which ACE 
inhibitors were used at PCI or not. Most of the excess bleeding episodes in the group 
not on ACE-inhibitors were peri-procedural from the arterial access site. 
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Figure 6-5   KM estimates of BARC 2 to 5 bleeding rates in patients stratified into 4 
groups based on age below and above 70 years and baseline Hb below and above 12 g/dl; 
number of events/number in group at start shown 
The association of ACE-inhibitor use with lower bleeding rates was not constant 
over time of patient recruitment: the rate of BARC 2 to 5 bleeding in the first 
recruitment phase was 3.9% with ACE-inhibitors vs. 9.9% without, p < 0.01; and in the 
second phase, 6.0% vs. 7.7%, p = 0.82. This change is not simply due to higher femoral 
access route in the first phase compared to the second: BARC 2 to 5 bleeding rates in 
femoral access cases were 4.7% with ACE-inhibitors vs. 9.0% without, p = 0.04; and in 
radial access cases, 3.7% with ACE-inhibitors vs. 9.5% without, p = 0.10. The 
association of ACE-inhibitor use with reduced bleeding rates was more prominent when 
IIbIIIa inhibitors were used at PCI: BARC 2 to 5 bleeding rates were 4.8% vs. 7.5% 
with and without ACE-inhibitors in those not receiving IIbIIIa inhibitors (p = 0.17); but 
4.0% vs. 12.4% in those receiving IIbIIIa inhibitors, p <0.01. It is possible that the 
difference over time may be partly explained by the lower rate of IIbIIIa inhibitor use in 
the second recruitment phase compared to the first (35.5% vs. 22.4%, p < 0.01). 
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There also seems to be an important difference in the effect of ACE-inhibitors on 
bleeding rate between men and women: BARC 2 to 5 bleeding rates in men were 2.9% 
vs. 8.9% with and without ACE-inhibitors (p < 0.01), but in women these rates were no 
different: 10.5% vs. 9.6% (p = 0.82). 
 
Figure 6-6   KM estimates of cumulative incidence of BARC 2 to 5 bleeding in patients 
stratified by use or no use of ACE-inhibitors at PCI 
 
6.4. Bleeding and antiplatelet compliance 
6.4.1. Aspirin compliance 
Aspirin was given before PCI in nearly all patients (963, 99.5%) and was 
relatively well tolerated with the majority, 89%, continuing to take it long-term or until 
death. Aspirin was discontinued by 102 (10.5%) patients, only 12 of whom reported 
having to stop aspirin specifically due to bleeding problems, see Figure 6-7. 
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Figure 6-7   Pie chart showing reasons for discontinuation of aspirin in OPERA patients 
6.4.2. Clopidogrel compliance 
Clopidogrel was received by 915 patients before PCI and a further 24 patients 
received prasugrel at PCI but were changed to clopidogrel shortly afterwards. Of these 
939 patients, clopidogrel was discontinued after 12 months according to guidelines for 
treatment of ACS in 677 (72.1%). Only 6 (0.6%) patients discontinued clopidogrel 
because of bleeding problems. Figure 6-8 illustrates the reasons for clopidogrel 
discontinuation. 
Clopidogrel was never discontinued by 105 (11.2%) patients. In 11 of these, 
clopidogrel was continued long-term as a single antiplatelet due to aspirin intolerance. 
In the other 94 patients, DAPT with aspirin and clopidogrel was continued indefinitely 
for unclear reasons, which could include patient or physician preference or simple 
oversight. 
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Figure 6-8   Pie chart showing reasons for discontinuation of clopidogrel in OPERA 
patients 
6.4.3. Prasugrel compliance 
Prasugrel was received by 53 patients before PCI; 48 of these were PPCI cases (as 
was the local protocol at the time of recruitment). In 20 cases, only prasugrel loading 
dose was given and the patient was switched to clopidogrel following PCI. There were 
21 patients who took the recommended 12 months of prasugrel; 9 others continued 
indefinitely, 1 patient stopped due to allergy, 1 patient died while still on prasugrel, and 
1 further patient discontinued the drug for unclear reasons. No patient had to stop the 
drug because of bleeding problems. 
6.5. The association of bleeding with mortality 
BARC 2 to 5 bleeding was associated with a higher rate of all-cause, cardiac and 
non-cardiovascular death during long-term follow-up. The crude death rates in patients 
with and without BARC 2 to 5 bleeding were: for all-cause mortality, 31.6% vs. 10.9%, 
p < 0.01; for cardiac death, 10.5% vs. 3.8%, p = 0.02; and for non-cardiovascular death, 
17.5% vs. 5.3%, p < 0.01. Even discounting the 5 patients who died as a direct result of 
bleeding, patients with BARC 2 to 5 bleeding still appeared to have greater all-cause 
mortality (25.0%, p < 0.01) and non-cardiovascular mortality (15.4%, p < 0.01) when 
compared to patients without bleeding (the rate of cardiac death was no longer 
different). However, after adjustment for age (Cox regression), the association of non-
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fatal BARC 2 to 5 bleeding with all-cause mortality lost statistical significance: for age, 
aHR (95% CI) 1.090 (1.07 to 1.11) per year, p < 0.01; for BARC 2 to 5 bleeding, aHR 
1.80 (1.0 to 3.23), p = 0.05 
The median (IQR) time from non-fatal BARC 2 to 5 bleed to death was 766 
(1218) days. The specific causes of death in the 18 deceased patients with BARC 2 to 5 
bleeding can be divided into those deaths directly related to bleeding and those without 
a clear relationship with bleeding, as follows: 
Cause of death directly related to bleeding (5 patients): 
 Femoral artery bleed: 1 patient 
 Bilateral chronic subdural haematoma: 1 patient 
 Upper GI bleed: 1 patient 
 Bleeding oesophageal varices: 1 patient 
 Bleeding from malignant colo-vaginal fistula: 1 patient 
Cause of death not directly related to bleeding (13 patients): 
 Terminal cancer: 4 patients 
 CCF/valvular heart disease: 2 patients 
 CCF/ischaemic cardiomyopathy: 2 patients 
 Cerebral infarction: 2 patients 
 COPD and breast cancer: 1 patient 
 Cirrhosis: 1 patient 
 Pneumonia and chronic pancreatitis: 1 patient 
The relationship between bleeding and subsequent adverse clinical events is 
explored further in Chapter 7. 
6.6. Association of BARC 2 to 5 bleeding with antiplatelet and 
anticoagulant medication 
A record was made where possible of antiplatelet and anticoagulant medication 
taken at the time of BARC 2 to 5 bleeding events. In most cases (43 of 57 patients with 
BARC 2 to 5 bleeding), bleeding occurred while still receiving DAPT with aspirin and 
the index P2Y12 inhibitor. In 2 further cases a bleeding event took place while the 
patient was on DAPT but with a different P2Y12 inhibitor to that given at the index PCI 
(PAT ID 1018 and 1049). 6 patients had a BARC 2 to 5 bleed while on no P2Y12 
inhibitor, 5 of these while on aspirin alone (PAT ID 280, 629, 682, 740 and 317) and 1 
while on Warfarin alone (PAT ID 289). A further patient had a BARC 2 to 5 bleed on 
- 151 - 
warfarin and clopidogrel (PAT ID 657). In 5 cases it was not possible to verify whether 
bleeding had taken place while taking the index P2Y12 inhibitor (PAT ID 378, 582, 507, 
576 and 753). 
Of 53 patients given prasugrel prior to PCI, on-prasugrel BARC 2 to 5 bleeding 
occurred in 2 (3.8%) – but note that there was a high rate of switching from prasugrel to 
clopidogrel immediately following PCI. Of 910 patients given clopidogrel prior to PCI, 
on-clopidogrel BARC 2 to 5 bleeding occurred in 43 (4.7%). 
6.7. Chapter 6 summary points and discussion 
 Bleeding was relatively common, reported in about 9% of the population 
over long-term follow-up. 
 Bleeding was often chronic and recurrent. 
 The commonest types of bleeding were epistaxis and GI tract bleeding. 
 Peri-procedural bleeding rate was high mainly due to femoral artery access 
site haematomas. 
 Bleeding rate clearly decreased after about 12 to 13 months (the duration of 
DAPT). 
 Most bleeding episodes were of minor clinical severity. Fatal bleeding was 
rare with only 5 cases throughout long-term follow up. 
 The main baseline characteristics associated with bleeding were low pre-
procedural Hb level and increasing age. 
 ACE-inhibitors appeared to be protective against peri-procedural arterial 
access site bleeding – but only in men. 
 Aspirin discontinuation was relatively common, seen in 10%, usually due to 
GI tract disturbance rather than bleeding. Clopidogrel discontinuation before 
12 months was rare and many (11%) continued clopidogrel beyond 12 
months. 
 Bleeding was strongly associated with subsequent mortality, although this 
association was lost after adjustment for age. None of the deaths in patients 
who had bleeding were overtly haemorrhagic in nature. 
 
6.7.1. Bleeding rates in comparison with published data 
The total bleeding rate (BARC 1 to 5) at 12 months in OPERA was 4.0%. In 
TRYTON TIMI 38 the rate was very similar: 3.8% with clopidogrel (5.0% with 
prasugrel) at 15 months (TIMI definitions). In PLATO Invasive the rate of non-CABG 
related bleeding was comparatively high with PLATO definitions: 7.1% with 
clopidogrel (8.9% with ticagrelor) at 12 months. However, with TIMI definitions total 
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non CABG related bleeding was similar: 3.9% with clopidogrel (4.6% with ticagrelor). 
Note that patients in both the PLATO and TRYTON TIMI 38 studies were selected as 
being at low risk of bleeding, so perhaps the bleeding rates in OPERA are a little lower 
than one would expect in an all-comers population. 
6.7.2. Risk factors for bleeding 
In OPERA the main baseline characteristics associated with bleeding were 
advanced age and anaemia: bleeding was very uncommon in those under 70 years old 
and only 1 patient under 50 years reported any bleeding at all over long-term follow-up.  
In contrast, the rate of bleeding in the over-80s approached 25% by 3.5 years of follow-
up. The rate of bleeding was noticeably higher during the first 13 months after PCI, 
corresponding to the duration of DAPT. This leads us to a treatment dilemma in that 
while older patients have the worst coronary disease and highest rates of recurrent ACS, 
they are least able to tolerate the side effects of DAPT. This will surely become more of 
a problem in a patient population which continues to age. 
6.7.3. Bleeding and mortality 
There has been a great deal of concern in the recent published literature regarding 
an apparent strong association with bleeding events and subsequent all-cause mortality 
in PCI patients, such as the 2011 paper by Mehran, Pocock et al. However, unlike these 
studies, in the OPERA study an effort was made to investigate the cause of all deaths 
individually in detail, especially in patients who had reported bleeding problems during 
follow up. While we also found an apparent association between bleeding and mortality, 
on closer inspection we found that deaths directly related to bleeding were very rare and 
the association was most likely due to confounding factors such as advanced age, 
present in both those with bleeding problems and those who died. 
Therefore, while bleeding problems in older people following PCI are frequently 
encountered, a fear of bleeding should not necessarily preclude these patients from 
being offered PCI when found to have severe coronary disease. Certain manoeuvres 
could lower the risk of bleeding in the elderly however, such as the use of proton pump 
inhibitors to lower the chance of peptic ulceration; or shortening the duration of DAPT. 
Also we observed in our population a considerably lower rate of peri-procedural 
bleeding (mainly femoral access site) in men taking ACE-inhibitors. This was 
presumably due to lower blood pressure in patients on these drugs, which could not be 
demonstrated as blood pressure in the cath lab or in recovery was not recorded in the 
study database. The effect good blood pressure control may have on bleeding rates in 
patients on DAPT has not been studied to the best of our knowledge. 
- 153 - 
Chapter 7 Platelet function testing   
In this chapter the association of P2Y12 receptor inhibition, measured using the 
VerifyNow bedside method, on the incidence of ischaemic and haemorrhagic events 
following PCI is studied. To improve the ability to detect associations we have analysed 
clinical adverse events which occurred while the affected patient was currently taking 
the same P2Y12 inhibitor they were on when the platelet function test was performed 
(„on-treatment events‟) with censorship at cessation of treatment. The dataset of 789 
patients used for analyses in Chapter 7 incorporates all patients from the OPERA ACS 
cohort (presented in Chapters 1 to 6) who had a VerifyNow test result and who did not 
have emergent PCI (all PPCI patients excluded). 
Note: the VerifyNow Base value represents the degree of thrombin receptor 
(PAR)-mediated platelet reactivity and is independent of the effect of ADP P2Y12 
receptor inhibition; the PRU value represents ADP P2Y12 receptor-mediated reactivity; 
and the %inhibition value is derived from the difference in platelet reactivity between 
the Base and PRU and gives an indication of the magnitude of effect of the antiplatelet 
drug. 
7.1. VerifyNow platelet function test results 
Of 872 patients presenting with ACS with the exception of PPCI patients, 789 
patients (90%) had a VerifyNow platelet function test result. PPCI patients who had a 
test result recorded were excluded from the analysis as we could not be confident of an 
accurate test given the short time from P2Y12 inhibitor administration and testing. Most 
of the patients with no test result had been pre-treated with a IIbIIIa inhibitor; this drug 
makes the VerifyNow P2Y12 test invalid. 
7.1.1. Distribution of Base, % inhibition and PRU values 
In these 789 patients the median (IQR) PRU was 242 (126) and the median 
%inhibition value was 20% (39%). The median Base value was 308 (85). The 
distributions of the PRU, % inhibition and Base values are shown in Figures 7-1, 7-2 
and 7-3. The following observations can be made: 
 All 3 platelet reactivity measurements showed a very high degree of 
variability between patients 
 Most (78%) patients had some degree of platelet inhibition with clopidogrel, 
but the %inhibition range was very wide, from 0% to 98% 
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 177 (22%) patients had 0% inhibition; i.e. in more than 1 fifth of patients, 
the VerifyNow device measured no effect of clopidogrel on platelet 
reactivity 
 The Base value (platelet reactivity in response to thrombin receptor 
activation) had a normal distribution (skewness <  0.01; kurtosis 0.02) 
 95 (12.0%) patients had Baseline reactivity values which were low enough 
to fall into the „responder‟ PRU range (< 238); these patients had 
particularly low PRU levels, median 161 (133) 
 PRU was not normally distributed (skewness -0.32; kurtosis -0.35) 
 PRU was strongly linked to the Base value – if Baseline reactivity was high, 
PRU was generally high also. This is highlighted in Figure 7-4 
 
Figure 7-1 Histogram showing distribution of VerifyNow PRU in 789 patients, PPCI 
patients excluded 
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Figure 7-2 Histogram showing distribution of VerifyNow %inhibition in 789 patients, 
PPCI patients excluded 
 
 
 
Figure 7-3 Histogram showing the distribution of the VerifyNow „Base‟ value in 789 
patients, PPCI patients excluded 
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Figure 7-4 Box and whisker plots showing the PRU of 789 patients ranked into 10 „Base 
value‟ percentile groups 
 
7.1.2. VerifyNow values and baseline characteristics 
Platelet reactivity was different in patients with and without certain baseline 
characteristics. VerifyNow Base, PRU and %inhibition for patients with and without 
selected dichotomous baseline characteristics are shown in Table 7-1. The single factor 
with the greatest apparent association with platelet reactivity was pre-procedural Hb 
level. In addition, age, gender, diabetes, renal function, pre-procedural platelet count 
and BMI all appeared to correlate with platelet reactivity. 
7.1.2.1. Age and platelet reactivity 
VerifyNow Base platelet reactivity increased with age (2-tailed Spearman‟s rho = 
0.278, p < 0.01). However, elderly patients tended to have lower Hb levels; the mean 
Hb in patients under and over the age of 80 years was 14.0 vs. 12.1 g/dl, p < 0.01. The 
variation in Base reactivity with age disappeared when Hb level was taken into account. 
- 157 - 
PRU was weakly correlated with age (rho = 0.129, p < 0.01) but this seemed to be 
confined to those with the very highest PRU values only. There was no correlation 
between P2Y12 %inhibition and age; see Figure 7-5. 
 
 
 
Figure 7-5   Scatter graphs (with line of best fit) and box-and-whisker plots (with line at 
median value) showing the relationship between age and VerifyNow Base, PRU and % 
inhibition values 
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7.1.2.2. Pre-procedural haemoglobin concentration and platelet reactivity 
Haemoglobin (Hb) concentration was the baseline characteristic with the greatest 
impact on platelet reactivity: generally, anaemia was associated with high reactivity and 
polycythaemia with low reactivity. The interactions between Hb level and the 3 
VerifyNow platelet function test parameters are illustrated in Figs. 7-6 to 7-11. There 
was a moderately strong inverse correlation (Spearman‟s Rho) between baseline 
reactivity and Hb: -0.55, p < 0.01. This relationship was approximately linear 
throughout the range of Hb. 
There was a similar inverse relationship between PRU and Hb, but the correlation 
was weaker due to the wide range of PRU values. Furthermore the relationship was 
non-linear, with lower PRU values seen at both extremes of Hb. In patients with Hb 
levels above 12 g/dL there was no correlation between the degree of platelet inhibition 
(%inhibition) and Hb, but intense inhibition was more often seen in anaemic patients: 
median %inhibition levels in these 2 groups were 35 and 18, p ≤ 0.01. 
7.1.2.3. Gender and platelet reactivity 
Female patients overall had higher VerifyNow Base reactivity than males (see 
Table 7-1). However, women had lower Hb levels than men (mean 12.8 vs. 14.2 g/dL, p 
<0.01). Base reactivity was no different between males and females when stratified into 
groups with similar haemoglobin concentration. Women had greater clopidogrel-
mediated platelet inhibition (i.e. higher % inhibition values), although this may have 
been partially related to having a lower BMI than men. PRU was not different overall 
between men and women. 
7.1.2.4. Renal function and platelet reactivity 
Baseline platelet reactivity was higher in patients with poor renal function: there 
was a modest negative correlation between eGFR and the Base value (Spearman‟s rho = 
-0.278, p < 0.01); Table 7-1. However, patients with renal dysfunction were often 
anaemic. After allowance for baseline Hb level, patients with renal dysfunction had the 
same Base platelet reactivity as those with good renal function. 
There was greater inhibitory effect from clopidogrel in patients with poor renal 
function: correlation between eGFR and %inhibition was -0.104, P < 0.01. Patients with 
very poor renal function (eGFR < 30) in particular had markedly higher %inhibition: 20 
vs. 45 (p < 0.01). These patients had lower PRU despite higher baseline reactivity. 
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Figure 7-6  Box and whisker plot of VerifyNow BASE in patients stratified by pre-
procedural haemoglobin level 
 
 
Figure 7-7  Scatter plot of VerifyNow BASE levels against pre-procedural Hb in g/dL with 
automatic line of best fit 
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Figure 7-8  Box and whisker plot of VerifyNow %Inhibition in patients stratified by pre-
procedural haemoglobin level; horizontal line at median value 
 
 
Figure 7-9  Scatter plot of VerifyNow %inhibition levels against pre-procedural Hb in g/dL 
with automatic line of best fit 
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Figure 7-10  Box and whisker plot of VerifyNow PRU in patients stratified by pre-
procedural haemoglobin level 
 
 
Figure 7-11   Scatter plot showing the correlation with VerifyNow PRU and values with 
pre-procedural haemoglobin concentration, automatic line of best fit 
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7.1.2.5. Platelet count and platelet reactivity 
Pre-procedural platelet count was weakly associated with baseline reactivity (rho 
= 0.132, p < 0.01 between Base and platelet count). The degree of platelet inhibition 
also increased with platelet count (rho = 0.195, p < 0.01 between %inhibition and 
platelet count), but there was little correlation between PRU and platelet count (rho = -
0.089, p = 0.02). 
7.1.2.6. Body Mass Index and platelet reactivity 
There was no significant correlation between BMI and the Base value. However, 
PRU and %inhibition were both weakly correlated with BMI (0.117, p < 0.01; and -
0.158, p < 0.01), indicating less antiplatelet effect in larger patients. 
7.1.2.7. Blood pressure and heart rate 
There was no correlation between platelet reactivity and either pre-procedural 
blood pressure or heart rate. 
7.1.2.8. SYNTAX score and platelet reactivity 
There was no correlation between the angiographic severity/extent of coronary 
disease (SYNTAX score) and platelet reactivity. 
7.1.2.9. Diabetes and platelet reactivity 
Patients with diabetes (DM) had higher platelet reactivity (both Base and PRU) 
and less %inhibition than those without. However, when baseline Hb level was taken 
into account, Base was not different between those with and without DM. Those with 
DM did seem to have higher %inhibition even when corrected for baseline Hb. 
However, patients with DM had worse renal function than those without: an eGFR <60 
occurred in 40.7% with DM vs. 30.6% in those without, p = 0.02. Renal dysfunction 
tended to increase the effect of clopidogrel (see Section 7.1.2.4).Therefore, although 
platelet reactivity values did appear different in those with DM, this was likely due to 
differing renal function and Hb levels. 
7.1.2.10. Pre-procedural medication and platelet reactivity 
In patients receiving proton pump inhibitors (PPI), platelet reactivity (both the 
Base and PRU values) was higher than in those not receiving PPIs, with no difference in 
level of inhibition. Note that anaemic (Hb < 12.0 g/dL) patients were more likely to be 
taking a PPI: 47.3% vs. 29.0%, p < 0.01, suggesting that, as with the examples above, 
any apparent association of PPI use and platelet reactivity may be confounded by the 
effect of Hb level on platelet reactivity. 
- 163 - 
There was no difference in platelet reactivity between patients receiving or not 
receiving ACE-inhibitors, „statins‟ or beta-blockers. 
 
7.1.2.11. Patients with angiographically thrombotic lesions 
Patients with angiographic thrombus had slightly lower baseline reactivity, and 
non-significantly higher PRU, with less platelet inhibition than those with non-
thrombotic lesions. 
 
7.2. Independent predictors of adequate response to clopidogrel 
The binary logistic regression analysis of characteristics associated with PRU 
<238 are listed in Table 7-2. The only 2 independent predictors were pre-procedural Hb 
level and the VerifyNow Base value. 
Table 7-1  Baseline characteristics associated with adequate response to clopidogrel 
Characteristic Odds ratio 95% confidence 
interval 
P value 
Use of proton pump inhibitor 1.29 0.92 to 1.82 0.15 
Age over 80 years 1.78 0.90 to 1.82 0.10 
VerifyNow Base value, per point 0.98 0.98 to 0.99 < 0.01 
PMH of diabetes 1.34 0.89 to 2.17 0.15 
Pre-procedural Hb level, per g/dL 0.82 0.72 to 0.93 < 0.01 
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Table 7-2   Base, PRU and % inhibition values in patients with and without selected dichotomous baseline characteristics 
Characteristic Median (IQR) Base 
value without 
characteristic 
Median (IQR) 
Base value with 
characteristic 
P value Median (IQR) 
PRU without 
characteristic 
Median (IQR) PRU 
with characteristic 
P value Median (IQR) % 
inhibition without 
characteristic 
Median (IQR) % 
inhibition with 
characteristic 
P value 
Age ≥ 80 years 305 (85) 336 (72) < 0.01 240 (125) 265 (131) 0.02 20 (39) 18 (43) 0.79 
Female 296 (79) 343 (69) < 0.01 241 (117) 246 (154) 0.74 17 (35) 28 (47) < 0.01 
Diabetes 303 (83) 326 (92) < 0.01 239 (130) 271 (130) < 0.01 20 (39) 16 (32) 0.02 
Smoker 308 (96) 309 (81) 0.822 241 (137) 244 (122) 0.679 21 (45) 19 (37) 0.762 
2nd phase of recruitment 306 (88) 318 (75) 0.46 241 (129) 254 (117) 0.07 20 (39) 17 (33) 0.07 
Presented with UA 308 (83) 317 (94) 0.12 241 (121) 254 (154) 0.48 20 (39) 21 (41) 0.71 
Presented with NSTEMI 306 (95) 309 (80) 0.85 243 (150) 241 (116) 0.74 19 (40) 20 (39) 0.98 
Presented with STEMI 309 (83) 296 (103) 0.06 243 (122) 239 (148) 0.78 20 (39) 18 (42) 0.73 
Previous IHD 299 (83) 314 (91) < 0.01 241 (129) 241 (126) 0.90 20 (37) 20 (42) 0.45 
History of lung disease 305 (84) 318 (102) 0.33 243 (123) 229 (144) 0.29 19 (40) 26 (42) 0.06 
eGFR < 30 305 (84) 332 (100) 0.05 243 (125) 220 (177) 0.03 20 (38) 45 (51) < 0.01 
PVD 307 (86) 305 (73) 0.42 241 (130) 255 (97) 0.20 20 (40) 15 (26) 0.25 
Hb < 10 g/dL 306 (84) 335 (200) 0.22 242 (126) 236 (266) 0.36 20 (39) 44 (75) 0.08 
PPI use 299 (81) 320 (85) < 0.01 235 (133) 254 (119) < 0.01 20 (40) 19 (30) 0.27 
Statin use 300 (102) 306 (82) 0.88 266 (132) 240 (126) 0.75 17 (32) 20 (40) 0.83 
Thrombotic lesion 310 (62) 294 (60) 0.01 241 (124) 256 (146) 0.65 21 (39) 14 (31) 0.01 
- 165 - 
7.3. Recurrent MI and platelet reactivity 
The median (IQR) PRU in patients with recurrent troponin-positive ACS, fatal MI 
or stent thrombosis (on-treatment events only) was higher than those patients without: 
284 (129) vs. 241 (123), p = 0.04; see Fig. 7-12. The Base value was also higher in 
those with than without recurrent MI (325 (83) vs. 308 (84), p = 0.02). The % inhibition 
value was not significantly different (p = 0.27). 
The rate of recurrent on-treatment MI in patients in the non-responder category 
(„ischaemic threshold‟ of PRU 238) was more than twice that seen in responders, shown 
in Fig. 7-13, although this was of borderline statistical significance. Note that nearly all 
the recurrent ACS in non-responders occurred within the first 5 months following PCI. 
These results are the same when an alternative ischaemic PRU threshold of 208 
(ADEPT-DES registry) is used. 
 
Figure 7-12   Box-and-whisker plot showing the difference in PRU in patients with and 
without recurrent MI; on-treatment events only 
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Figure 7-13   Kaplan-Meier rates of recurrent MI in patients above and below an 
„ischaemic PRU threshold‟ of 238; on-treatment events only 
The rate of on-treatment recurrent MI over long-term follow up by groups of PRU 
octiles can be seen in figure 7-14. Patients with PRU values in the upper ranges have the 
highest rates of recurrent MI. However, the relationship between PRU and recurrent MI 
is not linear: there is no apparent incremental benefit in terms of further reduction in MI 
rate in patients with PRU under a value of about 200. 
PRU octiles were generated by automatic ranking; the 8 groups each contain 
approximately 100 subjects. Regarding baseline characteristics, these groups were fairly 
similar except for the highest octile, PRU 338 to 458. This group was generally higher 
risk for adverse events; for example they were older, had worse renal function, lower 
Hb and higher EuroSCORE. 
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Figure 7-14  Bar chart showing the rate of recurrent MI (troponin positive ACS, fatal MI 
and stent thrombosis) while on treatment with index P2Y12 inhibitor over long-term 
follow up 
Individual characteristics associated with recurrent troponin-positive ACS while 
on treatment with the index P2Y12 inhibitor are shown in Table 7-2. There was no 
association between recurrent MI and age, sex, BMI, clinical syndrome at presentation 
or stent type. The association of PRU and recurrent MI was of only borderline 
significance. After adjustment, SYNTAX score and diabetes were the 2 factors which 
independently predicted recurrent MI: aHR 1.05 (1.01 to 1.08, p < 0.01) per SYNTAX 
point and 2.70 (1.29 to 5.65, p < 0.01) if diabetic. 
The apparent prognostic effect of SYNTAX score on recurrent MI rate was 
considerably stronger in clopidogrel resistant patients; the effect was still present in 
responders although event rate was approximately halved. This is shown in Figure 7-15. 
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Table 7-3   Baseline characteristics associated with on-treatment recurrent MI in patients 
with platelet function test results 
 
7.3.1. Stent thrombosis and platelet reactivity 
There were only 11 cases of stent thrombosis (any type) which occurred on the 
index P2Y12 inhibitor in the non-PPCI subgroup of 789 patients; all occurred within 1 
year of PCI. The median (IQR) PRU in patients with and without stent thrombosis was 
322 (64) vs. 241 (123), p < 0.01. The Base value was not different between patients 
with and without stent thrombosis (p = 0.59). 
Regarding the „ischaemic threshold‟, only 1 of the 11 patients with a stent 
thrombosis had a PRU under 238. This patient (PAT ID 405) had a PRU of 153 and 
suffered a subacute thrombosis of a saphenous vein graft stent at day 6 post PCI, treated 
successfully by thrombus aspiration and implantation of a further stent. 
Characteristic Hazard Ratio 
(unadjusted) 
95% C.I. P value 
Lower Upper 
2
nd
 Phase of recruitment 2.80 1.24 6.31 0.01 
Haemoglobin, per g/dL 0.77 0.62 0.95 0.01 
Haemoglobin < 12 g/dL 2.50 1.06 5.92 0.04 
History of heart failure 4.90 1.17 20.64 0.03 
Previous revascularisation 2.91 1.41 6.00 < 0.01 
Previous IHD 4.23 1.73 10.33 < 0.01 
Diabetes 3.21 1.56 6.61 < 0.01 
Renal dysfunction, eGFR < 60 2.55 1.24 5.23 0.01 
PRU < 238 0.47 0.26 1.03 0.06 
PCI to LMS 5.88 2.05 16.82 < 0.01 
PCI to restenotic lesion 4.02 1.40 11.49 0.01 
PCI to calcified lesion 2.92 1.41 6.03 < 0.01 
EuroSCORE, per point 1.04 1.01 1.07 < 0.01 
SYNTAX score, per point 1.06 10.3 1.09 < 0.01 
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Figure 7-15   KM estimates of recurrent MI (including fatal MI and stent thrombosis) stratified by SYNTAX tertile; population is divided into 
clopidogrel responders (left hand side graph) and non-responders (right hand side graph); patients were censored at cessation of index P2Y12 
inhibitor so only on-treatment events shown; PPCI patients excluded 
 
- 170 - 
7.3.2. Death and platelet reactivity 
Of the 789 patients in this subgroup analysis, there were 34 all-cause and 19 
cardiac on-treatment deaths over long term follow-up. Although on-treatment cardiac 
death rates were low (1.3% in responders vs. 2.4% and in non-responders at 1 year), 
there was a trend for a lower cardiac death rate in clopidogrel responders; log rank p = 
0.06. The relationship between death rate and PRU was not clearly linear. All-cause and 
cardiac on-treatment death rates tended to be lowest in patients with PRU in the mid 
range, with higher rates in both patients with very high and very low PRU values, 
shown in Figures 7-15 and 7-16. There were no cases of on-treatment cardiac death 
during long-term follow up in patients with PRU within the range 132 to 246. 
 
 
Figure 7-16  Bar chart showing the rate of all-cause death while on treatment with index 
P2Y12 inhibitor over long-term follow up 
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Figure 7-17  Bar chart showing the rate of cardiac death while on treatment with index 
P2Y12 inhibitor over long-term follow up 
 
Regarding the 5 patients in the lower 4 PRU octiles who suffered a cardiac on-
treatment death, the specific causes of death were: 
 PAT ID 811: recurrent NSTEMIs, COPD exacerbation and heart failure 
 PAT ID 611: contrast nephropathy leading to renal failure and pneumonia 
 PAT ID 15: MI, heart failure 
 PAT ID 38: massive gastro-intestinal bleed and MI 
 PAT ID 406: sudden death at home; coroner ruled „coronary 
atherosclerosis‟ as cause of death 
Regarding the 8 patients in the lower 4 octiles who suffered a non-cardiac on-
treatment death, specific causes were: 
 PAT ID 27: cerebral infarction 
 PAT ID 353: cancer 
 PAT ID 224: cancer 
 PAT ID 33: cancer 
 PAT ID 892: cancer 
 PAT ID 131: cancer 
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 PAT ID 165: hanging 
 PAT ID 414: cancer 
There seemed to be a higher rate of death from cancer in patients with intense 
P2Y12 platelet inhibition, with the lowest rates in those with mild levels of inhibition; 
Figure 7-18. 
7.3.3. Combined endpoint of cardiac death and recurrent MI 
The rate of the combined endpoint of on-treatment stent thrombosis, recurrent MI 
and cardiac death according to PRU is shown in Figure 7-19. The lowest event rate 
occurs in patients with PRU within the range 176 to 242, which corresponds very 
closely with the ARMYDA-PROVE optimal range. Patients with very high platelet 
reactivity while on DAPT, with PRU within the range 338 to 458, had the worst 
prognosis. However, the association between this combined adverse endpoint and 
optimal PRU did not quite reach statistical significance: HR 0.4 (0.14 to 1.13, p = 0.08). 
 
 
Figure 7-18  Bar chart showing the rate of death caused by cancer over long-term follow 
up in patients stratified by VerifyNow %inhibition; number of deaths/number in group 
shown above each bar 
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Figure 7-19  Bar chart showing the rate of the combined endpoint of on-treatment 
recurrent MI, stent thrombosis and cardiac death over long term follow-up 
7.4. Platelet reactivity and stroke 
There were 22 cases of stroke or TIA recorded over long-term follow up; only 5 
cases occurred within the first year of PCI however. Other than 1 patient with bilateral 
subdural haematomas, all cases were due to cerebral infarction, although 2 of these 
underwent haemorrhagic transformation. The stroke rate was higher in patients in the 
highest 2 quartiles of Base reactivity (>350): 4.6% vs. 1.3%, p < 0.01. 
7.5. Bleeding, anaemia and platelet reactivity  
7.5.1. On-treatment bleeding and PRU 
There were 36 cases of BARC 2 to 5 bleeding while on treatment with the index 
P2Y12 inhibitor over long term follow up. These bleeds occurred mainly from either the 
femoral puncture site or from the GI tract. The median PRU (IQR) in patients 
experiencing a BARC 2 to 5 bleed was non-significantly lower than in those without 
bleeding: 212 (179) vs. 243 (122), p = 0.097; see Figure 7-19. The median %inhibition 
(IQR) for the same groups was 32 (62) vs. 19 (38), p = 0.02; see figure 7-20. The 
bleeding rate was particularly high in patients with the lowest PRU, shown in Figure 7-
21. 
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Figure 7-20   Box and whisker plots showing the distribution of ‘VerifyNow PRU’ in 
patients with and without BARC 2 to 5 bleeding; only events while patient on index P2Y12 
inhibitor included 
 
 
Figure 7-21 Box and whisker plots showing the distribution of ‘VerifyNow %inhibition’ in 
patients with and without BARC 2 to 5 bleeding; only events while patient on index P2Y12 
inhibitor included 
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Figure 7-22   Bar chart showing proportion of patients experiencing BARC 2 to 5 bleeding 
while on treatment with the index P2Y12 inhibitor according to PRU 
When patients were stratified into groups above and below the ARMYDA-
PROVE (Mangiacapra et al, 2012) „bleeding threshold‟ of PRU 179 significantly more 
BARC 2 to 5 bleeding occurred in hyper-responding patients (below 179) than in other 
patients, illustrated in the KM survival curve, Figure 7-21 [N.B. patients were censored 
at the first BARC 2 to 5 bleed, cessation of the index P2Y12 inhibitor, last follow-up or 
death]. There was a high early bleeding rate in hyper-responders, mostly due to femoral 
haematoma, but there also appears to be a higher rate of bleeding over long term follow 
up. 
Baseline characteristics of patients in these 2 PRU groups are compared in Table 
7-4. There was no difference in age, sex, EuroSCORE or SYNTAX score between the 2 
groups. However, hyper-responding patients: 
 weighed nearly 4 kg less on average than the other patients 
 had only half the incidence of diabetes 
 were more likely to have poor renal function 
 were less likely to be on treatment with proton pump inhibitors 
 had higher pre-procedural Hb concentration 
 had higher pre-procedural platelet counts 
 were more likely to receive a procedural IIbIIIa inhibitor 
The characteristics individually associated with on-treatment BARC 2 to 5 
bleeding, excluding patients receiving PPCI, are listed in Table 7-5. After adjustment, 
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the factors independently associated with bleeding were a history of heart failure, PRU 
below 179 and a history of hypertension. The use of ACE inhibitors and increasing 
haemoglobin concentration were both independently associated with lower bleeding 
rates. Age was not independently associated with bleeding after adjustment, either as a 
continuous variable per year or as a categorical variable as age > 80 years (Table 7-6). 
 
 
Figure 7-23   Cumulative incidence of BARC 2 to 5 bleeding while on index P2Y12 
inhibitor, stratified into groups above (n = 580) and below (n = 203) PRU 179; PPCI 
patients excluded 
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Table 7-4  Table comparing baseline characteristics in P2Y12 inhibitor „hyper-
responding‟ patients (PRU < 179) with patients with PRU ≥ 179 
Baseline characteristic PRU <179 
N = 204 
PRU ≥179 
N = 585 
P value 
Demographics and clinical syndrome    
Mean (SD) Age, years 61.4 (12.4) 62.6 (11.9) 0.20 
       Age  ≥ 80 years 12 (5.9%) 45 (7.7%) 0.39 
Female 58 (28.4%) 139 (23.8%) 0.18 
Median (IQR) weight, kg 78.0 (20.4) 81.6 (19.3) < 0.01 
Median (IQR) Body Mass Index 26.8 (6) 28.3 (6) < 0.01 
Any history of smoking 141 (69.1%) 405 (69.7%) 0.875 
Presented with unstable angina 31 (15.2%) 86 (14.7%) 0.864 
Presented with NSTEMI 138 (67.6%) 420 (71.8%) 0.262 
Presented with STEMI 35 (17.2%) 79 (13.5%) 0.20 
Median (IQR) EuroSCORE 2.8 (4.3) 2.8 (4.2) 0.43 
Median (IQR) SYNTAX score 9.0 (10.8) 8.0 (11.0) 0.55 
First phase of recruitment  175 (85.8%) 472 (80.7%) 0.10 
Previous medical History    
Previous revascularisation, any 33 (16.2%) 105 (17.9%) 0.56 
Previous clinical IHD, any 104 (51%) 291 (49.7%) 0.76 
Diabetes 21 (10.3%) 113 (19.4%) < 0.01 
Hypertension 92 (45.1%) 314 (53.7%) 0.04 
Stroke 7 (3.4%) 26 (4.4%) 0.53 
Heart failure 6 (2.9%) 8 (1.4%) 0.14 
Blood results (pre-procedural)    
Median (IQR) serum Cr concentration, µmol/L 96 (24) 94 (25) 0.95 
Median (IQR) eGFR, ml/min/1.73m
2
 72 76 0.15 
eGFR  < 60 ml/min/1.73m
2
 69 (34.3%) 179 (31.5%) 0.46 
eGFR <30 ml/min/1.73 m
2
 14 (7.0%) 17 (3.0%) 0.01 
Cr >200 µmol/L 10 (4.9%) 13 (2.2%) 0.05 
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Median (IQR) Hb concentration, g/dL 14.3 (2.6) 14.0 (2.0) 0.05 
Hb <12 g/dL 29 (15.3%) 61 (11.4%) 0.17 
Median (IQR) platelet count, x10
9
/L 252 (80) 244 (82) 0.05 
Median (IQR) white cell count, x10
9
/L 8.0 (2.8) 8.0 (3.0) 0.97 
Median (IQR) PRU (VerifyNow) 118 (69) 273 (87)  
Procedural medication    
Aspirin 196 (96.6%) 564 (96.7%) 0.90 
Clopidogrel 200 (98.0%) 585 (100%) < 0.01 
Prasugrel 4 0  
Heparin 190 (93.1%) 541 (92.6%) 0.81 
IIbIIIa inhibitor 68 (33.3%) 152 (26.0%) 0.04 
Bivalirudin 15 (7.4%) 47 (8.1%) 0.76 
ACE inhibitor 136 (69.7%) 404 (73.2%) 0.36 
Beta blocker 157 (80.5%) 456 (81.7%) 0.71 
HMG-CoA reductase inhibitor 183 (89.7%) 524 (89.6%) 0.96 
Proton pump inhibitor 50 (24.5%) 207 (35.4%) < 0.01 
Median (IQR) time on index P2Y12 inhibitor, 
days 
366 (130) 366 (73) 0.91 
Procedural characteristics    
Femoral access 179 (87.7%) 491 (83.9%) 0.19 
DES used 119 (58.3%) 331 (56.6%) 0.66 
More than 1 vessel treated 48 (23.5%) 127 (21.7%) 0.59 
Calcified lesion 43 (21.1%) 109 (18.6%) 0.45 
Thrombotic lesion 36 (17.6%) 96 (16.4%) 0.68 
TIMI flow <  III in any vessel at start 5 (2.5%) 22 (3.8%) 0.38 
Procedural complication, any 29 (14.2%) 89 (15.2%) 0.73 
Procedural complication, angiographic 24 (11.8%) 83 (14.2%) 0.38 
Procedural complication, clinical (non-
haemorrhagic) 
3 (1.5%) 3 (0.5%) 0.175 
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Table 7-5   Table showing univariable characteristics associated with BARC 2 to 5 
bleeding before adjustment; events on index P2Y12 inhibitor only; PPCI patients excluded 
 
 
  
 Hazard Ratio (as 
univariate) 
95% C.I. P value 
Lower Upper 
Haemoglobin, per g/dL 0.65 0.55 0.77 < 0.01 
ACE inhibitor 0.42 0.22 0.79 < 0.01 
History of heart failure 9.12 3.22 25.83 < 0.01 
More than 1 vessel treated 2.11 1.11 4.00 0.02 
Age, per year 1.08 1.05 1.11 < 0.01 
Female sex 3.16 1.70 5.87 < 0.01 
Weight, per kg 0.98 0.95 1.00 0.02 
Previous IHD 2.71 1.36 5.43 < 0.01 
Hypertension 2.23 1.14 4.39 0.02 
Renal dysfunction, eGFR < 30 5.36 2.24 12.85 < 0.01 
Smoking 0.50 0.27 0.92 0.03 
PRU < 179 2.75 1.42 5.34 < 0.01 
PCI to LMS 6.59 2.76 15.71 < 0.01 
     
EuroSCORE, per point 1.06 1.04 1.09 < 0.01 
SYNTAX score, per point 1.05 1.02 1.08 < 0.01 
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Table 7-6   Baseline characteristics independently associated with BARC 2 to 5 bleeding 
while on index P2Y12 inhibitor 
Characteristic Hazard Ratio 95% C.I. P value 
Lower Upper 
Pre-procedural haemoglobin, per 
g/dL 
0.769 0.632 0.934 < 0.01 
ACE inhibitor use 0.444 0.218 0.902 0.03 
History of heart failure 4.638 1.348 15.955 0.02 
History of hypertension 2.24 1.020 4.922 0.05 
PRU < 179 2.775 1.365 5.641 < 0.01 
 
7.6. Anaemia and adverse events 
Platelet reactivity and Hb level had a strong inverse relationship in patients in the 
OPERA study, as discussed in section 7.1.2. Anaemic patients were more likely to 
experience BARC 2 to 5 bleeding, as discussed in Chapter 6. The bleeding rates for the 
cohort of OPERA patients who had platelet function testing (as studied in this chapter 
so far) relative to baseline Hb level are shown in Figure 7-24. 
Anaemia was also associated with a higher rate of non-haemorrhagic 
cardiovascular events, as discussed in Chapter 5. Figures 7-25 to -27 show the rates of 
recurrent MI, all-cause death and combined cardiac death and MI over long-term 
follow-up in patients stratified by Hb octile. The baseline Hb level was a strong risk 
factor for death in this study: over a median follow up of 3.7 years, 1 third of patients 
with a Hb level of < 12 g/dL at recruitment had died. 
The 3-way relationship between platelet reactivity, anaemia and adverse events is 
illustrated in Figure 7-28, showing by far the highest risk patients over long-term follow 
up are those who have the combination of anaemia and high platelet reactivity. The 91 
patients in this group had a 70% event rate. In contrast, anaemic patients with low 
platelet reactivity had a relatively good prognosis, as did those with high platelet 
reactivity who were not anaemic. 
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Figure 7-24  Rates of BARC 2 to 5 bleeding during long-term follow-up stratified by pre-
procedural Hb level 
 
 
Figure 7-25  Rates of recurrent troponin positive acute coronary syndrome during long-
term follow-up stratified by pre-procedural Hb level 
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Figure 7-26  Rates of all-cause death over long-term follow-up stratified by pre-procedural 
Hb level 
 
 
Figure 7-27  Rates of the combined endpoint of cardiac death and MI during long-term 
follow-up, stratified by pre-procedural Hb level 
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Figure 7-28  3-dimensional bar chart showing the combined rate of MI and cardiac death 
over long term follow up; patients are stratified into 16 groups based on quartiles of pre-
procedural Hb and quartiles of VerifyNow Base platelet reactivity 
 
7.7. Combined ischaemic and haemorrhagic adverse endpoint 
and PRU 
The rate of the combined adverse endpoint of on-treatment BARC 2 to 5 bleeding, 
cardiac death, MI and stent thrombosis over long-term follow up according to PRU is 
shown in Figure 7-29. The lowest combined event rate occurs in patients with PRU 176 
to 242; patients in the lowest and highest PRU octiles have equally high event rates. 
Figure 7-30 shows this combined event rate over the first year from PCI for the 
cohort when patients are divided into the 3 groups determined by the „ARMYDA-
PROVE‟ investigators: hyper-responders (PRU < 179), optimal range PRU and hypo-
responders (PRU > 238). 
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The characteristics associated with the combined adverse endpoint are shown in 
Table 7-7. After adjustment, the strongest independent predictors of the combined 
adverse event were non-optimal PRU, SYNTAX score and decreasing Hb. In a model 
with these 3 parameters, adjusted HRs for optimal PRU, SYNTAX score per point and 
Hb per g/dL were 0.35 (0.13 to 0.96, p = 0.04), 1.03 (1.01 to 1.06, p = 0.02) and 0.80 
(0.68 to 0.97, p < 0.01). 
 
 
Figure 7-29  Rate of the combined adverse on-treatment event rate of BARC 2 to 5 
bleeding, cardiac death, MI and stent thrombosis over long term follow up stratified by 
PRU octile 
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Figure 7-30  Kaplan-Meier estimates of combined adverse events rates (cardiac death, MI, 
stent thrombosis or BARC 2 to 5 bleeding) for patients stratified into 3 PRU groups as 
defined by the ARMYDA-PROVE investigators; censored on cessation of index P2Y12 
inhibitor 
7.1. Long-term off-treatment ischaemic adverse events and 
baseline platelet reactivity 
Patients with higher Baseline platelet reactivity appeared to have a worse long-
term prognosis after coming off DAPT, with higher rates of MI, cardiac death and 
stroke. Figure 7-30 shows the estimated rates of the combined adverse endpoint of off-
treatment stroke, MI and cardiac death in patients stratified into Base quartiles. In a 
model with VerifyNow Base, SYNTAX score and EuroSCORE, Base was an 
independent predictor of this combined endpoint: aHRs (95% C.I.s) 1.53 (1.21 to 1.92) 
per 50 Base points, p < 0.01; 1.05 (1.02 to 1.08) per EuroSCORE point, p < 0.01; and 
1.04 (1.01 to 1.07) per SYNTAX score point, p = 0.02. 
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Table 7-7   Table showing characteristics associated with 1 year on-treatment combined 
adverse endpoint 
Characteristic Hazard Ratio 
(as univariate) 
95% C.I. P value 
Lower Upper 
2
nd
 recruitment phase 1.83 1.06 3.17 0.03 
Presented with NSTEMI 2.12 1.08 4.16 0.03 
Presented with STEMI (convalescent PCI) 0.30 0.09 0.95 0.04 
Haemoglobin, per g/dL 0.71 0.61 0.82 < 0.01 
ACE inhibitor 0.57 0.34 0.95 0.03 
History of heart failure 7.79 3.35 18.10 < 0.01 
Age, per year 1.05 1.02 1.07 < 0.01 
Female sex 1.70 1.01 2.87 0.05 
BMI, per point 0.93 0.88 0.99 0.02 
Previous revascularisation 2.27 1.33 3.86 < 0.01 
Renal dysfunction, eGFR < 60 2.92 1.75 4.86 < 0.01 
Optimal PRU  0.34 0.13 0.84 0.02 
PCI to LMS 5.06 2.30 11.12 < 0.01 
PCI to calcified lesion 2.58 1.54 4.31 < 0.01 
EuroSCORE, per point 1.05 1.04 1.07 < 0.01 
SYNTAX score, per point 1.05 1.03 1.08 < 0.01 
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Figure 7-31  KM curves showing time from PCI to combined MI, stroke and cardiac death 
after cessation of treatment with index P2Y12 inhibitor, stratified into quartiles of 
VerifyNow Baseline platelet reactivity 
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7.2. Chapter 7 summary points and discussion 
 All 3 VerifyNow measures of platelet reactivity were highly variable. The 
Baseline value (reactivity to thrombin) was normally distributed but the 
distribution of PRU (reactivity to ADP) was moderately skewed. The 
distribution of %inhibition values was extremely skewed, as about a fifth of 
patients had no measureable P2Y12-mediated inhibition. 
 The PRU level was influenced by multiple baseline factors. The VerifyNow 
Base value (platelet reactivity to a thrombin-like agonist) and the pre-
procedural Hb level were the 2 factors with the greatest apparent effect on 
PRU. 
 Proton pump inhibitors had no effect on %inhibition values in this study. 
 A PRU level above around 200 was associated with higher rates of recurrent 
MI and of cardiac death, although these associations were of only borderline 
statistical significance. 
 There was no dichotomous association between all-cause death and PRU 
above the „ischaemic cut-off‟; however, death rate and PRU formed a U-
shaped curve, with the lowest death rates at mid-level PRU. 
 There were more deaths due to cancer in patients with the greatest levels of 
platelet inhibition. 
 Very low PRU (below about 100) was associated with increased rates of 
BARC 2 to 5 bleeding and anaemia. 
 The previously published ARMYDA-PROVE optimal PRU range of 179 to 
238 appeared to fit very well with optimal combined clinical outcomes at 1 
year in the OPERA study. 
 Base reactivity was an important independent predictor of long-term off-
treatment ischaemic adverse events including stroke, MI and cardiac death. 
 Anaemia was predictive of all types of adverse event including bleeding, 
death and MI, but only in patients with high Baseline reactivity values. 
Patients with both Hb in the lowest quartile and Base in the highest quartile 
had a 60% adverse event rate over 3.5 years. 
7.2.1. Comparison of levels of platelet inhibition in OPERA with the 
published literature 
The mean PRU level in ARMYDA-PROVE study (elective PCI) by Mangiacapra 
et al, 2012, was 206 +/- 72. Mean PRU in OPERA was considerably higher at 235 +/- 
91. This is a large difference and possibly relates to the relative timing of the 
clopidogrel loading dose in the 2 studies. In OPERA, most patients had been on 75 mg 
per day at the time of PCI with a remote loading dose given on the day of admission 
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with ACS; in contrast, in ARMYDA-PROVE, 88% of participants received a 600mg 
loading dose >6 hours before PCI, close to the time of the platelet function test which 
was performed in the catheter laboratory at the time of PCI, as in OPERA. It is known 
that higher doses of clopidogrel produce greater platelet inhibition as measured by 
VerifyNow, shown in several large studies (Gladding et al, 2008; Price et al, 2011). In 
the GRAVITAS study (Price et al) the median PRU in patients on 75 mg of clopidogrel 
for 30 days was even higher than OPERA at 250 (IQR 206 to 298). In another important 
study of platelet reactivity and PCI, ADAPT-DES (Stone et al, 2013), the mean PRU 
was 188 which is lower than all the other studies. In ADAPT-DES, clopidogrel could be 
given either as 600mg loading >6 hours, 300 mg loading >12 hours or 75 mg for at least 
5 days before VerifyNow testing – the PRU by subgroup is not given, nor is the 
proportion of patients in each subgroup. These large variations in average PRU between 
different studies shows that, if optimal PRU cut-offs are to be established, it is 
important that the timing of the VerifyNow test in relation to the antiplatelet loading 
dose is specified. 
7.2.2. PRU and clinical outcomes 
In common with other similar studies the PRU level in OPERA appeared to be 
related to adverse clinical events. Patients with a PRU above 238 had 2 to 3 times the 
rate of MI at 12 months than those with PRU <238: 6.3% vs. 2.5%; p = 0.01 (log rank 
test). In the same groups there was little difference in the rates of cardiac death (2.7% 
vs. 1.6%, p = 0.32); although there was a trend for greater all-cause mortality (4.3% vs. 
2.1%, p = 0.09). These results are not dissimilar to those from the large ADAPT-DES 
study (Stone et al, 2013), in which the rates of MI and all-cause death at 12 months in 
patients with PRU above and below the ischaemic PRU threshold were 3.9% and 2.7% 
(p = 0.01) and 2.4% vs. 1.5% (p = 0.3) (the ischaemic threshold was PRU 208 in that 
study; however, identical results were seen using PRU 230). 
It is unclear why a reduction in MI rate in clopidogrel responders compared to 
non-responders does not translate into a more definite reduction in death rate. However, 
in most platelet reactivity studies the death rate and recurrent MI rate do not follow the 
same pattern of relationship to PRU. In OPERA while there is a clear „threshold effect‟ 
for recurrent MI with a lower rate below PRU 238 and a higher rate above this (Figure 
7-14), this is not so obvious for death (Figures 7-16 and 7-17). Death and PRU seem to 
have a more u-shaped relationship, with a higher rate at both very low and very high 
PRU levels and a low rate in the mid PRU range. 
In ADAPT-DES the finding of excess deaths in patients with very low PRU was 
assumed to be related to bleeding, as bleeding rates were seen to be higher in those with 
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low PRU. However, in OPERA deaths were studied in greater detail than is usual in this 
type of study and deaths were found to be very rarely due to bleeding. Although 
bleeding was indeed more common in those with low PRU (see Figures 7-22 and 7-23), 
as in ADAPT-DES, the commonest cause of death in OPERA patients with very low 
PRU levels was in fact cancer, with only 1 death involving haemorrhage. It may be that 
very low PRU in clopidogrel-treated patients is simply a marker of general frailty or co-
morbidity. Whatever the explanation, there is a strong signal that the safest PRU to have 
after PCI for ACS on DAPT with aspirin and clopidogrel is in the mid range, around 
PRU 200, similar to the ARMYDA-PROVE optimal range; see Figures 7-19 and 7-30. 
7.2.3. The VerifyNow Base value 
In OPERA the VerifyNow Base value, like PRU, was highly variable. The Base 
value indicates platelet reactivity mediated via activation of platelet PAR-1 thrombin 
receptors. The VerifyNow test manufacturers noted the high variation in general 
baseline platelet reactivity between individuals and incorporated the thrombin channel 
into their device to act as an individual control for each patient, producing the 
VerifyNow „%inhibition‟ value. The Base value has not generally been a focus of 
investigation in clinical research and rarely even mentioned in platelet function testing 
studies. However, it is useful for the study of the platelet reactivity variability in ACS 
patients because it is unaffected by either of the oral antiplatelet agents used to treat 
these patients (aspirin and P2Y12 receptor inhibitors). 
In OPERA, Base reactivity was associated with the level of platelet reactivity in 
response to ADP (the PRU) in clopidogrel-treated patients. High Base reactivity 
conferred a much higher chance of „clopidogrel resistance‟. Clopidogrel resistance as 
defined by PRU ≥238 was seen in 23.7% and 76.0% of those in the lowest and highest 
Base quartiles. Furthermore, the Base value in OPERA carried substantial long-term 
prognostic information after cessation of DAPT (Fig 7-31), being an independent 
predictor of MACE. For some reason neither of these important observations have been 
studied to any great extent in the recent literature. It is largely unknown why platelet 
reactivity to thrombin varies so widely between individuals; and whether it is a 
relatively fixed quantity for each person or whether it can change and, if so, how often 
and in response to what stimuli. There is some limited evidence to suggest it can be 
changed, explored further in Chapter 9. In OPERA, the main baseline characteristic to 
be associated with Base reactivity was the haemoglobin level. 
- 191 - 
7.2.4. Speculation on the cause of the link between anaemia, platelet 
reactivity and adverse events 
Anaemia is present in approximately 20% of patients presenting with ACS and has 
long been recognised as an independent predictor of adverse events, including all-cause 
mortality, as described in the meta-analysis by Lawler et al, 2013. However, the exact 
reasons for the adverse cardiovascular prognosis conferred by anaemia remain elusive. 
In OPERA there were strong relationships between platelet reactivity and haemoglobin 
level (Figures 7-6 and 7-7); and between platelet reactivity, Hb and adverse clinical 
outcomes (Figure 7-28). Anaemic patients with highly reactive platelets were the 
highest-risk group in OPERA, although not all anaemic patients had high platelet 
reactivity and in fact anaemic patients with low platelet reactivity did as well as those 
with normal haemoglobin levels. I would like to propose that changes in platelet 
reactivity can occur as a direct response to changes in Hb level; and that this is a 
potential pathophysiological mechanism for the increased cardiovascular event rates 
seen in anaemia. 
It may seem odd in evolutionary terms that humans might have developed a 
mechanism to increase platelet reactivity in response to anaemia when it seems clear 
that this could lead to more frequent arterial thrombotic events. However, the usual 
cause of anaemia in wild animals is traumatic bleeding. A mechanism for increasing 
platelet reactivity in response to anaemia could have evolved in our common ancestors 
in order to stop bleeding, conserve blood and more rapidly regain normal oxygen 
carrying capacity. This mechanism would certainly confer a survival advantage in wild 
animals. Although atherosclerosis is well documented in primates (Stout and Lemmon, 
1969) and other animals, in the wild animals die of predation, starvation and disease 
before they die of myocardial infarction. Biological systems for homeostatic regulation 
of bleeding, thrombosis and platelet reactivity which might predispose to arterial 
thrombosis therefore persist into old age, as there are no evolutionary mechanisms to 
modify them. A sudden increase in platelet reactivity due to a drop in Hb level might 
get a young wild animal up and running sooner than its competitors; but in an old 
human with degenerative atherosclerotic disease it might be enough to trigger an MI. 
Atherosclerosis, MI and anaemia all become more common with age, amplifying the 
problem as the years go by. 
By what mechanism might haemoglobin concentration affect platelet reactivity? 
One obvious possible intermediary is erythropoietin, a hormone released in response to 
anaemia to mediate erythrocyte production. The administration of erythropoietin has 
been known for some time to cause an increase in whole blood platelet aggregation 
(Taylor et al, 1991). Furthermore, the treatment of anaemia by the administration of 
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erythropoietin has never been shown to lower cardiovascular risk and in fact seems to 
have the reverse effect. These observations have been made mainly from studies of 
patients with renal failure with anaemia, in whom recombinant erythropoietin injections 
are a common treatment (Horl, 2013). There is some data to suggest that erythropoietin 
can directly and markedly increase platelet reactivity in humans (Stohlawetz et al, 
2000). An interaction between anaemia, platelet reactivity, erythropoietin and adverse 
thrombotic events is plausible and certainly requires further study. 
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Chapter 8 Myocardial injury from peri-procedural biomarker 
levels and its association with prognosis 
 Chapter 8 explores the OPERA study biomarker data, with a focus on 
identification of PCI-induced myocardial injury and its relationship, if any, with 
prognosis. Patients undergoing emergent PCI for STEMI (PPCI) were excluded from 
most of these analyses, as there is no way to distinguish procedure-induced myocardial 
injury from that caused by the acute MI. Biomarkers were measured using the Cardiac 
Plus Array from Randox, except for Troponin I, measured with the Advia Centaur 
highly sensitive assay from Siemens. The Randox array was a research tool at the time 
of this study whereas the Siemens troponin assay was in current clinic use. Technical 
specifications for these assays are available in the Appendices. 
The biomarkers measured were: 
 CK-MB and highly sensitive Troponin I (TnI), recommended as 
biomarkers of choice for the diagnosis of MI in current clinical guidelines 
 Myoglobin; no longer recommended for use in diagnosis of MI as not 
cardio-specific, the same isoform of the enzyme being released readily 
from both skeletal and cardiac muscle 
 Glycogen phosphorylase BB (GPBB) and Human Fatty Acid Binding 
Protein (H-FABP), 2 novel cardiac biomarkers 
 Carbonic Anhydrase III; not a cardiac biomarker and released only from 
skeletal muscle; intended to be of use to establish the proportion of 
myoglobin which is of cardiac origin 
 
8.1. Biomarker data completeness 
There was a significant amount of missing biomarker data, particularly at the 12 
hour time point when blood samples were sometimes not obtained. Table 8-1 shows the 
overall data completeness for each biomarker at each time point. 
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Table 8-1  Data completeness for serum biomarkers at each time point for 872 patients; 
patients undergoing PPCI excluded 
Assay   0 hours 4 hours 12 hours All 3 time 
points 
Randox Array:    Myoglobin  
 
 
 
 
96.1% 
 
 
88.2% 
 
 
80.0% 
 
 
77.4% 
   CK-BM 
   HFABP 
   GPBB 
   CAIII 
Advia Centaur TnI  90.5% 82.1% 73.3% 66.5% 
8.2. Biomarker Upper Limit of Normal values 
The upper limit of the normal range (ULN) for each biomarker was available from 
the assay manufacturers‟ product information sheets as the 95th or 99th percentile 
population of healthy individuals. To verify these normal range values for the OPERA 
study population, Time 0 biomarker values were displayed graphically in ascending 
order to identify an inflection point (the first major deviation of the graph). Inflection 
points could be seen for myoglobin, CK-MB, H-FABP, CAIII and GPBB; see Figures 
8-1 to 8-5. These visually estimated values, all slightly lower than the published 99
th
 
percentile cut-off values, were used as the ULN in the following analyses. For TnI an 
inflection point could not be discerned and the published value of the 99
th
 percentile of a 
normal population was used for the analysis. 
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8.2.1. Myoglobin normal range 
Figure 8-1 shows the distribution of time 0 myoglobin levels sorted into ascending 
order, from which a conservative cut-off for a normal range of < 45 ng/mL can be 
estimated for our population. This level is similar to the 99
th
 percentile of a healthy 
population published by the company of 74 ng/mL. 
 
Figure 8-1  Myoglobin (Randox array) levels at Time 0 for non-PPCI patients sorted into 
ascending order, showing first major deviation from normal range at approximately 
45ng/mL, illustrated with horizontal line 
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8.2.2. CK-MB normal range 
Figure 8-2 suggests an approximate normal range for CK-MB of < 2.4 ng/mL for 
OPERA patients, close to the manufacturer‟s published value for the 99th percentile of a 
healthy population of 2.69 ng/mL. 
 
Figure 8-2  CK-MB (Randox array) Time 0 levels for non-PPCI patients sorted into 
ascending order; first major deviation from normal range at approximately 2.4 ng/mL 
shown with horizontal line  
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8.2.3. H-FABP normal range 
The published 99
th
 percentile of the Randox Cardiac Plus Array H-FABP in a 
healthy population is 3.0 ng/ml. I have used a cut-off of 2.0 ng/ml for OPERA patients, 
derived as shown in Figure 8-3. 
 
Figure 8-3  H-FABP (Randox array) levels at Time 0 for non-PPCI patients sorted into 
ascending order. Inset shows same curve magnified with an oblique line to illustrate 
probable normal range. The first major deviation from normal range, at approximately 
2.0 ng/mL, is marked by horizontal line 
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8.2.4. Glycogen phosphorylase BB (GPBB) 
The published 99
th
 percentile for GPBB is 7.88 ng/ml. I have used a conservative 
cut-off 4.0 ng/ml for the normal range, see Figure 8-4. 
 
Figure 8-4  Time 0 GPBB (Randox array) levels in non-PPCI patients sorted into 
ascending order, with inset showing the same curve magnified; first major deviation from 
normal at approximately 4.0 ng/mL shown by horizontal line 
  
- 199 - 
8.2.5. Carbonic anhydrase III 
Figure 8-5 shows the approximate normal range of CA III level for our population 
was < 30 ng/mL. The published 99
th
 percentile for a normal population is 86 ng/mL. 
 
Figure 8-5  Carbonic anhydrase III (Randox array) levels at Time 0 in non-PPCI patients 
sorted into ascending order; first major deviation from normal range at approximately 30 
ng/mL shown by horizontal line 
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8.2.1. Cardiac Troponin I (cTnI) normal range 
In contrast to the other biomarkers, a clear „normal range‟ cut-off value for TnI 
could not be identified using the inflection point method, as shown in Figure 8-6. For 
the high-sensitivity troponin assay used in this study (Advia Centaur TnI Ultra, 
Siemens), the published 99th percentile in healthy patients, 0.04 ng/mL, was taken as 
the ULN in these analyses. 
 
Figure 8-6  Highly sensitive troponin I (Advia Centaur) at Time 0 for non-PPCI patients 
sorted into ascending order, with inset showing the same curve magnified; horizontal line 
at 0.04 ng/mL, the 99
th
 percentile from a normal population. 
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8.3. Biomarker levels pre-PCI 
The proportion of patients with biomarker levels < ULN (OPERA study values) at 
the start of the procedure varied widely between biomarkers, from 48% for TnI to 87% 
for myoglobin (Table 8-3). There were associations between biomarker elevation > 
ULN at Time 0 and patient baseline characteristics, shown in Table 8-2. 
One factor was associated with elevation of all 6 biomarkers: enrolment into the 
study during the 2
nd
 recruitment phase (2010 to 2012). There was a significantly shorter 
time from admission to hospital with ACS to PCI in patients in the 2
nd
 recruitment stage 
compared with those in the 1st: 5 days vs. 7 days, P < 0.01. 
The only other characteristic associated with elevation of TnI at Time 0 was an 
ACS presentation with MI (as opposed to TnI negative ACS/UA). In contrast, elevation 
of CK-MB, myoglobin and H-FABP was associated with multiple baseline 
characteristics. Note that elevation of the skeletal muscle biomarker, CAIII, was 
associated with much the same characteristics. There was no sign that GPBB level was 
affected by baseline characteristics. 
Table 8-2   Table showing all clinical features significantly associated with elevation of any 
biomarker above the ULN at Time 0 (just prior to PCI); P < 0.05; PPCI patients excluded 
 TnI† CK-MB* Myoglobin* H-FABP* GPBB* CAIII* 
Recruited 2nd stage ✔ ✔ ✔ ✔ ✔ ✔ 
> 80 years old × ✔ ✔ ✔ × ✔ 
Presented with MI ✔ ✔ × ✔ × × 
Highest EuroSCORE quartile × ✔ ✔ ✔ × ✔ 
Highest SYNTAX quartile × ✔ ✔ ✔ × ✔ 
eGFR < 60 ml/min/1.73 m2 × ✔ ✔ ✔ × ✔ 
Diabetes × × ✔ ✔ × ✔ 
Hypertension × × ✔ ✔ × ✔ 
Hb < 12 g/dL × × ✔ ✔ × ✔ 
Peripheral vascular disease × × × ✔ × ✔ 
✔ There were significantly more patients with biomarker levels above the ULN when characteristic 
present 
×   There was no significant difference in the proportion of patients with biomarker levels above the ULN 
when characteristic present 
*   Randox Cardiac Plus Array assay                      †   Siemens‟ ADVIA Centaur TnI-Ultra assay 
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8.4. Biomarkers levels post-PCI 
For patients with normal range biomarker levels at Time 0 hours there was a small 
increase in average levels at 4 hours for all biomarkers, and a further small increase 
from 4 to 12 hours (except for the non-cardiac biomarker CAIII), displayed in Table 8-
3. 
On an individual patient basis, biomarker levels above the upper limit of the 
normal range (ULN) following PCI, either at 4 hours, 12 hours or both, was very 
common. TnI was the biomarker most frequently elevated, with levels above the ULN 
seen in 71.7% at 12 hours; and myoglobin the least frequently elevated, seen in 20.6% 
at 12 hours (Table 8-4). H-FABP, myoglobin and GPBB had a heterogeneous pattern of 
elevation over the 4 and 12 hour time points. In contrast, patients with elevation of CK-
MB and troponin I had a much more ordered pattern of release, with a small early rise 
and a greater late rise. These patterns of biomarker elevation are shown in Figures 8-7 to 
8-11. 
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Table 8-3  Median (IQR) biomarker levels in non-PPCI patients; only those with biomarker levels < ULN at Time 0 AND with results available at all 3 time 
points are included 
 ULN, 
ng/mL 
Total number patients 
with biomarker levels < 
ULN at Time 0 (% of total 
non-PPCI cohort) 
Number of patients with 
biomarker levels < ULN, with 
complete results (% of 
previous column) 
Median (IQR) biomarker level, ng/mL 
Time point: 0 hours 4 hours  12 hours 
CK-MB* 2.4 675 (80.5%) 548 (81.2%) 1.26 (0.89) 1.41 (1.02) 2.04 (2.16) 
Myoglobin* 45.0 729 (87.0%) 583 (80.0%) 20.32 (15.8) 23.53 (22.58) 27.21 (23.75) 
H-FABP* 2.0 500 (60.0%) 412 (82.4%) 1.29 (0.61) 1.63 (1.16) 1.89 (1.54) 
GPBB* 4.0 583 (70.0%) 472 (81.0%) 1.0 (1.64) 2.06 (2.6) 2.23 (2.65) 
CA III* 30.0 676 (80.7%) 540 (79.9%) 15.23 (9.31) 18.07 (14.8) 18.91 (14.78) 
TnI† 0.04 381 (48.3%) 275 (72.2%) 0.003 (0.014) 0.019 (0.05) 0.097 (0.342) 
*Randox Cardiac Plus Array assay 
†Siemens‟ ADVIA Centaur TnI-Ultra highly sensitive troponin I assay           
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Figure 8-7   Changes in myoglobin level after PCI in 150 patients who were myoglobin 
negative at Time 0 but positive at either 4 or 12 hours 
 
 
Figure 8-8   Changes in CK-MB levels after PCI in 213 patients who were CK-MB 
negative at Time 0 but positive at either 4 or 12 hours 
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Figure 8-9   Changes in H-FABP level after PCI in 216 patients who were H-FABP 
negative at Time 0 but positive at either 4 or 12 hours 
 
 
Figure 8-10   Changes in GPBB level after PCI in patients who were GPBB negative at 
Time 0 but positive at either 4 or 12 hours (1 extreme outlier, PAT ID 578, excluded for 
clarity) 
- 206 - 
 
Figure 8-11   Changes in high sensitivity TnI level after PCI in 193 patients who were TnI 
negative at Time 0 but positive at either 4 or 12 hours 
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Table  8-4   Number (%) of patients (biomarker negative at Time 0, results at all 3 time points) with biomarker levels at various thresholds above the upper 
limit of the normal range (ULN) at 4 and 12 hours post PCI 
* Randox Cardiac Plus Array assay                       † ADVIA Centaur TnI-Ultra assay 
 ULN (OPERA study 
values), ng/mL 
Above ULN ≥  5× ULN ≥ 10× ULN ≥ 50× ULN 
4hr 12hr 4hr 12hr 4hr 12hr 4hr 12hr 
CK-MB, ng/mL * 2.4 3 (0.5) 218 (38.6) 3 (0.5) 23 (4.1) 3 (0.5) 7 (1.2) 0 0 
Myoglobin, ng/mL* 45.0 104 (15.6) 124 (20.6) 3 (0.5) 8 (1.3) 0 1 (0.2) 0 0 
H-FABP, ng/mL* 2.0 150 (32.7) 200 (47.2) 12 (2.6) 12 (2.8) 4 (0.9) 2 (0.5) 0 0 
GPBB, ng/mL* 4.0 112 (21.2) 101 (20.7) 8 (1.5) 6 (1.2) 2 (0.4) 2 (0.4) 1 (0.2) 0 
CA III, ng/mL* 30.0 117 (19.0) 128 (23) 5 (0.8) 6 (1.1) 0 0 0 0 
Hi Sens TnI, ng/mL† 0.04 112 (33.4) 213 (71.7) 18 (5.4) 103 (34.7) 10 (3.0) 70 (23.6) 1 (0.3) 23 (7.7) 
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8.5. Comparison between serum and plasma biomarker levels  
The Time 0 blood sample taken for biomarker measurement was stored both as 
serum (derived from centrifugation of coagulated blood) and plasma (from 
centrifugation of anticoagulated blood, thereby containing clotting factors and 
fibrinogen). Blood was stored as serum only at the 4 and 12 hour time points. 
Biomarker levels at Time 0 were measured both in the serum and in the plasma of about 
half the patient cohort. Patients in this subgroup all enrolled during the first recruitment 
phase of the study but were otherwise similar to the overall cohort. 
Correlation between the plasma and serum results was strong for TnI and CK-MB, 
slightly weaker for H-FABP and only modest for myoglobin and GPBB (Table 8-4). 
Scatter plots of serum and plasma levels for H-FABP and TnI can be seen in 
Figure 8-12 and 8-13, showing reasonably linear associations (more so for TnI) but with 
scattered outliers. Particularly when TnI was in the lower range many patients can be 
seen to test positive on the serum sample but negative on the plasma sample, and vice 
versa. 
 
Table 8-5   Median (IQR) biomarker levels at Time 0 in subgroup of non-PPCI patients 
who had both plasma and serum samples tested; with Pearson‟s Correlation Coefficient 
 
 Number of 
patients 
Median level 
in serum, 
ng/ml 
Median level 
in plasma, 
ng/ml 
Correlation P value 
CK-MB, ng/mL * 423 1.32 (1.33) 1.42 (1.28) 0.96 < 0.01 
Myoglobin, ng/mL* 423 20.34 (21.71) 20.7 (17.0) 0.79 < 0.01 
H-FABP, ng/mL* 423 1.63 (1.48) 1.49 (1.41) 0.92 < 0.01 
GPBB, ng/mL* 423 1.85 (2.82) 3.84 (4.52) 0.61 < 0.01 
CA III, ng/mL* 423 15.8 (13.27) 12.64 (10.76) 0.74 < 0.01 
Hi Sens TnI, ng/mL† 340 0.037 (0.345) 0.046 (0.43) 0.98 < 0.01 
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Figure 8-12   Scatter plot of Time 0 H-FABP results obtained from plasma vs. serum, non 
PPCI patients; logarithmic transformation performed for clarity; automatic straight line 
of best fit added 
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Figure 8-13   Scatter plot of Time 0 highly sensitive TnI results obtained from plasma vs. 
serum, non PPCI patients; logarithmic transformation performed for clarity. Automatic 
straight line of best fit added 
 
8.6. Biomarker elevation post-PCI and baseline characteristics 
Elevation of biomarker levels following PCI was associated with a variety of 
baseline and procedural characteristics, although these elevations were often 
inconsistent between the different biomarkers. Table 8-7 lists the characteristics 
significantly associated with any biomarker elevation above the ULN post PCI (P < 
0.05). The more biomarkers that were elevated with each characteristic, the higher its 
position in the table. 
There were 10 factors which were associated with a rise in all 3 of the traditional 
biomarkers (CK-MB, troponin I and myoglobin) at either 4 or 12 hours: prolonged 
fluoroscopy time, multi-vessel PCI, intervention to calcified lesions and Type C lesions, 
long stent length, high EuroSCORE, anaemia, age over 80 years, severe renal 
dysfunction and diabetes. A further 6 factors were associated with a rise in 2 out of 3 of 
the traditional biomarkers. For all the characteristics associated with a TnI rise at 12 
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hours, and for most of those associated with a rise in 12 hour myoglobin, a significant 
rise was detectable by 4 hours. In contrast, the 4 hour time point was too early to predict 
a 12 hour rise with CK-MB. 
Regarding the novel biomarkers, HFABP was more likely to be elevated above 
normal at either 4 or 12 hours in patients with all the above 10 main characteristics 
associated with traditional biomarker elevation. In marked contrast, GPBB was elevated 
above normal in patients with only 1 of those characteristics (age > 80 years). CA III 
(the non-cardiac skeletal muscle marker) was elevated above normal in patients with 
prolonged fluoroscopy time, high EuroSCORE and diabetes. 
 
8.7. Cardiac biomarkers and platelet reactivity 
Median biomarker levels for patients grouped into the 3 ARMYDA-PROVE 
ranges for optimal, hypo- and hyper-response to clopidogrel are shown in Table 8-7. 
Platelet function did not have any association with biomarker levels in the OPERA 
study. 
Table 8-6   Median (IQR) biomarker levels in biomarker-negative patients (for all 4 
biomarkers) at Time 0 hours, stratified by PRU level according to ARMYDA-PROVE 
thresholds for clopidogrel response; PPCI patients excluded; patients with any missing 
values excluded 
Biomarker 
(ng/mL) 
PRU < 179 
N = 42 
PRU 179 to 238 
N = 46 
PRU > 238 
N = 89 
P value across 3 
groups 
Myoglobin, 4 hour 18.47 (14.31) 20.14 (22.11) 21.61 (18.65) 0.24 
Myoglobin, 12 hour 22.68 (21.06) 23.83 (24.87) 20.85 (23.83) 0.59 
CK-MB, 12 hour 1.44 (2.16) 1.41 (1.72) 1.62 (1.56) 0.87 
TnI, 4 hour 0.01 (0.04) 0.02 (0.05) 0.15 (0.03) 0.15 
TnI, 12 hour 0.06 (0.25) 0.12 (0.26) 0.08 (0.24) 0.49 
H-FABP, 4 hour 1.33 (0.91) 1.67 (1.1) 1.56 (0.97) 0.47 
H-FABP, 12 hour 1.79 (1.39) 1.77 (1.17) 1.6 (0.92) 0.64 
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Table 8-7   Characteristics associated with cardiac biomarker elevation above ULN post 
PCI at either 4 or 12 hours (P < 0.05), in non-PPCI patients with levels < ULN at baseline 
 TnI† CK-MB* Myoglobin* H-FABP* GPBB* 
Fluoroscopy time ≥ 10 minutes ✔ ✔ ✔ ✔ × 
PCI to more than 1 vessel ✔ ✔ ✔ ✔ × 
Total stent length ≥ 30 mm ✔ ✔ ✔ ✔ × 
EuroSCORE 4
th
 quartile (≥ 6.4) ✔ ✔ ✔ ✔ × 
Anaemia; Hb ≤ 12.0 g/dL ✔ ✔ ✔ ✔ × 
Calcified lesion treated ✔ ✔ ✔ ✔ × 
Patient aged ≥ 80 years ✔ ✔ ✔ ✔ ✔ 
Diabetes ✔ ✔ ✔ ✔ × 
Type C lesion treated ✔ ✔ ✔ ✔ × 
Renal dysfunction; eGFR ≤ 30 ✔ ✔ ✔ ✔ × 
Patient presented with MI ✔ ✔ × × × 
More than 1 stent implanted ✔ × ✔ ✔ × 
PCI to left main stem × ✔ ✔ ✔ ✔ 
Bifurcation lesion treated × ✔ ✔ ✔ × 
IIbIIIa inhibitor given × ✔ ✔ × × 
History of stroke ✔ × ✔ × × 
Previous revascularisation × ✔ × ✔ × 
Hypertension × × ✔ × ✔ 
SYNTAX 4
th
 quartile (≥ 15.5) ✔ × × ✔ × 
Peripheral vascular disease × × ✔ ✔ × 
Treated with B blocker ✔ × × × × 
PCVI to thrombotic lesion ✔ × × × × 
Saphenous vein graft treated × × ✔ × × 
Severe aortic stenosis × × ✔ × × 
Localised dissection × ✔ × × × 
Poor flow, any vessel × × × ✔ × 
Restenotic lesion treated × × × × ✔ 
Stent diameter 2.5 mm or less × × × ✔ × 
✔ There were significantly more patients with biomarker levels above the ULN when characteristic 
present 
×   There was no significant difference in the proportion of patients with biomarker levels above the ULN 
when characteristic present 
*   Randox Cardiac Plus Array assay              †   Siemens‟ ADVIA Centaur TnI-Ultra assay 
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8.8. Cardiac biomarkers and clinical outcome 
8.8.1. Troponin elevation and adverse events 
In patients who were TnI negative at Time 0 hours, elevation of TnI above the 
ULN at 4 hours was associated with approximately twice the rate of the combined 
endpoint of recurrent ACS, death or further unplanned revascularisation at 1 year, see 
Figure 8-14. There was no significant difference in individual or composite adverse 
event rate in patients who did and did not have elevation of TnI above the ULN at 12 
hours, but note that this was a smaller group of 296 patients due to missing 12 hour 
biomarker results. 
The characteristics individually associated with this composite adverse endpoint 
are listed in Table 8-7. After adjustment, elevation of TnI lost statistical significance; 
the most important factors were the occurrence of a major procedural complication and 
a high SYNTAX score. In a model including major complications, high SYNTAX, high 
EuroSCORE and 4 hour TnI >ULN, respective aHR (95% CI) were 5.24 (1.52 to 
17.98), p < 0.01; 5.93 (1.77 to 19.95), p < 0.01; 2.13 (0.83 to 5.47), p = 0.12; and 1.99 
(0.90 to 4.40), p = 0.09. 
8.8.2. H-FABP and adverse events 
In patients who were H-FABP negative at Time 0 hours, there was no association 
with elevation at 4 hours and combined adverse events at 1 year. 
Time 0 hours (immediately pre-PCI) H-FABP levels were associated with adverse 
events, but only for patients who were clopidogrel-resistant. Patients who were both 
clopidogrel resistant and who had elevation of H-FABP at Time 0 hours were 2 to 3 
times more likely to experience an adverse event than other patients (Figure 8-15). 
8.8.3. Procedural MI 
Only 1 patient could be said to have had a procedural MI according to the 
Universal Definition criteria: PAT ID 355 had prolonged chest pain following the 
procedure. He had another coronary angiogram to investigate this pain the following 
day. No angiographic abnormalities were seen and his ECGs shown no dynamic 
changes but TnI and CK-MB, both < ULN at Time 0 hours, were elevated at 12 hours 
(1.79 and 11.3 ng/ml respectively). This patient died 5 years later of a recurrent MI and 
gastric cancer. 
- 214 - 
 
Figure 8-14   KM unadjusted estimates of combined recurrent MI, death or further 
revascularisation at 1 year in patients who were TnI negative at Time 0, stratified by 
elevation and no elevation of TnI above the ULN at 4 hours; PPCI patients excluded 
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Table 8-8   Univariable characteristics associated with 1 year composite outcome of MI, 
death or further revascularisation in 381 patients who were TnI negative at Time 0 hours 
(P ≤ 0.01) 
 HR 
(unadjusted) 
95% CI P Value 
Lower Upper 
Major procedural complication* 5.08 1.55 16.65 < 0.01 
SYNTAX ≥ 8 (highest 2 quartiles) 5.03 1.94 13.06 < 0.01 
SVG intervention 3.64 1.41 9.43 < 0.01 
EuroSCORE ≥ 3.2 (highest 2 quartiles) 3.27 1.47 7.24 < 0.01 
> 1 stent implanted 3.12 1.85 7.48 < 0.01 
Previous revascularization 2.93 1.47 5.84 < 0.01 
> 1 vessel intervention 2.67 1.34 5.33 < 0.01 
TnI > ULN at 4 hours 2.60 1.22 5.56 0.01 
Smallest stent diameter ≤ 2.5 mm 2.48 1.24 4.94 0.01 
Total fluoroscopy time > 10 minutes 2.45 1.20 4.98 0.01 
*8 patients in this subgroup of 381 had a major procedural complication. These were: 1 case of coronary dissection 
with poor flow; 3 cases poor flow without obvious dissection; 1 case of occlusion of a large side branch; 2 cases of 
VF; and 1 case of self-limiting coronary perforation. 
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Figure 8-15   KM estimated combined adverse event rate (all cause death, definite or 
probable stent thrombosis and recurrent myocardial infarction) at 1 year in patients 
stratified into 4 groups based on Time 0 H-FABP  less than or greater than the ULN, and 
clopidogrel response or non-response
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8.9. Chapter 8 Summary Points and Discussion 
 Elevation of cardiac biomarkers following PCI in ACS patients was 
common, but procedural MI according to the latest Universal Definition 
very rare (1 patient). 
 Biomarker elevation was more common in patients with a variety of 
baseline characteristics which would tend to prolong the procedure or 
require multiple balloon inflations such as calcified lesions, long lesions 
and more than 1 stent. 
 High sensitivity cTnI was not ideal for detection of procedural myocardial 
injury in this ACS population: the high rate of elevation of baseline levels 
and the low rate of clearance from the body did not allow a clear peri-
procedural injury signal. H-FABP levels however were more commonly 
back to normal pre-procedure and gave a more plausible injury signal 
 H-FABP was often elevated at 12 hours which could indicate subclinical 
ongoing myocardial ischaemia in some patients after PCI 
 There was little evidence of an increase in myocardial injury in patients 
with an apparent angiographic procedural complication such as poor flow 
or dissection. 
 Clopidogrel-resistant patients (bedside VerifyNow test, PRU ≥238) did not 
have any greater myocardial injury than responders; there was no 
correlation between PRU and post-procedural biomarker levels. 
 TnI elevation above the ULN in patients who are negative at the start of 
the procedure was associated with a worse prognosis in an unadjusted 
analysis, but after adjustment the difference was no longer significant. The 
most important determinates of outcome were high SYNTAX score and 
the occurrence of a major procedural complication. 
 Post-procedural H-FABP elevation was not associated with adverse events; 
however, pre-procedural elevation was strongly associated with adverse 
events, but only in clopidogrel-resistant patients. 
 
8.9.1. Troponin elevation following PCI in previous studies 
Troponin elevation following PCI has been reported in many studies. In a meta-
analysis of 15 trials and 7578 patients with normal baseline troponin (Testa et al, 2009), 
28.7% following PCI had elevation above the URL. Regarding procedural MI, 14.5% 
had elevation of troponin more than 3 times the URL, the cut-off suggested by the 
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Universal Definition of MI document at the time (Thygesen et al, 2007; note that this 
document has since been updated). Testa et al found an association between procedural 
MI and subsequent adverse events and recommended that troponin testing following 
PCI became mandatory:  
“At follow up of 18 months any troponin elevation was associated with an increased 
risk of MACE [OR 1.48 (1.12–1.96), NNH = 20], death [OR 2.19 (1.59–3.00), NNH = 
50], MI [OR 3.29 (2.71–6.31), NNH = 33] and re-PCI [OR 1.47 (1.06–2.03), NNH = 
25]” 
However, both the causal nature of these findings and the relevance of troponin 
elevation to patient management have been disputed. Neither the 2014 ESC/EACTS 
Guidelines on myocardial revascularization nor the 2015 ESC guidelines for the 
management of acute coronary syndromes in patients presenting without persistent ST-
segment elevation even mention testing for procedural biomarker release, let alone 
make it a mandatory requirement. 
Of 275 patients who had baseline troponin within the normal range in OPERA and 
results available at all 3 time points, 33.4% had elevation at 4 hours and 71.7% at 12 
hours. This was a remarkably high proportion and suggests that troponin elevation 
following PCI is the norm, at least in an ACS population. Note that a highly sensitive 
assay was used in OPERA which was unavailable at the time of the studies included in 
the Testa meta-analysis – older, less sensitive assays had higher thresholds for the ULN. 
Also, it is possible some of the troponin released following PCI in patients who have 
recently had an MI is due to a „washout‟ effect from reperfused myocardium rather than 
from myocardial necrosis occurring secondary to the procedure; this is purely 
speculative however. 
8.9.2. Possible causes of enzyme elevation following PCI 
Balloon inflation within a coronary artery causes a period of iatrogenic myocardial 
ischaemia. This is often severe enough to cause transient ischaemic ST segment changes 
on the ECG which virtually always resolve within a short time after restoration of 
circulation. In a study of 108 patients undergoing single vessel elective PCI, Balian et al 
(2006) observed >1mm of ST shift (using intracoronary ECG) during PCI in 37%. 
Cardiac enzyme release was much more common during cases with ECG ischaemia 
during the procedure than without (93% vs. 19%, p < 0.001). No obvious angiographic 
complications occurred but lesion type B2/C (complex), balloon inflation time, stent 
length and the number of stents per patient were all factors associated with ECG 
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ischaemia. It seems the more complex the disease, the longer the procedure and a higher 
chance of myocardial ischaemia and necrosis. 
Troponin release in the OPERA study was associated with many different patient 
baseline characteristics (Table 8-7).  Elevations in all 4 of the cardiac biomarkers we 
studied (troponin I, myoglobin, H-FABP and CK-MB) were seen in patients with the 
following: fluoroscopy time ≥ 10 minutes, PCI to more than 1 vessel, total stent length 
≥ 30 mm, calcified lesions, type C lesions, EuroSCORE 4th quartile (≥ 6.4), patient 
aged ≥ 80 years, diabetes, anaemia, and renal dysfunction. All these factors would be 
seen more often in cases in which more complex and difficult angioplasty was required, 
equating to longer myocardial ischaemia times and cardiac biomarker release. Another 
possible explanation put forward is embolization of plaque debris and cholesterol 
released during PCI, with ischaemic damage to the myocardium due to occlusion of tiny 
vessels not visible angiographically. This is plausible but would be very hard to 
objectively demonstrate. The above factors, however, would all predispose to a higher 
chance of micro-embolisation during PCI. 
The reason for more myonecrosis in anaemic patients is less clear. Izgi et al (2006) 
found anaemia and the number of balloon inflations performed to be the only 
independent predictors of myocardial necrosis following PCI in elective patients. 
Anaemia was associated with complex disease in OPERA patients: the difference 
between median SYNTAX score in patients with Hb below and above 12 g/dL was 
considerable: 15.5 vs. 8.0, p < 0.01. Anaemic patients therefore would require more 
complex and prolonged procedures (median fluoroscopy times were 11.3 vs. 9.0 
minutes in those with Hb below and above 12 g/dL; p < 0.01). However, anaemia itself 
could potentially cause more myonecrosis by worsening myocardial hypoxia during 
balloon inflations. 
It has also been postulated that thrombus formation during PCI could be a 
potential source of procedural myocardial necrosis (Balian et al). In OPERA, platelet 
reactivity had no association with cardiac biomarker release which would tend to 
discourage this hypothesis. If intracoronary thrombus formation during the procedure 
was a significant cause of myocardial necrosis, patients with highly reactive platelets 
should have a higher risk of thrombosis and therefore more myocardial necrosis, which 
was not seen. Patients are anticoagulated during PCI and obvious thrombus formation is 
rarely a problem. 
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8.9.3. Association of procedural biomarker elevation and prognosis 
As in most previous similar studies, post procedural troponin elevation in OPERA 
was associated with a higher rate of adverse events during follow-up (Figure 8-14). 
However, after adjustment for other baseline characteristics this was no longer 
statistically significant. Virtually all the troponin elevations in OPERA were too small 
to indicate the loss of any significant volume of myocardium as a result of the 
procedure. It is likely that troponin elevation is a marker of advanced atherosclerotic 
disease and it is this which carries the adverse prognosis. Post-procedural H-FABP 
elevation had very little association with subsequent risk of clinical events, which 
reinforces the impression that transient balloon-associated myocardial ischaemia is of 
little consequence per se. 
An interesting finding was that elevated H-FABP levels were found in 40% of 
patients just prior to PCI (the baseline blood sample) and furthermore this was 
associated with adverse events during follow-up. A high rate of troponin and CK-MB 
would be expected in an ACS population several days after admission, as these 
biomarkers take days to clear from the blood. However, H-FABP is both very rapidly 
released from ischaemic myocardium (Viswanathan et al, 2012) and very rapidly 
excreted via the kidneys. In a study of 50 patients with STEMI undergoing reperfusion 
therapy (Glatz et al, 1994), H-FABP levels peaked at 5.7 hours and plasma levels were 
normal by 24 hours. In contrast, CK-MB level peaked at 11.7 hours but took 50 to 70 
hours to normalise. The average wait from admission to PCI for OPERA patients was 6 
days. This high rate of ongoing myocardial ischaemia in these patients indicated by 
elevated H-FABP levels, days after their admission with chest pain, occurred despite 
standard treatment with bed rest, anticoagulants and dual antiplatelet therapy. Similar 
rates were seen in patients presenting with UA, NSTEMI and STEMI, even in 
clopidogrel-responders. This implies that a long delay to angiography and intervention 
following ACS is a high risk strategy which should be avoided. 
The second interesting finding regarding pre-procedural H-FABP elevation was its 
association with adverse outcomes following PCI, but only in patients resistant to 
clopidogrel (Figure 8-15). Patients H-FABP-negative at baseline had a low risk of 
further events following PCI regardless of whether or not they responded to clopidogrel. 
In OPERA, persistent elevation of H-FABP following admission (but prior to 
revascularisation) probably indicated a subset of patients with more critical coronary 
disease. These patients were more likely to have thrombotic lesions; thrombotic vs. non-
thrombotic lesions were associated with baseline elevation of H-FABP, TnI and CK-
MB: 34.4% vs. 16.7%, 32.4% vs. 16.3% and 41.9% vs. 19.2% respectively; p < 0.01 for 
all. Furthermore, patients with elevated baseline H-FABP were older and had both 
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higher EuroSCOREs and SYNTAX scores. However, effective P2Y12 inhibition with 
clopidogrel reduced their risk of adverse events following PCI to a level identical with 
lower-risk, H-FABP-negative patients. Pre-procedural H-FABP was an excellent 
marker of adverse prognosis after PCI in OPERA and may indicate patients who would 
benefit from a longer duration of antiplatelet therapy. 
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Chapter 9 Final overview and Discussion 
Acute coronary syndrome (ACS) is not only the commonest cause of death 
worldwide, but survivors are known to be at considerable risk of recurrent adverse 
clinical events for years after the index event. In a recent highly detailed national 
registry study from Sweden of 97254 ACS survivors (Jernberg et al, published on-line 
2015), the estimated rate of a composite endpoint of MI, stroke or cardiovascular death 
at 1 year was 18.3%, with a further 20% experiencing this endpoint during the 
subsequent 36 months. This is despite modern treatment of ACS including high rates of 
coronary revascularisation, usually by PCI, accompanied by extensive pharmacological 
treatment designed to inhibit platelet thrombus activation and to modify the 
conventional cardiovascular risk factors for coronary disease such as hypertension, 
hyperlipidaemia and diabetes. 
Recurrent adverse events are often be partially iatrogenic, resulting from the 
treatments delivered during the index event such as stent failure and bleeding while on 
DAPT. Recurrent ACS may be caused either by „de novo‟ coronary lesions or by a stent 
malfunction such as restenosis or stent thrombosis, the latter more frequent in patients 
with inadequate platelet inhibition. Regarding haemorrhagic adverse events, DAPT 
must be continued for 12 months in most ACS patients undergoing PCI, but this therapy 
is known to increase bleeding rate. The risk of bleeding is the factor which limits the 
intensity of platelet inhibition which can be achieved in ACS patients. Clinically 
significant bleeding may lead to hospitalisation, the discontinuation of antiplatelet 
therapy (which in turn may increase the risk of ischaemic events), disability and death. 
A small proportion of bleeding events are directly fatal, and even non-fatal bleeding 
appears to be a strong risk factor for subsequent mortality, although the reasons for this 
are not entirely clear. 
There were 2 main aims of this prospective observational study: to document, 
classify and investigate all adverse events experienced by ACS patients over a 
minimum period of 1 year post-PCI; and to find any independent associations between 
baseline patient characteristics and these adverse events, to risk stratify patients. 
Characterising those at risk of treatment failure can help us to understand why recurrent 
adverse events occur in some patients and not others, and may lead to changes in 
management which might improve outcomes. Furthermore, cardiovascular therapeutics 
is a large and continually developing field and, even if current technology is insufficient 
to help all patients with ACS, the ability to define the highest risk patients is essential to 
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develop and target new treatments which could improve the health and prospects of 
survival of ACS patients in the future. 
The adverse outcomes we documented were recurrent ACS and its various clinical 
syndromes, stent thrombosis, death (cardiac, vascular and all-cause), binary restenosis, 
repeat revascularisation and bleeding, and composites of these. ARC criteria were used 
when available to define ischaemic events and bleeding was defined using BARC 
criteria. The baseline characteristics we studied included standard demographic data, 
medical history and procedural technical details, but we also included some recent 
innovations which have the potential to improve risk stratification but which are not in 
routine widespread clinical use. These were the SYNTAX score, an angiographic risk 
scoring system; a range of traditional and novel cardiac biomarkers measured in blood 
taken before and after PCI; and the VerifyNow P2Y12 device, a bedside platelet 
function test. 
The study was designed to be inclusive and, although recruitment was not 
consecutive and the time frame was broad, the lack of exclusion criteria ensured a 
cohort of patients likely to represent the general local ACS population. Distinct early 
and late recruitment periods allowed us to study changes in baseline patient 
characteristics, therapeutic interventions and clinical outcomes over time. We achieved 
a high rate of completeness of clinical follow-up to 1 year post PCI (98.5%) and many 
patients had detailed follow up for years after, with a median clinical follow-up of 3.5 
years and mortality tracking of 5.4 years. 
9.1. Recurrent ACS and death rates 
To summarise the main findings concerning recurrent ACS and death: recurrent 
ACS most commonly presented clinically as NSTEMI and occurred in 6.7% at 1 year 
following PCI. The rate gradually decreased over the 1
st
 year and stabilised over long-
term follow-up to approximately 1.8% per year. Definite, probable or possible stent 
thrombosis was diagnosed in 18 of the 111 total cases of recurrent ACS (16%). Stent 
thrombosis usually presented clinically as either STEMI or out of hospital cardiac arrest 
and more than half the patients with stent thrombosis died. All-cause and cardiac death 
rates were 2.9% and 2.0% at 1 year.  Cardiac death rate gradually decreased over the 
first year, after which the rate stabilised for the duration of follow-up. The all-cause 
death rate decreased after about 3 months following PCI, to remain constant for the 
remainder of the study. Non-cardiac death was more common than death of cardiac 
cause overall, although cardiac death was more common up to 1 year. The commonest 
individual causes of death over a median of 5.4 years of follow-up were: metastatic 
cancer (27%), recurrent acute MI (18%), cardiac failure (15%), sepsis (13%) and 
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ischaemic stroke (8%). Just over half of all cardiac deaths were due to an acute MI and 
at least half of fatal MIs were due to a stent thrombosis. 
The rates of adverse events in OPERA compare favourably with those from 
published contemporary clinical trial data. There are 2 large-scale international 
antiplatelet therapy trials in ACS patients undergoing coronary intervention which 
recruited patients at around the same period as OPERA: the TRITON-TIMI 38 trial 
(Wiviott et al, 2007) and the PLATO invasive study (Cannon et al, 2009). Both these 
trials had higher adverse event rates than those seen in OPERA. TRITON had a 
particularly high non-fatal MI rate, disproportionate to the death rate which was similar 
to that in OPERA. In PLATO, both the MI and the all-cause death rates were nearly 
twice those in OPERA. The high MI rate in TRITON and PLATO may be due to the 
inclusion of biomarker-only „procedural MI‟; the study protocols did allow for inclusion 
of biomarker-only MI according to the then current Universal Definition of MI. 
The ADEPT-DES registry (Greg Stone et al, 2013) was a major observational 
study from the U.S. looking at how ischaemic and haemorrhagic adverse events related 
to the results of platelet function testing in 8582 patients undergoing PCI. DAPT 
consisted of aspirin and clopidogrel. In this study the MI and death rates at 1 year were 
3.1% and 1.9%, both slightly lower than OPERA, and the 1 year definite/probable stent 
thrombosis rate was extremely low at 0.83% at 1 year. However only about half the 
patients in this study had presented with ACS. The inclusion of stable patients would be 
expected to lower the study cohort‟s risk of recurrent adverse cardiac events, as the MI 
and stent thrombosis rates in stable patients undergoing elective PCI in the modern era 
are very low. As an example to illustrate this, the TRIGGER-PCI trial (Trenk et al, 
2012) designed to investigate the use of prasugrel in clopidogrel-resistant patients with 
stable coronary disease was halted early due to low event rates: of 423 patients 
randomised, only 1 patient experienced the study endpoint (CV death or MI) and the 
trial was terminated after 6 months. 
These outcome comparisons suggest that the ACS patients in the OPERA study 
were managed at least as well as the patients in these high profile contemporary trials. 
OPERA patients, being unselected, should have been a higher risk cohort than those in 
the randomised trials and one might expect worse outcomes rather than better. Baseline 
characteristics such as age and co-morbidities appeared similar between all 3 cohorts, 
except for more STEMI patients in PLATO. However, the baseline characteristic we 
found in OPERA to be the strongest determinate of outcome, the SYNTAX score, was 
absent from the PLATO and TRITON trials and from the ADEPT-DES study. Nor were 
any other clinical risk scores provided, making the baseline risk of future adverse events 
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of patients in these studies harder to determine. The large difference in adverse event 
rates in these studies, which contain patients of similar characteristics undergoing the 
same treatment for the same condition in the same era, may also be partially explained 
by the use of individual and often opaque definitions, particularly for MI and 
particularly when „silent‟ procedural MIs are counted. Furthermore, the outcomes 
following coronary intervention may be variable between different countries. 
Although the OPERA study patients fared well compared to other contemporary 
ACS patient cohorts, the rate of recurrent adverse events was still rather too high, 
particularly for patients with a high baseline risk profile. Patients with the lowest 
SYNTAX scores (lowest quartile, median 2.0) had an estimated rate of recurrent MI, 
further unplanned revascularisation or all-cause death of 8% at 3.4 years; but patients in 
the highest quartile (median 22.3) had rates of 26%. If SYNTAX score was 30 or more 
(5.8% of the cohort) the rate was 38%. For the same 3 groups, estimated cardiac death 
rates at 5.4 years were <1%, 9% and 19%. Future efforts to reduce adverse event rate 
will need to focus on these higher risk patients. The single baseline characteristic with 
the strongest association with recurrent ACS rate was the SYNTAX score with an 
approximately linear relationship. A history of tobacco smoking and the use of older 
generation stents were the other 2 independent risk factors for recurrent ACS in the 
overall cohort. SYNTAX score was also a strong independent predictor of further 
unplanned revascularisation, cardiac death and all-cause death over long-term follow-
up. The score is discussed further in Section 9.3. 
9.2. Unplanned revascularisation 
To summarise the main findings regarding unplanned further revascularisation: the 
rate of further unplanned revascularisation was 6.9% at 1 year but this rate decreased 
gradually over the duration of follow-up. There were similar 1 year rates of TLR and of 
non-TLR at 3.7% and 3.2%. Overall 42% of cases of further revascularisation occurred 
after the patient presented with recurrent ACS, a scenario more common with TLR than 
with non-TLR; the remainder re-presented with exertional angina. Further 
revascularisation was achieved by PCI about 90% of the time, usually with implantation 
of DES, although a small number of patients required CABG. Nearly all cases of TLR 
were undertaken to treat „stent failure‟; and most patients with stent failure who 
survived to reach hospital underwent further revascularisation. Binary restenosis, 3 
times more frequent overall than stent thrombosis, was the specific reason for most 
cases of TLR. Binary in-stent restenosis was found in just under half the cases of 
recurrent UA and NSTEMI. In contrast to stent thrombosis, restenosis had no apparent 
impact on the overall mortality rate, nor was restenosis (or the treatment for it) found to 
be the direct cause of any patient‟s death. 
- 226 - 
The type of available stents changed considerably over the course of this study, 
with BMS used more than DES early in the study recruitment period and „Xience‟ 
everolimus-eluting stents becoming the most frequently implanted device towards the 
end. There was a definite improvement in the crude overall binary restenosis rate with 
the introduction of Xience stents, at 3.7% vs. 7.2% compared to other stents, although 
note the total length of follow-up was shorter with Xience stents which were introduced 
in the 2
nd
 recruitment phase. BMS restenosis rate was 6.2%. Taxus stents were the worst 
performers with a restenosis rate of 11.1% in this study. 
The estimated 1 year and 2 year cumulative TLR rates with Xience stents in the 
OPERA study were 2% and 3%, compared to 4% and 6% for all other stent types 
combined. For BMS the rates at 1, 2 and 3 years were 4%, 5% and 6%. Xience stents 
came into use after publication of the „SPIRIT‟ family of trials. SPIRIT V (Grube et al, 
2011) was a post-marketing surveillance study of 2700 patients after implantation of 
Xience stents, about half of whom had presented with ACS. The 1 year TLR rate was 
1.8%, very similar to that found in the OPERA study. Stent type was an important 
determinate of 1 year outcomes in the OPERA study, with only half the rate of TLR 
seen with the most modern types of DES than with „1st generation‟ DES and BMS. 
Although restenosis and stent thrombosis have become less common early after PCI, 
they have not been eliminated, occurring in approximately 4% and 2% respectively over 
total follow-up in the OPERA study in patients receiving Xience stents. 
The latest generation of DES inhibit neointima formation in the months following 
implantation; however, they appear to have a greater propensity to aggressive re-growth 
of new atheromatous tissue (Neoatherosclerosis) which occurs later than the traditional 
early neointimal restenosis seen with BMS, but causes eventual catch-up of the overall 
rate of stent failure. This can be seen in OPERA, in which 6 month TLR rates in 
patients receiving DES only and BMS only were 1.7% and 3.0%, but cumulative rates 
at 3 years were 6.4% and 6.0%. Neoatherosclerosis formation can be clearly observed in 
living patients with restenosis of DES using OCT during coronary angiography (Kang 
et al, 2011) and the phenomenon is discussed in detail in a review by Park et al, 2012. 
This problem may also account for the low but persistent risk of stent thrombosis with 
DES which appears to last for many years after implantation. The stent thrombosis rate 
in OPERA was too low to allow investigation of this individual adverse endpoint in 
BMS and DES recipients. However, ACS (all types) rates for BMS, DES (all types) and 
Xience stents were very similar in the OPERA study: 5.0%, 5.0% and 5.2% at 6 
months, and 11.2%, 10.5% and 11.6% at 3 years. 
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More work, therefore, is required to improve long-term stent safety. It is possible 
that further technological refinement will result in even better outcomes, although 
metallic stent technology may be reaching its limit: struts cannot become much thinner 
without the stent losing radial strength; and polymer drug-elution platforms are now 
„biocompatible‟ with little evidence of an immediate inflammatory response in the 
vessel wall. The „bio-absorbable scaffold‟ is the next stage in the evolution of stent 
technology and may be less likely to cause neo-atheroma, as these novel polymer 
devices are designed to gradually and completely dissolve over 2 to 3 years after 
implantation (Onuma and Serruys, 2011). Certainly they seem to have very low 
restenosis rates in early trials, but the superiority of these devices over modern metallic 
stents has yet to be proven. Bio-absorbable scaffold struts are more bulky than those of 
modern metallic stents and studies so far have shown at least as frequent thrombosis 
rates with the new scaffold as with the older stent (Serruys et al, 2015).  
9.3. SYNTAX score 
Based on the results of this study, if we were permitted only 1 baseline 
characteristic to predict the risk of further cardiac adverse events of any sort, this would 
be the SYNTAX score. It is unusual among clinical risk scoring systems in that it 
requires the input of no standard baseline characteristics and is purely based on the 
coronary angiogram. The score was developed to be a relatively objective means of 
assessing the severity of coronary artery disease in patients taking part in the SYNTAX 
trial, an important study of PCI vs. CABG in 1800 patients with extensive coronary 
disease, multi-vessel and/or left main coronary disease (Serruys et al, 2009a). In this 
trial the score was found to be highly predictive of recurrent adverse events in patients 
undergoing PCI but not in those undergoing CABG. In the study patients were stratified 
into low (< 22), intermediate (23 to 32) and high (≥ 33) SYNTAX groups with a median 
score for the whole cohort of 28. These scores are very high comparison to the OPERA 
cohort, with a median score of 9 and only 34 patients with SYNTAX ≥ 33, many of 
whom had a history of previous CABG. They are therefore very different populations. 
However, within the range of SYNTAX scores we observed in the OPERA study and 
despite associations between the SYNTAX score and multiple other baseline high risk 
features, there was a significant independent and probably linear association with 
SYNTAX score and adverse ischaemic outcomes. 
The SYNTAX score was considerably more successful at predicting outcome in 
OPERA than was the EuroSCORE, which was not an independent predictor of adverse 
events. The EuroSCORE was devised to assess the risk of early mortality in patients 
undergoing CABG and is known to be effective for this purpose (Nashef et al, 1999), 
but the factors associated with poor outcomes following CABG and PCI are different. 
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Adverse events following CABG are mostly peri-operative and are related to the general 
frailty of the patient and the presence of co-morbidities such as respiratory and 
cerebrovascular disease. In contrast, major peri-procedural adverse events following 
PCI are relatively rare, but later events are more common and are often due to the 
presence of residual disease following PCI or stent failure, the likelihood of which 
increase with increasing SYNTAX score. The number and complexity of proximal 
coronary artery lesions (essentially what the SYNTAX score measures) in patients 
undergoing CABG is relatively less important, as grafts can be placed onto healthy 
vessel distal to the stenosis. A recent analysis of causes of death in the SYNTAX trial 
(Milojevic et al, 2016) showed that, although all-cause mortality was not statistically 
different between the CABG and PCI groups, the rate of death due to definite MI was 
much higher in the PCI group compared to the CABG group: 4.1% vs. 0.4%, HR (95% 
CI) 8.43 (2.99 to 23.67); p <0.0001. In this as in previous analyses, the SYNTAX score 
was an independent predictor of cardiac mortality after PCI but not after CABG. 
Although the SYNTAX score is a good predictor of recurrent adverse events 
following PCI, it is not clear how patients who are identified as being at high risk of 
recurrent events by means of the SYNTAX score could have their treatment modified to 
reduce this risk. Performing more extensive PCI was shown to be detrimental in the 
SYNTAX trial in which all lesions had to be treated if possible. Improvements in stent 
design (as discussed above) and pressure wire guidance of PCI (the FAME II study, de 
Bruyne et al, 2012) are all possible ways in which outcomes may improve. However, 
part of the risk carried by increasing SYNTAX score is due to its association with other 
baseline characteristics which themselves are related to increased adverse event rate 
risk; these would need to be addressed individually where possible to further lower risk. 
9.4. Bleeding 
To summarise the main results regarding bleeding: clinically significant bleeding 
(BARC 2 to 5) occurred in 3.8% at 1 year. There was a high initial rate due to access 
site bleeding. The rate dropped after most patients discontinued DAPT, shortly after the 
1 year mark, but events continued to occur for the duration of follow-up at a lower rate. 
The commonest types of bleeding were epistaxis and GI bleeding (mainly lower GI e.g. 
haemorrhoids). Most cases were clinically trivial or mild and for many patients low-
level bleeding was a chronic recurrent problem. Patients with bleeding had a higher 
mortality rate than those without bleeding, but this finding was confounded by other 
baseline characteristics which were associated with mortality and bleeding, particularly 
advancing age and the presence of anaemia pre-PCI. Bleeding was an uncommon direct 
cause of death, occurring in 5 patients over long-term follow-up. Only 2 or possibly 3 of 
these cases could be said to be directly related to the intervention or adjunctive 
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pharmacology (1 arterial access site bleed, 1 GI bleed several days after PCI and 1 case 
of subdural haematoma at 55 days). 
Bleeding induced by antiplatelet and anticoagulant medication is a major concern 
for ACS patients, particularly those invasively managed due to the risk of stent 
thrombosis if DAPT has to be discontinued prematurely. Large vascular access site, GI 
or intracranial bleeds may prove fatal; and many studies have documented alarmingly 
high mortality rates later on in those who experience non-fatal bleeding. In the OPERA 
study there was an initial high rate of BARC 2 to 5 bleeding which was mainly due to 
vascular access site haematomas, the majority of patients having undergone femoral 
access procedures. After the first few days the bleeding rate dropped and levelled out, 
and then decreased further at about 13 months, approximately the point after which 
patients changed from DAPT to single antiplatelet therapy. 
Regarding bleeding rates in comparison to other contemporary trials, both the 
TRITON and PLATO trials thoroughly reported bleeding events as safety endpoints, 
but neither trial could make use of the BARC criteria which were published following 
the completion of these studies. However, TIMI major and minor non-CABG related 
bleeding criteria together probably approximate to the BARC 2 to 5 criteria. Non 
CABG-related TIMI major and minor bleeding occurred in the PLATO invasive 
clopidogrel arm in 3.9% at 1 year; and 3.8% in the clopidogrel arm of TRITON at 15 
months. The BARC 2 to 5 bleeding rate in OPERA at 1 year was much the same, 3.8%. 
In ADEPT-DES, „clinically relevant‟ bleeding at 1 year was reported in 6.2%, a higher 
rate than the other studies. 
The most important baseline risk factor for bleeding in OPERA was increasing 
age, with BARC 2 to 5 rates at 3.4 years of 0% in the under 40s compared to 21.4% in 
the over 80s. Anaemia at baseline was also an independent marker of future bleeding 
problems. Another factor, the use of ACE-inhibitors, was associated with a lower risk of 
bleeding although this appeared to be confined to men only. Several risk scores for 
bleeding based on multiple baseline risk factors have been developed although recent 
studies to validate them have shown poor predictive value (Dobies et al, 2014). From 
the information available in the OPERA study, formal bleeding risk scores would seem 
unnecessary, with most of the predictive power coming from the 2 parameters age and 
anaemia. The BARC 2 to 5 bleeding rates at 30 days, 1 year and 3.4 years in patients 
who were both anaemic (Hb < 12 g/dl) and aged 70 or over were 7.5%, 13.8% and 
25.0%, with excess bleeding rates compared to the other groups seen both early and late 
in follow-up (Figure 6-5). This should therefore be the group to concentrate on if 
manoeuvres to reduce bleeding rates are to be considered. 
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The fatal bleeding rate (BARC 5) in OPERA was 0.3% at 1 year (3 cases). By 
comparison, fatal bleeding occurred in 0.1% at 15 months in the clopidogrel arm of 
TRITON (5 cases). Fatal bleeding was, oddly, not reported as a separate endpoint in the 
PLATO Invasive study, although it was in the PLATO entire cohort study: 0.3% in the 
clopidogrel arm (23 events) at 1 year. In OPERA, the specific causes of the 1 year 
haemorrhagic fatalities were: 
 An 80 year old man died within 24 hours of PCI from the combination of 
exsanguination from a punctured femoral bypass graft (a route of last 
resort to allow treatment of intractable angina when no other access sites 
could be found) and myocardial ischaemia. This patient was given a IIbIIIa 
inhibitor following PCI in view of poor coronary flow. Other than this 
tragic event there were no other fatalities from access site bleeding, the 
main effects of which were increased discomfort and delayed discharge 
 One patient died of a massive GI bleed. This occurred in a 79 year old lady 
4 days post PCI, after her discharge home. She was anaemic at baseline 
(Hb 10.7 g/dl) but was not taking a prophylactic PPI. She was given a 
IIbIIIa inhibitor during PCI and she had an unusually high level of 
clopidogrel inhibition and correspondingly very low platelet reactivity: 
%inhibition of 80%, PRU of 63.  
 One patient died at 55 days from chronic subdural haematomas diagnosed 
in the weeks following PCI. This was a 77 year old lady with diabetes and 
chronic renal failure who was given a IIbIIIa inhibitor at the time of PCI. 
She had had trouble with hypoglycaemic attacks and was at risk of head 
injury from these. 
All these patients were elderly, had several other risk factors for bleeding, and had 
all been given IIbIIIa inhibitors in addition to DAPT. The only haemorrhagic death 
which may have been avoidable in retrospect was the GI bleed, which was due to 
endoscopically proven peptic ulceration and may have been prevented by use of a PPI. 
There is no reason why PPI prophylactic therapy should not be part of standard care in 
elderly patients who require DAPT. For elderly patients generally, it may be possible to 
reduce bleeding by limiting the intensity and/or duration of DAPT – however, there is 
little or no evidence to support these strategies, and reducing the degree of platelet 
inhibition would likely result in increased rates of recurrent ischaemia. The ideal 
duration of DAPT in elderly patients, a group with both high bleeding and thrombotic 
risk, is unknown. 
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Strategies to reduce bleeding rates are of course desirable in order to reduce 
patient discomfort and length of hospital stay, and possibly reduce the overtly 
haemorrhagic death rate, although this appears to be very low in most studies. There 
remains the question of the apparent association of bleeding with subsequent mortality. 
Although this finding was replicated in the OPERA study, detailed examination of the 
circumstances of each death of a patient in whom BARC 2 to 4 bleeding had previously 
been recorded revealed no case in which bleeding played a significant role in the death. 
All these patients died of either advanced organ failure or metastatic cancer. It seems 
that non-fatal bleeding is therefore a marker of increased risk of death due to its 
association with serious co-morbidities and advanced age, rather than as a direct 
precipitant. 
9.5. Platelet reactivity, anaemia and adverse events 
To summarise the main findings regarding the associations between platelet 
function testing and adverse outcomes: platelet reactivity, both Base and PRU, was 
highly variable between patients. There was no measureable platelet inhibition from 
clopidogrel (0% inhibition) in more than a fifth of patients, and more than half of the 
total cohort had a PRU above the „ischaemic threshold‟ of 238 i.e. were „clopidogrel 
resistant‟. The baseline characteristics most strongly correlated with PRU level were the 
Base value (direct relationship) and pre-procedural Hb (inverse relationship). The 1 year 
recurrent ACS rate in clopidogrel non-responders (high PRU) was approximately 2.5 
times that in responders, but this difference was only of borderline statistical 
significance. The 1 year rates of death and of combined death and MI in non-responders 
were about twice those seen in responders; again these findings were of borderline 
statistical significance. 
Patients with „hyper-response‟ (PRU < 179) had a significantly increased risk of 
bleeding. PRU had a U-shaped rather than a linear association with adverse clinical 
events: the lowest event rate occurred within a PRU range which corresponded closely 
with the optimal range previously published by the ARMYDA-PROVE group. No 
patient in this group experienced a cardiac death during the entire follow-up period. The 
lowest and highest PRU octiles had equivalent combined adverse event rates. 
The Base value carried considerable long-term prognostic information, with a 
higher rate of ischaemic events over long-term follow-up in patients with high Base 
platelet reactivity. 
Anaemia prior to PCI was a powerful marker of poor prognosis in this study, 
being associated with bleeding, recurrent ACS and death. One third of patients with Hb 
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levels < 12 g/dL died during long-term follow-up. However, anaemia often occurred in 
patients with multiple other high-risk features including age and SYNTAX score. There 
was a strong interaction between anaemia and platelet reactivity. Anaemic patients with 
high platelet reactivity did badly following PCI, but anaemia combined with low 
platelet reactivity was not associated with adverse events. By the same token, high 
platelet reactivity only seemed to be a poor prognostic sign when accompanied by 
anaemia. 
 
The OPERA study patients with „clopidogrel resistance‟ based on the results of a 
VerifyNow test had 2.5 times more MACE events than clopidogrel responders, but this 
difference was of only borderline statistical significance. The lack of statistical 
significance was likely to be because clopidogrel resistance was remarkably common, 
seen in more than half the patients (in fact many had no detectable platelet inhibition at 
all), yet the majority of these patients experienced no ill effects. 
Coronary thrombosis is a complex, incompletely understood pathological event 
and there are probably multiple reasons for the high level of toleration of clopidogrel 
resistance, but one could speculate the following: 
 These patients were all in receipt of an additional antiplatelet agent, aspirin, which is 
known to be clinically very effective in isolation in the setting of acute MI. 
 Most patients were only partially resistant to clopidogrel, with a very broad range of 
degree of inhibition in the cohort; even partial inhibition would be expected to lower 
the chances of coronary thrombosis. 
 Patients had a very wide range of baseline platelet inhibition to thrombin (the Base 
value) with an almost normal distribution. Furthermore this measurement correlated 
well with the risk of longer term, off-clopidogrel ischaemic events. Many patients in 
the study already had a low risk of recurrent ischaemia by having naturally low 
platelet reactivity to thrombin, mitigating the consequences of clopidogrel 
resistance. 
 Even in the absence of any antiplatelet agents, only a proportion of coronary stents 
would be expected to thrombose thanks to the body‟s natural anti-clotting 
homeostatic mechanisms. The proportion one would expect to thrombose without 
antiplatelets is entirely unknown and such a study could never be performed in man. 
Among the highest risk patients in this cohort were anaemic patients with high 
platelet reactivity. Furthermore, platelet reactivity as measured by the VerifyNow BASE 
test, and to lesser extent the PRU test, was highly variable and inversely proportional to 
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Hb level: the lower Hb level, the higher the platelet reactivity. While the association 
between Base and Hb was fairly linear, the PRU-Hb curve had more of an inverted U-
shape because of a greater frequency of anaemia in patients with hyper-response to 
clopidogrel. Anaemic patients had a wide distribution of PRU values but those with 
high Hb levels had low platelet reactivity range within a narrow range. 
This inverse association between platelet reactivity and Hb has been observed 
before by other investigators but the mechanisms by which it occurs are unknown. One 
might in fact expect the converse situation: people with strongly reactive platelets 
should have less blood loss and therefore higher Hb levels. This implies that changes in 
Hb level induce changes in platelet reactivity. It is plausible that a negative feedback 
mechanism between Hb and platelet reactivity exists for reasons of maintaining 
homeostasis. In a state of anaemia, an increase in platelet reactivity would be desirable 
to reduce bleeding and preserve Hb levels. Conversely, in the pro-thrombotic state of 
polycythaemia, a decrease in platelet reactivity would lower the risk of arterial and 
venous thrombosis. 
One author who noted the association of PRU with VerifyNow Hb has suggested 
that this is an artefact caused by the light transmission basis of the test: a higher 
haematocrit may increase turbidity of the blood sample and decrease light transmission 
(Kim et al, 2014). This was concluded because there was no apparent Hb/platelet 
reactivity interaction when using the Multiplate analyzer, a point-of-care test which 
relies on changes in electrical impedance rather than light transmission. However, 2 
other investigators who noted the interaction with the VerifyNow test and Hb went on 
to confirm the interaction using light transmission aggregometry (LTA) (Frelinger et al, 
2013 and Toma et al, 2012). As LTA uses plasma devoid of erythrocytes, the interaction 
cannot be an artefact caused by changes in light transmission due to haematocrit. 
An unexplained lack of mortality benefit has been observed in many trials of dual 
antiplatelet therapy where platelet inhibition has been intensified either by increasing 
the dose of clopidogrel or substituting it for prasugrel. The ADEPT-DES registry (Stone 
et al, 2013) showed that the stent thrombosis rate in patients with high platelet reactivity 
on clopidogrel was considerably higher than in other patients (adjusted HR 2·49 [95% 
CI 1·43 to 4·31], p=0·001); yet the adjusted mortality rate between the 2 groups was no 
different. This was put down to an increased mortality rate in patients with clinically 
relevant bleeding, although the direct cause of the additional deaths in anaemic patients 
was not reported. Furthermore, unexpectedly higher mortality rates were seen in all 5 
trials of oral IIbIIIa antagonists in the 1990s, drugs which inhibit platelet aggregation 
very powerfully, the IIbIIa molecule being the final common pathway for aggregation 
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(Chew et al, 2001). This outcome was not explained by bleeding and put down to an 
unknown toxic effect of the drugs, which are no longer available. All these studies point 
to some kind of hazard incurred by very low platelet reactivity. 
From the OPERA study results, this hazard does not appear to derive either from 
premature antiplatelet drug discontinuation (which might occur after a bleeding 
episode), or from the direct effects of bleeding, although bleeding rates are certainly 
higher in this group. Anaemia and bleeding have been well described as risk factors for 
death after ACS and PCI, but death directly caused by bleeding is rare; MI-related death 
is much more common. If a negative feedback loop between Hb and platelet reactivity 
does exist, this could account for the paradoxically worse prognosis seen in patients 
with more intense platelet inhibition on clopidogrel. The more the P2Y12 receptor is 
inhibited, the higher the chances that bleeding would lead to a drop in Hb level, so 
triggering a protective increase in baseline platelet reactivity. If baseline reactivity 
increases, PRU would also increase, as these values are strongly linked (Figure 7-28). 
This would imply the existence of a mid-range optimal level of platelet inhibition. This 
is indeed found in the OPERA and some, but not all, similar studies. 
 
Figure 9-1  Diagram to show a hypothetical adverse circular relationship between 
bleeding, anaemia and myocardial infarction which could result in worse outcomes in 
certain patients 
Although no studies have been published which document changes in individual 
platelet reactivity in response to changes in Hb level, there is some evidence that 
platelet reactivity can change considerably in response to a range of other non-
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pharmacological stimuli. For example, Vij et al (2009) demonstrated that high altitude 
produces a marked reduction in platelet reactivity on testing with several agonists 
(collagen, adrenaline and ADP). Individual patient platelet aggregation rates have been 
shown to increase after respiratory tract infection (Kreutz et al, 2007). How these 
stimuli can change platelet reactivity is, however, completely unknown. 
Previous evidence for a VerifyNow optimal range 
Previous platelet function studies using the VerifyNow system have focused on 
identification of the „ischaemic‟ PRU threshold and on the risk of stent thrombosis 
rather than on bleeding, yet a firm consensus ischaemic has not been decided upon 
(Tantry et al, 2013). While an association with more intense P2Y12 platelet inhibition 
and bleeding has been previously demonstrated, likewise there is no consensus on a 
VerifyNow PRU bleeding threshold. Furthermore, most antiplatelet studies exclude 
patients thought to be particularly at risk of bleeding, a design feature likely to diminish 
the adverse impact of intense platelet inhibition. However, in addition to ARMYDA-
PROVE, 2 further studies have identified a therapeutic PRU range using the VerifyNow 
device. All 3 studies used Receiver Operator Characteristic curves to estimate bleeding 
and ischaemic thresholds. 
Campo et al (2011) found evidence for a PRU bleeding threshold of 86, based on 
19 bleeding events at 1 year in 300 patients undergoing PCI (the ischaemic threshold 
was 238). This bleeding threshold is substantially lower than that proposed by the 
ARMYDA-PROVE investigators. However, the design of the former study was to test 
platelet function at 30 days and only patients with adverse events after this time point 
were included. In contrast, Patti and the ARMYDA-BLEEDS investigators (2011) 
derived a different bleeding threshold of 189 from events up to 30 days (15 bleeding 
events) in a similar sized cohort of 310, a similar PRU value to that found by the 
ARMYDA-PROVE investigators (PRU 179). 
While the larger cohort of 732 patients in ARMYDA-PROVE increases this 
study‟s discriminatory ability, many of the adverse events in ARMYDA-PROVE were 
procedure-related: 27 of 36 bleeding events were entry site haematomas and 45 of 57 
ischaemic events were peri-procedural MI. The longer-term relevance of this range to 
an unselected ACS population of patients on DAPT was not known. 
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9.6. Cardiac biomarker elevation and adverse events 
To summarise the main findings regarding cardiac biomarkers in the OPERA 
study: pre-procedural biomarker elevation was common, particularly with TnI, despite a 
median time from admission with ACS to PCI of 6 days. Post-procedural biomarker 
elevation in patients who were biomarker-negative at Time 0 hours was common at both 
the 4 and 12 hour time points, with the highest levels at 12 hours even for the rapidly-
excreted biomarker H-FABP. Post-procedural Biomarker elevation was associated with 
the severity of coronary disease and increased interventional complexity, but not with 
angiographic complications. Post-procedural biomarker elevation was not an 
independent predictor of adverse events. Pre-procedural (rather than post-procedural) H-
FABP proved to be an independent predictor of adverse outcomes when combined with 
when platelet reactivity. 
Biomarker elevation was frequent in OPERA study patients at all 3 time points it 
was tested (0, 4 and 12 hours). It is likely that in some cases this was residual elevation 
from the ACS which led to hospital admission, days before PCI. However, the rapidly 
excreted biomarker H-FABP was also elevated in many patients, suggesting the 
possibility of ongoing ischaemia in some despite initial pharmacological therapy. Pre-
procedural H-FABP elevation was only of prognostic importance following PCI in 
patients with a poor response to clopidogrel. 
The results of the post PCI biomarker analysis were disappointing from a 
prognostic point of view, with no independent association with adverse outcome seen. 
Post-PCI enzyme elevation was usually of low magnitude, suggesting little procedural 
myocardial damage, and was more likely in the presence of certain mechanical factors 
such as calcification, longer lesion length and greater number of lesions. These factors 
would generally lead to longer procedures with more frequent and aggressive balloon 
dilatation, when the transient myocardial ischaemia inevitably induced by PCI would be 
expected to be greater. 
All the biomarkers tested continued to rise following PCI from 4 to 12 hours. 
Particularly with the rapidly excreted biomarker H-FABP one might expect an early rise 
followed by a fall at 12 hours. Some patients showed this pattern, but in some H-FABP 
continued to rise by 12 hours. Still others had a 12 hour rise but no 4 hour rise. Delayed 
release of cardiac enzymes in patients undergoing reperfusion to ischaemic myocardium 
is of interest as it might imply delayed ongoing ischaemia. It seems unlikely that 
myocardial perfusion normalises immediately following PCI in all patients and it may 
- 237 - 
be either that the enzyme is „washed out‟ as perfusion gradually improves (a cardiac 
biomarker washout phenomenon following reperfusion has been observed in patients 
undergoing revascularisation in acute ST elevation MI); or the late peak represents 
„reperfusion injury‟ in which, theoretically, the oxidative stress induced by restoration 
of the blood supply can cause further damage to myocytes 
Myocardial injury may possibly continue for several hours after stent implantation 
due continuing ischaemia from mechanical or embolic phenomena, for example partial 
occlusion of small vessels due to trapped side branches or distal embolisation of 
atheromatous material. Another possibility is that platelet activation and thrombus 
formation occurs after the anticoagulation has worn off, with subsequent distal 
embolisation of thrombus to occlude peripheral branches. Against this is the complete 
lack of a difference in platelet reactivity in the patients with and without biomarker 
elevation. 
Transient impairment of renal clearance of myoglobin due to contrast-induced 
renal dysfunction might also be considered a cause of late biomarker elevation. 
However, there was no significant difference in pre-procedural creatinine between 
patients with a 4 hour peak and those with a 12 hour peak (95 µmol/L vs. 97 µmol/L, p 
= 0.77), nor was there a significant difference between the volume of contrast used in 
the same groups (median 215 ml vs. 250ml, p = 0.57). 
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9.7. Overall conclusions 
1. Patients who present with ACS have an unacceptably high rate of recurrent ACS, 
despite coronary intervention and other attempts to modulate the disease process. 
This rate did not diminish during the course of the OPERA study. There is clear 
evidence of an increase in the rate of recurrent ischaemic events in patients with 
ACS undergoing PCI who have high platelet reactivity on clopidogrel. Nevertheless, 
no study has shown clear health benefits of increasing the intensity or duration of 
long term antiplatelet therapy in unselected patients, there is a lack of benefit seen 
with prasugrel (a strong P2Y12 inhibitor) over clopidogrel (TRITON-TIMI 38), there 
were high recurrent event rates with ticagrelor (PLATO) and there is a very adverse 
risk profile associated with bleeding and anaemia, which are more common with 
prolonged DAPT. The current evidence therefore discourages a strategy of universal 
long-term intense P2Y12 receptor inhibition and reasons for this lack of benefit 
should be sought. 
2. The findings of our study support the existence of an optimal therapeutic 
VerifyNow PRU in ACS patients following PCI who are unselected with regard to 
bleeding risk. A PRU level within a fairly narrow range around 200 while on 
treatment with clopidogrel and aspirin was associated with an extremely low risk of 
long-term adverse events. The safety and efficacy of PCI and DAPT might in future 
be further improved if a mid-range „therapeutic‟ level of P2Y12 inhibition could be 
reliably achieved, particularly for those patients at increased risk of bleeding, the 
elderly and the frail. However, it is by no means clear how achieving and 
maintaining an optimal PRU long term with currently available health resources can 
be done. Unfortunately, projects attempting to achieve optimal PRU have so far 
failed to show any clinical improvement with this strategy, although this lack of 
success could in part be due to poor study design. 
3. Post-procedural elevation of cardiac biomarkers was very common and was 
associated with adverse prognosis, although this was likely due to confounding 
factors. However, pre-procedural H-FABP was a promising risk marker for 1 year 
adverse events; adequate response to clopidogrel (PRU <238) appeared to reduce 
the risk associated with baseline H-FABP elevation to that associated with normal 
H-FABP levels. H-FABP as a marker of ongoing ischaemia could have a useful role 
in clinical management of ACS patients, for example to guide the urgency and 
intensity of treatment in non-STEACS patients. It also has a potential role in 
identification of a sub-group of patients who would benefit from longer-term DAPT. 
4. The SYNTAX score was a valuable risk prediction tool in the OPERA study and it 
is recommended that this score is calculated in all patients who require 
revascularisation. The SYNTAX trial has shown that patients with very high scores 
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have a greatly reduced rate of cardiac death at 5 years when they undergo 
revascularisation by CABG rather than PCI. 
5. Stent design changed considerably during the OPERA study. This was associated 
with improvements in short term outcomes but longer term benefit was not so 
obvious, possibly due to the problem of neoatherosclerosis formation. 
Bioabsorbable scaffolds are currently in development and hold great promise but 
also have their limitations. Stents and scaffolds are likely to continue change and 
improve. 
6. Platelet reactivity to thrombin (as the VerifyNow Base result) was extremely 
variable in OPERA patients and high values appeared to be associated with long 
term adverse prognosis, particularly in anaemic patients. This leads to the 
speculation that the well-recognised adverse prognosis conferred by anaemia could 
in fact be caused by an increased propensity to arterial thrombosis, mediated by an 
increase in platelet reactivity as a direct response to low Hb levels. Platelet reactivity 
is known to vary in individuals in response to certain factors, but has not yet been 
shown to alter based on Hb levels. Platelet reactivity as a risk factor for MI has 
never been studied in the general population. 
 
9.8. Suggestions for future research 
1. Current antiplatelet therapy regimes in patients with ACS are not fully effective in 
reducing recurrent cardiovascular events. New therapies must be targeted at patients 
at the highest risk of recurrent events. Presently, studies could be undertaken in 
which the markers of risk identified in the OPERA study are used to stratify for 
long-term antiplatelet therapy. Future studies could look at the benefits of novel 
antiplatelet therapies such as the PAR-1 inhibitors as alternatives for P2Y12 therapy 
failure. The most promising novel markers of adverse prognosis from OPERA were 
pre-procedural H-FABP elevation, high SYNTAX scores and high thrombin-
mediated platelet reactivity (VerifyNow Base). All 3 could be determined with 
relative ease in the cath lab at the time of PCI. 
2. Approximately half the cases of further revascularisation in OPERA were to a non 
target lesion. Presumably these lesions developed after the initial ACS treatment. It 
would be a useful exercise to re-analyse the initial angiograms and patient 
characteristics for clues as to why this might happen. 
3. In patients receiving P2Y12 inhibitors we should continue to seek ways to tailor 
platelet inhibition to achieve moderate levels of P2Y12-mediated reactivity, enough 
to prevent thrombosis but not too much to induce bleeding or anaemia. This would 
probably require the use of a wider variety of drug doses than is currently available.  
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4. We have hypothesised from the OPERA data that anaemia may be capable of 
inducing a rebound increase in non P2Y12 mediated platelet reactivity, in this case 
in response to thrombin, which accounts for the poor cardiovascular prognosis 
associated with anaemia. The observation that platelet reactivity and haemoglobin 
level may be dependent requires further investigation, as does the finding of wide 
variability in thrombin receptor mediated platelet reactivity, as both of these were 
linked strongly to prognosis. It would be relatively simple to design a study 
involving a group of patients with anaemia in which platelet function was tested 
when anaemic and then again after normal Hb levels were regained. Another study 
looking at platelet reactivity in relation to subsequent ACS in patients without prior 
CAD or antiplatelet therapy would also be relatively simple to design, although 
would be likely to require large numbers. 
 
9.9. Strengths and limitations 
The strengths of this study include the unselected patient data source, the large 
size of the cohort, data relating to drug compliance and adherence, „hard‟ clinical 
adverse events arbitrated by an independent panel of experts, highly detailed follow-up 
data, long length of follow-up and the linkage of data to the Medical Research 
Information System. 
The main limitation of this study is its observational design, meaning that all 
findings and associations are hypothesis-generating only. Other limitations include the 
interruption to patient recruitment, the long recruitment time span and the non-
consecutive nature of recruitment. There was only 1 PRU test per patient, performed at 
the time of PCI - this may lead to underestimation of the level of platelet inhibition for 
patients having emergent PCI; these patients had to be excluded from this part of the 
study. Next, the 600mg clopidogrel loading dose was achieved by a variety of dosing 
schedules. However, the effect of this on PRU is likely to be minimal due to the 
prolonged time from admission to PCI in this study – most patients were effectively on 
stable DAPT therapy at the time of their VerifyNow test. We did not test for aspirin 
resistance; however, aspirin resistance is rare compared to clopidogrel resistance and 
evidence of adverse clinical consequences from aspirin resistance is inconclusive. We 
did not investigate the newer P2Y12 inhibitors prasugrel or ticagrelor, to which the 
results of this study cannot be extrapolated. Regarding biomarker analyses, many 
patients had missing results, mainly at the 12 hour time point. Regarding the SYNTAX 
score, all scoring was performed by 2 operators (UMS and IRP) and scoring accuracy 
was not corroborated by an independent observer.  
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